2008 LES Membership Directory

Make the
Connections
that Count
Contact LES today at (703) 836-3106 or visit our website at www.lespowernetworking.org

SPONSORS
2008 YEARLY POWER NETWORKING
SILVER SPONSOR
W
elcome to Power Networking at the 2008 Licensing Executives
Society U.S.A. and Canada Annual Meeting.
On behalf of the LES Board of Trustees and the 2008 Annual Meeting
Committee, I’d like to thank you for participating in this important part of the
LES Annual Meeting experience. LES Power Networking combines state-of-the-
art technology with personal connections to help you make the most of your
valuable time.
2008 ANNUAL MEETING POWER NETWORKING
GOLD SPONSORS
Through LES Power Networking, you’ll be able to search corporate and individual
profiles of other Annual Meeting participants to find the best contacts for your
technology needs or interests. All registrants will be able to invite one another
to meet during the 2008 annual meeting, and confirm your availability in real
time. Participants will receive email messages when they receive a new
meeting request.
Watch the Power Networking displays for your name, and then check with the
Power Networking registration desk to retrieve your messages.
Power Networking will be available throughout the 2008 Annual Meeting:
Sunday, October 19 7:00 a.m. – 7:00 p.m.
Monday, October 20 7:00 a.m. – 6:00 p.m.
Tuesday, October 21 7:00 a.m. – 6:00 p.m.
Wednesday, October 22 7:00 a.m. – 5:00 p.m. 2008 ANNUAL MEETING POWER NETWORKING
SILVER SPONSOR
The full set of individual and corporate profiles is posted on the Annual
Meeting web site, www.les2008.org.
Finally, we’d like to recognize the 2008 LES Power Networking sponsors who
made it possible for LES to add this valuable feature to this year’s meeting.
Their support has been instrumental to the success of LES Power Networking.
We hope you’ll make the most of this important element of the LES Annual Meeting.
Thank you. 2008 ANNUAL MEETING POWER NETWORKING
BRONZE SPONSOR
Walter Copan Pamela Demain
2008 Annual Meeting Chair LES Trustee, Partnering
2008 SPONSORS
Make the
Connections
that Count
E M B R A C I N G P A R T N E R S H I P S
You’ve
You’v
ve dis
discovered
scovered something significant.
sign
nificantt.
Now
Now disc
discover
over us!
Please ccontact:
on
ntact:
Barbara
Bar bara Y
Yanni
anni
an
nni
Vice
Vice President Licensing
President and Chief Licensing
gOOfficer
ffi er
ffic
Merck
M erck & Co.,
Co., Inc.
Inc.
Merck
One M erckk Drive
Drive
Box
PO B ox 100
0
Whitehouse
Whitehousse Station,
Station, NJ 08889-0100 USA
U
TTelephone:
elephone:
elephone: 908–423–4350
FFax:
ax: 908–735–1201
908–73
35–1201
w ww.merck
c .com/licensing
www.merck.com/licensing
“We are serious abo

about
out our commitment too strategic alliances. Our ur goal is for our partners
tners
and us to remain inn the forefront of turni
ing scientific breakthro
turning oughs into medicines th
breakthroughs hat
that
make a difference. We have established a clear path to partnerin ng, and invite you to explore
partnering, ex
y strengths with ou
the combination of your urs, and the successes we may share.”
ours,
– Mervyn Turner, PhD,
P Senior Vice President
Worldwide Licens
Licensing
sing and External Research
Copyright
Copyright © 2006-2008 Merck
Merck & C
Co.,
o., Inc.
Inc. All rights
rights reserved.
reser ved. LIC-2008-W-84848-AH
LIC-2008-W-84848-AH P
Printed
rinted in USA
SA
Caring and curing.
From cancer to heart disease to rare disorders affecting smaller
populations, Novartis is proud to be the innovative force that’s
bringing new optimism and hope to patients and their families.
No one can promise what the future holds for any individual
patient, but today millions are winning the fight against their
particular diseases, and enjoying life to the fullest.
Kenyon & Kenyon llp
The firm
Kenyon & Kenyon is one of the largest
International experience
Kenyon & Kenyon successfully works with
LES (U.S.A. and Canada)
full-service intellectual property law clients and attorneys around the world.
firms in the United States, with offices
in New York, Washington, DC and Silicon
The firm coordinates multinational
disputes, develops and maintains
thanks our sponsors for
Valley. The firm is a leader in enforcing international intellectual property
and defending intellectual property portfolios for its worldwide clients, and their generous support
rights for its global and domestic clients. has garnered long-standing relationships
We have been ranked as one of the top
United States law firms in contentious
with attorneys in every major industrial
country to provide global intellectual for this exciting feature
and non-contentious representation by, property services for our United States
among others, the most recent editions
of Managing IP’s World IP Survey,
and international clients. of the LES Annual Meeting.
International clients
Chambers, and The Legal 500.
We represent many of the world’s
The firm represents some of the world’s
best-known corporations in patent,
largest multinational corporations,
with a significant number of our clients
For more details on LES
trademark, copyright, trade secret, headquartered in Europe and Asia. This
unfair competition, false advertising,
antitrust and other litigation relating to
large and diverse practice assures that
we have real and current experience in
Power Networking, visit
intellectual property before the United many fields and are able to accommodate
States federal district and appellate
courts, state courts and administrative
different cultures and methods of doing www.lespowernetworking.org
business. The firm’s experience spans the
agencies such as the International Trade business spectrum. It represents clients
Commission. We also represent our in such technological areas as computers
clients in administrative proceedings such (both hardware and software),
as patent prosecution and interferences, biotechnology products and processes,
trademark prosecution, and trademark machinery, pharmaceuticals, and plastics.
oppositions and cancellations, and in Additionally, the firm provides services to
licensing, technology transfer and due clients in aerospace, photography, medical
diligence transactions. devices, metallurgy, basic chemicals and
The firm strives to provide the best client petrochemicals, environmental processes,
representation through its experience, financial services, food and beverages,
technological expertise, anticipation transportation vehicles, agribio products,
of client needs, clear and open robotics, and telecommunications. It
communication, and an understanding of also represents clients in entertainment
the vital role played by a comprehensive and the arts, toys, publishing, interactive
intellectual property protection and entertainment, travel, sports, marketing,
enforcement strategy. fashion, and advertising.
One Broadway, New York, NY 10004 I Ph: 212.425.7200 I Fax: 212.425.5288

New York Washington, DC Silicon Valley www.kenyon.com
LES (U.S.A. and Canada) is pleased to offer Power Networking.
This online tool assists participants arrange meetings with key
contacts throughout the 2008 Annual Meeting, provide designated
meeting points for informal conversations, and offers exclusive
private meeting space for power networking sponsors.
Make the LES takes networking to a whole new level. Join us for the
Connections targeted networking that hits the mark for efficiency and
effectiveness to make valuable business connections.
that Count How can Power Networking work for you? Here are the
Frequently Asked Questions (FAQs):
F R E Q U E N T LY A S K E D Q U E S T I O N S
Q. What is Power Networking? Q. Is Power Networking just for Deal Making?
A. It is a systematic way for meeting attendees to get together. A. No. Power Networking brings together people for learning
opportunities, jobs, partnering, brainstorming, asking
Q. How does Power Networking work? questions of an expert, mentoring, or meeting people
A. Everyone who registers for the 2008 Annual Meeting, outside your sector. In actuality, Power Networking serves
October 19-22 in Orlando will be asked to fill out a any purpose in which you need to connect with another
professional profile, which will then be posted for all individuals at the 2008 Annual Meeting.
conference attendees to preview and search. You can
determine, in advance or during the meeting, which Q. Who is facilitating and sponsoring Power Networking?
participants you would like to meet, and the LES Power A. LES (U.S.A. and Canada) Trustee Pamela Demain has
Networking system will schedule face-to-face meetings been instrumental in planning this exciting new dimension
at a time that is convenient for both parties. of the LES Annual Meeting. Pam is active in outreach at
Merck & Co., where she is the Executive Director of
Q. When and where will Power Networking take place? Corporate Licensing. Technology Vision Group, an inter-
A. Power Networking will be available throughout the entire national life science business development organization,
Annual Meeting from Sunday through Tuesday. Electronic will be on site to set up networking sessions, facilitate
message boards and email reminders will notify partici- the process and notify participants. Various companies
pants of their meeting requests. Pre-arranged networking are sponsoring this new LES initiative so that it is
will take place in a dedicated lounge, which will combine available to everyone attending the Orlando meeting
small semi-private meeting spaces with a relaxed at no extra cost. In return, sponsors will have private
“coffee house” style atmosphere complete with couches, rooms available for their networking needs.
tables, and refreshments.
Q. How can I register for Power Networking?
Q. LES Meetings have always had a large networking A. Once you are registered for the Annual Meeting,
component. How is Power Networking different? you will be asked to complete a profile and submit
A. Power Networking is a dynamic, strategic opportunity your list of potential networking partners. Participation
to make your meeting time more valuable. Due to the is free! Start looking forward now to the 2008 LES
large number of people attending the Annual Meeting, Annual Meeting and take advantage of this powerful
you could spend a lot of valuable time trying to find new resource in Orlando.
the people you need to network with. Power Networking
allows to make those connections in advance or at the
meeting itself. It offers a system for scheduling those
meetings as well as designated places to meet. This
systematic, targeted approach allows you to make the
most out of your networking time.
LES USA & Canada
2009 Power Networking Sponsorship Opportunies
Your Best Investments in the Licensing Marketplace
2009 POWER NETWORKING SPONSORSHIP LEVELS

LEVELS OF SUPPORT GOLD
• 4 complimentary meeting registrations
Gold $20,000
• Lead recognition on meeting signage and web site
Silver $15,000 • Complimentary ad in Power Networking program
Bronze $12,000 • Complimentary prominent booth in Tech Fair
• Private space for Power Networking
University* $4,000
SILVER
* - includes Universities, research institutions, start-ups, technology • 3 complimentary meeting registrations
incubators, and not-for-profit organizations. • Complimentary prominent booth in Tech Fair
• Complimentary ad in Power Networking program
• Dedicated recognition on meeting signage and web site
Here are some of the comments from prior • Private space for Power Networking
Power Networking users:
BRONZE
“I have used similar systems at other meetings, but the • 2 complimentary meeting registrations
LES Power Networking system was much easier to use and • Complimentary ad in Power Networking program
the contacts were much more productive for my business.” • Complimentary booth in Tech Fair
“Even though this was the first time I’ve used this type of • Reserved table throughout Power Networking
match-making system, I found it very helpful to connect with UNIVERSITY
potential contacts and established clients. I hope this will • 1 complimentary meeting registration
continue at future LES meetings.” • Complimentary poster session during 2009 Annual Meeting
• Preferred access to booth space in Tech Fair
• Complimentary ad in Power Networking program
89% of LES Power Networking participants 61% of meeting attendees would be 93% of Power Networking participants
believed that it should be part of every more likely to attend a meeting with Power found it added some or high value to their
LES Annual Meeting networking meeting experience
Founded in 1966, LES is a professional society comprised of over 6,000 members
engaged in the transfer, use, development, manufacture and marketing of
Intellectual Property. The membership includes a wide range of professionals,
including business executives, lawyers, licensing consultants, engineers,
academicians, scientists and government officials. Many major companies,
professional firms, and universities are represented within the Society’s
membership. Licensing Executives Society (U.S.A. & Canada), Inc. is a member Licensing Executives Society
(U.S.A. and Canada), Inc.
society of the Licensing Executives Society International, which has a worldwide 1800 Diagonal Road, Suite 280
Alexandria, Virginia
membership of over 12,000 members in more than 30 national societies, 22314-2840
representing over 85 countries.
Phone: 703-836-3106
Facsimile: 703-836-3107
For more information about the LES 2009 Meetings and
Contact: Eleanor de Leon
Power Networking, contact LES. E-mail: edeleon@les.org
Web site: www.lesusacanada.org
LES Power Networking 2008 Annual Meeting
1790 Analytics & 1790 Capital
130 Haddon Avenue | Haddonfield NJ 8033 | United States

Phone: (856) 216-1790 | Fax: (856) 216-2262
Contacts
Mr. Charles D'Angelo | Partner
Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
1790 works with Fortune 500 companies in technology evaluation, intellectual property
licensing, and M&A targeting and due diligence. We help our clients capitalize upon their
intellectual property holdings, and understand and evaluate the intellectual property owned by
their competitors.
1790 Analytics has unique abilities in both the Art and the Science of IP Evaluation. We are a
quantitative custom research firm and are recognized IP experts along with are unmatched patent
databases enable us to provide our clients with solutions that are objective and consistent, while
being customized to their unique needs. Here is a quick snapshot of our work:
Technology Evaluations:
Uses our suite of quantitative, objective patent metrics

Evaluates the strengths and weaknesses of companies’ patent portfolios
Assesses technological landscapes and identifies emerging threats and opportunities
Uses our patent metrics and extensive experience in investment analysis

Locates companies whose technology makes them promising investments
Carries out due diligence of technology prior to investment decisions
Uses our Patent Risk-Opportunity (PRO) analysis

Identifies patents that may be most dangerous if bought by a competitor
Locates patents offering the greatest technological opportunities if bought by our client
Company Profiles Page 1

Uses our Technology Valuation Tool (TVT)

Values patent portfolios by benchmarking them against others of similar size and quality
Triangulates internal and external values to produce robust overall valuations
Uses our N-Degree analysis to navigate through citation networks

Identifies non-obvious targets for opportunity and infringement licenses
Uncovers licensing opportunities for non-core technologies
Company LES Interests
1790's main focus is on patents as we have the world’s most comprehensive patent databases at
our disposal. We maintain, in house, patents from the USPTO, EPO and WIPO. All of our
databases are organic and maintained by us. We do not outsource any of our analysis.
Types of Companies your Company Would Like to Meet with

We would like to continue to work with Fortune 500 company's and have worked with several
departsment within them. Including; R&D, Licensing/Business Develepment, M&A, Compeitive
Intelligence, Legal and, of course the IP group that may head up all these areas.
Company Goals for the LES Annual Meeting

1790 would like to meet more folks interested in understanding their company's IP position. We
are leaders in our space and believe with our custom approach for our clients, we are able to
help them make better and more informed IP decisions.
Product Opportunities
Country(s) Available for

Product Name Therapeutic Area Phase of Development
Partnering
N Degree (patent
Technology Not Applicable
targeting)

3Com Corporation
350 Campus Drive | Marlborough MA 01752 | United States

Phone: (508) 323-1085 | Fax: (508) 323-1111 | Website: www.3com.com
Contacts
Mr. Richard A. Baker | Director of IP Licensing / Congressional Candidate
Organization Type
Industrial Corporation
Industry Sector
High Technology
Company Overview
3Com Corporation (NASDAQ: COMS) is a leading provider of secure, converged voice and data
networking solutions for enterprises of all sizes. 3Com offers a broad line of innovative products
backed by world class sales, service and support, which excel at delivering business value for its
customers. Through its TippingPoint division, 3Com is a leading provider of network-based
intrusion prevention systems that deliver in-depth application protection, infrastructure
protection, and performance protection. 3Com also owns H3C Technologies Co., Limited (H3C),
a China-based provider of network infrastructure products. H3C brings innovative and cost-
effective product development and manufacturing and a strong footprint in one of the world's
most dynamic markets. For further information, please visit www.3com.com, or the press site
www.3com.com/pressbox.
3Com owns one of the most extensive and valuable patent portfolios in the networking world.
Years of investment in research and development created a number of premier communications
products, and led to one breakthrough invention after another. 3Com exercised great diligence in
the capture of these inventions, resulting in an outstanding patent portfolio.

Critical invention areas include Ethernet switch technology, Voice over Internet Protocol,
Wireless communications, modem technologies, network security, and power over Ethernet.
Patents are applicable to the United States and a number of foreign countries.

3Com is interested in licensing out its extensive patent portfolio, and is also interested in selling
a few select patents that are outside our core product focus.
Country(s)
Product Name Therapeutic Area Phase of Development Available for
Partnering
Data exchange system for use

with personal information N/A Not Applicable United States
devices
Abbott Laboratories
200 Abbott Park Road | Abbott Park Illinois 60064 | United States
Phone: 847-937-6100
Contacts
Ms. Regina M. Anderson | Senior Licensing Manager
Ms. Lisa M. Anselmino | Sr. Director, Licensing & IP, Diagnostic Division
Ms. Margarita Chavez | Sr. Manager, Global Licensing & New Business Development
Mr. William R. Killian | Senior Director, Nutrition New Business Development & Licensing
Dr. Steven Kuemmerle | Director, Scientific Assessment & Tech Licensing
Ms. Melea Lusk | Senior Manager, Licensing & Business Development
Mr. Ned R. McCoy | Sr. Director, Intellectual Property
Mr. Mark D. Rost | Technology Licensing Manager
Ms. Sucharitha Sastry Brown | Senior Manager, Global Licensing & New Business Development

Organization Type
Industry Sector
Health Care
Early stage and tech transfer
The changing legal environment and application to licensing
Global licensing challenges
Asset Valuation
New trends in licensing partnerships
Intellectual property management
Negotiation strategy
While we are open to discussions with companies actively engaged in a variety of therapeutic
areas, we seek opportunities to complement our active R&D and commercial programs in the
following areas:
Antivirals
Immunology
Metabolic Disease
Cardiovascular
Neuroscience/Pain
Oncology
Anti-infectives
Renal Care

Acute Care
Abbott has a heritage of long-lasting relationships. Over the years, we have worked with our
partners to commercialize numerous products that lead their categories—many with over $1B in
sales. At LES meetings we seek in-licensing opportunities, research and development
collaborations, as well at out-licensing opportunities under the right situations.
Abe, Ikuoka, & Katayama
Fukuoka Bldg. 9F | 2-8-7 Yaesu, Chuo-ku | Tokyo 104-0028 | Japan

Phone: +81 3 3273 2600 | Fax: +81 3 3273 2033
Contacts
Ms. Sumiko Kobayashi | Patent Attorney
Acacia Technologies Group
500 Newport Center Drive | Suite 700 | Newport Beach CA 92660 | United States
Phone: (949) 480-8308 | Fax: (949) 480-8379 | Website: www.acaciatechnologies.com
Contacts
Mr. Eric Brown | Vice President, Medical and Optics Portfolios
Mr. Jon Eastman | Vice President, Business Development
Mr. Dooyong Lee | Executive Vice President
Mr. James A. Trueman | Vice President, Business Development
Industry Sector
High Technology
Company Overview

The companies comprising the Acacia Technologies Group, a division of Acacia Research
Corporation (NASDAQ: ACTG), are in the business of acquiring, licensing and enforcing
patents. We help patent holders to protect their patented inventions from unauthorized use and to
generate revenue from licensing and, if necessary, enforcing their patents. We currently own or
control more than 95 portfolios and have established a long track record of success with around
600 licenses. Our professional staff includes in-house patent attorneys, licensing executives and
engineers.
Some examples of our successful licensing and enforcement programs are as follows:
 V-Chip: $25.6 million from TV manufacturers worldwide

 Video/Image Enhancement: More than $60 million to date
 Digital Media Transmission (DMT®): Recurring royalties from more than 300 licenses
to date, in most instances without litigation
Our clients are primarily small/mid-size companies and individual inventors who have limited
resources to deal with unauthorized users, but include some large companies looking to turn their
patents into revenue. In a typical client arrangement, we generally become the owner or
exclusive licensee of the patent, and the client receives a percentage of our net recoveries from
licensing and enforcement, up-front cash or both.

Acacia is interested in identifying patent licensing and acquisition opportunities and building
relationships with law firms that have extensive patent litigation experience.
Accenture
11951 Freedom Drive | Reston VA 20190 | United States
Phone: (703) 947-4030 | Fax: (704) 632-4630
Contacts
Mr. Paul Roberts |
Adherex
4620 Creekstone Drive | Suite 200 | Durham NC 27703 | United States
Phone: (919) 484-8484 | Fax: (919) 484-8001 | Website: www.adherex.com
Contacts
Dr. William Peters | Chief Executive Officer & Chairman

Company Overview
Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and
development of novel cancer therapeutics. We are in the business of solving problems for
patients with cancer. We have multiple products in the clinical stage of development, including
eniluracil, ADH-1 and sodium thiosulfate (STS). Eniluracil, an oral dihydropyrimidine
dehydrogenase (DPD) inhibitor, is being developed to improve the tolerability and effectiveness
of 5-fluorouracil (5-FU), one of the most widely used oncology drugs in the world. ADH-1 is a
biotechnology compound which selectively targets N-cadherin, a protein present on certain
tumor cells and the blood vessels of solid tumors. STS is a chemoprotectant being developed to
reduce or prevent hearing loss that may result from treatment with platinum-based chemotherapy
drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and
a management team with expertise in identifying, developing and commercializing novel cancer
therapeutics, Adherex aims to become a leader in developing innovative treatments that address
important unmet medical needs in cancer. For more information, please visit our website at
www.adherex.com.

Partnering
Neoplasms, Cancer, Europe, United States,

ADH-1 Not Applicable
Oncology Canada, Japan
Neoplasms, Cancer,
Eniluracil Not Applicable United States, Canada, Japan
Oncology
Neoplasms, Cancer, Europe, United States,

STS Not Applicable
Oncology Canada, Japan
Adolor Corporation
700 Pennsylvania Drive | Exton Pennsylvania 19341 | United States

Phone: 484-595-1014 | Fax: 484-595-1573 | Website: www.adolor.com
Contacts
Mr. Bert Thomas | Director of Business Development

Organization Type
Industry Sector
Health Care
Company Overview
Adolor Corporation is a biopharmaceutical company dedicated to the discovery, development

and commercialization of novel prescription pain management products. Adolor's mission
addresses a simple goal: to provide enhanced relief for the millions of people who suffer from
pain each year.
Adolor commenced operations in 1994 and was listed on NASDAQ as ADLR in 2000. Today,
the company has approximately 115 employees working in areas including discovery research,
clinical development, manufacturing, business development, regulatory affairs and marketing.
Pain is the most common symptom causing people to seek medical treatment in the United
States. More than 25 million people in the United States each year experience chronic moderate-
to-severe pain and pain causes more disability than cancer and heart disease combined.
The company was founded to capitalize on emerging proprietary development in cloned opioid
receptors and continues today as a leader in the discovery and development of novel opioid
receptor-targeted therapeutics. Additionally, Adolor's scientific staff is actively assessing other,
non-opioid molecular targets. These research efforts work towards developing products that
maintain or improve opioid-like pain relief while reducing or eliminating opioid side effects.
Entereg® (alvimopan), Adolor's lead product, is a peripherally-acting mu opioid receptor (PAM-

OR) antagonist designed to block the negative effects of opioids, like morphine, on the
gastrointestinal (GI) tract without interfering with central nervous system (CNS) mediated
analgesia. Entereg, the first FDA approved therapy for postoperative ileus, was approved by the
FDA on May 20, 2008 to accelerate upper and lower GI recovery following partial large or small
bowel resection surgery with primary anastomosis. Entereg is available for short-term use in
hospitals registered under the Entereg Access Support and Education (E.A.S.E.TM) program.
Entereg is also being developed to manage negative GI side effects associated with opioid use.
These side effects can negatively impact quality of life for millions of patients using opioid
analgesic products to treat many different types of pain.
Adolor is collaborating with GlaxoSmithKline (GSK) for the development and

commercialization of Entereg for postoperative ileus (POI).
Adolor has an exclusive worldwide collaboration with Pfizer Inc to develop and commercialize
novel pain compounds from Adolor's second development program, the Delta Opioid Receptor
Program. ADL5859 and ADL5747 are proprietary Delta opioid receptor agonist candidates with

the potential to treat a wide range of inflammatory, neuropathic and acute pain conditions.
By applying its knowledge and expertise in pain management, along with ingenuity, Adolor
Corporation is seeking to make a positive difference for patients, caregivers, and the medical
community.
Agreement Answers
5278 Clover Drive | Sheffield Village OH 44035 | United States

Phone: (440) 934-0718 | Fax: (440) 934-0796
Contacts
Mr. Vincent E. Young | Consultant
Akin Gump Strauss Hauer & Feld LLP
2 Palo Alto Square | Suite 400 | Palo Alto CA 94306 | United States
Phone: 650-838-2188 | Fax: 650-838-2001
Contacts
Mr. Ned Barlas | Senior Counsel
Organization Type
Law Firm
Industry Sector
High Technology
Company Overview
The law firm founded by Robert S. Strauss and Richard A. Gump in 1945 is one of the
world's largest firms. Our growth has come by understanding client problems - and
solving them with a strategic combination of legal, practical and political skills. As we
proceed in a new millennium marked by dramatic advances in technology and the
expansion of international business into new markets, we are well-positioned to
provide legal services that meet the changing needs of our clients on a 24/7 basis.

Our vision is to address the array of legal challenges you may encounter in achieving
your business goals. This vision has brought us depth, diversity and experience. And,
we are still a first-generation firm. Those who built the firm continue to serve the
clients that have grown with us.
Among our lawyers are men and women with different talents and approaches to the
law. Yet they also possess striking similarities, starting with the ability to see creative
solutions others might miss. Our lawyers are not satisfied until they have met the
highest standards of legal service. In every area of the law, we focus on achieving
results that help your business.
Alabama Launchpad
500 Beacon Parkway West | Birmingham AL 35209 | United States

Phone: (205) 943-4709 | Fax: (205) 943-4799 | Website: www.alabamalaunchpad.com
Contacts
Mr. Glenn E. Kinstler | Director
Industry Sector
Industry/University/Government Interface
Company Overview
Alabama Launchpad is a 501(c)(3) not-for-profit organization dedicated to the support of
technology and high-growth entrepreneurship in Alabama. Alabama Launchpad represents a
unique collaboration between seven public research universities in the state and the business
community. Our programs are designed to create community environments that nurture high-
growth entrepreneurship. We acknowledge the concept that existing industries create 70 to 90
percent of the new jobs in the state, and that commercialization of new technologies will
leverage the existing base of industry and universities and prepare us for "the New Economy".
Alabama Launchpad will help entrepreneurs connect to investors, experienced technology
managers, and service providers.

Alabama Launchpad has created an online searchable database of technologies available for
license from state universities and Alabama-based federal labs. Our goal is to promote

commercialization and licensing opportunities in Alabama.
Alexion Pharmaceuticals, Inc.
352 Knotter Drive | Cheshire CT 06410 | United States

Phone: (203) 271-8173 | Website: www.alxn.com
Contacts
Dr. Mike Liu | Associate Director, Global Commercial Development
Organization Type
Industry Sector
Health Care
Company Overview
Alexion Pharmaceuticals is a global biotechnology company that develops and delivers life-
changing drug therapies for patients with serious and life-threatening medical conditions.
Alexion’s first marketed product is a complement inhibitor called Soliris™ (eculizumab), the
first treatment for paroxysmal nocturnal hemoglobinuria (PNH), a rare, disabling and life-
threatening blood disorder defined by chronic red blood cell destruction, or hemolysis. In
March 2007, the FDA approved Soliris to treat all patients with PNH in the U.S. Following the
first-ever European accelerated review process, in June 2007 the European Commission (EC)
approved Soliris for the treatment of all patients with PNH in Europe.
Alexion (NASDAQ: ALXN) was formed in 1992 and currently employs 400 people. Alexion is
actively engaged in discovering and developing novel therapies targeting blood disorders,
autoimmune diseases, inflammatory conditions, cancer and other severe diseases.
For more information, visit www.alexionpharm.com or www.soliris.net.


Partnering
Soliris
n/a Not Applicable South America, Asia
(eculizumab)
Alfred Mann Foundation for Biomedical Engineering
5500 Campanile Dr. | SDSU | San Diego California 92182-1230 | United States
Phone: 619-594-2510
Contacts
Dr. A. Stephen Dahms | President/CEO
Alioscopy USA
4445 Eastgate Maill | Suite 200 | San Diego CA 92121 | United States
Phone: (858) 212-3020 | Fax: (858) 408-3334 | Website: www.AlioscopyUSA.com
Contacts
Mr. Philippe Roche | CEO
Organization Type
Industry Sector
High Technology
Company Overview
Alioscopy is the manufacturer and patent owner of a very unique 3D technology that delivers an
impressive and “undescriptable” 3D experience. The finesse of the technology is built on a
specific process that allow multiple applications, and can be applied any device using any
graphic source display device including: mobile communications, games, laptops, kiosks, digital

signage, medical and military applications, etc.

Expose our technology to potential licensees, in multiple industry and market segments.
Alita Pharmaceuticals Inc.
Two Radnor Corporate Center, Suite 420 | 100 Matsonford Road | Radnor PA 19087 | United
States
Phone: 484-253-1510 | Fax: 484-253-1544 | Website: www.alitapharma.com
Contacts
Mr. Paul Evans | VP, Strategic Partnering & Business Development
Organization Type
Industry Sector
Health Care
Company Overview
Founded in September 2006 and funded solely by Warburg Pincus, a global leader in private
equity, Alita Pharmaceuticals is a specialty pharmaceutical company focused on the development
and commercialization of novel urologic and female healthcare products.
Through acquisition and licensing, Alita is building a deep pipeline of novel, Phase I to Phase III
drugs and biologics that target urologic and female health conditions. Alita specifically targets
product candidates with clinical proof of concept that address therapeutic challenges clinicians
face due to a lack of efficacious and/or safe treatment alternatives. Having successfully
assembled a strong, experienced clinical and regulatory senior management team with proven
track records in drug development, the company is poised to successfully design, implement and
execute the clinical development programs and regulatory strategies required to efficiently and
effectively commercialize such a pipeline of therapeutics. Having successfully completed the in-
licensing of its first product earlier this year, a biologic for reducing the frequency of
uncomplicated recurrent urinary tract infections, Alita is already demonstrating an ability to
design and execute clinical development programs as well as to manage and establish successful
relationships with partners, FDA, key lead investigators, and other important stakeholders.
Alita's vision, experience, team and strategic approach offer the following benefits to potential
partners:

- Proven experience in drug development and commercialization

- Clear and focused corporate vision
- Ability to provide focused, non-competing resources to each portfolio product
- Single investor who shares vision and knows the level of commitment required
- Strategic, efficient, and defined infrastructure plan
- Nimble organization that allows for effective trade-off decisions and efficiency
- Commercially integrated approach

Core to Alita's growth strategy is the licensing and acquisition of development stage products
that target diseases of the uro-genital tract. Alita's international experience allows it to partner
globally. While the company intends to focus on the United States for its own commercialization
efforts, all development planning is conducted with a global perspective and positions Alita as an
ideal partner for a wide-range of companies. As a small focused company, Alita can work
effectively and efficiently with its partners, regulatory authorities and customers.
Alita is interested in meeting with companies looking to outlicense, partner, or divest products
that treat diseases of the uro-genital track and that would be prescribed by either urologists or
obgyns.
In-licensing
Acquisition

Allens Arthur Robinson
Level 28, Deutsche Bank Place | Sydney NSW 2000 | Australia

Phone: 61.2.92304000
Contacts
Mr. Richard Hamer | Partner
AllerPharma
#4-133 The West Mall | Toronto ON M9C 1C2 | Canada

Phone: (416) 622-5789 | Fax: (416) 622-0893
Contacts
Mr. Rajan Puri | Director, Business Development
Industry Sector
Health Care
Company Overview
AllerPharma is a rapidly growing Canadian pharmaceutical company focused on specialty

prescription products. We are a fully integrated commercial operation lead by an experienced
management team with a track record of success within the Canadian market. Our national sales
and marketing team currently promote an allergy vaccine. We are looking for complementary
allergy medications as well as prescription medications in the following fields - ophthalmology,
dermatology and respiratory.
AllerPharma is interested in establishing mutually beneficial licensing agreements for late-stage

specialty products.

AllerPharma is interested in meeting with companies which have late-stage or approved specialty
pharmaceutical products that have not been launched in Canada. We plan to leverage our success
in the allergy market with complementary allergy medications as well as prescription
medications in the following fields - ophthalmology, dermatology and respiratory.

AllerPharma hopes to meet with a number of partners to discuss potential in-licensing of
products for the Canadian market.
Alpharma
440 Route 22 East | Bridgewater NJ 8807 | United States

Phone: (908) 566-3876 | Website: www.alpharma.com
Contacts
Mrs. Tran Koch | Director, Business Development
Organization Type
Industry Sector
Health Care
Alston & Bird LLP
3201 Beechleaf Court, Suite 600 | Raleigh NC 27604 | United States

Phone: 919.862.2200 | Fax: | Website: www.alston.com
Contacts
Mr. Michael McCoy | Partner

Altitude Capital Partners
485 Madison Avenue | Suite 2300 | New York NY 10022 | United States
Phone: (212) 584-2190 | Fax: (212) 826-0826 | Website: www.altitudecp.com
Contacts
Mr. Kenneth K. Cho | Managing Director - Strategic Alliances
Mr. Amar Mehta | Partner
Organization Type
Financial Services
Company Overview
Altitude Capital Partners is a leading private investment firm focused on investing $250 million
of capital in businesses which own compelling intellectual property assets.
We seek to invest in portfolio companies that have valuable patents, trademarks/brands,

copyrights, royalty streams, trade secrets, and other intangible assets which will create a
competitive advantage in creating value. We possess the investment flexibility to provide
common equity, preferred stock, subordinated or secured debt which allows our portfolio
companies to fund working capital for organic growth, acquisitions, strategic IP licensing /
litigation activities or to facilitate distributions to existing shareholders. Our goal is to combine
our private equity investment experience and our value added intellectual property expertise to
be the premier investors for understanding the opportunities and risks associated with intellectual
property assets.
Altitude is well capitalized and positioned to provide a wide array of financial structures and
solutions through its committed private equity fund, Altitude Capital Partners, L.P. Our investors
include numerous hedge funds, family offices and other institutional and high net worth
investors. Altitude approaches each transaction as a partnership/strategic relationship, with no
pre-conceived economic structure or governance. We generally expect to realize value from our
investments through initial public offerings, strategic sales, passive receipts of royalty streams or
licensing outcomes.
Altitude's inter-disciplinary team has extensive intellectual property knowledge, and broad
transactional, licensing, litigation and private equity investment experience. Our due diligence
process utilizes our internal team and an extensive team of external economic consultants,
technical experts, business/management consultants and IP lawyers to provide expert analysis of

the assets and the market for those assets. This is critical for us as financial investors and can be
used as a valuable tool of unbiased judgment for our partners.
Altitude has the resources and abilities to craft solutions in all areas of Intellectual Property.
Altitude has experience in a myriad of industries and technologies including communications,
information technology, medical devices, pharmaceutical, manufacturing, computers,
biotechnology, e-commerce, software, entertainment, media, financial, automotive, network
security, wireless data communication and electronics.
Alvarez & Marsal

Two Liberty Square | Suite 300 | Boston MA 2109 | United States
Phone: (617) 449-7800 | Fax: (617) 449-7801 | Website: www.alvarezandmarsal.com
Contacts
Ms. Pauline Booth | Managing Director
Miss Amy Goot | Director
Company Overview
About Alvarez & Marsal Dispute Analysis & Forensic Services
For 25 years, Alvarez & Marsal has set the standard for working with organizations to solve
complex problems, boost performance and maximize value for stakeholders.
Alvarez & Marsal Dispute Analysis & Forensic Services provides sophisticated financial and
economic analysis to assist clients in resolving high-stakes issues ranging from internal matters
to litigation, as well as a range of analytical and investigative services to major law firms,
corporate counsel and management of companies, universities and research institutes involved in
complex financial disputes. As litigation becomes ever more technology-driven A&M focuses
experienced professionals on electronic discovery and data mining requirements for faster results
and insight.
Alvarez & Marsal's Licensing Advisory Services practice includes a team of experts who bring a
wide range of functional, industry and geographic experience in licensing and intellectual
property issues. Our senior professionals bring decades of expertise in license and contract
management, compliance, forensic accounting, intellectual property valuation and dispute
analysis to assist business to protect and maximize the value of IP. Our services include:
- License and Contract Management

- Risk Assessment and Compliance Programs
- License compliance inspections/royalty audits
- IP Valuation
- Dispute Analysis
- Expert Witness Testimony
- Technology Asset Management
Visit us at www.alvarezandmarsal.com
Licensors who require assistance with any of the following issues:
- managing, montoring or assessing licensee compliance including royalty audits
- license portfolio risk assessment
- IP valuation
- IP infringement damage analysis
American Express
200 Vesey Street, World Financial Center | 49th Floor | New York NY 10285 | United States
Phone: (212) 640-1473 | Fax: (212) 640-0361
Contacts
Mr. Tracey R. Thomas | Head Patent Counsel

American Red Cross

Holland Laboratory | 504 Scott Street | Rockville MD 21702-5012 | United States
Phone: 301/738-0861 | Fax: 301/738-0581
Contacts
Mr. Barry M. Datlof | Dir, Patents and Licensing
AmiCOUR International
111 South Stough Street | Hindale IL 60521-3016 | United States

Phone: 312.848-8488 | Fax: 202-904-2127 | Website: www.amicour.com
Contacts
Mr. Scott Bechtel | President
Mr. Ray Throckmorton | Senior Vice President
Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
AmiCOUR International LLC provides IP consulting and litigation support services in the
areas of technology, engineering, accounting/royalty auditing, patent brokering, and professional
tools. The company serves leading technology corporations, premier IP law firms, and renowned
educational and research institutions. In addition, the company's premier research tool,
sciRAPTOR, is capable or reading patent related text electronically in order to identify
related patents and potential licensees. Initial consultations are free and work may be performed
on a project or hourly basis.

AmiCOUR International LLC actively participates in the High Technology Sector committee
leadership and membership. The company supports the LES Certified Licensing Professional
(CLP) program, including developing professional tools and presenting workshops which
include information on best practices.


The AmiCOUR team invites portfolio managers and/or IP attorneys from corporations,
institutions, and law firms to discuss projects and AmiCOUR capabilities. IP managers with
active licenses are invited to meet with the AmiCOUR accounting/auditing team to discuss
license compliance and auditing needs. The AmiCOUR brokering team invites patent owners to
discuss the uniquely successful AmiCOUR approach to driving value from patents. In addition,
potential patent buyers are invited to meet with members of the AmiCOUR team to discuss
available patents and strategic portfolio needs.
Amicus Therapeutics
6 Cedar Brook Drive | Cranbury NJ 08512 | United States

Phone: (609) 662-2000 | Website: www.amicustherapeutics.com
Contacts
Mr. Bradley Campbell | VP Business Planning
Company Overview
Amicus Therapeutics (Nasdaq: FOLD), is a biopharmaceutical company developing small

molecule, orally-administered pharmacological chaperones for a range of genetic diseases.
Pharmacological chaperones are designed to selectively bind to and stabilize proteins in cells,
leading to improved protein folding and trafficking, and increased activity. Amicus is initially
targeting Fabry, Gaucher, and Pompe disease.
Anacor Pharmaceuticals
1020 East Meadow Circle | Palo Alto CA 94303 | United States

Phone: (650) 543-7525
Contacts
Dr. Karin M Hold | Director of Business Development
Organization Type

Industry Sector
Health Care
Company Overview
Anacor Pharmaceuticals is a biopharmaceutical company developing novel small-molecule

therapeutics derived from its boron chemistry platform to treat infectious and inflammatory
diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal for
the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. AN2690 is
expected to begin Phase 3 development by the end of 2008. Anacor also has a portfolio of other
topical product candidates in development for the treatment of psoriasis, gingivitis, acne, vaginal
candidiasis and tinea pedis. The company has entered into a worldwide license, development and
commercialization agreement with Schering for the development and commercialization of
AN2690 for all indications including the treatment of onychomycosis. In addition, Anacor
entered into a research and development agreement with GSK for novel antiviral and
antibacterial systemic therapeutics.
We are currently looking for companies interested in:
 Dermatology: We are currently seeking Ex-U.S. partnership opportunities for our

dermatology portfolio which includes products in preclinical and clinical for psoriasis,
tinea pedis and atopic dermatitis (AN2728, AN2898, AN2718).
 Autoimmune/Inflammation/Respiratory: We are currently seeking partnership and
R&D collaboration opportunities for systemic applications of our anti-inflammatory
compounds based on our boron chemistry platform.
 Oral care: We are currently looking for partnership opportunities for AN0128 for
potential use in oral care. AN0128 demonstrates dual anti-inflammatory and anti-
bacterial activity. We believe that this combination of antibiotic and anti-inflammatory
properties gives AN0128 the potential to treat a number of indications, including
gingivitis.
Meet companies interested in our pipeline of dermatology products and

Autoimmune/Inflammation/Respiratory products.

Analysis Group, Inc.
1899 Pennsylvania Ave NW | Suite 200 | Washington DC 20006 | United States

Phone: (202) 530-2004 | Fax: (202) 530-0436
Contacts
Mr. John Browning | Vice President
Ms. Carla Mulhern | Managing Principal
Anaqua, Inc.
The Prudential Tower | 800 Boylston Street, 44th Floor | Boston MA 02199 | United States
Phone: (617) 375-5808 | Fax: (617) 421-1511
Contacts
Mr. Mark Bullard | Business Development
Industry Sector
High Technology
Company Overview
Making IP a business matter, not just a legal matter
Anaqua provides Intellectual Asset Management software and services to help companies gain
competitive advantage from their intellectual property portfolios.
 Robust License Management capability designed to support both internal cross-licensing

and external licensing.Portfolio Management
 IP Business Intelligence
 Collaborative, Web-based Prosecution
Anaqua - The choice of global IP Leaders
Anaqua’s intellectual property management software is designed for all types of IP, including
patents, trade secrets, trademarks, domain names and copyrights. Anaqua manages the full

lifecycle of IP processes, from invention disclosure and review through patent filing and
prosecution to licensing and royalty collection. Its trademark management includes online search
request, search clearance, trademark application, registration and renewal as well as trademark
licensing. The ANAQUA solution incorporates modules for conflicts, agreements and general
matters. Unlike traditional docketing systems, the ANAQUA system is designed to enhance
business productivity for all participants in the IP management process – attorneys and
paralegals, researchers and engineers, portfolio managers, licensing professionals and other
business managers.

Anaqua is a software vendor providing IAM and licensing management software for IP-owning
enterprises.
Any company with significant IP in- or out-licensing activity.
Anaqua is looking to meet with companies with significant IP licensing activity who need better
license management infrastructure.

Partnering
ANAQUA n/a Not Applicable Worldwide
AngioDynamics, Inc.
603 Queensbury Avenue | Queensbury NY 12804 | United States

Phone: (518) 798-1215 ext 327 | Fax: (518) 798-3625 | Website: www.angiodynamics.com

Contacts
Mrs. Tina Barth-King | Intellectual Property/Technology Analyst
Applied Biosystems
850 Lincoln Center Drive | Foster City CA 94404 | United States

Phone: +1.650.554.3274 | Fax: +1.650.638.6081
Contacts
Mr. Charles Moehle | Senior Director of Licensing
Company Overview
About Applied Biosystems Inc.
Applied Biosystems Inc. (formerly known as Applera Corporation) is a global leader in the
development and marketing of instrument-based systems, consumables, software, and services
for academic research, the life science industry and commercial markets. Driven by its
employees' belief in the power of science to improve the human condition, the company
commercializes innovative technology solutions for DNA, RNA, protein and small molecule
analysis. Customers across the disciplines of academic and clinical research, pharmaceutical
research and manufacturing, forensic DNA analysis, and agricultural biotechnology use the
company’s tools and services to accelerate scientific discovery, improve processes related to
drug discovery and development, detect potentially pathogenic microorganisms, and identify
individuals based on DNA sources. Applied Biosystems has a comprehensive service and field
applications support team for a global installed base of high-performance genetic and protein
analysis solutions. Applied Biosystems Inc. had FY08 revenues of $2.2 billion and is
headquartered in Norwalk, CT. On June 12, 2008, Applera Corporation and Invitrogen
Corporation (NASDAQ: IVGN-NEWS) announced that their Boards of Directors had approved
a definitive merger agreement under which Invitrogen will acquire all of the outstanding shares
of Applied Biosystems stock. Ther merger is subject to customary closing conditions and is
targeted to close in the fall of 2008.
Arcion Therapeutics Inc
2400 Boston St | Suite 330 | Baltimore MD 21224 | United States

Phone: 410 522 8701 | Fax: (443) 836-0451 | Website: www.arciontherapeutics.com

Contacts
Ms. Kerrie L Brady | COO
Organization Type
Industry Sector
Health Care
Company Overview
Arcion Therapeutics Inc. is a clinical stage company focused on the development of new,
targeted treatments for severe pain. Arcion has a pipeline of products being developed for the
treatment of painful diabetic neuropathy, post-herpetic neuralgia and other forms of moderate to
severe pain.
Arena Pharmaceuticals, Inc.
6166 Nancy Ridge Drive | San Diego CA 92121-3223 | United States

Phone: 858. 453.7200 ext 302 | Fax: 858. 453.7210 | Website: www.arenapharm.com
Contacts
Mr. Louis J. Scotti | Vice President, Marketing & Business Development
Organization Type
Industry Sector
Health Care
Company Overview
Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and
commercializing innovative oral drugs for patients with serious diseases and disorders, such as
obesity and insomnia. We have a diverse portfolio of drug candidates, both proprietary and
partnered. Our lead proprietary drug candidate, lorcaserin hydrochloride, is intended for the
treatment of obesity and is being evaluated in a Phase 3 clinical program.

Arizona State University
699 S. Mill Avenue | Suite 601, Room 691AA | Tempe AZ 85042 | United States
Phone: (480) 965-6158 | Fax: (480) 965-0421
Contacts
Mr. William Loux | Director of Business Development
Organization Type
University
Industry Sector
Company Overview
Arizona Science and Technology Enterprises LLC (AzTE) was established in 2003 as an
Arizona Limited Liability company with the ASU Foundation as its sole member. Pursuant to
agreements with Arizona State University, AzTE operates as the exclusive intellectual property
management and technology transfer organization for ASU. AzTE conducts its activities on
behalf of ASU in accordance with policies of the Arizona Board of Regents and ASU. AzTE also
collaborates with other universities on technology transfer.
The AzTE executive team is comprised of industry and university veterans with years of
professional experience in:
 technology evaluation
 product development
 technology marketing
 capital formation
 operations/management
 IP protection
 industry relationships
 licensing & commercialization

Arizona Technology Enterprises, LLC
699 South Mill Avenue, Suite 601 | The Brickyard, Room 691AA | Tempe AZ 85281 | United
States
Phone: (480) 965-5670 | Fax: (480) 965-0421
Contacts
Dr. Thomas Goodman | Director of Business Development, Life Sciences
Organization Type
University
Industry Sector
High Technology
Company Overview
Arizona Technology Enterprises at Arizona State University works with university inventors and
industry to transform scientific progress into products and services. Arizona Technology
Enterprises transfers technologies invented at ASU to the private sector by mining university
research, prosecuting patents, negotiating licenses, and marketing inventions. Technology
transfer benefits the public by contributing to new product creation and new economic
opportunities. Technology transfer facilitates ASU’s efforts to attract and retain superior faculty
and graduate recruitment, while returning income to the inventor and the University to support
ongoing research.
Artificial Muscle, Inc.
925 Hamilton Ave. | Menlo Park CA 94025 | United States

Phone: (650) 331-2893 | Fax: (650) 331-2877
Contacts
Dr. JOHN BASHKIN | BUSINESS DEVELOPMENT DIR, MEDICAL SECTOR
Organization Type

Industry Sector
High Technology
Company Overview
Artificial Muscle, Inc. (AMI) designs and manufactures actuators and sensors based on its
proprietary electroactive polymer artificial muscle (EPAM) technology. EPAM devices are
lightweight, virtually silent, and highly power efficient alternatives to traditional electromagnetic
actuators, small motors, generators, and sensors. AMI serves a multi-billion dollar market with
artificial muscle-based components for consumer product, medical, industrial, automotive,
aerospace and cleantech applications.

Consumer electronics, medical device and pharmaceutical companies. AMI clients include those
companies looking for new actuator and sensor technologies that offer lower cost with improved
performacne and an enhanced user experience wiht products that are silent duriing operation,
generate virtually no heat, and power efficient.

AMI hopes to expand its contacts in the cnsumer electronics and medical device industries and,
through thse contacts, explore opportunities for inclusion of AMI components in innovative
products on an OEM basis.

Partnering
EPAM
n/a Not Applicable
Actuators
ASRC Research and Technology Solutions
NASA's GSFC Mail Code 504 | 8800 Greenbelt Road | Greenbelt MD 20771 | United States
Phone: (301) 286-3487 | Fax: (301) 286-0301

Contacts
Mrs. Mary M. Stahl | Technology Transfer Engineer
Astellas US LLC
Three Parkway North | Deerfield IL 60015 | United States

Phone: (847) 317-8948 | Fax: (847) 317-5977
Contacts
Mr. Gary Gabrielsen | Vice-President, Business Development
Mr. Kohei Kishi | Assistant Director, Business Development
Organization Type
Industry Sector
Health Care
Company Overview
Astellas US LLC is a US subsidiary of Astellas Pharma Inc, which was established as a merger
of two big Japanese Pharma, Yamanouchi and Fujisawa, in April of 2005, and is now second
largest Japanese pharmaceutical company (Global net sales is $8.5Bn in 2007).
Astellas US has achieved a rapid growth in the US market and its sales is $1.7Bn in 2007.
Astellas US is currently focusing on 5 therapeutic areas;

Transplant/Immunology: Prograf
Urology: VESIcare, Flomax
Cardiovasculr: Adenoscan, Lexiscan, Vaprisol
Infectious Disease: Mycamine, AmBisome
Dermatology: Protopic, Amevive
AstraZeneca
P.O. Box 15437 | Wilmington DE 19850 | United States

Phone: 1 302 886 3000

Contacts
Mr. Johan Hoegstadt | Vice President, Neuroscience SPBD
AtheroGenics, Inc.
8995 Westside Pkwy | Alpharetta Georgia 30004 | United States

Phone: 678-336-2500 | Fax: 678-336-2501 | Website: www.atherogenics.com
Contacts
Mr. Philip J. Krape | Senior Director Business Development
Dr. William C. Montgomery | Sr. VP, Business Development & Alliance Mgmt
Company Overview
AtheroGenics is focused on the discovery, development and commercialization of novel drugs

for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease
(atherosclerosis). AtheroGenics has commenced enrollment in a Phase III clinical trial called
ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study) to study its lead drug
candidate AGI-1067 as an oral therapy for the treatment of diabetes. In addition, the Company
has a development program studying AGI-1096, an oral agent in Phase I that is being developed
for the prevention of organ transplant rejection in collaboration with Astellas. For more
information about AtheroGenics, please visit http://www.atherogenics.com.

Partnering
AGI-1067 n/a Not Applicable
Atomic Energy of Canada Limited
Chalk River Laboratories | Chalk River ON K0J 1J0 | Canada

Phone: (613) 548-3311 | Fax: (613) 584-1812 | Website: ww.aecl.ca

Contacts
Mr. Theodore J. Chiasson | Manager, Intellectual Property Operations
Organization Type
Government Agency or Laboratory
Industry Sector
Energy
Auburn University
Office of Technology Transfer | 215 East Thach Avenue | Auburn AL 36830 | United States
Phone: 334-844-7962 | Fax: 334-844-5963 | Website: ott.auburn.edu/
Contacts
Dr. Brian A. Wright | Associate Director for Commercialization
Organization Type
University
Industry Sector
Industry/University/Government Transactions
Company Overview
The primary goal of the Office of Technology Transfer at Auburn University is to create an
environment which will (1) encourage the creation of technology-based intellectual property at
Auburn, (2) manage this intellectual property to promote its adoption by industry and (3) foster a
close and productive relationship between Auburn researchers and industry.

Out licensing, research collaborations.

Auburn University is a public land grant university, with particular interests in engineering,

agriculture, veterinary medicine (animal health), biotechnology, nanotechnology, electronics &

information technology, wireless communications, software, materials, sensors, homeland
security, pharmaceuticals & therapeutics, aquaculture, poultry science and transportation
technology. We are generally interested in meeting with any companies in those areas.

Professional advancement from the sessions and quality networking opportunities to meet
potential licensing and collaboration partners.
Avid Technology, Inc.
Avid Technology Park | 1 Park West | Tewksbury MA 1876 | United States

Phone: (978) 640-6789
Contacts
Mr. Jason A. Duva | Director, Intellectual Property
AXCAN PHARMA
721 Route 202/206 South | Bridgewater New Jersey 08807 | United States
Phone: 908-672-0904
Contacts
Mr. Reda Ayache | Senior Director, Business Development
Organization Type
Industry Sector
Health Care
Company Overview
Axcan Pharma is a leading specialty pharmaceutical company that develops and markets a wide
range of products to treat gastrointestinal diseases and disorders, such as inflammatory bowel
disease, cholestatic liver diseases, irritable bowel syndrome, and complications related to

pancreatic insufficiency. All Axcan’s activities underscore the Company's single, well-defined
Mission - to improve the quality of care and health of patients suffering from gastrointestinal
diseases and disorders by providing effective therapies for patients and their specialized
caregivers.
Baker & McKenzie
Level 27, A.M.P. Centre | 50 Bridge Street | Sydney NSW 2000 | Australia
Phone: +61 2 9225 0200 | Fax: +61 2 9225 1595
Contacts
Ms. Margarita Divina | Lawyer
Company Overview
Baker & McKenzie provides sophisticated legal advice and services to the world's most dynamic
global enterprises and has done so for more than 50 years. Our network of lawyers is among the
world's most diverse; with over 3,600 locally qualified, globally experienced lawyers operating
in 38 countries and 70 offices.
Our offices in Sydney and Melbourne work with major Australian businesses and international
companies operating in Australia. With 85 partners and over 215 lawyers, we have the critical
mass to work on the most demanding of projects.
Baker Botts
30 Rockefeller Plaza | 45th Floor | New York NY 10112 | United States

Phone: (212) 408-2535
Contacts
Mr. Steven P. Lendaris |

Banner & Witcoff, Ltd.
1100 13th Street, NW | Suite 1200 | Washington DC 20005-4051 | United States

Phone: (202) 824-3223 | Fax: (202) 824-3723
Contacts
Mr. Gary Fedorochko | Shareholder
Barnes & Thornburg LLP
1 North Wacker Drive | Suite 4400 | Chicago IL 60606 | United States

Phone: (312) 338-5917 | Fax: (312) 759-5646
Contacts
Mr. William M. Lee | Attorney & Counselor
Mr. Mark J. Nahnsen | Attorney
BASF SE
ED/DN - H 201 | Ludwigshafen 67056 | Germany

Phone: +49 173 3479245 | Website: www.basf.com
Contacts
Mr. Christian Beil | Manager
Organization Type
Industry Sector
Chemicals
Company Overview

BASF at a glance
In its business segments, BASF posted sales of €58,0 billion in 2007. Our strategic goal is to
continue to grow profitably. Around 95,000 employees on five continents are the key to our
success.
Profile
We have focused our business even more closely on our customers.

Our segments
 Chemicals
 Plastics
 Performance Products
 Functional Solutions
 Agricultural Solutions
 Oil & Gas
have been restructured according to related products, customer industries and production
processes. This will enable us to more effectively combine our competencies and knowledge and
bring our products and system solutions faster to market. In addition, our investors will be better
able to assess BASF.
We combine economic success with social responsibility and environmental protection. We

make our contribution to finding the answers for global challenges, such as climate protection,
energy efficiency, nutrition and mobility.

in- and out-licensing
Basham, Ringe & Correa, S.C.
Paseo de los Tamarindos 400-A | 9th Floor. Col. Bosques de las Lomas | Mexico,
D.F. 5120 | Mexico
Phone: +52 55 5261 0448 | Fax: +52 55 5261 5338

Contacts
Mr. Eduardo Kleinberg Drucker |
Bausch & Lomb
1400 N Goodman Street | Rochester NY 14609 | United States

Phone: +1.585.338.5129 | Fax: +1.585.338.0380 | Website: www.bausch.com
Contacts
Mrs. Cynthia Edington | Manager, Business Development
Dr. Zhenze Hu | Director of Pharmaceutical Evaluation and Licensing
Company Overview
Bausch & Lomb is the eye health company, dedicated to perfecting vision and enhancing life for
consumers around the world. Its core products include soft and rigid gas permeable contact
lenses and lens care products, and ophthalmic surgical and pharmaceutical products. The Bausch
& Lomb name is one of the best known and most respected healthcare brands in the world.
Bausch & Lomb manages its commercial operations on a regional basis and the research and
development and product supply functions are managed on a global basis. The company markets
five broad categories of products:
Contact Lenses: Sales of contact lenses represented 30% of consolidated 2004 revenues. The
company's contact lens offerings span the entire spectrum of wearing modalities and include
such well-known brand names as PureVision, SofLens66 Toric, SofLens One Day, SofLens
Comfort, SofLens Multi-Focal, Boston and Optima FW.
Lens Care: The sale of contact lens care solutions represented 23% of consolidated 2004
revenues. The company's lens care products include the ReNu brand of chemical disinfectants as
well as the Sensitive Eyes and the Boston lines of products for cleaning contact lenses.
Pharmaceuticals: Sales of pharmaceuticals products accounted for 24% of consolidated 2004

revenues. The company's offerings include generic and proprietary prescription pharmaceuticals,
over-the-counter eye drops and other medications. Offerings in the prescription/proprietary
category include Lotemax, Alrex and Zylet, the company's lines of steroid eye drops; and outside
the U.S., carteol, a non-selective beta blocker; Minims preservative-free, single-dose drops; and
Liposic ointment for dry eye. In the over-the-counter segment the company's leading products
include the Ocuvite and PreserVision lines of ocular vitamins.

Cataract and Vitreoretinal Surgery: Products used for cataract and vitreoretinal surgery
procedures accounted for 16% of consolidated 2004 revenues. The company offers a full suite of
products in this area, including intraocular lenses and delivery systems, the Millennium line of
phacoemulsification equipment, and other surgical devices and instruments.
Refractive Surgery: Sales of products used in refractive surgery accounted for 7% of

consolidated 2004 revenues. Offerings in this area include the Zyoptix system for personalized
vision correction (customized LASIK) and the Hansatome microkeratome.
The Company is headquartered in Rochester, New York. Bausch & Lomb's 2004 revenues were
$2.2 billion; it employs approximately 12,400 people worldwide and its products are available in
more than 100 countries.
Bayer Animal Health
P.O. Box 390 | Shawnee Mission KS 66201 | United States

Phone: (913) 268-2073 | Fax: (913) 268-2541
Contacts
Dr. Stuart Nibbelink | Technology Manager
Organization Type
Industry Sector
Health Care
Company Overview
Bayer HealthCare, LLC, Animal Health Division, is a leader in providing quality veterinary
products for both companion animals and food animals. Our goal is to develop first or best-in-
class therapeutics that will positively impact veterinary care.
Tech Transfer
University Research
Technology Collaboration/In-licensing

Bayer HealthCare Pharmaceuticals
800 Dwight Way, P.O. Box 1986 | Berkeley CA 94701 | United States
Phone: 510-705-5000
Contacts
Dr. Alfred G. Amend |
Mr. Kevin Johnston | Mgr., Business Development
Mr. Kevin Kuehm | VP Global Transactions
Company Overview
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer

HealthCare LLC, a division of Bayer AG. In the United States, Bayer HealthCare
Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic
Imaging, Specialized Therapeutics, Hematology/Cardiology and Oncology. The company's aim
is to discover and manufacture products that will improve human health worldwide by
diagnosing, preventing and treating diseases.
Bayer Healthcare Pharmaceuticals [Canada]
77 Belfield Road | Toronto Ontario M9W 1G6 | Canada

Phone: 416.240.5316
Contacts
Ms. Lise V. Taylor | Manager, New Business Opportunities
Company Overview
Bayer HealthCare Pharmaceuticals Inc. is the Canadian pharmaceuticals unit of Bayer AG. In
Canada, Bayer HealthCare Pharmaceuticals is focussed in Women's Healthcare, Diagnostic
Imaging, Specialized Therapeutics, Hematology/Cardiology, Anti-infectives and Oncology. The
company's aim is to discover and manufacture products that will improve human health
worldwide by diagnosing, preventing and treating diseases.


Bayer Healthcare Pharmaceuticals has local discretion to in-license for Canada late stage
products in our areas of therapeutic focus.
Bayer Schering Pharma AG
Muellerstrasse 178 | Berlin 13342 | Germany

Phone: +49.30.468.15275 | Fax: +49.30.468.95275 | Website: www.bayerscheringpharma.de
Contacts
Dr. Daniel Horn | Senior Director Global Transactions
Dr. Michael A. Yeomans | Senior Vice President Global Business Development & Licensing
Company Overview
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research
and business activities are focused on the following areas: Diagnostic Imaging,
Hematology/Cardiology, Oncology, Primary Care, Specialized Therapeutics and Womens
Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in
specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a
contribution to medical progress and strives to improve the quality of life. Find mor information
at www.bayerscheringpharma.de
BD
1 Becton Drive MC305 | Franklin Lakes NJ 7417 | United States

Phone: (201) 847-4555 | Fax: (201) 847-4851
Contacts
Ms. Susan Chan |

Becerril, Coca & Becerril, S.C.
Thiers No. 251, 9 to 14th Floors and PH | Col. Anzures | Mexico, D.F. 11590 | Mexico
Phone: +(52 55) 5263 8730 | Fax: +(52 55) 5263 8731 | Website: www.bcb.com.mx
Contacts
Mr. Hector E. Chagoya Cortes | Technology Analysis & Transfer, Manager
Mr. Jose Antonio Romero | Director of Licensing
Organization Type
Consulting Firm
Company Overview
WE ARE CELEBRATING OUR 40th ANNIVERSARY
The mission of our Firm is to be a leader in the market of Intellectual Property and Technology
Transfer services having at the same time a deeply humanistic organization that promotes a high
feeling of identity among its members towards the Firm, and a propositive philosophy boosting
our aim to spread the Intellectual Property culture in favor of the economic and intellectual
development of our country.
BC&B has patent agents expert in all areas of technology (IT-communications, biotechnology,
chemistry, mechanical, consumer products, electronics, etc.) and has a strong team of attorneys
at law for other IP rights and litigation, as well as a highly skilled in-house translation team with
technical background. BC&B is not only engaged in the prosecution and enforcement of all
kinds of intellectual property rigths, but also in business oriented activities such as technology
licensing, patent searches and competitive intelligence, due dilligence for technology
transfer, valuation, documentation of trade secrets and drafting of patent applications and
agreements.

BC&B is interested in serving as a bridge between companies and corporations in developed
countries with Mexican and Latin American companies through technology transfer by
simplifying communication, as well as in helping companies to take the best advantage of the IP
systems of Mexico and Latin America.

1. People interested in seeking opportunities for R&D investment at low cost by using the
Mexican or other Latin American R&D systems, as an option for cost effective R&D as an
outsourced activity in every field of technology.
2. People interested generally in acquiring intellectual property in Mexico or Latin America.
3. People interested in gaving a skilled interlocutor for conducting technology transfer activities
or negotiations with Mexican or Latin American entities.
Providing information on the Mexican and Latin American IP and R&D systems and inform
about the practice related to IP prosecution, enforcement and technology transfer in Mexico and
Latin America.
Becton Dickinson Pty Ltd
4 Research Park Drive, Macquarie Research Park Par | North Ryde New South Wales Australia
Phone: +61 2 8875 7000 | Fax: +61 2 8875 7100
Contacts
Ms. Christina E. Braden-Moore | Manager, Global Business Development
Company Overview
BD, a leading global medical technology company that makes and sells medical devices,
instrumented systems and reagents, is dedicated to improving peoples health throughout the
world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing
infectious diseases, and advancing research and discovery of new drugs and vaccines. The
Companys capabilities are instrumental in combating many of the worlds most pressing diseases.
Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs more than
25,000 people in approximately 50 countries throughout the world. The Company serves
healthcare institutions, life science researchers, clinical laboratories, industry and the general
public. For more information, please visit www.bd.com.

Bereskin & Parr
600 Boul. de Maisonneuve Ouest | Suite 2800 | Montreal QC H3A 2J2 | Canada
Phone: 514-868-0203 | Fax: 514-868-0208 | Website: www.bereskinparr.com
Contacts
Mr. Philip L. Conrad |
Ms. France Côté | Patent Agent/Partner
Organization Type
Law Firm
Company Overview
Bereskin & Parr is a leading Canadian intellectual property law firm and serves clients in over
100 countries worldwide. With its 200 people, including more than 75 lawyers, patent and trade
mark agents, and technical consultants, Bereskin & Parr is consistently rated in Canada as the
market benchmark for intellectual property law. The firm’s hallmarks of delivering the highest
levels of excellence, integrity and professionalism provide clients with customized solutions for
the use, licensing, protection and enforcement of patents, trade marks, copyright, industrial
designs, and trade secrets, as well as issues including transactions, portfolio management,
packaging requirements, promotional and advertising claims. With depth of experience and
diverse technical backgrounds, Bereskin & Parr offers focused, timely advice and practical, cost-
effective results.
Bereskin & Parr was founded in 1965, and has offices in Toronto, Mississauga, Waterloo region
and Montréal. Further information about Bereskin & Parr and its approach to intellectual
property law can be found at www.bereskinparr.com.

Bereskin & Parr assists corporations in registering their intellectual property rights (patents, trade
marks, copyright, industrial designs) and in licensing these rights to others.

Firms or corporations interested in registering or licensing intellectual property rights in Canada.
Please feel free to contact France Côté (fcote@bereskinparr.com) or Philip Conrad

(pconrad@bereskinparr.com) if you would like to arrange a meeting to discuss options for

registering or licensing intellectual property rights in Canada.
Berkshire Group
P.O. Box 237 | West Hurley NY 12491 | United States

Phone: (845) 679-2815 | Fax: (845) 679-6111 | Website: www.berkshiregroupulster.com
Contacts
Mr. Gerald A. Habib | Principal
Bingham McCutchen LLP
2020 K. Street NW | Washington DC 20006-1806 | United States

Phone: (202) 373-6091 | Fax: (202) 373-6001 | Website: www.bingham.com
Contacts
Dr. Malcolm McGowan | Partner
Organization Type
Law Firm
We provide a full range of services to help develop, manage and protect our clients'
intellectual property assets, from obtaining patents, trademarks and copyrights to
addressing related legal challenges.
Bingham has over 115 litigators, prosecutors and transactional lawyers practicing in centers of
business and technology across the United States and in London, Hong Kong and Tokyo. These
include the foremost authorities on U.S. district court patent litigation and Federal Circuit
appeals as well as on International Trade Commission proceedings, interference actions and
reexaminations.
We are highly skilled in complex litigation and patent, trademark, copyright and trade secret law;
30 of our litigators are admitted to practice before the U.S. Patent and Trademark Office. And,
just as critically, we offer former managers, engineers and professionals from research

institutions, technology companies, universities and medical centers. We also have five lawyers
with Ph.D.s and 35 lawyers with scientific or technical degrees.
Our team brings this winning combination of legal experience, technical know-how and passion
for the work to the following areas:
Litigation
 Patent Litigation
 Trade Secret Litigation
 Patent Interferences
 Trademark, Trade Dress, Lanham Act and Domain Name Litigation
 International Trade Commission
 Copyright Litigation
Prosecution
 Patent Assessment and Protection

 Trademarks, Trade Dress and Domain Names
 Pre-Litigation Investigations
 Counseling
Transactional
 Licensing
 Distribution Deals
 Technology Transfers
 Systems Integration
 Development Arrangements
 Outsourcing
BioConsult Hebert Rousseau, Inc.
740, 50th Avenue | Lachine QC H8T 2T8 | Canada

Phone: (514) 637-6287 | Fax: (514) 637-4674 | Website: www.bioconsulthr.com/
Contacts
Dr. Benoît Hébert | President / Consultant

Organization Type
Consulting Firm
Industry Sector
Health Care
Company Overview
BioConsult Hebert Rousseau Inc. specializes in functions related to business development,

licensing (BD&L) and strategic planning. We can support your BD&L team in its licensing
activities or support management teams that have no internal BD&L functions.
Company Specialization & Expertise

 In/Out Licensing
 Acquisitions/Divestments
 Portfolio Planning
 Strategic Planning
 Product/Technology (RE)positioning
 Technology Benchmarking
 Business Proposition Analysis
 Due Diligence Management
 Negotiations

Companies looking for distributors of pediatric products in the Canadian market.
 Client recruitment
 In-license / distribution agreements of pediatric products for Canadian territory
 Equity financing for clients
o Kalgene: phase III oncology product;
o GI Newco:
 Project #1: Clinical stage, drug repositioning in hepatology
 Project #2: Late non-clinical stage for Celiac disease project
 Out-licensing of client projects

Bio-I.P. Management Co.
1144 Glen Ellen Place | San Marcos CA 92078 | United States

Phone: +1.858.349.0950
Contacts
Dr. Vasu Pestonjamasp | Principal
Industry Sector
Health Care
Company Overview
Vasu Pestonjamasp, Ph.D. is the Managing Director of Bio-I.P. Management Co., a San Diego-
based consulting firm specializing in scientific, technical, and business-related writing, and
advising about business development/marketing strategies in various areas. Vasu has been the
originator, organizer, and Chair/Co-chair of various business events.
Vasu completed her postdoctoral research at Harvard Medical School and the University of
California San Diego (UCSD), and also did project work at the University of Massachusetts
Medical Center in Worcester, Massachusetts.
Vasu received her Ph.D. from Cancer Research Institute/Tata Memorial Center, Bombay, India,
which is an affiliate of MD Anderson Cancer Center, Texas, USA.
Vasu is currently the Chair-Elect and Sponsorship Chair for Licensing Executives Society's San
Diego Chapter, and also held the positions of Program Committee Chair (2006-2007) and Co-
Chair (2005-2006).

Biotech and pharma companies, service providers.
Marketing agreements, market research, in-licensing, research collaborations, finding customers

or services.

BioMarin Pharmaceutical Inc
105 Digital Drive | Novato CA 94949 | United States

Phone: (415) 506-6700 | Fax: (415) 382-7427 | Website: www.bmrn.com
Contacts
Mr. Joshua Grass | Senior Director Business and Corporate Development
Organization Type
Industry Sector
Health Care
Company Overview
Company Overview
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and
medical conditions. The company focuses primarily on developing first-to-market therapeutics
for rare genetic and metabolic diseases. BioMarin is seeking partners to develop innovative
products searching specialist markets in a range of therapeutic areas.
With three growing products on the market, BioMarin has transitioned from a product
development-focused company to a fully integrated commercial biopharmaceutical company
with growing revenues and an exciting product pipeline.
BioMarin’s core competency is its ability to identify and quickly advance therapeutic drug
candidates from research through clinical development to commercialization. Our development
efforts have produced two unique enzyme replacement therapies, Aldurazyme and Naglazyme
for the serious genetic diseases MPS I and MPS VI, respectively and more recently the
small molecule therapeutic, Kuvan, for phenylketonuria.
More recently we have demonstrated our ability to successfully launch and commercialize new
therapeutics on a global scale. In 2006 and 2007, BioMarin established its commercial presence
in the United States, Europe and Latin America. Outside of these territories BioMarin has

established relationships with key distributors in order to reach patients in other international
markets.
Current Alliances
• Partnership with Merck Serono for the development and commercialization of Kuvan™
(sapropterin dihydrochloride) and Phenylase™ for the treatment of PKU as well as other
indications, including diseases involving vascular dysfunction. BioMarin retains all U.S. rights;
Serono has all Ex-U.S. rights (excluding Japan).
• Partnership with Daiichi Suntory Pharma Co., Ltd for extensive preclinical and clinical data on
6R-BH4 and access to commercial grade 6R-BH4.
• Partnership with Merck Eprova AG, a subsidiary of Merck KGaA for intellectual property
relating to the manufacturing of Kuvan™ for PKU.
• Joint venture with Genzyme Corporation for the development and commercialization of
Aldurazyme® worldwide. BioMarin is responsible for manufacturing Aldurazyme® and
Genzyme is responsible for sales and marketing.
Intellectual Property Status
BioMarin has 285 issued patents, including approximately 35 patents issued by the U.S. Patent
and Trademark Office. BioMarin's portfolio of pending patent applications totals 190
applications, including approximately 40 pending U.S. applications.

Patents, trademarks, tech transfer, valuation, intellectual asset management, university research.

All interested parties

In-licensing, out-licensing, research collaborations, marketing agreements, finding customers or

services.
BioMatch, LLC
P.O. Box 14713 | Research Triangle Park NC 27707 | United States

Phone: (919) 680-4466 | Fax: (919) 680-4477
Contacts
Ms. Julia Barnes-Weise | Managing Member
Organization Type
Industry Sector
Health Care
Company Overview
We are an experienced, well-connected business development and licensing consultancy.

Health care product licensing
Pharmaceutical and biotech companies interested in working with an external business

development consultant (CLP)
We would like to meet with companies who are looking for experienced business development
professionals (CLP) to assist with their licensing and business development needs.


Partnering
Licensing
n/a Not Applicable North America
opportunities
BioSante Pharmaceuticals
111 Barclay Boulevard | Lincolnshire IL 60069 | United States

Phone: (847) 478-0500 x115 | Website: www.biosantepharma.com
Contacts
Mrs. Joy A. Thomas | VP Corporate Development
Organization Type
Industry Sector
Health Care
Company Overview
BioSante is a specialty pharmaceutical company focused on developing products for female
sexual health, menopause, contraception and male hypogonadism. BioSante's lead products
include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante
under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the
treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through
FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor
symptoms associated with menopause, currently marketed in the U.S. Also in development are
Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II
clinical development using BioSante patented technology. The current market in the U.S. for
estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives
approximately $3.0 billion. The company also is developing its calcium phosphate technology
(CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional
information is available online at www.biosantepharma.com.


Partnering
LibiGel n/a Not Applicable North America, China, Israel
Biovail Pharmaceuticals, Inc.
700 Route 202/206 North | Bridgewater NJ 8807 | United States

Phone: (908) 927-1843 | Fax: (908) 927-1443 | Website: www.biovail.com
Contacts
Dr. Rajiv Khosla | V.P. Technology Licensing & Alliances
Ms. Christine C. Mayer | Senior Vice Pres., Business Development Services
BioXcel Corporation
228 Village Pond Rd | P.O. Box 0306 | Guilford, CT 06437 | United States
Phone: +1 203-458-1435 | Website: www.bioxcel.com
Contacts
Dr. Krishnan Nandabalan | CEO & President
Company Overview
BIOXCEL CORPORATE PROFILE
Analytics Driving DecisionsTM
BioXcel is your Global Commercial Partner for analytics support throughout the biopharma/life
sciences/healthcare and related industries.

Our US-based executives work seamlessly with the BioXcel Analytical and Commercial Center
(BACC) based in India to provide scientific and business support in the following areas:
 Licensing/due-diligence
 Competitive intelligence
 IP assessment
 R&D portfolio management
 Market research/expansion
 Product launch in India
 Investment assessment
 Equity research
This is accomplished through flexible analytics teams (MS-level analysts, MBAs, PhDs, MDs,
patent agents) that save your internal, “core” personnel for other key activities.
BioXcel’s R&D Innovation Map of Pan-Asian Countries provides information on licensing

opportunities, technology platforms, key partnerships, and financial profiles in the Asian
biopharma and life sciences marketplace. In addition, our Intelligence Group (Xcel*IntelTM)
offers support for investment risk analysis, corporate alliances, and outsourcing in the Indian
market place.
We serve >50 customers world-wide, including, in the US: Eli Lilly, Alexion, Idenix, Trubion,
Canaan Partners; in the UK: Vectura, Plethora; and in Europe: Merck-Serono, Actelion, Palau,
and Santhera.
BioXcel delivers unique value through our scalable “Commercial Engine”
and relevant technological and business expertise.
http://bioxcel.com/

Blaney McMurtry LLP
2 Queen Street West | Suite 1500 | Toronto ON M5C 3G5 | Canada

Phone: (416) 593-1221 | Fax: (416) 593-5437 | Website: www.blaney.com
Contacts
Mr. Bruno P. Soucy | Lawyer
Organization Type
Law Firm
Company Overview
Based in the heart of Toronto’s financial and business district and backed by over 115 lawyers,
Blaney McMurtry recently celebrated its 50th year of helping clients overcome challenges and
seize opportunities.
A Blaney McMurtry lawyer takes the time to understand your needs and concerns. Our aim is to
find the right solution for you. Quickly. Cost-effectively.
Our business clients appreciate Blaney McMurtry's depth of experience, creativity, and expertise
in both litigation and business law. Our private clients appreciate Blaney McMurtry's
comprehensive, yet personalized approach to advice and representation — whether it's dispute
settlement or estate planning.
Serving Clients Around the World
Blaney McMurtry reaches across borders for assistance in representing clients' interests
anywhere in the world. As part of the TAGLaw network, we have access to the resources and
expertise of leading lawyers in every province of Canada, as well as in major centres throughout
the United States, and globally.
Our Service Philosophy
Blaney McMurtry is not like other firms. We’ve charted a course that’s different. We’re trusted
advisors, not just legal technicians. What sets us apart from many firms and other lawyers is our
track record in actually working within this philosophy.

We recognize that in addition to the requisite legal knowledge and expertise, in order for there to
be a good working relationship, it is necessary for a law firm and its client to have a compatible
work ethic and style.
Keeping this in mind, it is our practice to identify a specific partner within the firm to be
responsible for the client’s work, liaising with the client or its in-house counsel, in all matters
that arise during the conduct of the client’s business.
In certain situations, the legal work may be done by a junior lawyer or clerk, or with assistance
from a lawyer in a related practice area, bearing in mind the nature and complexity of the issues
involved. The client is kept informed at all times when a decision is taken to have another
member of the firm involved, and the client’s input is sought and encouraged before any such
decision is made.

Practice Areas:
Aboriginal
Alternative Dispute Resolution
Architectural/Construction/Engineering
Aviation
Business Reorganization & Insolvency
Class Actions
Commercial Litigation
Corporate/Commercial
Corporate Finance & Securities
Corporate Insurance
E-Commerce
Entertainment Law
Environmental
Family/Matrimonial
Government Procurement & Litigation

Immigration
Information Technology
Insurance Coverage Counsel
Insurance Defence Litigation
Intellectual Property
Labour & Employment
Life Sciences
Municipal, Planning & Expropriation
Privacy
Real Estate & Leasing
Sports Law

Tax
Wills & Estates

Our firm acts and represents both institutional clients as well as owner-managed businesses.
Blu Networks
Level 16, 1 Sentral | Jalan Stesen Sentral 5 KL 50470 | Malaysia

Phone: -2904 | Fax: -10690
Contacts
Dr. Rafi Daud | Senior Vice President- Intellectual Property
Boehmert & Boehmert
Pettenkoferstr. 20-22 | Munich Bavaria 80336 | Germany

Phone: +49-89-559680 | Fax: +49-89-347010
Contacts
Dr. Jan Krauss | Patent Attorney
Dr. Dorothe Weber-Bruls | Patent Attorney
Boliven LLC
488 Madison Avenue | 8th Floor | New York City NY 10022 | United States
Phone: (646) 710-3916 | Fax: (646) 710-3901 | Website: www.boliven.com
Contacts
Mr. Ryan Bloom | Vice President

Organization Type
Consulting Firm
Company Overview
Our mission is to advance innovation and the common good
Our vision is to help leading inventors and entrepreneurs connect and collaborate with the
information and professionals they need to innovate and to succeed.
What is Boliven?
Boliven is a trusted community of leading innovators -- distinguished scientists, inventors, and

entrepreneurs that have built and are building great companies, seasoned patent attorneys and
intellectual property professionals, directors and licensing professionals at top technology
transfer offices, and world class venture investors.
To enhance the trustedness and privacy of the community, Boliven is open only by invitation of
existing members. When you join Boliven, you create a profile that enables you to identify your
educational and professional background. You have complete control over your profile and may
elect to share it with other Boliven members, just your collaborators, or keep it entirely private.
We believe that you should be in control of who, if anyone, gets to see your professional profile
or knows whether or not you're using Boliven.
As a member of Boliven, you can:
 Search and analyze patent information from the U.S. Patent and Trademark Office, the
European Patent Office, and Japan Patent Office.
 Find patent attorneys and agents who can advise you regarding your innovative ideas,
enhancing your freedom to operate, and streamlining your licensing agreements.
 Invite your trusted colleagues to join your network of trusted collaborators on Boliven
and share intellectual property and patent-related information with them in a secure
environment.

At Boliven, we are interested in connecting with a host of people including inventors,
entrepreneurs, tech transfer, patent, and licensing professionals.

Borden Ladner Gervais LLP
1200 Waterfront Centre | 200 Burrard St. P.O. Box 48600 | Vancouver BC V7X 1T2 | Canada
Phone: +1.604.687.5744 | Fax: +1.604.687.1415
Contacts
Mr. Douglas Copland | Barrister and Solicitor
Company Overview
Borden Ladner Gervais LLP is a leading, full-service, integrated national law firm focusing
on business law, litigation and intellectual property solutions for our clients. With more than
700 lawyers, intellectual property agents and other professionals in Calgary, Montreal,
Ottawa, Toronto, Vancouver and Waterloo Region, clients turn to us for assistance with their
legal needs, from major litigation to corporate finance and patent registration.
The members of the Intellectual Property (IP) Group of Borden Ladner Gervais specialize in
providing advice on the development, protection, exploitation and use of intellectual property
and information technology.
Borden Ladner Gervais is a leader in Canadian intellectual property practice. The IP Group
of Borden Ladner Gervais is responsible for over 35,000 patent applications and patents,
close to 30,000 trade-mark applications and registrations and 2,500 industrial design
applications and registrations.
Our professionals have the scientific and legal backgrounds necessary to effectively advise
clients on a wide range of IP -related legal issues. We offer a wide range of technological
expertise. Many of the professionals in our Group hold advanced scientific degrees,
engineering degrees and advanced graduate degrees in the fields of biotechnology, chemistry,
physics, electronics, electrical engineering, engineering physics, as well as PhDs in the
respective fields of analytical chemistry, applied chemistry, genetics, nutrition & metabolism,
plant biogenetics, oncology and telecommunications. Having a considerable number of years
at the bench and having published in peer-reviewed journals, our scientific experts bring an
insider’s understanding to their practice.
We have now established a patent practice group in our Vancouver office and look forward
to developing closer relationships with our west coast colleagues.
BOSE Corporation
The Mountain | Framingham MA 01701 | United States

Phone: (508) 766-6511 | Fax: (508) 323-1111 | Website: www.bose.com

Contacts
Mr. Don Drinkwater | Licensing Manager
Boston University
53 Bay State Road | Boston MA 02215 | United States

Phone: (617) 358-3795 | Website: www.bu.edu/otd
Contacts
Mr. Jonathan J. Jensen | Licensing Associate
Organization Type
University
Industry Sector
Company Overview
The mission of Technology Development is to promote commercialization of technologies

arising from Boston University faculty research. Whether we begin with novel concepts, mature
academic technologies or emerging companies, OTD’s suite of support services and industry
experts provides the opportunity to achieve success at every stage along the path to commercial
success. The four core groups are:
 Translational Research & Corporate Relations

Supports faculty that participate in translational research programs.
 Technology Transfer
Protects intellectual property, primarily through patenting, markets these technologies
and negotiates licenses with industry or faculty start-ups.
 New Ventures
Provides advice, guidance and support to those in the BU community exploring the
possibility of starting a new company.
 Business Incubation
Offers early-stage companies state-of-the-art office space, laboratories and a host of
support services for launching new technology ventures.

We are interesting in networking with companies who may be interested in sponsoring or in-
licensing BU technology. We are also interested in networking with inventors and entrepreneurs.
We are interested in learning more about industry trends and best practices in patenting,
licensing, etc...


High tech and life science based companies including but not limited to energy, medical devices,
diagnostics, therapeutics, photonics, pharma, etc...
Our goal is to strengthen our professional network with the potenial for out-licensing, research
collaborations, etc...
BP America Inc.
546 Timber Lane | Lake Forest IL 60045 | United States

Phone: (312) 953-1083 | Fax: (847) 234-4134
Contacts
Ms. Ada C Nielsen | Director
Ms. Judith Paul | Sr. Supply Chain Management Specialist
Mr. Ekkehard Schoettle | Attorney
Mr. John Somich | IA Strategy Manager
Organization Type
Company Overview
The purpose of our business is to provide products that satisfy human needs, fuel progress and
economic growth and to maintain and invest in a sustainable environment
With a workforce of nearly 100,000 employees, BP operates globally, with business activities
and customers in more than 100 countries across six continents.
Every day, we serve millions of customers around the world. To put this in perspective, our
businesses and brands – among them BP, Castrol, ARCO, Aral, Ultimate, Connect and am/pm –
reach nearly as many consumers as Wal-Mart, the world’s largest retailer.
To manage such an expansive operation BP is organized into three different business segments:
 Exploration and production

 Refining and marketing
 Gas, power and renewables
Bracewell & Giuliani, LLP
711 Louisiana | Suite 2300 | Houston TX 77002 | United States

Phone: 713-223-2300 | Fax: 713-221-1212
Contacts

Dr. Michael R. Samardzija |

Mr. Jeffrey Whittle | Partner
Organization Type
Law Firm
Industry Sector
Health Care
Company Overview
Bracewell & Giuliani LLP is a prominent international law firm. With more than 400 lawyers in
Texas, New York, Washington DC, Connecticut, Dubai, Kazakhstan, London, we serve clients
concentrated in the energy and financial services sectors worldwide.
Bracewell & Giuliani helps businesses and not-for-profit institutions to fully exploit their
intellectual assets through a combination of effective portfolio management and strategic
business agreements. We also work with clients to identify, protect, transfer and license their
intellectual property assets through a network of associated firms in Canada, Mexico, Japan,
Korea, China, Europe, the Middle East, South America and throughout the world.
Our attorneys understand the business realities behind technology use and application. We have
extensive experience with the procedures and requirements of the U.S. Patent and Trademark
Office. We use this combined knowledge to ensure effective prosecution and maintenance of
patent portfolios and — when necessary — to aggressively enforce clients’ intellectual property
rights.
We have deep experience in a wide range of technologies and with various industry
applications. A number of our attorneys served as patent examiners with the U.S. Patent and
Trademark Office and as in-house counsel at both start-up and institutional technology
companies. We draw on this knowledge base to assist companies at every stage of development,
from new high-tech ventures to Fortune 100 companies and multinational corporations.
Bracewell has an established patent preparation and protection practice. Each year, we secure
hundreds of patents on behalf of our clients. We also provide assistance in protecting and, where
appropriate, registering intellectual property rights in trademarks, service marks, trade names,
trade dress, copyrights, trade secrets and other proprietary information.
We offer assistance with patents, trademarks, tech transfer, and intellectual asset management.


Universities and Lifesciences companies at all stages. We have a very strong expertise in the
oncology sector.

Finding customers
Bramson & Pressman
1100 E. Hector Street | Suite 410 | Conshohocken PA 19428-2312 | United States

Phone: (610) 260-4444 | Fax: (610) 260-4445 | Website: www.b.p.com
Contacts
Mr. Robert S. Bramson | Partner
Brinks Hofer Gilson & Lione
524 South Main Street | Suite 200 | Ann Arbor MI 48104 | United States
Phone: (734) 302-6000 | Fax: (734) 994-6331
Contacts
Mr. Allen R. Baum | Partner
Mr. Thomas Filarski |
Mr. Michael N Spink | Shareholder
Bristol-Myers Squibb Co.
Rt. 206 & Province Line Rd. | Princeton NJ 08540 | United States
Phone: 1-609-252-4000 | Website: www.bms.com
Contacts
Mr. Michael Cucolo | Associate Director EST&L
Company Overview
A Next-Generation BioPharma Leader
Around the world, Bristol-Myers Squibb medicines help millions of patients in their fight against
serious diseases such as cancer, heart disease, diabetes, HIV/AIDS, rheumatoid arthritis, hepatitis

B and psychiatric disorders. Additionally, our philanthropic programs have given new hope to
some of the world’s most vulnerable citizens.
Every day, Bristol-Myers Squibb employees demonstrate their commitment to our mission to
extend and enhance human life. While we trace our beginnings back 150 years to a small brick
building in Brooklyn, New York, we have become a global biopharmaceutical leader for the
future. By uniquely combining the reach and resources of a major pharmaceutical company with
the can-do spirit of an innovative biotech company, we are transforming into a new kind of
enterprise – a next-generation BioPharma leader.
Since 2002, we’ve introduced nine new medicines for the treatment of psychiatric disorders,
cancer, HIV and other serious diseases. Two of the medications are biologic products. In the
fight against serious disease, biologics – or protein-derived therapies – are playing an
increasingly prominent role.
Other biologics, as well as scores of additional investigational medicines, are advancing rapidly
through our R&D pipeline. Bristol-Myers Squibb is recognized as having one of the most
productive and promising pipelines in the industry.
To accelerate the discovery and development of important new therapies, we are complementing
and enhancing our internal capabilities with innovative alliances, partnerships and acquisitions.
We call this our “String of Pearls” strategy. Overall, we’re making strategic choices regarding
when and how we incorporate partners, assets, technologies or geographies into our flexibly
integrated organization.
What sets us apart? It’s our commitment to patients with serious disease, our focus on finding
innovative medicines to combat those diseases and our dedication to extending and enhancing
human life.
As a BioPharma leader, Bristol-Myers Squibb has an exciting future. And, as we make a

difference in the lives of patients, we say, “Together we can prevail.”
Bristol-Myers Squibb Company
Rt. 206 & Province Line Rd. | Princeton NJ 8540 | United States
Phone: 1-609-252-4000 | Website: www.princetontechnologyconsulting.com
Contacts
Dr. Peter B. Kramer | Senior Director

Company Overview
A Next-Generation BioPharma Leader
Around the world, Bristol-Myers Squibb medicines help millions of patients in their fight against
serious diseases such as cancer, heart disease, diabetes, HIV/AIDS, rheumatoid arthritis, hepatitis
B and psychiatric disorders. Additionally, our philanthropic programs have given new hope to
some of the world’s most vulnerable citizens.
Every day, Bristol-Myers Squibb employees demonstrate their commitment to our mission to
extend and enhance human life. While we trace our beginnings back 150 years to a small brick
building in Brooklyn, New York, we have become a global biopharmaceutical leader for the
future. By uniquely combining the reach and resources of a major pharmaceutical company with
the can-do spirit of an innovative biotech company, we are transforming into a new kind of
enterprise – a next-generation BioPharma leader.
Since 2002, we’ve introduced nine new medicines for the treatment of psychiatric disorders,
cancer, HIV and other serious diseases. Two of the medications are biologic products. In the
fight against serious disease, biologics – or protein-derived therapies – are playing an
increasingly prominent role.
Other biologics, as well as scores of additional investigational medicines, are advancing rapidly
through our R&D pipeline. Bristol-Myers Squibb is recognized as having one of the most
productive and promising pipelines in the industry.
To accelerate the discovery and development of important new therapies, we are complementing
and enhancing our internal capabilities with innovative alliances, partnerships and acquisitions.
We call this our “String of Pearls” strategy. Overall, we’re making strategic choices regarding
when and how we incorporate partners, assets, technologies or geographies into our flexibly
integrated organization.
What sets us apart? It’s our commitment to patients with serious disease, our focus on finding
innovative medicines to combat those diseases and our dedication to extending and enhancing
human life.
As a BioPharma leader, Bristol-Myers Squibb has an exciting future. And, as we make a

difference in the lives of patients, we say, “Together we can prevail.”
Brooks Kushman, P.C.
1000 Town Center | 22nd Floor | Southfield MI 48075 | United States

Phone: (248) 358-4400 | Fax: (248) 358-3351 | Website: brookskushman.com

Contacts
Mr. Earl J. LaFontaine | Attorney
Buchanan Ingersoll & Rooney PC
1737 King Street | Suite 500 | Alexandria VA 22314-2727 | United States

Phone: (703) 836-6620
Contacts
Mr. Patrick C. Keane | Partner
Mr. Brian O'Shaughnessy | Shareholder
Burns & Levinson LLP
125 Summer Street | Boston MA 02110-1624 | United States

Phone: (617) 345-3263 | Fax: (617) 345-3299 | Website: www.pscboston.com
Contacts
Mr. Jacob N. Erlich | Patent Attorney/Partner
Business & Licensing Strategies, LLC
67 Candace Lane | Chatham NJ 7928 | United States

Phone: (973) 701-0928 | Fax: (973) 701-9377
Contacts
Ms. Bette Schultz | President
C.A.T.I
WI United States
Phone:
Contacts
Mr. Nathan Walker |

Cabinet Beau de Loménie
158 Rue de L'Universite | Paris 75007 | France

Phone: 33144188900 | Fax: 33144180423
Contacts
Mr. Mike S. Ryu | Attorney
Organization Type
Law Firm
Company Overview
Since it was founded in 1930, Cabinet Beau de Loménie has grown to become one of the largest
firms of Industrial Property counsel in France and in Europe. It is present in several cities in
France and also in Munich, in Germany.
Cabinet Beau de Loménie employs more than 200 people, including about 40 Industrial Property
attorneys, under the direction of five partners.

Cabinet Beau de Lomenie covers the whole IP field. We have a specialized team for assisting our
clients in licensing (in/out), helping them valuating their IP rights, in particular their patents and
know-how. We are also very active in due diligence work, which makes LES an intersting forum
for us to take part.
CAMBIOTEC AC.
Av. Canal de Miramontes 1469 | Churubusco Country Club | Mexico, D.F. 04210 | Mexico
Phone: +52-55 53365511 | Fax: +52-55 53365512 | Website: www.cambiotec.org.mx
Contacts
Dr. Jose Luis Solleiro Rebolledo | Director
Organization Type
Consulting Firm
Industry Sector

CAMBIOTEC A.C. is interested in TECHNOLOGY INTELLIGENCE and TECH TRANSFER,
PATENTS, VALUATION, MARKET BUSINESS PLANNING

Campbell Alliance
8045 Arco Corporate Drive | Suite 500 | Raleigh NC 27617 | United States
Phone: 919-844-7100 | Fax: 919-844-7560
Contacts
Mr. Gautam Aggarwal |
Mr. Jonathon Fendelman |
Mr. James Forte | Director of Public and Media Relations
Mr. Jonathan Klein | Associate, Public and Media Relations
Mr. Barrett Rankin | Senior Consultant
Organization Type
Consulting Firm
Industry Sector
Health Care
Company Overview
About Campbell Alliance

Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical
and biotechnology industries. The firm's clients include most of the world's top 20
pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance
is organized into practice areas, each specializing in a critical industry function, including Brand
Management, Business Development, Clinical Development, Managed Markets, and Sales.
From its locations in Raleigh, N.C., Parsippany, N.J., Los Angeles, San Francisco, Chicago,
Boston, Philadelphia, New York City, and Atlanta, the firm serves clients throughout North
America, Europe, and Japan. For more information on Campbell Alliance, please visit
http://www.campbellalliance.com.
About the Business Development Practice at Campbell Alliance

The Business Development Practice at Campbell Alliance helps licensing executives achieve an
edge over the competition. Our consultants provide experienced counsel to clients who need
assistance developing business development strategies, identifying partners, prioritizing targets,
evaluating opportunities, and negotiating deals.
The firm's team includes seasoned consultants and industry professionals in pharmaceutical and
biotech business development who have identified, assessed, and executed numerous in-licensing
deals. They have also been valuable in aiding out-licensors, helping clients improve internal
processes for pharmaceutical business development, and assisting top executives chart new
strategies in corporate development.

Canadian Space Agency
6767 Route de L'Aeroport | Saint.Hubert QC J3Y 8Y9 | Canada

Phone: (450) 926-4959 | Fax: (450) 926-4613
Contacts
Mr. Richard Goulet | Senior Officer, Intellectual and Technology Transfer
Ms. Isabelle Lamoureux | Officer, Intellectual Property and Technology Transfer
Cancer Research Technology Limited
Sardina House, | Sardina Street | London WC2A 3NL | United Kingdom

Phone: +44.207 269 3640 | Fax: +44.207 269 3641
Contacts
Mr. Phil L'Huillier | Director, Business Management
Company Overview
CRT sources, develops and commercialises new cancer therapeutics, vaccines, diagnostics and
enabling technologies. The company's strategy is focused on both the discovery and clinical
stages of the pharmaceutical development process.
1. Discovery
CRT sources novel discoveries through a network of alliances and partnerships in the UK, EU,
North America (via subsidiary company CRT Inc, based in Boston) and Australia. We work
closely with leading international cancer scientists and their institutes to protect intellectual
property arising from their research. Discoveries are either partnered with industry for further
development or progressed with translational funds either in the academic institute or in CRT's
Discovery Laboratories prior to partnering.
CRT's laboratories build on novel discoveries using our drug discovery expertise to create
attractive commercial proposition through collaboration with world-class academic investigators.
In our laboratories we develop small molecule and biological cancer therapies from the
discovery stage as far as in vivo proof of concept studies. With more than 90 highly experienced
scientists drawn from pharma, biotech and academia, CRT has knowledge and expertise to apply
an industrial model to all areas of early drug discovery and biotherapeutic development.
2. Clinical Development
CRT and Cancer Research UK have recently established an innovative Clinical Development
Partnerships (CDP) initiative targeting leading biotechnology and pharmaceutical companies that

have de-prioritised clinical agents. CDP seeks to sponsor, manage and support early-stage
clinical trials bringing new life to these deprioritised or under-resourced anti-cancer agents.
CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research
in the world. Further information about CRT can be found at www.CancerTechnology.com.

Partnering
Clinical Development
Cancer Preclinical Testing
Partnerships
Capital Royalty L.P.
1000 Main Street | Suite 2500 | Houston TX 77002 | United States

Phone: +1.713.209.7350 | Fax: +1.713.209.7351 | Website: capitalroyalty.com
Contacts
Mr. David Carter | Principal
Mrs. Nicole J. Clarke Luck | Associate
Mr. James Webster | Managing Partner
Company Overview
The Capital Royalty Fund
Capital Royalty is focussed on providing an alternative source non-dilutive capital to the
healthcare sector. Our fund acquires existing royalty streams and has been involved in
structuring royalty financings with both biotechnology and pharmaceutical companies.
Investments are made primarily in products that have received regulatory approval, including
pharmaceuticals, biotechnology products, drug delivery technologies, diagnostics, medical
devices and over-the-counter drugs.
Strategy
The Capital Royalty Fund’s strategy is to acquire healthcare-related royalty interests as part of a
diversified royalty portfolio. Specifically, the Fund’s strategy is to:
Focus on commercialized products approved by regulatory agencies

Provide capital in exchange for a percentage of sales on commercialized products
Fund commercial launch of products in exchange for a royalty interest
Finance product acquisitions in return for royalty interests

Royalty Interests
Biopharmaceutical sellers of royalty interests can use proceeds to fund product development,
product acquisitions, launch costs and sales force expansion while minimizing dilution to
existing shareholders. Universities and inventors who decide to monetize royalty assets can
diversify risk, fund early stage technology and fund operating and capital budgets.
Why sell your royalty interest?
Fund future product development

Delay out-licensing
Fund product acquisition
Fund launch costs
Minimize dilution
More dependable and user-friendly than public capital markets
Fund capital requirements
Fund other projects
Fund earlier stage development efforts
Manage personal risk
Diversify assets
Estate planning
Matching grants for research
Advantages of Royalty Financing
Leverages future revenues

Non-dilutive to EPS
Monetizes intellectual property assets
Can be structured creatively
No board issues
Company retains control of asset
Our People: A World-Class Management Team
Charles W. Tate, Chairman and Founding Partner (ctate@capitalroyalty.com)

Jim Webster, Managing Partner (jwebster@capitalroyalty.com)
Harry Loveys, Principal (hloveys@capitalroyalty.com)
David Carter, Principal (dcarter@capitalroyalty.com)
Cargill Inc.
15407 McGinty Road West | Mail Stop #69 | Wayzata MN 55391 | United States
Phone: (952) 742-2581 | Fax: (952) 742-6909
Contacts
Mr. Edward Levine | Senior IP Attorney

Carlton Fields, P.A.
P.O. Box 019101 | Miami FL 33131-9101 | United States

Phone: (305) 539-7370 | Fax: (301) 530-0055 | Website: www.carltonfields.com
Contacts
Ms. Nancy J. Flint | Attorney
Carnegie Mellon University
4615 Forbes Avenue | Suite 302 | Pittsburgh PA 15213-3890 | United States

Phone: (412) 268-1241 | Fax: (412) 268-7395
Contacts
Mr. Omer Riaz | Manager, Business Development
Cassels Brock & Blackwell LLP
40 King Street West, Suite 2100 | Toronto ON M5H 3C2 | Canada

Phone: (416) 869-5721/(416) 860-6883/(416) 869-5777 | Fax: (416) 640-3205/(416) 642-
7147/(416) 640-3206 | Website: www.casselsbrock.com
Contacts
Mr. Daniel Bourque | Partner/Lawyer
Ms. Bernice M. Karn | Partner/Lawyer
Mr. Stephen Selznick | Partner/Lawyer
Organization Type
Law Firm
Company Overview
Cassels Brock is a Toronto-based law firm of more than 200 lawyers focused on serving the
transaction and advisory needs of Canada’s most dynamic business sectors.
Center for Advanced Technology & Innovation
2320 Renaissance Blvd | Sturtevant WI 53177 | United States

Phone: (262) 898-7512
Contacts
Ms. Kate Walker |

Industry Sector
Consumer Products
Company Overview
Center for Advanced Technology and Innovation
CATI was founded in June 2001 as a private, non-profit 501(c) 3 entity by academic, workforce
development, and economic development organizations in Southeastern Wisconsin. CATI’s
vision is to be a source of innovation for entrepreneurs, companies, and students seeking new
opportunities by harnessing the research and development engine of U.S. industry.
At its core, CATI is a unique tech transfer model designed to leverage private industry
intellectual property by acquiring late-stage technologies via out-licensing, joint venture, or
donation, and matching those with the strategic strengths of the regional economy.
CATI - A Tool for Regional Economic Development
Economic development efforts across the world have undergone a substantial transformation,
with growing competition causing local, regional and statewide economic development groups to
focus on value-added services that distinctively position them for new wealth and tax base
creation.
Economic development must remain a locally based effort, but success requires a broader
vision and scope.
CATI offers a partnership model that can be leveraged to support regional and statewide
economic development efforts on a number of levels:
Training and Technical Services
CATI can provide economic development staff training on integrating technology and know-how
transfer as a programmatic tool for your economic development group.
CATI Regional Partnerships
CATI has launched several partnerships in cooperation with regional and statewide economic
development groups interested in replicating the CATI programming model, as well as being tied
into a growing national network of private industry technologies available for licensing.
The CATI Advantage
Technology Commercialization Joint Ventures with CATI

With any patent donation or joint venture opportunity, there is a need for aggressive plan and
strategy for finding the appropriate match and application for the technology. CATI develops a
full commercialization plan and targets existing companies for licensing opportunities, or in
many cases, has formed management teams around technologies to form new ventures. To date,
CATI has acquired patented technologies and entered into joint venture agreements with global
companies including Kraft Foods, S. C. Johnson & Sons, International Specialty Products, and
Caterpillar.
Licensing CATI Technologies
CATI has a great deal of interest in securing licensing agreements for its technologies, whether
with an existing company or through the development of new ventures. This can include, but is
not limited to, exclusive license agreements and examinations of the technologies. CATI
licensing opportunities are primarily with late-stage technologies, which in many cases, can
minimize the necessary research and development efforts required to bring the product or
process to market. CATI can also make available marketplace data and strategic research
associated with the licensed technologies.
©2006 CATI (Center for Advanced Technology & Innovation) - All Rights Reserved
We would be interested in meeting with people involved in tech transfer, intellectual asset
managment, and individuals in the consumer product's industries.

Our goals for the meeting would include identifying in-licensing, and out-licensing
opportunities, marketing agreements, and developing more relationships regionally.
Country(s)
Partnering
Equipment for the production
food Not Applicable
of gelled simulated items

Center for Biophysical Sciences and Engineering
1530 Third Avenue South | Birmingham Alabama 35294 | United States

Phone: +1.205.975.9590 | Fax: +1.205.934.2659 | Website: www.cbse.uab.edu
Contacts
Ms. Sharney Logan | Director Business Development
Industry Sector
Health Care
Company Overview
The CBSE (Center for Biophysical Sciences and Engineering) is structure based drug discovery
research center focused on the determination of structure / function relationships of biologically
important molecules. We have an integrated platform of HTP services and capabilities
addressing the "gene to lead" discovery pipeline. We are positioned to work with both academic
and industrial partners to meet the need for the expression and structural analysis for proteins of
interest and optimization of lead compounds. Our experience with industry partners has resulted
in the development of pharmaceuticals for preclinical and clinical trials to treat chronic and
infectious diseases such as T-cell mediated and various oncologic diseases, bone loss disorders,
acute coronary syndromes, influenza, bacillus anthracis, and others. Current internal discovery
programs are focused on Cystic Fibrosis, Influenza, and anti-bacterial drugs to treat class a
pathogens such as anthrax, the plague and tularemia.
Two of the latest novel technologies relevant to the discovery of new drug targets currently
available for licensing and /or collaborations are:
1) New expression system for membrane proteins : (lentiviral expression capable of scaled
production for difficult to express proteins). This advanced vector design also has application in
the generation of transgenic animal models.
2) Optimization for Formulation Solution Conditions (a quantitative HTP system for

predicting protein stability/solubility parameters for pharmaceutical formulations). Success has
been demonstrated 1) by improving protein crystallization conditions for those needing
diffraction quality crystals and 2) optimizing protein formulations (i.e. vaccine development)
Drug Discovery Collaborations
Companies interested in licensing technologies developed at the CBSE

Corporate Venture Groups

Companies interested in exploring licensing opportunities and or collaborative
activities, Investors interested in early stage technologies

out licensing opportunities, research collaborations, and new Fee For Service projects
Country(s) Available
for Partnering
Protein Crystallization and
All Pre-Target Validation
Optimization
Protein Expresssion System All Not Applicable Worldwide
Structure Base Drug
All Pre-Target Validation
Design
Centers for Disease Control and Prevention (CDC)
Technology Transfer Office | 4770 Buford Highway, MS K-79 | Atlanta GA 30341 | United
States
Phone: 770-488-8600 | Fax: 770-488-8615
Contacts
Dr. Andrew Watkins | Director, Technology Transfer Office
Company Overview
Located in Atlanta, Georgia, the Centers for Disease Control and Prevention (CDC)
[www.cdc.gov] is internationally recognized for protecting the health and safety of people
around the world. The CDC Technology Transfer Office (TTO) [www.cdc.gov/tto] facilitates
access to CDC’s world-renowned scientists, engineers and state of the art laboratories. The TTO
also administers activities related to patents, trademarks, copyrights, trade secrets, licensing
intellectual property to businesses, negotiating Biological Materials Licensing Agreements
(BMLAs) and Cooperative Research and Development Agreements (CRADAs) with the private
sector and academia. These activities benefit the public by transferring scientific expertise and

technology from government laboratories to industry, thereby encouraging the development of

improved health care products, processes, and services.
Country(s)
Partnering
E-184-91 Exchangeable Template
DNA synthesis Preclinical Testing United States
Reaction
Austrialia,
Belgium,
Germany,
E-232-93 Assay for Sensitive immunodeficiency,
France, United
Detection of Reverse Transcriptase leukemia, Preclinical Testing
Kingdom,
(RT) Activity lymphoma
United States,
Italy, Sweden,
Japan
I-003-05 Reduction in
Staphylococcus Epidermidis Viable Staphylococcus
Biofilm Formation on the Surface of Epidermidis, Preclinical Testing Worldwide
a Hydrogel Coated Catheter Using catheter
S. epidermidis Bacteriophage
I-004-04 Family Healthware -
assessment, family
Assessment, Classification, and Preclinical Testing Worldwide
medical history
Intervention Guide
I-005-03 Simple, Rapid, and
Sensitive Real-Time PCR Methods Human
for Detecting Drug Resistance in Immunodeficiency Preclinical Testing Worldwide
Human Immunodeficiency Viruses Viruses, HIV
(HIV)
Austrialia,
I-005-96 Antigenically Reactive
Hepatitis A, HAV, Europe, United
Regions of Hepatitis A Virus Preclinical Testing
Virus States, Canada,
Polyprotein
Japan
I-005-98 Method for Rapid Austrialia,
Detection of HIV Phenotypic Europe,
HIV, Anti-viral Preclinical Testing
Resistance to Anti-Viral Drugs 3TC Canada,
and Nevirapine United States
I-006-04
Human
Development/Characterization of
Innunodeficiency Preclinical Testing Worldwide
Large Volume Panels of Plasma,
Virus, HIV
PMBC, and DBS from HIV Strains
I-007-04 Artificial Human Mutation Human mutational Preclinical Testing Worldwide

Controls for Diagnostic Testing controls, Diagnostic

Testing
I-007-97 Attenuation of Bartonella Cat Scratch Fever,
Preclinical Testing United States
by Targeted, Deletion Mutagenesis Bartonella
Australia,
I-009-98 Treatment/Prevention of
Canada,
Inflammation by Inhibiting Inflammation Preclinical Testing
United States,
Substance P
Europe
I-012-96 Inhibitors of Casein Kinase
Canada,
II (protein Kinase CK2) Inhibit HIV, HIV-1, CK2 Preclinical Testing
United States
HIV-1 Replication
United States,
I-013-00 Neutralizing Immunogenic Hepatitis E, Virus, Austrialia,
Preclinical Testing
Hepatitis E Virus Polypeptides HEV Europe,
Canada
I-014-04 Immunoassay for
orthopoxvirus,
Diagnosis of Orthopoxvirus Preclinical Testing Worldwide
variola, monkeypox
Infection
I-015-02 Primer Extension
Enrichment Reaction (PEER) Primer Extension Preclinical Testing Worldwide
Protocol
I-015-98 Synthetic Peptides Austrialia,
HAV, Hepatitis A
Immunoreactive with Hepatitis A Preclinical Testing Europe, United
Virus
Virus Antibodies States, Canada
I-018-03 Novel Coronavirus
SARS, Coronavirus Preclinical Testing United States
Isolated from Humans (SARS)
Austrialia,
I-018-97 Engineered Antigens for
Europe, United
the Detection of Anti-HCV Activity Hepatitis C, HCV Preclinical Testing
States, Japan,
in Human Sera
Canada
I-019-04 Novel Human T-Cell Human T-Cell
Lymphotropic Virus, Designated Lymphotropic, Preclinical Testing Worldwide
HTLV-3 Virus, HTLV-3
I-021-98 Diagnostic Surveillance of Austrialia,
Porcine Xenograft Recipients for Porcine Endogenous Europe, Japan,
Preclinical Testing
Evidence of Infection by Porcine Retrovirus, PERV United States,
Endogenous Retrovirus (PERV) Canada
United States,
I-022-00 Respiratory Syncytical Respiratory
Canada,
Virus (RSV)G Glycoprotein Syncytical Virus, Preclinical Testing
Austrialia,
Conatins RSV
Europe
I-022-98 New Diagnostic Reagents Austrialia,
Hepatitis C, HCV Preclinical Testing
for the Detection of Anti-HCV Europe,

Activity in Human Sera Canada,

United States
I-023-04 Use of Cyanidin-3-
Glucoside as an Anti-Tumor Tumor, Anti-tumor Preclinical Testing Worldwide
Treatment
Respiratory Austrialia,
I-029-99 CD40 Ligand Adjuvant for
Syncytial Virus, Preclinical Testing Europe, United
Respiratory Syncytial Virus
RSV States, Canada
Canada,
Brazil,
Austrialia,
Syphillis, STD,
I-040-98 PCR/Serological United States,
Treponema Preclinical Testing
Diagnosis Using Arp gene Japan, China,
pallidum
China (Hong
Kong S.A.R.),
Europe
Central Life Sciences/Farnam
301 W Osborn Rd | Phoenix AZ 85013 | United States

Phone: 602-321-0191 | Fax: 866-227-8168 | Website: www.farnam.com
Contacts
Mr. Rick Blomquist | President; Branded Products
Industry Sector
Consumer Products
Company Overview
Central Life Sciences (Farnam Companies Inc and Wellmark)
Central Life Sciences is synonymous with quality of living for your home and pets as well as a
healthier environment… an environment that is better for people, pets, plants, livestock and
everything consumers care about.
Central Life Sciences is fully integrated to develop, manufacture, and market end-use products
for a diversified group of pest control markets. Since its origins the company has continued to
provide innovative and proprietary products and is a brand leader in the following markets:
Consumer – Pet Animal Care, Household products - Zodiac, VET-KEM, PreStrike, Comfort
Zone, bioSpot, and Adams
Equine – Premium branded horse health care products including Farnam, Vita Flex and Red Cell

Professional – Products for homes, restaurants, commercial food processing and public places -
Zoëcon, Extinguish, Mavrik, Enstar, Apistan, Dianex, and other brands.
Public Health – Control of mosquitoes - Altosid and other brands.
Farm & Feed – Products for the control of flies, lice, and other economic pests on cattle and
swine - Starbar, Altosid IGR and other brands.
Active Ingredient License & Supply – Providing proprietary active ingredients and licensing
technology to brands including Raid, Frontline, and Hartz.
Central Life Sciences market leadership is based on its strong brands and its ownership and
broad applications of proprietary active ingredients.
S-Methoprene: fleas, flies, mosquitoes, stored product beetles
S-Hydroprene: cockroaches, stored pest product
S-Kinoprene: white fly control
Central Life Sciences also owns rights to traditional chemistry.

Tau Fluvalinate: A synthetic pyrethroid formulated primarily in Apistan® and Mavrik®
1. Propetamphos: An organophosphate formulated primarily in Catalyst®
2. Nithiazine: A nitromethylene-heterocycle formulated primarily in QuikStrike®
3. Etofenprox: Etofenprox is a pyrethroid ether insecticide that is well tolerated by
mammals, including cats.
Central Life Sciences also owns exclusive channel licenses to:

Dinotefuran: U.S. fly bait market
Fenpyroximate: Apiary insecticide
Diflubenzuron: Fly control / Equine feed thru
Central Life Sciences also owns or has exclusive rights to the Federal EPA registrations of the
seven (7) AIs listed above and owns a drug master file (DMF) for the S-Methoprene AI.
1. Methoprene has recently been exempted by the EPA for all requirements for
tolerances when applied to food and feed. This eliminates the need for conducting
residue studies.
1. Wellmark owns over 348 end-use product federal EPA registrations and an FDA
approval for its flea pill.
1. Farnam has 91 registrations.
2. Together, Central Life Sciences owns 439 registrations at EPA.

Interested in patents, trademarks, technology, chemistry, in-licensing


Interested in meeting with companies offering technology, patents, trademarks

Goals include in-licensing and marketing agreements
Centric Health Resources, Inc.
17877 Chesterfield Airport Road | Chesterfield MO 63005 | United States

Phone: (636) 519-2758 | Fax: (866) 862-8818 | Website: www.centrichealthresources.com
Contacts
Ms. Penny B. Bemus | Vice President, Business Development
Industry Sector
Health Care
Company Overview
Centric Health Resources is a nationwide organization serving the specialized needs of
individuals with certain rare and chronic genetic disorders, along with their families, specialist
physicians and healthcare payers. As a specialty pharmacy employing patient centered health
management services, Centric Health Resources works with patient advocacy organizations,
pharmaceutical companies, biotech firms and managed care organizations to deliver prescribed
therapies and specialized health services. The company’s comprehensive approach reduces
health care spending and improves the quality of life for patients and their families.
Biotech firms with orphan drugs in Phase II/III and after.
Pharma companies with established drugs that service small patient populations looking to
increase market share or re-launch in a direct distribution model with health management as an
extra service that adds value to the patients and all constituents.
Consulting firms that work with biotech firms on their commercialization.
Partner with biotech firms that are interested in maximizing their return on investment and
increasing their company's strategic earnings multiple by partnering with Centric in a unique,
proven, direct specialty distribution model.

Product commercialization, specialty pharmacy, and distribution focused on rare, chronic

disorders.
Health management services.
Direct distribution model.
Centrix Pharmaceutical, Inc.
31 Inverness Center Parkway | Suite 270 | Birmingham AL 35242 | United States

Phone: (205) 991-9870 | Fax: (205) 991-9420 | Website: www.cenrx.com
Contacts
Mr. John R. Booth | President and CEO
Organization Type
Industry Sector
Health Care
Company Overview
Centrix Pharmaceutical is a privately owned, closely held pharmaceutical marketer of

prescription and non-prescription products. Centrix utilizes its own sales team to market products
to physicians and allied health professionals throughout he U.S. The company's primary interest
are in pediatrics and womens health however consideration is given to tangential products
opportunities.
Centrix utilizes contract manufacturers and partner companies to produce its product range. The
Company seeks to acquire, in-license, or devlop additional products (including prescription &
non-prescription products, medical foods and medical devices) for its sales and marketing team.
Late stage or currently marketed products are preferred.
Companies with existing products that may be available for co-promotion, in-licensing, or
acquisition opportunities. Products with intellectual property, proprietary knowledge, or other
protection.

Organizations who lack commercialization teams but have product(s) and seek access to or
expanded opportunity in the U.S. market, particurlarly in the areas of pediatrics, womens health,
and gastroenterology.
Seeking in-licensing, co-promotion, and acquisition opportunities. Prefer very late stage or
currently marketed products.
Explore out-licensing opportunities for exisiting Centrix products.
for Partnering
Covaryx(TM) and Estrogen South America, Puerto
Not Applicable
Covaryx(TM) HS replacement Rico, Mexico
Dicel(TM) and Dicel(TM) South America, Puerto
Cough and cold Not Applicable
DM Suspension Rico, Mexico
South America,
Maxaron Forte Iron replacement Not Applicable
Mexico, Puerto Rico
Cephalon, Inc.
41 Moores Rd | Frazer PA 19355 | United States

Phone: (610) 738-6315 | Fax: (610) 883-5751
Contacts
Ms. Lynn Brookes | VP, Business Development
Organization Type
Industry Sector
Health Care
Company Overview

Cephalon is a fully integrated specialty pharmaceutical company engaged in the discovery,

development, and marketing of products to treat human diseases. We are primarily focused on
four therapeutic areas, including central nervous system disorders, pain, cancer, and
addiction. Our products for central nervous system disorders include PROVIGIL, which contains
modafinil, for improving wakefulness in patients with excessive daytime sleepiness associated
with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSA/HS), and shift work sleep
disorder (SWSD); GABITRIL for use as adjunctive therapy in the treatment of partial seizures in
epileptic patients; and NUVIGIL, a single-isomer formulation of modafinil. Our pain
therapeutics portfolio comprises FENTORA and ACTIQ for the management of breakthrough
cancer pain in opioid tolerant patients and AMRIX, an extended-release skeletal muscle
relaxant. Our oncology portfolio comprises TRISENOX an intravenous arsenic-based targeted
therapy; CEP-701 an oral small molecule tyrosine kinase inhibitor; TREANDA a multi-
functional hybrid cytotoxic; MYOCET a cardio-protective chemotherapy agent used to treat late-
stage breast cancer; and TARGRETIN a treatment for cutaneous T-cell lymphoma; and
ABELCET an anti-fungal product used by cancer patients. We also have VIVITROL, which is
indicated for alcohol dependent patients who are able to abstain from alcohol in an outpatient
setting and are not actively drinking when initiating treatment. We have established direct
presense in 21 countries worldwide. The company was founded in 1987 and is headquartered
Frazer, Pennsylvania.

Cephalon is insterested in meeting with companies with clinical stage candidates to explore in-
licensing/collaboration opportunities.
In-licensing and collaboration.
Ceteris, Inc.
53 West Jackson Blvd | Suite 1651 | Chicago IL 60604 | United States

Phone: (312) 253-0925 | Fax: (847) 247-9224
Contacts
Mr. David Jarczyk | Director
Organization Type
Consulting Firm
Company Overview
Ceteris’ experts have extensive experience in performing intellectual property valuations for tax
and financial reporting purposes, mergers and acquisitions, and disputes. We have helped our

clients develop comprehensive intercompany transfer pricing strategies, perform reasonable

royalty rate determinations, and value sales and purchase transactions.
Ceteris provides a thorough understanding of IP strategies, valuation methodologies and

transactions used within industry and jurisdiction-specific contexts. Our sophisticated analytical
approach leads to unbiased insights and information that is presented in a manner that is clear,
concise, compelling and defensible.
Ceteris’ services include:

 Intellectual property valuations
 Business and legal entity valuations
 Closely held or thinly traded company valuations
 Executive compensation determinations (options, phantom stock, share appreciation
rights)
 Financial asset valuations
 Intellectual property migration strategies
 Cost sharing and buy-in payment analyses
Our valuation services are used for the following purposes:

 SFAS 141 and 142 goodwill impairment and purchase price valuations
 Purchase price accounting for tax purposes
 Lost profits analyses
 Intercompany transaction pricing
 Acquisitions and divestitures of assets
 Evaluations of acquisition candidates
 Purchase offers
 Buy/sell agreements
 Litigation cases
 Tax and financial reporting compliance
Chadbourne & Parke LLP
30 Rockefeller Plaza | New York NY 10112 | United States

Phone: (212) 408-1127 | Fax: (646) 710-1127 | Website: www.chadbourne.com
Contacts
Mr. Frank Vellucci | Partner
Organization Type
Law Firm

Company Overview
Chadbourne & Parke LLP is deeply committed to the success of our clients. As an international
law firm with over 480 attorneys in 13 offices around the world, we help clients navigate the
complexities of the global marketplace through interrelated, cross-border practice groups. Our
lawyers from our numerous offices regularly work together and share their knowledge, talents
and resources. This multidisciplinary approach enables us to achieve efficient, effective and
practical results for our clients around the world.
Since the Firm's founding in 1902, Chadbourne has been dedicated to providing practical
business solutions to a diverse range of clients in many practice areas and industries. More
specifically, Chadbourne has extensive experience serving both domestic and international
pharmaceutical companies with R&D license issues, joint ventures, asset and stock acquisitions,
commercialization collaborations, technology transfer arrangements and strategic alliances in
this industry.

We are interested in meeting pharmaceutical companies seeking advice on corporate/product
acquisition/disposition transactions.
Chevy Chase BioPartners
9208 Jones Mill Rd | Chevy Chase MD 20815 | United States

Phone: 301-922-3188
Contacts
Mr. Debra K. Bowes | Principal
Chewtech - I/S
Dandyved 19 | Vedle 2100 | Denmark

Phone: +45 72 15 10 13
Contacts
Mr. Nicolai Kanved | Senior Manager - JDR & Licensing
Children's Hospital Boston
300 Longwood Avenue | Boston MA 02115 | United States

Phone: (617) 919-3019 | Fax: (617) 919-3031

Contacts
Dr. Alexander D. Augst | Associate Licensing Manager
Dr. Maude Tessier | Associate Licensing Manager
Organization Type
Research Institution
Industry Sector
Health Care
Company Overview
Children’s Hospital Boston
Children’s Hospital Boston (CHB), a Harvard Medical School and Howard Hughes Medical
Institute-affiliated institution, is the world’s leading pediatric enterprise with annual research
funding of over $179M. In the laboratories and clinics, our researchers seek to identify factors
that contribute to both childhood and adult diseases, and develop effective treatments. The 600
scientists that comprise the hospital community possess a broad range of world class research
expertise, including oncology, cardiovascular disease, protein therapeutics, neuroscience, stem
cells, genomics and informatics.
The Intellectual Property Office

The Intellectual Property Office (IPO) provides a gateway to CHB researchers and technologies
in all major biomedical disciplines for both pediatric and adult markets. The IPO’s 15-person
team engages in all transactions with industry from research collaborations, start-up formation,
IP licensing, and clinical trial coordination, generating revenues of ~$20M in 2007. Later this
year the IPO will launch its Technology Development Fund to accelerate the development and
translation of CHB’s innovations to complement the patenting and licensing activities. The IPO
team evaluates ~100 new inventions, and files over 100 patent applications on new and existing
technologies per year. On average, the IPO negotiates ~30 license and option agreements, and
~15 corporate sponsored research agreements. To date, CHB inventions have lead to 9 products
in clinical trials and 8 medical products on the market, including, Revlimid®, Thalomid®,
Cardioseal®, Starflex®, Namenda® and Neumega®.

We are interested in meeting companies of all sizes who are looking for new opportunities in
Therapeutics, Medical Devices, Stem Cell Discoveries, Tissue Engineering,

Bioinformatics/Medical Informatics, and many other research areas. Please visit our website for
a list of inventions:
http://www.childrenshospital.org/cfapps/research/data_admin/Site49/mainpageS49P12sublevel1
3.html

Children's Hospital Boston is seeking large and small entities and start-up ventures interested in
licensing hospital inventions as well as partners for research collaborations and product
development activities.
Children's Hospital of Philadelphia
34th Street and Civic Center Blvd. | Philadelphia PA 19104 | United States
Phone: (215) 590-5645 | Website: stokes.chop.edu/
Contacts
Dr. Gregory L. Baker | Associate Director, Commercialization
Dr. Vikas Sharma | Licensing Associate
Organization Type
Industry Sector
Health Care
Company Overview
The Children’s Hospital of Philadelphia has a long and distinguished tradition of research that
has spanned more than 80 years and positioned the Hospital as a world-renown pediatric research
center. With more than 325 researchers and access to a huge patient population, CHOP can
provide the pharnaceutical, diagnostic, and medical device industries a venue to evaluate
technologies and collaborate on research projects. We have established relationships with many
major pharmceutical and biotech companies, and we are aggressively seeking more partners to
commercialize the promising intellectual property being developed in CHOP's research
laboratories. Our areas of expertise include the fields of oncology, medical devices,
immunology, diabetes, hemophilia, infectious diseases, molecular diagnostics and others.

CHOP representatives at LES would like to meet with companies active in the fields of
oncology, medical devices, immunology, diabetes, hemophilia, infectious diseases, and
molecular diagnostics. For further information, please contact Greg Baker, Associate Director of
Commercialization, at bakerg@email.chop.edu.


CHOP's primary goals at LES 2008 include out-licensing technologies in the fields of oncology,
medical devices, immunology, diabetes, hemophilia, infectious diseases, molecular diagnostics
and others. In particular we have interesting IP related to a stroke therapeutic, an anthrax
vaccine, a cancer vaccine, AAV gene therapy, magnetic nanoparticles for delivery of siRNA,
gene therapy vectors, and therapeutic compounds, and diagnostic IP that includes genome wide
associations and biomarkers.
We will also be establishing industry contacts to explore partnering opportunities related to

clinical trials, genome wide association studies, and general funding mechanisms for industry
partners to gain early access to emerging intellectual property at the hospital.
China Patent & Trademark Agent (USA) Ltd.
22/ F., Great Eagle Centre | 23 Harbour Road | Wanchai China (Hong Kong S.A.R.)
Phone: 852 2828 4688 | Fax: (212) 809-8118
Contacts
Mr. Hong Luo | President
China Patent Agent (H.K.) Ltd.
22/F, Great Eagle Centre, 23 Harbour Roa | Wanchai, HK | Hong Kong China
Phone: 852 2828 4688 | Fax: 852 2827 1018
Contacts
Ms. Jianying Wang |
Mr. Dapeng Wen |
Chipworks
3685 Richmond Road | Suite 500 | Ottawa ON K2H 5B7 | Canada

Phone: (613) 829-0414 | Fax: (613) 829-0515
Contacts
Ms. Julia Elvidge | President
Ms. Sandra Lowenstein | Marketing Manager
Mr. Wayne W. Lucky | Manager.Sales
Mr. Terry Ludlow | CEO
Mr. Michael Thumm | VP Patent Intelligence
Organization Type
Consulting Firm

Industry Sector
High Technology
Company Overview
Chipworks patent intelligence provides technical evidence and claim charts to semiconductor
and microelectronic patent holders, and the firms that represent them. We work closely with our
clients to help generate more revenue from patent assets, decrease royalty payments and protect
vital markets. Our patent assertion methodologies, deep technical expertise and broad market
view make us the only choice in the semiconductor industry to augment your IP team. We have
15 years experience building defense strategies against the most aggressive semiconductor patent
holders. 23 of the top 25 patenting organizations use Chipworks.
 Semiconductor manufaturers
 Electronics manufacturers
 IP Groups
 Law Firms
 All worldwide geographies
Country(s)
Partnering
Intellectual Property Services;
Technical Competitive Analysis n/a Not Applicable Worldwide
Church & Dwight Inc.
469 North Harrison Street | Princeton NJ 8543 | United States

Phone: (609) 279-7780 | Fax: (609) 683-7007
Contacts
Ms. Tammy Talerico-Payne | Director of Licensing

CIMA LABS INC.
10000 Valley View Rd. | Eden Prairie Minnesota 55344 | United States
Phone: +1-952 947 8748 | Fax: +1 952 947 8711 | Website: www.cimalabs.com
Contacts
Dr. Richard J Welter | V.P. Business Development
Organization Type
Industry Sector
Health Care
Company Overview
CIMA LABS INC., a world leader in the drug delivery partnering business, specializes in
formulating, taste-masking and manufacturing of pharmaceuticals utilizing its orally
disintegrating tablet (ODT), oral transmucosal (OTM), solubilization (MicroSolv), and oral
powder drug delivery technologies.

CIMA would like to meet with pharmaceutical and biotechnology companies. Please contact
John C. Nagel, Sr. Director, Business Development to arrange a meeting.

Identification of new partners and out licensing of CIMA Labs' drug delivery technologies.
for Partnering
DuraSolv® n/a Not Applicable Worldwide
Lyoc n/a Not Applicable Worldwide
MicroSolv (Solubilization
n/a Not Applicable Worldwide
Delivery Technology)
Oral Powder n/a Not Applicable Worldwide
OraSolv® n/a Not Applicable Worldwide
OraVescent® n/a Not Applicable Worldwide

Cincinnati Childrens Hospital
3333 Bernet Avenue | MLC 7032 | Cincinnati OH 45229 | United States

Phone: 513-636-7695 | Fax: 513-636-8453
Contacts
Dr. Joseph Fondacaro | Executive Director, Corporate Alliances
CJ America, Inc.
400 Kelby Street | 19th Floor | Fort Lee NJ 07024 | United States
Phone: (201) 461-7407 (316) | Website: www.cj.net
Contacts
Mr. Chang Y. Kim | Branch Manager
Organization Type
Industry Sector
Health Care
Company Overview
CJ CheilJedang Corp. is one of the Korea’s largest conglomerates with revenue of U$ 10 bil.
focusing itself on its four key business divisions: Pharmaceuticals; Food; Entertainment; and
Logistics.
CJ started the pharmaceutical business in 1984, and its pharmaceutical division has quickly
grown to become a highly regarded leading pharmaceutical company with the annual
pharmaceutical sales of U$ 350 Mil. and 1000 employees in South Korea.
Also, we actively do strategic investment in stem cell research field and other biotechs in
Oncology, CNS and Metabolism.
Clarke, Modet & Cia. de Mexico, S.A.
San Francisco 310 | Col. Del Valle | Mexico, D.F. 03100 | Mexico
Phone: +52 55 5340 2300 | Fax: +52 55 5523 6418

Contacts
Mr. Elpidio Salde¤o | QC & Technology Consultant
Clean Diesel Technologies, Inc.
300 Atlantic Street | Suite 702 | Stamford CT 06901-3522 | United States

Phone: (203) 327-7050 | Fax: (203) 323-0461 | Website: www.cdti.com
Contacts
Dr. Walter G Copan | Executive Vice President and Chief Technology Officer
Organization Type
Industry Sector
Energy
Company Overview
Clean Diesel Technologies (NASDAQ: CDTI) is a cleantech company providing sustainable
solutions to reduce emissions, increase energy efficiency and lower the carbon intensity of on-
and off-road engine applications. Clean Diesel’s patented technologies and products allow
manufacturers and operators to comply with increasingly strict regulatory emissions and air
quality standards, while also improving fuel economy and power. The Company’s solutions,
which are in commercial use worldwide, significantly reduce emissions formed by the
combustion of fossil fuels and biofuels, including particulate matter (PM), nitrogen oxides
(NOx), carbon monoxide and hydrocarbons. Clean Diesel solutions also reduce carbon dioxide
(CO2) emissions, a key greenhouse gas associated with global climate change.
Clean Diesel develops and manages intellectual property from original concept to full scale
commercial deployment. Its offerings include ARIS® Selective Catalytic Reduction (SCR); the
patented combination of SCR and Exhaust Gas Recirculation; hydrocarbon injection for
emissions control applications; Platinum Plus® Fuel-Borne Catalyst (FBC); the Purifier™
family of particulate filter systems; and its Wire Mesh Filter particulate filter technologies. The
company licenses its technologies to industry leaders and distribution partners for new
equipment and for retrofit markets. Clean Diesel collaborates with leading universities and
research institutes to identify, develop and prepare technologies for commercialization. The
Company was founded in 1995 and is headquartered in Stamford, Connecticut. A wholly owned
subsidiary, Clean Diesel International, LLC, is based in London, England. For more information,
please visit www.cdti.com.


The LES provides connection opportunities for Clean Diesel Technologies with companies
interested to evaluate and license its patents and technologies for emission reduction and energy
efficiency applications. Clean Diesel also is interested in sources of new patents,concepts and
technologies for in-licensing or acquisition, including innovations from universities, research
organizations and companies.

Clean Diesel Technologies would be interested to meet with automotive companies, engine
manufacturers and suppliers to the industry to consider licensing Clean Diesel's patented
technologies for emission reduction, energy efficiency and renewable fuels. The company is
also interested in new concepts and promising IP for emission control, alternative fuels and
efficient power systems from universities, research organizations and companies.

Clean Diesel Technologies provides industry-leading patented technologies to enhance fuel
efficiency and reduce harmful emissions. The products and technologies from Clean
Diesel enable engine and vehicle manufacturers together with Tier 1 suppliers to meet regulatory
standards, and also to differentiate their offerings in the marketplace. Clean Diesel is an
innovation company whose products and technologies are available to industry partners for
license and distribution. Clean Diesel is a focal point for universities, research institutes
and other companies seeking to commercialize the most promising inventions which reduce
harmful emissions and also lower CO2 greenhous gas emissions. We identify new technologies
with potential to deliver substantial emissions reductions from transportation and power
generation, while improving engine efficiency. These include alternative fuels and renewables,
engine and vehicles systems technologies, power generation and storage, catalysts, substrates,
filtration / separation media, and advanced materials.

Partnering
Emission reduction
n/a Not Applicable
systems
CNSE, Valbany
NanoFab 300 South | 255 Fuller Road | Albany NY 12203 | United States
Phone: (518) 437-8686 | Fax: (518) 437-8603
Contacts
Mr. Pradeep Haldar | Director & Professor

Cole Valuation Partners Limited
80 Richmond St. West | Suite 2000 | Toronto ON M5H 2A4 | Canada

Phone: (416) 364-9719 | Fax: (416) 364-9707
Contacts
Mr. A. Scott Davidson | Partner
Colgate-Palmolive Company
909 River Rd. | Piscataway NJ 08855-1343 | United States

Phone: 732-878-7230
Contacts
Dr. Kathy L Gross | Director
Ms. Mary Beth Robles | Vice President
Organization Type
Industry Sector
Consumer Products
Coller Capital
410 Park Ave | New York NY 10022 | United States

Phone: (917) 601-0639 | Website: www.interdigital.com
Contacts
Mr. Bruce G. Bernstein |
Coller IP Fund
Coller Capital, Inc. | 410 Park Avenue | New York NY 10022 | United States
Phone: (212) 609-2984 | Fax: (212) 644-9133 | Website: www.colleripcapital.com
Contacts
Dr. Peter D. Holden | Managing Director

Comcast
One Comcast Center | Philadelphia PA 19103 | United States

Phone: (215) 280-3952 | Fax: (215) 286-7891 | Website: www.comcast.com
Contacts
Mr. Mark Dellinger | VP, Intellectual Property Strategy
Mr. James J. Finnegan | Senior Vice President, Intellectual Property Strategy
Organization Type
Industry Sector
High Technology
Compass Strategic Consulting, Inc.
129 Church Street | Suite 400 | New Haven CT 06510 | United States
Phone: (203) 777-9570 | Fax: (203) 777-9572 | Website: www.compassconsulting.biz
Contacts
Mr. Paul K. Gallagher | President
Computer Patent Annuities
225 Reinekers Lane | Suite 400 | Alexandria VA 22314 | United States

Phone: (703) 236-3182
Contacts
Mr. Richard Kolar | Sr. IP Analyst
ConocoPhillips Company
McLean Bldg 1110 | 600 North Dalry Ashford | Houston TX 77079-1175 | United States
Phone: (832) 202-3270 | Fax: (281) 293-2127
Contacts
Dr. Gary Haag | Senior Counsel

Corium International, Inc.
235 Constitution Drive | Menlo Park California 94025 | United States

Phone: 1.650.298.8255 | Fax: 1.650.298.8012
Contacts
Dr. Deborah A. Fox | Vice President, Business Development
Organization Type
Industry Sector
Health Care
Company Overview
Corium International, Inc. (Corium) is a private company engaged in the research, development
and manufacture of advanced transdermal drug delivery technologies and products. Using its
proprietary delivery technologies and its development and manufacturing expertise, Corium has
developed a number of active and passive transdermal products with enhanced therapeutic or
safety profiles. This self-funded product pipeline spans several therapeutic areas and is in various
stages of development. Corium also has several partner-funded products with small, medium and
large pharmaceutical companies in various stages of development, ranging from research and
development to manufacturing. On September 20, 2007 Corium completed a $25.1 million
Series C financing led by Essex Woodlands Health Ventures. In connection with the financing,
StrataGent Life Sciences, Inc., an Essex Woodlands Health Ventures portfolio company focused
on needle-free delivery of drugs, merged into Corium.
Corium’s drug delivery products are based on three core proprietary technologies that offer the
unique ability to deliver both small molecules and larger protein-based biologics.
· MicroCorTM: MicroCorTM is an active transdermal technology acquired from The Procter &
Gamble Company (“P&G”) and further developed by Corium that utilizes proprietary
mechanical microporation (“microneedle”) technology for transdermal delivery of
therapeutic proteins, peptides and vaccines. Currently protected by over 80 U.S. and
international patents issued and pending, this technology enables the effective transdermal
delivery of small and large molecules from a fully-integrated, disposable, user-friendly
device.
· CorplexTM: CorplexTM is a versatile polymer technology that can be utilized in many drug
delivery and medical product applications. Currently protected by over 95 U.S. and
international patents issued and pending, this proprietary technology provides superior
adhesion to both dry and wet surfaces and offers the flexibility of rapid or sustained drug
delivery.

· Microjet: Microjet, developed by StrataGent, is a liquid microjet technology that is able to

deliver existing formulations of small and large molecules painlessly through the skin.
Currently protected by 4 pending US patents, this proprietary technology can deliver liquid
drugs that have previously been given only by injection as a bolus or in a controlled,
programmable fashion.
Corium plans to commercialize its advanced drug delivery products over the next several years
through partnerships with pharmaceutical and biotech companies. Corium also seeks
collaborations with companies wishing to optimize the delivery of their proprietary drugs,
proteins and vaccines. Corium is headquartered in Menlo Park, California, with manufacturing
facilities in Grand Rapids, Michigan.

Partnering
Transdermal BPH
Urology Not Applicable Worldwide
Product
Cornell Research Foundation, Inc.
395 Pine Tree Road | Ste 310 | Ithaca NY 14850 | United States
Phone: (607) 254-2330 | Fax: (607) 254-5454 | Website: www.cctec.cornell.edu
Contacts
Mr. Scott MacFarlane | Senior Tecnology Manager

Partnering
Nanocomposite
n/a Not Applicable
Additives
Silicon photonic
n/a Not Applicable
technology
Sub-50 nm Lithography n/a Not Applicable
Superhydrophobic
n/a Not Applicable
coating/film

Cornerstone Research
1919 Pennsylvania Avenue, N.W. | Suite 600 | Washington DC 20006 | United States
Phone: (202) 912-8900 | Fax: (202) 912-8999
Contacts
Mr. Shankar Iyer | Senior Manager
Covidien
675 McDonnell Blvd | Hazelwood MO 63042 | United States

Phone: (314) 654-3072 | Fax: (314) 654-3319
Contacts
Mr. Peter Higuchi | Director, Business Development & Licensing
Mrs. Melissa Klug | Director, Strategy & Portfolio Management
Mr. Matthew J. Kraus | Vice President Business Development
Ms. Kathleen Miller |
Mr. David E. Silver | VP Portfolio Mgmt. & Bus. Develop.
Mr. Giovanni Venditti | Director - Business Development
Organization Type
Industry Sector
Health Care
Company Overview
Covidien is a $10B healthcare products company. Covidien, Ltd. engages in the development,
manufacture, and sale of healthcare products for use in clinical and home settings worldwide.
The company was incorporated in 2000 and is based in Hamilton, Bermuda. It operates through
four segments: Medical Devices, Pharmaceutical Products, Imaging Solutions, and Medical
Supplies.
The Pharmaceutical Products segment ($0.9B Net Sales) offers dosage pharmaceuticals, active
pharmaceutical ingredients, and specialty chemicals. The focus of the Pharmaceutical Products
segment is to create a specialty pharamceutical busienss that is focused on acquiring, licensing
and developing branded pain management pharmaceticals. The branded business is $120MM
business with an sales and marketing organization of 100 sales reps.

The Medical Devices segment provides endomechanical instruments, soft tissue repair products,
energy devices, oximetry and monitoring products, airway and ventilation products, vascular
devices, sharpsafety products, clinical care products, and other medical device products.
The Imaging Solutions segment provides radiopharmaceuticals, such as radioactive isotopes and
associated pharmaceutical products used for the diagnosis and treatment of disease; and contrast
products, including contrast delivery systems and contrast agents.
The Medical Supplies segment offers nursing care products, including woundcare products;
medical surgical products, such as operating room supply products and related accessories,
electrodes, and chart paper product lines; and original equipment manufacturer products, which
include medical supplies, such as needles and syringes; and incontinence products. Covidien's
customers include hospitals, surgi-centers, imaging centers, alternate site facilities, drug
manufacturers, and retailers.
Licensing of pain management products
Product acquisitions
Company acquisitions
Co-development collaborations
Product development companies with pain managment analgesics in later stages of clinical
development
Licensing of marketed products
Drug delivery platforms

Partnering
Pain management
Analgesia Not Applicable
analgesics

Covington & Burling LLP
620 Eighth Avenue | the New York Times Bldg | New York NY 10018 | United States
Phone: (212) 841-1025 | Website: www.cov.com
Contacts
Mr. John Gourary | Partner
Company Overview
Covington & Burling LLP is a preeminent international law firm, known for its industry
practices, creativity and ability to address the most cutting-edge and sophisticated corporate,
litigation and regulatory matters. Covington has 650 lawyers practicing from offices in Beijing,
Brussels, London, New York, San Francisco and Washington. Covington is consistently ranked
among the top U.S. and international firms. Notable rankings include:
 American Lawyer "The A-List" – a listing of twenty elite US law firms;

 PLC Cross Border Quarterly Magazine – Life Sciences Industry & Regulatory Super
League (2005 - 2008) - recognized as the #1 life sciences firm worldwide and the #1 life
sciences regulatory practice worldwide; and
 Corporate Board Member “America’s Best Corporate Law Firms” – the top 20 firms
identified by corporate directors and general counsel.
CRA International
One South Wacker Drive | 34th Floor | Chicago IL 60606 | United States
Phone: (312) 357-1000 | Fax: (312) 357-1001 | Website: www.crai.com/ip
Contacts
Mr. Robert B. Goldman | Principal
Mr. Daniel McGavock | Vice President
Dr. Richard Razgaitis | Sr. Advisor
Mr. Keith A. Walker | Director, IP Analytics
Organization Type
Consulting Firm
Company Overview
CRA International is the clear firm of choice for high-stakes business decisions, transactions,
disputes, and compliance matters in which the economic value and risks associated with IP and

intangible assets must be addressed in a timely manner with analytical rigor, objectivity, and
thoroughness.
CRA's IP Practice service offerings include:
Litigation: Expert Testimony; Damages Analysis; Settlement / Risk Analysis
Valuation: Advanced Valuation Models; Compliance-driven Valuations
Strategy: IP Strategic Audits / Business Plans; IP Management Processes
Transactions: Licensing Strategy and Execution; Strategic Private Auctions; Strategic M&A Due
Diligence
Intelligence: Competitive Benchmarking; M&A Targeting and Due Diligence
CRA's Life Sciences Practice provides a comprehensive suite of services to companies in the
Life Sciences industry, including: Opportunity Assessment & Valuation; Pricing & Market
Access; Product & Portfolio Strategy; Licensing & Business Development; Litigation &
Arbitration Support; Public Policy & Regulatory Economics; and Intellectual Property Strategy.
CRA's Transfer Pricing Practice assists companies worldwide in planning, executing,

documenting and defending intercompany transactions, including those involving intellectual
property and other intangible assets.
CRA has over 600 consultants in over 20 offices in North America, Europe, and Asia-Pacific.
CRA is publicly traded and listed on the NASDAQ stock exchange using the ticker CRAI.
CSIRO
PO Box 225 | Dickson ACT 2602 | Australia

Phone: 61.2.6276 6961 | Fax: 61.2.6276 6273
Contacts
Mr. Adam Liberman | Lawyer

Company Overview
CSIRO (the Commonwealth Scientific and Industrial Research Organisation) is a statutory
research agency of the Government of Australia. We are one of the worlds largest and most
diverse scientific research institutions employing some 6,500 staff in more than 65 sites around
Australia and overseas. Our research collaborations stretch across more than 70 countries. We
conduct world-class research for many industry sectors spanning, Human Health, Agribusiness,
Energy and Transport, Information, Communication and Services, Manufacturing, Mineral
Resources and the environment. CSIRO is Australias largest single provider of Biotechnology
research.We are actively pursuing commercialisation ventures and alliances to enhance the
adoption of our research. CSIRO invests some A$20m annually in biotechnology research, being
a substantial part of the overall investment into biotechnology research in Australia. (Annual
Reports can be found at www.csiro.au).
C-Synergies LLC
150 Shoreline Walk | Alpharetta GA 30022 | United States

Phone: (770) 751-8768 | Fax: (770) 752-8495
Contacts
Ms. Corrine A. Sukiennik | President
Organization Type
Consulting Firm
Industry Sector
Consumer Products
Company Overview
C-Synergies LLC is a business consultancy providing start-ups to large companies with a range
of best practice management capabilities necessary to build brand equity and launch innovative
new products -- both essential to fuel business expansion and generate revenue growth.
C-Synergies LLC is led by the former Director of Kimberly-Clark Corporation's intellectual

asset brand and technology licensing programs. With a 20+ year tenure at the $15 Billion global
Consumer Products company, business leadership brought to C-Synergies is broad and diverse,
demonstrating expertise not only in Business Development via Licensing, but also in Mergers
and Acquisitions, Innovation Management, and International Business Expansion.
Today, C-Synergies works with prestigious world class service providers -- partners for
thoroughly understanding client business needs for the future. The result is an integrated
solutions approach linking strategy, brand building, and technology maximization -- all required
in our highly competitive and changing business environment.


- Intellectual Asset Management, Portfolio Maximization
- Trademarks, Brand Building, Brand Valuation
- Technology Identification, Transfer, and Valuation
- Innovation and Alliance Management
C-Synergies would like to meet with individuals that have interest in strengthening their
Intellectual Asset Programs, including areas of vision, infrastructure, management, and
administration. Key areas of focus include execution of:
- Alternative Go To Market Strategies
- Brand Building (In and Out Licensing)
- Technology Transfer (In and Out Licensing)
- Related Due Diligence and Compliance Management
Cumberland Pharmaceuticals Inc.
2525 West End Avenue, Suite 950 | Nashville TN 37203 | United States
Phone: (615) 255-0068 | Fax: (615) 255-0094 | Website: www.cumberlandpharma.com
Contacts
Ms. Elizabeth C Gerken | Director
Ms. Leslie Vancil | Business Development Associate
Organization Type
Industry Sector
Health Care
Company Overview
Corporate Profile
Cumberland Pharmaceuticals is a specialty pharmaceutical company whose mission is to

acquire currently marketed and late-stage development pharmaceutical products and grow

them through marketing to targeted, underserved physician segments. Cumberland is

dedicated to providing high quality products which address unmet medical needs.
The strategy for achieving these goals is comprised of five key components: rigorous
product selection, innovative financing, focused marketing, efficient operations and access
to a long-term product pipeline.
Cumberland Pharmaceuticals is committed to delivering exceptional products that have

undergone a multi-disciplinary analysis and evaluation. Target markets include critical
care, emergency medicine and gastroenterology. Products which demonstrate safety and
efficacy as well as competitive advantage represent ideal candidates.
The Company's most important resource is its people. An accomplished management team
is complemented by a distinguished board of directors and pharmaceutical industry
advisors who bring invaluable knowledge and insight to every area of operations. A
growing sales force of 64 experienced pharmaceutical representatives promotes
Cumberland's products nationwide, and includes specialty hospital and gastroenterology
sales teams.
Marketed Products
For information on our marketed products, please visit the product websites by clicking on the
links below.
Acetadote®
This product prevents or reduces liver damage resulting from acetaminophen overdose, the
leading cause of drug toxicity in the U.S. Promoted to hospitals and poison control centers
nationwide, Acetadote is the first injectable treatment available in the country for this potentially
lethal overdosing occurrence.
Kristalose®
Kristalose is a prescription laxative that we believe has significant advantages over competitive
products, and is being promoted to the most prolific prescribers of the class - gastroenterologists.
Pipeline
Phase III Development
Amelior®
Amelior is our intravenous formulation of ibuprofen which is currently in Phase III clinical trials.
We are preparing to submit our NDA for the product to the FDA in the second half of 2008. If
approved by the FDA, we expect Amelior to be the first injectable product available in the
United States for the treatment of pain and fever.

Cumberland Pharmaceuticals is interested in acquiring the rights to branded, prescription

pharmaceutical products in gastroenterology, hospital emergency medicine, and critical care.
Our subsidiary, Cumberland Emerging Technologies (CET), partners with several universities to
facilitate tech transfer of university research. CET builds on its relationship with Cumberland
Pharmaceuticals to help turn university research into marketable products.
Cumberland is interested in meeting with companies who have assets to divest in the areas of
gastroenterology, hospital emergency medicine, and critical care.
Please direct meeting requests to Elizabeth Gerken, Director of Business Development.
Our goals for attending the LES meeting include in-licensing of pharmaceutical products, and
university tech transfer collaborations.

Partnering
Hospital critical care, post-
Amelior Not Applicable Europe
surgical
Kristalose Gastroenterology Not Applicable Canada
D.P. Ahuja & Co.
53 Syed Amir Ali Avenue | Calcutta 700019 | India

Phone: +91 33 22819195 | Fax: +91 33 22819444
Contacts

Mr. Indrani Ghattacharya |

Mr. Sekhar Ranjan Gupta |
Organization Type
Law Firm
Company Overview
D.P. AHUJA & CO., is a full-service intellectual property firm, specialising in patent and
trademark filings, prosecution and litigation. D.P. AHUJA & CO. is committed to a tradition of
high ethical standards and excellence in professional services. Our firm combines the capabilities
of 124 members, including 34 Attorneys, 28 Managers and Support Staff to provide fully
integrated, high-quality legal and professional services. Our practice is technology-oriented and
our records, files and business data are fully computerised and updated on-line on a unique,
proprietary web-based document and information management system.
Further information about D.P. Ahuja & Co. can be found at www.dpahuja.com.

Patents, Tech Transfer and R & D Agreements.

Pharmaceutical, Telecom, Chemical, Electronics, Biotechnology, Software

Developments in Licensing and Tech Transfer agreements.
Dana-Farber Cancer Institute
Office of Research and Technology | Ventures, 44 Binney Street | Boston MA 2115 | United
States
Phone: (617) 632-5893 | Fax: (617) 632-4012 | Website: www.dana-farber.org/res/technology
Contacts
Mr. Anthony Del Campo | VP Research & Technology Ventures
Mr. Ojas P. Mehta | Associate Director, Research and Technology Ventures
Dannemann, Siemsen, Bigler & Ipanema Moreira
Rua Marques de Olinda, 70 | Botafogo | Rio de Janeiro . RJ 22251-04 | Brazil

Phone: +55-21 2553 1811 | Fax: +55-21 2553 1812/13
Contacts
Mr. CANDIDA R. CAFFE | Lawyer

Mr. Raul Hey | Partner

Mr. Gustavo Morais |
Datatek Applications Inc.
379 Campus Drive | Suite 100 | Somerset NJ 8873 | United States

Phone: (732) 667-1080 ext 119 | Fax: (732) 667-1091
Contacts
Mr. Gene Buterbaugh | Director of IP Business Development
Defined Health
418 Aeschenvorstadt 71 | Basel CH-4501 | Switzerland

Phone: +41 61 225 4207 | Fax: +41 61 225 4208 | Website: www.definedhealth.com
Contacts
Ms. Ginny E. Llobell | Vice President
Mr. Edward C. Saltzman | President
Ms. Linda A. Webb | Director of Marketing
Company Overview
Defined Health advises companies investing in drug discovery and development to identify and
value future medicines.
1. Established in 1983, Defined Health has more than 20 years experience in the global
biopharmaceutical industry.
2. Our expertise helps companies of all sizes make crucial and often tough decisions –
identifying which drugs have the most potential and which face the biggest challenges
3. We describe our advice as “unconventional insight” – that means our advice invariably
contains an aspect that is surprising or new
4. For our clients, our value is in providing an objective, informed, external view - helping
to answer the big questions of value. Such as:
What is the potential commercial value of this opportunity?

Does the science make sense?
What will be the standard of care in the next decade?
How will our potential drug fit in?

Who will prescribe it?

Should we acquire this asset? If yes, for how much?
How much do we need to invest to continue development?
Who will pay for it and what does it need to do to be paid for?
Our experience means each new project starts from a solid foundation of knowledge – deep in
the therapeutic area, wide in application.
We assess the potential of the science, the future clinical context, and the likely commercial
value, bridging across knowledge, resource or internal company communication gaps. We also
leverage knowledge from one therapeutic area to another, bringing insights that might otherwise
be missed.
Over the past two decades, Defined Health has helped to assess the value of many of the
industry’s headline partnering deals.
Find out more about Defined Health and our recent presentations on topical and therapeutic area
specific subjects at www.definedhealth.com.
Delphi Corporation
5725 Delphi Drive | Troy MI 48098 | United States

Phone: (248) 813-8076 | Fax: (248) 813-5008
Contacts
Mr. Eric K. Stief | Licensing Manager
Organization Type
Industry Sector
High Technology
Dennemeyer & Co.
175 North Franklin | Suite 400 | Chicago IL 60606 | United States

Phone: (312) 380-6496 | Fax: (312) 419-9440 | Website: www.dennemeyer.com
Contacts
Ms. Leah Christoforidis | Sales
Mr. Alexander Clemens | Marketing and Business Development
Mr. Wolfgang Danner |

Mr. Rodger D. Jackson | Managing Director

Mr. Tom Wiggins | Director, Business Development
Company Overview
Company Name: Dennemeyer & Co.
Profile: Global Full Service IP Management
Company Description:
For more than 45 years Dennemeyer is the industry’s first choice for full service global
IP management, and has established itself as the premier resource for comprehensive
intellectual asset services.
With an extensive network of local agents and associates, Dennemeyer has the
appropriate capabilities to provide clients with unparalleled efficiency and unmatched
cost-effectiveness.
Dennemeyer offers professional Software solutions, high quality Patent and Trademark
Portfolio Services and competent support through consulting and temporary on-site
assistance.
Website: www.dennemeyer.com
Department of Defense
9800 Savage Road | Fort Meade MD 20755 | United States

Phone: (443) 479-9569
Contacts
Ms. Marian Roche |
Development Capital Networks, LLC
14358 N. Frank Lloyd Wright Blvd | Suite 14 | Scottsdale AZ 85260 | United States
Phone: (602) 795-8825 | Fax: (877) 671-5998
Contacts
Mr. Paul H. Huleatt | Managing Director

Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
Development Capital Networks, LLC (DCN) is a professional firm devoted to building
problemsolving organizations. The firm specializes in:
• Technology commercialization
• Seed and venture Investing
• Private equity
• Development finance
• Knowledge based economic development
DCN provides advanced training, facilitation, and consulting to organizations concerned with
improving their systems for commercializing technologies, attracting capital for business
development, investing capital in entrepreneurs, and building communities with development
finance and advanced business skills. We manage projects and programs that integrate virtual
communities of financiers, developers, and innovators with federal programs. We work hand-in-
hand with our clients, leveraging our combined strengths and resources to achieve their goals.
We believe in the transformational power of networks. The heart of our service is not dependent
on a small team of experts. Rather, our success is rooted in the diversity of our team and our
ability to solve complex problems by systematically engaging and leveraging our extensive
national network of innovators, developers and investors—with whom we have existing
relationships.
DCN has created several such problem-solving programs and organizations. We helped launch
the National Association of Seed and Venture Funds in 1993 <www.nasvf.org>, the Latin
American Venture Capital Association in 2002 <www.lavca.org>, and the WBTshowcase in
2002 <www.wbtshowcase.com>. And in 2006, DCN began providing technical assistance to
National Science Foundation's Phase I SBIR grantees, leveraging DCN's national network of
mentors for over 450 NSF Phase I grantees.

Industy-SBIR partnerships
Industry-university partnerships
Intellectual Property Management
Licensing of IP developed by seed and early stage companies
Open Innovation for small businesses
University research
Government research


Fortune 1000 companies: External Technology Development professionals - Tech Scouts -
seeking new technologies developed by at universities and at private companies with the support
of the SBIR program.
Universities: University Tech Transfer professionals seeking to commericalize proprietary
technologies or spinning out new companies.
Intellectual Property Consulting Firms: IP professionals seeking to build relationships with
emerging, seed stage companies, some of which may be supported by SBIR funding.

Our firm is a for-profit entity where our clients non-profit organizations.
Our primary purpose of attending this year's LES conference is in support of the upcoming
WBTshowcase, an event Development Capital Networks produces each year in Dallas, TX
showcasing upwards of 100 investment and licensing opportunities. The event, March 24-25,
2009 is national in scope and is designed to support emerging companies - and technologies -
emanating from universities and federal labs to partner with qualified seed stage venture
investors and Fortune 1000 strategic partners.
The WBTshowcase is financially supported by corporate, government, and academic

organizations. However, the sourcing, screening, and mentoring of upwards of 100 presenters
each year is entirely voluntary and involves the collaborative input of over 200 investment,
licensing, and IP professionals.
Our mission at LES is to identify potential partnerships with those interested in commercializing
proprietary technologies.
DFM, Ltd.
8 Indianhead Road | Morristown NJ 7960 | United States

Phone: (973) 898-6662 | Fax: (973) 898-6664
Contacts
Dr. Douglas Munch | President

Dickstein Shapiro LLP
1825 Eye Street, NW | Washington DC 20006 | United States

Phone: (202) 420-2611 | Fax: (202) 420-2201 | Website: www.dicksteinshapiro.com
Contacts
Mr. Jon D. Grossman | Partner
Mr. Bradley Olson | Patent Attorney
Organization Type
Law Firm
Company Overview
Dickstein Shapiro LLP works with companies in developing strategies that capitalize on their
intellectual property assets to achieve the clients’ business objectives. The Firm has the
experience, skill, and knowledge to solve these and other intellectual property problems
successfully for clients striving to succeed in this ever-changing, highly competitive arena.
Recognized as industry leaders by publications such as Managing Intellectual Property and
Intellectual Property Today, Dickstein Shapiro is among the top patent and trademark firms in
the country.
Members of the Intellectual Property Practice have lectured extensively in the United States and
overseas for groups such as the ABA, AIPLA, and PLI. In addition, the Firm’s IP attorneys have
published, co-edited, and written chapters in numerous books, such as BNA’s Patent Litigation
Strategies and Aspen’s Intellectual Property Opinions, as well as articles on intellectual property
issues. The Firm’s IP attorneys prepared the Intellectual Property Primer for the Association of
Corporate Counsel, the first edition of which was so well received in 2003 that a second and
third edition were released in 2005 and 2008.
The Firm currently has more than 80 intellectual property attorneys practicing full-time with
significant experience in patent and trademark litigation. The Firm’s IP attorneys have handled
hundreds of litigations, including numerous jury trials. Most are registered patent attorneys, and
more than 60 members of the practice have technical degrees. In addition, a large number of
Dickstein Shapiro attorneys from other practice areas, including many former U.S. Attorneys and
assistant U.S. Attorneys, participate regularly in the Firm’s intellectual property litigation,
adding their depth of litigation experience to the practice.
Founded in 1953, Dickstein Shapiro is a multiservice law firm with more than 400 attorneys in
Washington, DC, New York, and Los Angeles. The Firm’s clients include more than 100 of the
Fortune 500 companies, start-up ventures and entrepreneurs, multinational corporations, leading

financial institutions, major motion picture studios, charitable organizations, and government
officials. Dickstein Shapiro’s core practice groups—Antitrust & Dispute Resolution, Business &
Securities Law, Corporate & Finance, Energy, Government Law & Strategy, Insurance
Coverage, and Intellectual Property—involve the Firm in virtually every major form of
counseling, litigation, and advocacy.
Digimarc Corporation
9405 SW Gemini Drive | Beaverton OR 97008-7192 | United States

Phone: (503) 469-4641 | Fax: (503) 469-4777 | Website: www.digimarc.com
Contacts
Mr. Thomas M. Horgan | Senior Director, Licensing
Organization Type
Industry Sector
High Technology
Company Overview
Digimarc is a leading innovator and technology provider, particulary in the area of digital
watermarking. We enable new digital media distribution models and solutions for media
identification and management, in addition to enhancing traffic safety and national security, and
combating fraud, counterfeiting and piracy.

patents, tech transfer, valuation, intellectual asset management

Digital watermarking providers, valuation consultants

out-licensing

Partnering
digital
? Not Applicable Worldwide
watermarking

Digital Thinking Inc.
3702 Clendenin Court | Austin TX 78732-2254 | United States

Phone: (512) 266-7126
Contacts
Mr. Don Jarrell | President
Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
Digital Thinking provides advisory and execution services to all size companies, and individual
inventors and entrepreneurs in the fields of intellectual property and product management,
covering IP strategy; licensing transactions; IA/IC/IP management education, policy/process
development and operations; alternative commercialization; technical investigations (reverse
engineering); patent evaluation; prior art searches and freedom to operate studies; and expert
witness searches and engagements. Technologies addressed include software, systems, and
electronic assemblies and components, including semiconductors.
Because of the breadth of coverage, and the complexity of IP strategies and matters, we welcome
early stage, no obligation conversations to discovery how we can best help. No matter what your
circumstances, if it involves intellectual property… let’s talk.
DJG Management Associates
1339 Vallee Drive | West Deptford NJ 8096-3139 | United States

Phone: (856) 848-6439 | Fax: (856) 848-7809
Contacts
Mr. David Gibson | President
Organization Type
Consulting Firm
Industry Sector
Chemicals
Company Overview

Intellectual Property marketing, including mining, organizing, prospectus development, lead

generation and license negotiations.

We are focused on intellectual property mining, prioritizing, and plan development towards
licensing opportunities.

Research oriented companies with interest in defining and developing their inventory of IP for
possible licensing.
Find customers for current clients; develop contacts for future IP licensing; meet prospective
clients.
DM Kisch Inc.
5 Inanda Greens Business Park | 56 Wierda Road West | Sandton Gauteng 2146 | South Africa
Phone: 27 113243025 | Fax: 27 118848875
Contacts
Mr. Kevin Dam |
Dolcera
201 A S. Delaware St #306 | San Mateo CA 94401 | United States

Phone: (650) 269-7952
Contacts
Mr. Samir Raiyani | CEO
Organization Type
Consulting Firm
Industry Sector
Health Care
Company Overview

Dolcera provides IP, technology and market research services as well as strategic inputs to some
of world's largest companies in high tech, life sciences and manufacturing. Our clients include
some of world's largest companies as well as some very exciting startups around the world.
We provide in-depth technology, IP and market analysis and help organizations find the value in
their ideas. We help them validate the ideas from a competitive standpoint as well. With
thorough subject-matter analysis and extensive research, Dolcera's experts have guided R&D,
licensing, business development and marketing teams identify several new and emerging multi-
billion dollar markets. We use our own knowledge-sharing platform for delivering our research
and analysis, and for collaborating with our clients.

Partnering
Dolcera
dashboard
Landscape reports n/a Not Applicable Worldwide
Dorsey & Whitney
666 Burrard Street, Suite 500 Park Place | Vancouver BC V6C 3J6 | Canada
Phone: +1.604.687.5151 | Fax: +1.604.687.8504
Contacts
Mrs. Ayleen Ito Lee | Attorney
Mr. Hiro Tachibana | Of Counsel
Company Overview
Global. Dorsey & Whitney LLP is among the largest law firms in the world, with 19 strategically
located offices. Our more than 650 lawyers and 750 support staff share the vision: to be a leader
by leveraging our core strengths worldwide. These strengths include the exceptional talents of
our lawyers, our expansive capabilities and the teamwork we employ in responding to our
clients’ needs.
Strength. We continue to build on our traditional strengths in corporate law and litigation
through our wide range of practice groups. We understand that clients’ needs are seldom
confined to strict categories and that major transactions and disputes often require advice that
spans practices. Focusing on clients’ needs is one of the reasons Dorsey is among the top legal
advisors.

Focus. We are committed to meeting the needs of our clients in the broadest sense. To that end
we team with clients to focus on delivering high-quality legal services in a timely and cost-
effective manner. We listen attentively to our clients’ many needs.
Value Added. Clients welcome the use of our broad team approach as we collaborate to develop
their strategic plans. We provide:
Enhanced value to an organization

Integrated legal services
Long-term relationship management
Dorsey’s approach is to provide added value to our clients by understanding and anticipating
their future business needs and challenges.
Dow Lohnes PLLC
1200 New Hampshire Ave., NW | Suite 800 | Washington DC 20036 | United States
Phone: (202) 776-2300 | Fax: (202) 776-4300 | Website: www.dowlohnes.com
Contacts
Mr. James M. Burger | Member
Organization Type
Law Firm
Industry Sector
High Technology
Company Overview
Firm Overview: Dow Lohnes serves as a strategic partner with its clients in a number of
dynamic industries including communications and traditional media, new media, information
technology, education, healthcare, real estate and more. Dow Lohnes’s service offerings have
grown as its clients’ businesses have become more complex and demanding. With offices in
Washington, DC and Atlanta, the firm has over 150 lawyers and professionals supported by
extensive resources and a considerable depth of experience. Dow Lohnes possesses the strength
of a large Washington-based regulatory practice as well as a sophisticated business and
transactional law practice. Together with litigation, intellectual property, tax and human
resource practices, the firm offers a comprehensive array of legal services. Above all, Dow
Lohnes is committed to working in partnership with its clients and providing them with superior
legal counsel.

Communications & Telecommunications: Dow Lohnes’s communications and

telecommunications groups encompass one of the largest and most diverse communications law
practices in the United States. Our lawyers represent all segments of the communications and
media industries including commercial and non-commercial broadcast stations, cable television
operators, cellular, PCS, paging and other wireless communications companies, local and long
distance landline service providers, commercial satellite operators and broadband service
providers. Dow Lohnes lawyers are well-versed in assisting other entities who need to know
how changes in the industry affect their non-telecommunications businesses.
Media & Information Technologies: Dow Lohnes’s media and information technologies
attorneys represent clients in traditional and new media, information technology,
telecommunications and other industries. The attorneys handle matters ranging from the
protection, acquisition, licensing and use of intellectual property to negotiating matters affecting
virtually every kind of internet business. Dow Lohnes represents some of the largest information
technology companies on transactions, intellectual property and public policy issues.
Intellectual Property: Dow Lohnes has developed a distinguished intellectual property, media
and information technology practice and represents a broad cross-section of businesses ranging
from traditional and new media to computer, software to communications and
telecommunications to education. The firm’s areas of expertise include trademark and copyright
law, patent law, unfair competition, and merchandising, as well as the protection, acquisition,
and licensing of intellectual property. Our clients include national media firms with interests in
broadcasting, as well as companies involved in computer hardware and software, the Internet,
entertainment, information technology, telecommunications, cable television, satellite
communications, newspapers and book publishing. We also represent a wide range of colleges,
universities and public broadcasting stations.
Litigation: Dow Lohnes litigators represent clients from large, publicly held companies to small,
closely held businesses, as well as individuals and estates. The firm’s litigators regularly
practice before federal and state trial and appellate courts throughout the country, and on teams
before federal agencies. The firm has specific expertise in areas such as securities litigation,
intellectual property and technology issues, communications and telecommunications,
commercial law, antitrust, federal and state taxation, Constitutional and First Amendment issues,
labor and employment, criminal law and government investigations, environmental law and
higher education.

Dr. Stephen Potter
Route de Champ-Fleuri 9 | Glion 1823 | Switzerland

Phone: +41 21 961 26 68
Contacts
Dr. Stephen Potter |
Company Overview
I am working independently in a variety of areas:
- pro-bono talks and advice to a number of organisations and societies on IP and R&D e.g. LES
in a variety of countries; Reseau Curie in France, EIRMA, ASTP and so on....
- acquiring IP in software and telecoms for a private US company
- acting for a limited number of companies to try to find investors or to help them transfer
technology
- acting as an IP advisor to a number of companies, including Versatile Connections in the UK
- I am living in Switzerland and have a very wide set of contacts and working experience in the
(fine) chemical, (generic) pharma, materials, printing and packaging, automobile, electronic and
telecommunication industries
- I have lived and worked in the US, UK, Switzerland and Germany and have fluent French and
German.

I am principally interested in acquiring software and telecoms patents but I'm also interested in
keeping up to date my knowledge in the bio/pharma/medical area and, the increasingly trendy
fields of novel energy sources/ renewables and so on....
To make as many high level contacts in the high-tech, bio/pharma and chemical/materials
industries as possible.
To renew contacts with my friends!

Dr. Susan Carson
5517 Dowgate Court | #204 | Rockville Maryland 20851 | United States

Phone: (301) 770-2145
Contacts
Dr. Susan Carson |
Dr. Wallace Oliver
110 Broadway | Wilmette Illinois 60091 | United States

Phone: (847) 436-1094 | Fax: (847) 251-6236
Contacts
Dr. Wallace Oliver | Attorney
Draths Corporation
6749 Troy Lane N | Maple Grove MN 55311 | United States

Phone: (952) 221-0927
Contacts
Mr. John Raley | Senior Director, Intellectual Assets
DRI Capital
22 St. Clair Avenue East | Suite 200 | Toronto Ontario M4T 2S3 | Canada
Phone: +1 (416) 863-1865 | Fax: +1 (416) 863-5161
Contacts
Mr. M. MacNaughtan | Executive Vice President, Head of Royalty Monetization Fund
Company Overview
DRI Capital Inc. (“DRI”), formerly Drug Royalty Corporation, is a privately held investment
management company, focused on the healthcare industry. DRI’s Royalty Monetization Fund
acquires existing royalty streams at competitive rates from companies, research institutions and
inventors. The Fund acquires royalties based on sales of commercialized pharmaceutical
products, medical devices and life sciences technology. With a fifteen year track record of

completing transactions and over $1 billion under management, DRI is a leader in monetizing
royalties.
Drinker Biddle & Reath LLP
1500 K Street NW | Suite 1100 | Washington DC 20005 | United States

Phone: (202) 842-8802 | Fax: (202) 842-8465
Contacts
Mr. Ronald Grudziecki | Partner
Duane Morris, LLP
1540 Broadway | New York NY 10036 | United States

Phone: (212) 692-1011 | Fax: (212) 692-1020 | Website: www.duanemorris.com
Contacts
Mr. Luke Anderson | Partner
Mr. Thomas F. Meagher | Partner
Organization Type
Law Firm
Company Overview
An Introduction to Our Firm
Duane Morris LLP, one of the 100 largest law firms in the world, is a full-service firm of more
than 600 lawyers. In addition to legal services, Duane Morris has independent affiliates
employing approximately 100 professionals engaged in other disciplines. With offices in major
markets, and as part of an international network of independent law firms, Duane Morris
represents clients across the United States and around the world. Throughout its more than 100-
year history, Duane Morris has fostered a collegial culture, where lawyers work with each other
to better serve their clients. Lawyers who are leaders in a range of legal disciplines and have
diverse backgrounds join Duane Morris in order to use the latest technology, professional
support staff and other resources in pursuit of clients’ goals.
Growth and Culture

Evolving from a partnership of prominent lawyers in Philadelphia more than a century ago,
Duane Morris now has offices in many major markets and, according to The National Law
Journal, is one of the fastest-growing law firms in the United States. The firm has doubled in
size in the past five years, and continues to expand across the country and overseas. Throughout

this expansion, Duane Morris remains committed to preserving the collegial culture that has
attracted so many talented attorneys. The firm’s leadership believes this culture is truly unique
among large law firms, and that outstanding legal work is best accomplished by skilled
professionals who respect each other and work well together.
Leadership and Experience

Duane Morris lawyers hold leadership positions in bar associations, as well as in educational,
cultural and charitable organizations and with community groups across the country. Many of the
firm’s attorneys come to Duane Morris after having held senior positions in government agencies
and large corporations. This range of experience is further enriched by the diverse backgrounds
of the firm’s attorneys. Duane Morris has long been committed to recruiting, retaining and
promoting talented female and minority lawyers, many of whom hold leadership roles at the
firm.
Technology and Infrastructure

The firm supports its attorneys in the practice of law with resources unsurpassed by those at any
major law firm. Trade publications have placed Duane Morris in the upper echelon of firms in
terms of utilizing technology. Hundreds of lawyers working around the globe quickly
communicate and collaborate using the firm’s integrated computer network, accessing
sophisticated research software, information-rich databases, and other knowledge-sharing tools.
Duane Morris’ clients also benefit from the contributions of professional-level support staff who
maintain the firm’s technological and administrative infrastructure and enable lawyers to focus
on providing valuable counsel and service to their clients.
DuPont Company
Barley Mill Plaza 26.1256 | PO Box 80026 | Wilmington DE 19880 | United States
Phone: (302) 992-2014 | Fax: (302) 992-6728
Contacts
Dr. David J. Wallan | Director . IP and Licensing
DuPont Company, Center for Collaborative Research
Experimental Station E357/202 | Route 141 Henry Clay Road | Wilmington DE 19880-
0357 | United States
Phone: (302) 695-6785 | Fax: (302) 695-6794
Contacts
Dr. Robert Gruetzmacher | Director, Technology Commercialization

E.B. Cross & Company
113 Sandy Ridge Place | Waterloo ON N2T 1C5 | Canada

Phone: (519) 884-4352 | Fax: (519) 884-1478
Contacts
Mr. E.B. Ted. Cross | President
Ebert Wolfe & Co.
6787 Via Casa Del Sol | Suite 101 | Carlsbad CA 92009 | United States
Phone: (760) 438-2122
Contacts
Mr. Paul Ebert | President
Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
Ebert Wolfe & Co.
♦♦♦♦♦
Your key to successful executive search
Ebert Wolfe & Co. is a well-established global executive search firm in business since 1986 with
offices in Scottsdale, Arizona and San Diego, California. Our professionals have experience
since 1974 in search and recruitment. Ebert Wolfe & Co. is committed to providing unparalleled
search and recruitment expertise, and to maintaining the highest professional standards in
accomplishing our mission.
Key factors leading to success
5. Depth of experience.
6. Responsive, timely completion of assignments.
7. Consultive approach to staff and leadership acquisition.

8. We conduct our relations with clients, candidates and the community in a manner consistent
with conventional codes of ethics, confidentiality and best practices.
9. Commitment extends to active participation in our client’s professional organizations.
10. Integrity and reputation within the industries we serve are of utmost importance to us. Therefore,
we will not accept an assignment that conflicts with the interest of past or present clients.
11. Most extensive resources and contact network within the industry niches we serve.
Ebert Wolfe - the right combination
Our commitment at Ebert Wolfe & Co. is to develop and maintain lasting client relationships by
providing professional and efficient service to fulfill staffing objectives.
♦♦♦♦♦
Visit our website www.ebertwolfe.com

Phone us 480.314.1000 or 760.438.3700
E-mail us

To provide information which can be helpful to individuals relative to HR, recruiting, and key
elements to succesfully carry out the human side of IP.

Any company or individuals that would like to discuss human capital and talent acqusition.
To renew membership acquaintances and develop new relationships with individuals and the
firms they represent.
To learn of new developments and information in all realms of licensing helpful to our business
and that of our client's as well.
To provide information and guidance and assistance to those seeking same to the best of our
knowledge and ability relative to talent acquisition.
To acquire new acquaintances where our services are likely to provide discernible value added.


Partnering
Executive Search
Services
Economic Development Partnership of Alabama
500 Beacon Parkway West | Birmingham AL 35209 | United States

Phone: (205) 943-4778 | Fax: (205) 943-4799 | Website: www.edpa.org
Contacts
Ms. Angela J. Wier | Vice President
Industry Sector
Company Overview
The Economic Development Partnership of Alabama (EDPA) is a statewide, privately funded,

not-for-profit corporation that works with industry, government, and educators to create more
economic opportunity in Alabama. With specific regard to licensing, EDPA works with
universities, research institutes, and federal labs in Alabama to promote Alabama technologies.
We are a funding partner for the new Alabama technologies database, available at
www.alabamalaunchpad.com. We are a strategic partner for collaboration within the state to
make it easy for the world to find Alabama technologies.

We are interested in meeting with industry representatives who are looking for specific
technology solutions. We want to make industry representatives aware of our web searchable
database of technologies available for license at www.alabamalaunchpad.com, on the tech
transfer tab.
We would like to meet with corporate personnel responsible for in-licensing technologies. We
are especially interested in talking to companies who are looking for specific technologies. The
Alabama team attending LES represents five research universities, one contract research
institute, and one federal lab. We are collaborating to promote Alabama technologies and to
listen to the needs of industry.


Helping research universities, research institutes, and federal labs in Alabama out-license their
technologies and participate in university/industry collaborations.

Partnering
Alabama
Not applicable Not Applicable
Technologies
Edell, Shapiro & Finnan, LLC
1901 Research Blvd | Suite 400 | Rockville MD 20850 | United States

Phone: (240) 864-2433 | Fax: (301) 762-4056 | Website: www.usiplaw.com
Contacts
Dr. Jeffrey I. Auerbach | Biotechnology Patent Attorney / Partner
Organization Type
Law Firm
Industry Sector
Health Care
Company Overview
Edell, Shapiro & Finnan, LLC is an intellectual property firm located in Rockville, Maryland.
The firm’s practice includes all areas of intellectual property law and, particularly focuses on the
preparation and prosecution of patent, trademark and copyright applications, license negotiation
and the counseling of clients on issues of infringement, validity and patentability. The firm’s
clients range from individuals and small companies to academic institutions to Fortune 500
companies located throughout the United States and the world. Members of the firm practice in
all areas of technology. ES&F’s clients range from multinational corporations to younger
companies to major academic and research institutions.

ES&F is interested in patent law and policy, technology transfer, licensing and university and
corporate research activities.

We are particularly interested in meeting with representatives of our existing clients, and with
representatives of potential new clients.


We are interested in meeting with representatives of our existing clients and in developing
relationships with new university and corporate clients, especially in the areas of biotechnology
and pharmaceutical patenting, counseling and licensing.
EI Bio, Enterprise Ireland
Technology House | Glasnevin | Dublin Dublin 9 | Ireland

Phone: +353-1-808-2000
Contacts
Miss Tara MacMahon | Solicitor
Organization Type
Company Overview
Enterprise Ireland is the trade and technology development agency for the government of
Ireland. Its mission is to support indigenous Irish industry and to help Irish companies to build
international partnerships and to penetrate overseas markets. It is also responsible for promoting
and supporting investment by the international food industry in Ireland and in encouraging start-
up companies to locate in Ireland.
We are particularly interested in meeting with food, ingredient, nutrition and consumer products
companies and entrepreneurs with a potential interest in Ireland. Our representative Tim Roche
will be delighted to meet with you during the show.
On behalf of our clients, Enterprise Ireland is seeking in and out-licensing opportunities, research
collaborations, marketing agreements and customers for a broad range of high tech, consumer
product and biotech/healthcare producers and service companies.
We are looking for expressions of need for technologies, products and market supply capabilities
that are founded on solid R&D & IP platforms and world-class manufacturing, service & supply
competencies.

e-IP: Tech Transfer Online.com
840 W. Long Lake Road, Ste. 145 | Troy Corporate Center | Troy MI 48098 | United States
Phone: (248) 593-5926 | Fax: (248) 593-1265 | Website: www.TechTransferOnline.com
Contacts
Mr. Christophe Sevrain | CEO
Industry Sector
Company Overview
e-IP (www.TechTransferOnline.com) is an online marketplace that facilitates the in- and out-
licensing, selling and buying of IP. This unique web site provides a central, global database for
organizations and individuals to search, list, license, buy, and sell published and non-published
IP in a secure setting.

Corporations, research labs and universities.
1. Introduce www.TechTransferOnline.com to listers and searchers of Intellectual Property.

2. Meet with licensing executives that would like to license or sell their inventions by
posting their technologies on www.TechTransferOnline.com.
Country(s)
Partnering
www.TechTransferOnline.com All Not Applicable

Eisenfuehr, Speiser & Partner
Zippelhaus 5 | Hamburg 20457 | Germany

Phone: -3097431 | Fax: -30974435
Contacts
Mr. Rainer Boehm | Attorney at Law
Elan Drug Technologies
3500 Horizon Drive | King of Prussia PA 19406 | United States

Phone: +1.610.270.8442 | Fax: +1.610.313.5182 | Website: www.elan.com/EDT/
Contacts
Mr. Shawn D. Bridy | Independent Consultant
Organization Type
Industry Sector
Health Care
Company Overview
Elan's Drug Delivery Business has a long and established history in the development and
manufacture of pharmaceutical dosage forms for pharmaceutical markets worldwide. With more
than 20 commercially - marketed products manufactured and developed for over 40 countries,
Ean brings more than 30 years of experience when addressing the drug delivery challenges
facing the pharmaceutical industry. In 2003 Elan completed a $178M investment at its fully
compliant FDA/EMEA approved site in Athlone, Ireland. Elan also has a manufacturing scale-up
and development facility approved for the manuacture of controlled substances (through
Schedule II) in Gainesville, Georgia. The company's development and scale-up facility in King
of Prussia, Pennsylvania is home to its proprietary NanoCrystal technology for the delivery of
poorly water-soluble compounds.

Out-licensing
Elan Pharmaceutical
3500 Horizon Drive | King of Prussia PA 19406 | United States

Phone: (610) 313-8867 | Fax: (610) 313-7096

Contacts
Mr. Don C. Reed | Director of Business Development
Eli Lilly & Company
Lilly Corporate Center | DC 1885 | Indianapolis IN 46285 | United States

Phone: 317-276-2000 | Website: www.lilly.com
Contacts
Mr. Timothy Dolan | Manager
Mr. Randy D. Loser | Assist. General Counsel
Mr. Mark Miller | Sr. Director, Corporate Business Development
Mr. Joshua Salisbury | Vice President, Corporate Business Development
Mr. Paul Stewart | Manager, Global Business Development
Mr. John R. Tupman | Sr. Director, Corporate Business Development
Company Overview
Lilly is developing a growing portfolio of best in class pharmaceutical products by applying the
latest research from our own laboratories and from collaborations with eminent scientific
organisations worldwide.
In 2007 the company’s world-wide sales were more than $18.7 billion. Lilly employs more than
40,000 people worldwide and markets medicines in 158 countries. Lilly Research Laboratories
(the R&D division of the company) employs approximately 7000 people from a wide variety of
disciplines. The company has R&D facilities in 7 countries and currently conducts clinical trials
in more then 60 countries around the world.
Lilly’s internal research efforts are focused in the following major therapeutic areas: cancer,
cardiovascular diseases, endocrinology, neuroscience and musculo-skeletal disorders.
Compounds in late stage development, and those currently being launched have promise to
address the needs of patients with sepsis, cancer, diabetes, depression, osteoporosis, erectile
dysfunction, urinary incontinence and attention deficit hyperactivity disorder.
In pursuit of innovation Lilly seeks to incorporate those cutting edge technologies which support
the high quality, rapid identification and investigation of novel compounds.
The company approach to innovation includes a commitment to the philosophy of “research

without walls” – a stated commitment to partnership and external collaboration. Currently Lilly
Research Laboratories has more than 120 active collaborations with external scientists.
Elusys Therapeutics, Inc.
25 Riverside Road | P.O.Box 102 | Pine Brook NJ 7058 | United States

Phone: (973) 808-0222 | Fax: (973) 808-0322 | Website: www.elusys.com

Contacts
Mr. Jeremy D. Middleton | Vice President, Corporate Development
Endo Pharmaceuticals
100 Endo Boulevard | Chadds Ford Pennsylvania 19317 | United States

Phone: 6105589800 x4270 | Fax: 4848404291
Contacts
Mr. Mahen Gundecha | Sr. Director
Dr. Sam Rasty | Director
Mr. Mehul Shah | Director
Organization Type
Industry Sector
Health Care
Environment Canada
1040 St. Joseph Blvd | Gatineau QC K1A 0H3 | Canada

Phone: (819)-934-5683 | Fax: (819) 953-7253
Contacts
Mr. George Botulynsky | Manager, Intellectual Property
Ericsson AB
Ericsson Allee 1 | Herzogenrath 52134 | Germany

Phone: +49 2407 575 681 | Fax: +49 2407 575 5040 | Website: www.ericsson.com
Contacts
Mrs. Gabriele Mohsler | Director
Organization Type
Industry Sector
High Technology

EscrowTech International, Inc.
333 South 520 West | Suite 230 | Lindon UT 84042 | United States
Phone: (801) 805-8202 | Fax: (801) 852-8203 | Website: www.escrowtech.com
Contacts
Mr. Jorge Sagastume | Vice President
Ethypharm North America
1500 Market Street | East Tower 12th Floor | Philadelphia PA 19102 | United States
Phone: (215) 246-3422 | Fax: (215) 665-5626
Contacts
Mr. Hafid Touam | CEO
Mr. Carl Vanderborght | Director Business Development and Marketing North America
Organization Type
Industry Sector
Health Care
Company Overview
Ethypharm focuses on developing, manufacturing and licensing pharmaceutical products based
on optimization of delivery through proprietary technologies, mainly oral solid modified release
formulations.
Ethypharm has a special focus on pain management, cardiovascular, oncology and CNS branded
and generic products. Over the years, Ethypharm has developed more than 50 branded and
generic products, based on its core proprietary technologies.
Ethypharm is present on the principal world health markets with manufacturing and R&D sites in
Europe, in North America, China and India.
Specialty Pharma Companies involved in Pain Management
Generic Distributors

Virtual Pharma Companies with needs for Development capabilities involving Drug Delivery
Systems
Large pharmaceutical companies seeking lice cycle extension opportunities
Licensing of products in late stages of development and available for the US market
Licensing of product in late stages of development and available for the Canadian market
Licensing of products ready to register in Mexico and Latin America
for Partnering
Buprenorphine Sublingual
Pain Management Not Applicable United States, Mexico
Tablet
Diclofenac/PPI Fix
n/a Not Applicable United States, Mexico
combination
Oxycodon QD Abuse
Pain Management Not Applicable North America
Deterent
Oxycodon QD Abuse
Pain Management Not Applicable
Deterrent
Oxycodone ODT IR Pain Management Not Applicable United States, Mexico
Secnidazole Tab Women's Health Not Applicable North America
Sexual
Sildenafil ODT Not Applicable North America
Dysfunction
Tramadol/APAP Fix
n/a Not Applicable United States, Mexico
combination ODT
Eurand
845 Center Drive | Vandalia Ohio 45377 | United States

Phone: 937-898-9669 | Fax: 937-898-1093

Contacts
Mr. Troy Harmon | Senior Director, Bus Dev
Mr. Vincent Parrino | Manager, Business Development
Industry Sector
Health Care
Company Overview
Overview
Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and
biopharmaceutical products based on its proprietary drug formulation technologies. With a
command of four distinct platforms, Eurand has one of the broadest oral drug delivery platforms
in the pharmaceutical industry. After collaborating with partners to ensure a full understanding
of the market and product requirements, Eurand creates development plans that are
technologically advanced and fully executable and defined in time and budget. By combining
technical resources and clinical/regulatory expertise, Eurand creates proprietary products that
meet and exceed our partners’ needs.
Eurand’s technology platforms include customized drug release, taste masking & orally
disintegrating tablets, bioavailability enhancement of poorly soluble drugs and drug
conjugation. These platforms provide competitive advantages in turning difficult drug candidates
into easy-to-administer, successful pharmaceutical products. Specifically, Eurand’s technologies
enable the development of new drug entities and serve as effective life-cycle management tools
in order to prolong the market life of products.
In May 2007, following a successful IPO, Eurand became a public company and is listed on the
NASDAQ Exchange under the symbol EURX. With more than 500 employees worldwide,
Eurand is a global company with integrated manufacturing/R&D facilities in the USA and
Europe.
Eurand’s ability to meet the drug optimization goals of its partners coupled with its broad and
validated technology platforms and multinational R&D and manufacturing infrastructure has
attracted many leading pharmaceutical companies as commercial partners. Since 2001, Eurand
has had four of its partnered products FDA approved and, currently, has many product
candidates in development internally and with partners. Since 2005, the Company has signed
twenty new co-development agreements with pharmaceutical companies located in the U.S.,
Europe and Japan.
Key Technologies
Eurand has successfully applied its technologies to drug products in a diverse range of
therapeutic areas including pain, CNS, cardiopulmonary, and gastrointestinal diseases. Eurand’s
proprietary drug formulation capabilities include four primary platforms encompassing nine
distinct technologies and covered by more than 300 patents. The Company’s premier
technologies include:

 Diffucaps®: Customized drug release technology with the flexibility to design sustained,
delayed, or pulsatile release profiles in once-daily dosages, optimizing PK and potentially
improving efficacy and tolerability;
 Microcaps®: Microcapsulation technology using solvent- and aqueous-based
coascervation, enabling taste-masking, separation of incompatible materials and
customized release;
 Microcaps® is one of the only GMP-scale coascervation technology in the world with
pharmaceutical products on the market;
 AdvaTab®: Latest generation in orally-disintegrating tablets (ODT) to improve patient
compliance through a more convenient dosage form; integrates taste-masking and
controlled-release technologies in a fast disintegrating tablet that utilizes standard
manufacturing processes;
 Biorise®: Bioavailability enhancement to improve absorption of poorly water soluble
drugs, resulting in reduced dose and improved onset of action; uses high energy process
to micronize drug crystals and encapture them in a carrier polymer; and
 Drug Conjugation: Covalently links drug molecules with biocompatible carbohydrate
carriers, offering the potential to extend drug half-life and target specific organs or
biological targets such as tumors.
Highlights
Eurand has four partnered products with approved NDA (one undisclosed) in the U.S. using its
Diffucaps® customized release technology:
 Metadate CD® (methylphenidate; ADHD): Marketed since 2001; licensed to Celltech

 Innopran XL® (propranolol; hypertension): Marketed since 2003; licensed to Reliant
Pharmaceuticals
 Amrix® (cyclobenzaprine; muscle relaxant): NDA approved in February 2007, acquired
by Cephalon, launched Q4 2007
Eurand has multiple partnered programs on track for NDA filings by 2008, many of which utilize
AdvaTab® ODT technology, particularly for CNS indications. One of these programs (EUR-
1048) is partnered with GlaxoSmithKline.
The Company has developed and manufactured fifty products for its partners. In addition,
Eurand has a number of Rx and OTC products available for licensing. In general, these products
are improved versions of existing drugs that incorporate its proprietary drug delivery
technologies. Eurand manufactures these products for pharmaceutical companies for marketing
throughout the world.
In 2006, the Eurand had revenues of approximately $109 million; through September 30, 2007,
the Company has reported revenues of $90.5 million.

Eurand is seeking opportunities to leverage its proprietary drug delivery and formulation
technologies in partnerships to enable the development of novel, value-added products in the
following areas:

12. NCE enablement

13. Drug life cycle management
14. Drug repurposing
15. OTC line extensions
for Partnering
AdvaTab(R) orally
Various Ready to Market Worldwide
distingrating tablets
Amrix(R) (extended release Skeletal muscle
Currently Marketed
cyclobenzaprine) relaxant
Diffucaps Controlled
Various Ready to Market Worldwide
Release Technology
EvaluatePharma USA, Inc.
4001 Kennett Pike Street | Suite 134-232 | Wilmington DE 19807 | United States
Phone: (877) 290-5354 | Website: www.evaluatepharma.com
Contacts
Ms. Margaret Nelson | Manager, Sales and Solutions
Company Overview
EvaluatePharma® is the premier source for pharmaceutical and biotechnology analysis
delivering unique insight into sector performance in a user-friendly, online subscription service.
We provide a comprehensive view of the industry and its past and expected future performance
by capturing the consensus of the equity analysts and seamlessly integrating them with the
historic results. We have just extended our consensus forecasts to 2014 on all product
forecasts, therapy area sales, company portfolio analysis and financial statements.
Since 1998 EvaluatePharma has provided clients in both industry and the investment community
with a forward-looking view of the market ranging from total market trends and therapeutic
overviews to individual company performance and product progress. All our analyses can be
edited, customized, downloaded into Excel and integrated with other sources or clients can
design their own bespoke reports giving full flexibility with the data.

Our premium service EvaluatePharma® Alpha is designed to identify the events that shape the
pharma and biotech markets and quantify their impact on product, portfolio and company
valuation with:
16. Calendar of Events: tracking future pivotal events impacting company valuation
including product approvals, trials, patent and litigation
17. Interactive NPV Analyzer: for future event outcome analysis with over 3500 product
NPVs linked to share price
18. EP Vantage: daily news service with comment and analysis
Evalueserve
1500 Purson Lane | Lafayette CA 94549 | United States

Phone: (925) 944-2476 | Fax: (925) 871-5113
Contacts
Mr. Marty Perelstein | Client Executive
Mr. George Sawyer | Client Executive
Organization Type
Company Overview
Evalueserve is a seven year old, 2500 person Intellectual Property/Business/Market research firm
with research centers located in India (2), China, Chile, and Romania. Evalueserve has
completed over 13,000 research projects for over 1,100 customers, including over 100 of the
Fortune 1000. Founded by executives from McKinsey and IBM, Evalueserve provides support to
licensing executives, corporate and outside counsel, IP Counsel, and Business Development
executives in High Tech, Life Sciences, Chemical, Consumer Goods industries.
Typical projects include market sizing, in- and out- licensing target analysis, new technology
identification, competitive intelligence, company profiles. Evalueserve's 135 person Shanghai
office has made it one of the best sources of information on business and IP in China.
Evalueserve has completed over 400 patent landscapes, over 100 patent portfolio analyses, 100
commercialization studies, etc.
EWI
1250 Arthur E. Adams Drive | Columbus OH 43221 | United States

Phone: (614) 688-5000 | Fax: (614) 688-5001

Contacts
Mr. Shuchi P. Khurana | Product Line Manager
Exploit Technologies Pte Ltd
30 Biopolis Street | #09-02 Matrix | Singapore 138671 | Singapore

Phone: 65-6478-8460 | Fax: 65-6873-7192
Contacts
Mr. Andrew Ang | Manager, Flagship Projects
Ms. Stephanie Kong |
Dr. Yee-Lin Lai | Manager, Commercialization
Mr. Gregory Lee | Manager
Dr. Sze Tiam Lin | Senior Vice President, Commercialization
Mr. Sean Ng |
Dr. Muhammad T Tabiin | Vice President
Mr. Peter Tay | Asst Vice President, Commercialisation
Ms. Barbara Um-Nothacker | Vice President, Intellectual Property Management
Organization Type
Industry Sector
Company Overview
Exploit Technologies Pte Ltd is the strategic marketing and commercialization arm of the
Agency for Science, Technology and Research (A*STAR), Singapore. Its charter is to identify,
protect and exploit Intellectual Property (IP) created by the 14 Research Institutes (RIs) funded
and managed by A*STAR. A*STAR is the national body promoting excellence in science,
technology and research, and received a block grant of US$4.5 billion from the Ministry of
Trade and Industry (Singapore) to support public R&D to benefit the local industy as it evolves
towards a knowledge-driven economy.
Exploit Technologies partners the Research Institutes of A*STAR and plays a proactive role to
bridge good research and development to the industry. This includes facilitating the IP
management process (i.e. the protection of inventions through patents, copyrights, etc.),
analyzing the strength of our IP and the market that they could serve, and working with
companies to commercialise the technologies. Exploit Technologies is committed to working
with our A*STAR researchers to generate and exploit IP for the benefit of Singapore.

Country(s)
Partnering
A method for three
dimensional vascularisation Imaging Preclinical Testing Worldwide
generation
Parkinson's, Chronic
Baculovirus Vectors for
neuropathic pain and Preclinical Testing Worldwide
Gene Delivery to Neurons
Alzheimer's.
Brain Atlas Brain, Stroke Ready to Market Worldwide
Differential Field Inversion
Pulse Electrophoresis Electrophoresis Ready to Market Worldwide
Technology & Device
Drug-Loaded Contact
Glaucoma, corneal wound
Lenses for Ophthalmic Drug Preclinical Testing Worldwide
healing
Delivery
Fluorocarbon surfactant
Catalysis, host matrix for
mediated synthesis of
synthesis of quantum dots Ready to Market Worldwide
nanoparticles with various
and magnetic nanoparticles
mesoporous structures
Immortalised mouse
Stem cells Preclinical Testing Worldwide
embryonic fibroblasts
Method of using baculovirus
Glioma therapy Preclinical Testing Worldwide
vectors for glioma therapy
Modulation of TRIP-Br
function and method of
Cancer, keloids, psoriasis Preclinical Testing Worldwide
treating proliferative
disorders
Molecular Diagnosis of
Cervical Cancer in HPV-16 Cervical cancer diagnosis Preclinical Testing Worldwide
Infected Patients
Mouse model for polycystic
Polycystic kidney Preclinical Testing Worldwide
kidney disease
New Age Antibiotics -
Anti-infectives Preclinical Testing Worldwide
Quorum Sensing
New Method of Gene
Delivery to Promote Nerve Peripheral Nervous System Preclinical Testing Worldwide
Regeneration
Novel Antifungal: a, b-
Anti-fungal Preclinical Testing Worldwide
unsaturated fatty acids block

Candida Albicans
Dimorphism
Novel Biodegradable
Cationic Core-Shell
Nanoparticles for Cancer, Gene Therapy Preclinical Testing Worldwide
Codelivery of Drug and
DNA
Novel Inhibitor of Protein
Cancer Preclinical Testing Worldwide
Tyrosine Phosphatase
pH-Triggered Thermally
Responsive Polymeric Core-
Cancer Preclinical Testing Worldwide
shell Nanoparticles for
Targeted Drug Delivery
Polymer Composite for
Laser Desorption Ionisation Analytical analysis Ready to Market Worldwide
Mass Spectrometry
Silica coated
nanocomposites of magnetic
Molecular imaging Preclinical Testing Worldwide
nanoparticles and quantum
dots
Technologies for Stroke
Stroke Preclinical Testing Worldwide
Imaging Analysis
Thermal sensitive wound Wound healing, Drug
Preclinical Testing Worldwide
dressing Loaded
West Nile Virus vaccine West Nile Virus Preclinical Testing Worldwide
Expression Genetics, Inc.
4200 Bellemeade Avenue | Evansville IN 47714 | United States

Phone: (812) 475-0684 | Fax: (812) 475-0684
Contacts
Mr. James McCarthy |
Faber Daeufer & Rosenberg PC
950 Winter Street | Suite 4500 | Waltham MA 2451 | United States

Phone: (781) 795-4710 | Fax: (781) 795-4747 | Website: www.fdrpc.com
Contacts
Ms. Sarah Shoaf Cabot | Principal

Farella Braun & Martel LLP
235 Montgomery Street | Russ Bldg, 20th Floor | San Francisco CA 94104 | United States
Phone: (415) 954-4400 | Fax: (415) 954-4480
Contacts
Ms. Stephanie Skaff | Partner
Fasken Martineau DuMoulin LLP
2100 - 1075 West Georgia Street | Vancouver BC V6E 3G2 | Canada

Phone: +1.604.631.4880 | Fax: +1.604.632.4880 | Website: www.fasken.com
Contacts
Mr. Kevin E. Holbeche | Lawyer/Patent Agent
Mr. Mark D Penner | Patent Agent/Lawyer
Mr. Timothy M. Squire |
FDC-Windhover
685 Route 202/206 | Bridgewater NJ 8807 | United States

Phone: (908) 547-2119
Contacts
Ms. Meredith Barnett | Product Manager
FemmePharma Global Healthcare, Inc.
37 West Avenue | Second Floor | Wayne PA 19087 | United States

Phone: (610) 995-0801 | Fax: (610) 995-0825 | Website: www.fpghc.com
Contacts
Mr. Joseph A. Plevelich | Commercial Operations
Industry Sector
Health Care
Company Overview
FemmePharma Global Healthcare, Inc. (FPGHC) is a specialty pharmaceutical company devoted
to the development of drugs and products for treating diseases and disorders disproportionately

affecting women throughout the world. FPGHC’s mission is to create value by developing
innovative “woman-friendly” products in identified areas of high unmet medical need and low
market penetration by existing therapeutic options. FPGHC is committed to developing safe and
effective drugs that minimize or eliminate unpleasant side effects associated with many drugs by
designing them in a manner specifically suited to a woman’s physiology, with an eye toward the
changing needs of women throughout their lives. By applying its proprietary technologies,
FPGHC is able to confer patent protection to a variety of drugs. FPGHC focuses on areas
conducive to rapid drug development with potential near-term market opportunities.
FemmePharma Global Healthcare, Inc. intends to develop these drugs and products for the
purpose of primarily commercializing and marketing the opportunities by itself. FPGHC believes
that certain market opportunities (e.g., high-prescribing OB/GYNs) will be conducive for
penetration by a sales force to be assembled by FPGHC. While FPGHC intends to utilize its
sales force wherever possible, FPGHC will examine all market opportunities to discern those
sales and marketing strategies that will maximize potential sales and returns to FPGHC. In
certain instances, FPGHC will partner with a contract sales organization to reach a broader
market. Finally, FPGHC will consider either partnering or licensing opportunities for its products
and technologies to address very large markets or overseas markets. FPGHC believes that its
novel approach to the treatment of diseases affecting women positions FPGHC as a unique
investment opportunity in the areas of both specialty pharmaceuticals and drug delivery.
Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
901 New York Avenue, NW | Washington DC 20001-4413 | United States

Phone: (202) 408-4000 | Fax: (202) 408-4400
Contacts
Mr. D. Brian Kacedon | Associate
Mr. Patrick O'Reilley | Partner
Mr. Michael V. O'Shaughnessy |
Mr. John C. Paul | Attorney
Mr. Kenneth E. Payne | Senior Counsel
Mr. E. Robert Yoches | Partner
First Principals Inc.
1768 East 25th street | Cleveland OH 44114 | United States

Phone: 216-881-8521 | Fax: 216-881-8522
Contacts
Dr. Stephen Weeks | President

Fisher Adams Kelly
GPO Box 1413 | BRISBANE QLD 4001 | Australia

Phone: +61 7 3229 2655 | Fax: +61 7 3221 0597
Contacts
Dr. Mark Alexander Horsburgh | Managing Partner, Patent & Trade Mark Attorney
Company Overview
Fisher Adams Kelly
Patent & Trade Mark Attorneys, Australia & New Zealand
www.fak.com.au
DID YOU KNOW?

At Fisher Adams Kelly we pride ourselves not only on our standard of professionals but also on
our commercial acumen. Our practitioners hold degrees in a wide range of scientific and
technical disciplines to ensure we have the understanding of our clients innovations needed to
fully protect them. Just as importantly, our people are selected for their experience in assessing
whether an innovation is commercially viable. This means we can help our clients make the right
business decision regarding their innovation and this is the Fisher Adams Kelly competitive
edge.
WHAT THIS MEANS FOR OUR CLIENTS AND REFERRERS

Fisher Adams Kelly can handle IP protection issues for any size organisation, locally and
internationally, large and small.
RANGE OF OUR EXPERIENCE

19. Patents
20. Trade marks
21. Designs
22. Copyright
23. Circuit layouts
24. Plant variety rights
25. Confidential information
26. Business names
27. Domain names

Trade Mark & Patent Practitioners
Corporate Organisations
Flamel Technologies SA
33 avenue du Dr. Georges Levy | Venissieux 69693 | France

Phone: 4 72 78 34 34 | Fax: 4-72-78-34-35 | Website: www.flamel.com
Contacts
Mr. Nigel McWilliam | Business Development Director
Organization Type
Industry Sector
Health Care
Company Overview
Flamel Technologies is one of the leading drug delivery companies worldwide with an important
expertise in polymer chemistry.
The company was founded in 1990.
In 1996, Flamel Technologies (FLML) became one of the first European Biotech companies to
enter the Nasdaq.
The Company has assembled a strong team of researchers expert in polymer science and
biochemistry, and owns a +60,000-square foot cGMP and FDA-approved pharmaceutical
production facility located in Pessac, France.
Flamel’s drug delivery platforms, Medusa® for therapeutic proteins and peptides, and
Micropump® for small molecules , have been developed to improve the therapeutic
characteristics, safety profile and ease of use of wide variety of drugs.
Medusa(R) is a polypeptide-like polymer nanocarrier that allows the delivery of protein drugs
with their full bioactivity (no chemical binding) over an extended period of time.
Micropump(R) is a flexible multiparticulate technology that increases the bio-absorbtion time of

oral drugs, increasing their efficacy (AUC, T-Max) and decreasing their side-effects (reducing C-
max). Micropump is used in the currently US-marketed COREG CR (carvedilol controlled
release) by GSK.

The Company is a recognized world leader in the innovation of delivery systems for small
molecule and protein drugs, providing tailored solutions to the biotech and pharmaceutical
industries for optimized controlled-release delivery of drugs. Flamel is turning already-marketed
or new drugs into more effective and safer medicines for itself and for its partners.
Flamel has partnership agreements with major pharmaceutical companies.

Multi-national pharmaceutical companies with a focus on proprietary products for both the
ethical and OTC field. Specialty pharmaceutical companies, focusing on a specific therapeutic
category, a specfic geography or a specific patient population.
Flamel is a partnering company and very actively seeking collaborations with companies with a
global, regional or national reach, who possess the commercial, clinical/medical focus in specific
therapeutic categories. Historically the focus of drug delivery companies has been on product life
cycle management opportunities: in addition to this focus Flamel is seeking opportunities to
partner earlier in the development of oral and injectable formulations of small and large
proprietary molecules. Flamel's strength are its polymer science, intellectual property and the
speed in the application of both in working with multi-national partners.
Flamel has internally derived product opportunities for which we are seeking development &
licensee partners.
for Partnering
Africa, Australia,
Europe, European Union,
ASACARD Cardiovascular Ready to Market
North America, South
America
CO-
AMOXICLAV Infectious diseases Phase I Worldwide
SR
FT-105 Basal
Diabetes Phase I Worldwide
Insulin
GENVIR infectious diseases (herpes) Phase III Worldwide

Endocrine diseases (growth

HGH XL Preclinical Testing Worldwide
disorders)
IFN ALPHA-2B
Hepatitis C Phase II Worldwide
XL
Oncology (renal cell
IL-2 XL carcinoma); infectious Phase II Worldwide
diseases (HIV)
Losartan
n/a Not Applicable
XL(TM)
METFORMIN
Diabetes Phase I Worldwide
XL
OMEPRAZOLE Digestive system (gastro-
Phase I Worldwide
XL oesophageal reflux disease)
Drug delivery technology,
TRIGGER-
abuse/misuse prevention Preclinical Testing Worldwide
LOCK
technology
Florida International University
11200 SW 8th Street | University Park MARC 440 | Miami FL 33199 | United States
Phone: (305) 348-0008 | Fax: (305) 348-
0081 | Website: osra.fiu.edu/intellectual_property/index.htm
Contacts
Dr. Susan Webster | Executive Director, Intellectual Property Management
Company Overview
Florida International University Miami’s Public Research University
Florida International University (http://www.fiu.edu/) emphasizes research as a major component
of its mission. FIU is ranked as a Research University in the High Research Activity category of
the Carnegie Foundation’s prestigious classification system.
FIU has dynamic research programs addressing high tech, biomedical, health and environmental
issues.
With 38,000 students, 1000 full-time faculty, and more than 117,500 alumni, FIU is the largest
university in South Florida and among the nation’s 25 largest colleges and universities.
FIU has built a state-of-the-art Motorola Bio/Nanofabrication Research Facility that will assist
scientists in harnessing molecular-sized particles to fight human disease and advance
breakthrough in the fields of electronics and communication technologies, among others.

Research conducted here will help meet the emerging needs of bio-and nano-technologies.
FIU is also advancing the world’s technology base by developing new technologies that will
allow for the creation of nanoscale materials to be used as drug-delivery vehicles and sensors.
Some of the technologies that we have available for licensing include:
ADAPTIVE SOL-GEL IMMOBILIZATION AGENTS FOR CELL DELIVERY

Inventor(s): Crumpler, E.; Vallejo, M. Patent Pending
COMPLIANCE MATCHING VASCULAR STENTS (CMS)

Inventor(s): Moore, J.; Berry, J. U.S. Patent 6,206,910 and 6,572,649
ELECTRIC FIELD AND TEMPERATURE PROBE

Inventor(s): Hagmann, M.; Babij, T. U.S. Patent 5,113,864
METHOD AND APPARATUS FOR DETECTING EXPLOSIVES

Inventor(s): Almirall, J.; Perr, J. Patent Pending
MULTIMODAL HUMAN-COMPUTER INTERFACE DESIGN TO HELP PEOPLE

WITH MOTOR DISABILITY
Inventor(s): Adjouadi, M.; Ayala, M.; Sesin, A.; Cabrerizo, M. Patent Pending
NEURAL STUDIO: AN ARTIFICIAL NEURAL NETWORKS SIMULATOR FOR

EDUCATIONAL
AND RESEARCH PURPOSES
Inventor(s): Ayala, M.; Adjouadi, M. Patent Pending
NOVEL TEMPERATURE CONTROLLED INTERNAL JACKETED CATHETER

Inventor(s): Crumpler, E.; elChurafa, M.; Ahmed, M.; Silva, H.
PANTHER SKINTM
Inventor(s): Torres, M.: Wu, K. U.S. Patent 5,251,849 and 6,722,611
PERSONAL DOSIMETER
Inventor(s): Hagmann, M. U.S. Patent 4,913,153
RESPIRATORY MOTION TRACKING SYSTEM AND METHOD FOR MOLECULAR

IMAGING

AND RADIATION THERAPY

Inventor(s): Franquiz, J.; Byrne, J.; McGoron, A.
SURFACE PLASMON RESONANCE DETECTION WITH HIGH ANGULAR
RESOLUTION
AND FAST RESPONSE TIME
Inventor(s): Tao, N.; Boussaad, S.; Huang, W. U.S. Patent 6,784,999
TRANSGENIC PRODUCTION OF SPIDER SILK

Inventor(s): Herrera, R.; Coll, J.; Almagro, J. Patent Pending
THREE-DIMENSIONAL MAGNETIC MEMORY

Inventor(s): Khizroev, S. Patent Pending
ULTRA-HIGH PERFORMANCE SCALABLE 3-D MICROSCALE CONVECTION

COOLING HEAT SINK
Inventor(s): Tao, Y.; Hao, Y.; Moreno, R. Patent Pending
INTERNET BASED SECURE, TRANSPARENT ACCESS CONTROL WITH CUSTOM

AUTHENICATION
Inventor(s): Prabakar, N. Patent Pending
For more information please contact Florida International University Office of Intellectual
Property Management at 305-348-0008 or visit
http://osra.fiu.edu/intellectual_property/index.htm.
Fluid Innovation Group, Inc.
3821 Juniper Trace | Suite 106 | Austin TX 78738 | United States

Phone: (512) 263-2363 x102
Contacts
Mr. Tom Hochstatter | Vice President, Business Development
Mr. Chris McKinzie | CEO
Organization Type
Consulting Firm
Industry Sector
High Technology

Company Overview
Fluid Innovation provides IP commercialization marketing, sales and consulting solutions. We
focus exclusively on Software based technology. The technology does not need to be patented in
order to have value in the marketplace. Fluid also maintains a database of over 1000 buyers
within the independent software vendor community to help streamline the licensing process.

Firms that invest heavily in Information Technology to solve internal business problems. Much
of this technology could be commercialized. Firms the provide or hire IT services/consulting
firms may also have retained rights to innovative software technology and/or workflow
solutions.
Country(s)
Partnering
Not applicable for non
www.fluidinnovation.com pharma-bio firms (should Not Applicable
not be mandatory)
Fluor Corporation
3 Polaris Way | Aliso Viejo CA 92698 | United States

Phone: (949) 349-7705 | Fax: (949) 349-7715
Contacts
Mr. Christopher J. Obaditch | Sr. Director, Intellectual Property Mgmt.
FMC Agricultural Products
20 Graystone Dr. | E. Northport NY 11731 | United States

Phone: (631) 368-1413
Contacts
Mr. Timothy M. Cusack | Global Technology Acquisition Leader

Foresight Science & Technology, Inc.
430 Angell Street | Providence RI 02906 | United States

Phone: (401) 273-4844 | Fax: (401) 273-4744
Contacts
Dr. Phyl L. Speser | CEO
Ms. Elaine F. White | Vice President, Busines Development
Forschungszentrum Karlsruhe
Von Helmholtz . Platz 1 | Leopoldshafen 76344 | Germany

Phone: 49 7247 822590 | Fax: 49 7247 824814 | Website: www.fzk.de
Contacts
Dr. Thomas Kroener | head of licensing group
Organization Type
Industry Sector
Company Overview
Forschungszentrum Karlsruhe GmbH is a research centre which is funded by the German federal
(90 %) and by the state (10 %) governments. It is one of 15 research centres in the Helmholtz
Association. The focal activity is energy research and development (petrol from plants and
agricultural wastes, hydrogen technology, combustion units, nuclear fusion technology, etc.), but
there are other topics like cancer research, materials sciences, etc. There are about 3,800
employees.
Beginning in 2008, Forschungszentrum Karlsruhe will merge with the Universität Karlsruhe
(University of Karlsruhe) to KIT, the Karlsruhe Institute of Technology. This will double the
research capacity. KIT will be the first merger of a publicly funded research centre with a
university in Germany

mainly interested in out-licensing of new technologies (nano-, microtechnology, environment,
superconductivity)
industrial companies interested in in-licensing new technologies


out-licensing, tech transfer
Fox Chase Cancer Center
333 Cottman Avenue | Philadelphia PA 19111 | United States

Phone: (215) 214-3985 | Fax: (215) 214-1440 | Website: www.patents.temple.edu
Contacts
Ms. Inna Khartchenko | Director of Licensing
FPInnovations
570 Boul. St-Jean | Pointe Claire QC H9R 3J9 | Canada

Phone: (514) 630-4114 | Fax: (514) 630-4105 | Website: www.paprican.ca
Contacts
Mr. Christopher J. Kanters | National Director, Intellectual Property, Contracts & Licensing
FRANKLIN & ASSOCIATES INTERNATIONAL LLC
230 Saint Francis Drive | Suite 1 | Santa Fe NM 87501 | United States

Phone: (505) 629-4371 | Fax: (505) 213-0642 | Website: www.faipatents.com
Contacts
Dr. Matthew F. Lambrinos | Member - European Patent Attorney, US Patent Agent
Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
FAI at a glance
A combined US and European patent practice providing high quality, efficient, and cost effective
patent prosecution services.

What we can offer
· one practitioner for direct US, EP and PCT prosecution - no more time and money spent
channeling matters through different outside counsel
· a streamlined US-EP patent prosecution process together with effective use of the PCT
before the EPO and USPTO
· strong scientific and industrial expertise (BEng(Hons) Elec. Eng. & PhD in Thin Film
Physics)
· focused prosecution, personal service, reduced risk of conflict of interest, and many other
benefits
· experience in handling national prosecution worldwide through established associates
The above benefits enable FAI to provide a unique patent prosecution service that can help our
clients procure more high quality patents internationally in a cost effective manner.
Our clients
Corporations, inventors and patent attorneys / law firms seeking assistance with patent
prosecution, particularly at the international level, that is both highly professional and cost
effective.
Technical fields
FAI specializes in a range of technical fields including semiconductors, optics, nanotechnology,

electro-mechanical devices, analogue and digital electronics, computer and computer program
related devices and business methods.
Offices
FAI has offices in London (UK) and Santa Fe (USA). For further information, please see our
website at http://www.faipatents.com/.
US, European, and International patent filing and prosecution.
High Technology and Energy sector provides.

Patent litigation expert witness services.
Clients seeking quality patent prosecution services and in particular:
1) Corporate in-house patent counsel requiring assistance with US, Euorpean and International
patent prosecution
2) Foreign patent attorneys / law firms requiring assistance with US and European patent
prosecution
3) US patent attorneys / law firms requiring assistance with European patent prosecution
4) Universities, Research Institutions and Inventors in High Technology, Energy and other
sectors.
5) US patent litigation attorneys seeking expert witness opinions
Establishing business relationships with clients interested in patent filing and prosecution.
Professional Development.

Partnering
Patent Legal
N/A Not Applicable
Services

Fraser Milner Casgrain LLP
1 Place Ville-Marie | Suite 3900 | Montreal Quebec H3B 4M7 | Canada

Phone: 514-878-8883 | Fax: 514-866-2241
Contacts
Mr. Robert D. McDonald | Partner
Fukuda & Kondo
7-15 Higashi Koiwa | 6-Chome, Edogawa | Tokyo 133-0052 | Japan

Phone: +81 3 3673 6715 | Fax: +81 3 3673 6715
Contacts
Mr. Chikao Fukuda | Lawyer (Attorney At Law)
Fulbright & Jaworski LLP
1301 McKinley Street | Suite 5100 | Houston TX 77010 | United States

Phone: 713-651-5583 | Fax: 713-651-5246
Contacts
Mr. Brett C. Govett | Partner
Mr. Robert Harrell | Partner
Mr. Douglas Williams | Partner
Future Innovations
Tahkokuja 10 | Espoo FI-02760 | Finland

Phone: +358 9 8053595 | Fax: +358 9 8597905 | Website: www.futureinnovations.fi
Contacts
Dr. Kari Sipila | CEO
Organization Type
Consulting Firm
Industry Sector

Company Overview
FUTURE INNOVATIONS
Management Consulting in the Fields of Innovations and Technology

Collaboration with Universities, Companies and other Organizations
Main activities
28. Inventions, Innovations, Consulting

29. Innovation Development Activities
30. Intellectual Property Strategy and Policy
31. Commercialization of Technology and IPR, Licensing
32. Innovations for Senior Citizens
33. Management
34. Mentoring
35. Networking and Cooperation
36. Lectures, Presentations, Articles

Large network within LES and especially in LES-Scandinavia
Galderma R&D
2400 Route Des Colles | BP87 | Biot 06410 | France

Phone: 0033-4-92952930 | Fax: 0033-4-92952236
Contacts
Dr. Robert Morrison | Head of US Licensing
Organization Type
Industry Sector
Health Care
Company Overview
About Galderma:

Galderma, one of the leading dermatology companies in the world, is a fully integrated specialty
pharmaceutical company with a global sales and marketing structure and worldwide product
development capability. Created in 1981 as a joint venture between Nestlé and L'Oréal, the
company has a worldwide presence in 65 countries and over 1,000 sales representatives
dedicated to dermatology. Galderma provides innovative therapeutic, corrective and
aesthetic solutions that meet the needs of dermatology patients and physicians. The company is
committed to improving the health of skin with an extensive line of products worldwide that treat
a range of skincare conditions including: acne, rosacea, fungal nail infections, psoriasis,
seborrheic dermatitis, hyper-pigmentation disorders, non-melanoma skin cancer and photo-
damage.
Contact:
Leila ZARIF, Ph.D., MBA

Head of Licensing
Galderma R & D
Les Templiers
2400 Route des Colles
06410 Biot
FRANCE
Phone: 33 (0)4 92 95 29 30
Fax: 33 (0)4 92 95 22 36
Email: leila.zarif@galderma.com
Therapeutics for dermatology diseases and related disorders

Companies and academic institutions wishing to out-license dermatology drug candidates at the
stage of IND or later in development as well as drug candidates for disorders that may be related
to dermatology.
Gallagher & Kennedy, P.A.
2575 E. Camelback Road | 11th Floor | Phoenix AZ 85016-9225 | United States

Phone: (602) 530-8440 | Fax: (602) 530-8500
Contacts
Mr. Paul E. Burns |

Gallop, Johnson & Neuman, LC
101 South Hanley | Suite 1700 | St. Louis MO 63105 | United States
Phone: (314) 615-6000 | Fax: (314) 615-6001 | Website: www.gjn.com
Contacts
Mr. John Kepler | Member
Organization Type
Law Firm
Industry Sector
High Technology
Genencor, A Danisco Division
925 Page Mill Road | Palo Alto CA 94304 | United States

Phone: (650) 846-7671 | Website: www.genencor.com
Contacts
Mr. Brian Carter | Vice President, Business Development
Organization Type
Companies who are interested in accessing enzyme technology for the conversion of biomass
into fermentable sugars for the production of cellulosic ethanol and other biochemicals.
Genentech, Inc.
1 DNA Way | South San Francisco CA 94080 | United States

Phone: +1.650.225.4938 | Fax: +1.650.225.3009 | Website: www.gene.com
Contacts
Mr. Kinney Horn | Mgr Business Development
Company Overview
Genentech is a leading biotechnology company that discovers, develops, manufactures and
commercializes biotherapeutics for significant unmet medical needs. Sixteen of the currently

approved biotechnology products originated from or are based on Genentech science. Genentech
manufactures and commercializes 12 biotechnology products directly in the United States. The
company has headquarters in South San Francisco, California and is traded on the New York
Stock Exchange under the symbol DNA. For press releases and additional information about the
company, please visit http://www.gene.com/.
General Mills, Inc.
P.O. Box 1113 | M04.15 | Minneapolis MN 55440 | United States

Phone: (763) 764-2422 | Fax: (763) 764-2268
Contacts
Ms. Susan Jacobson | Sr. Intellectual Property Mgr
Organization Type
Industry Sector
Consumer Products
Company Overview
General Mills is the world's sixth-largest food company. General Mills market in more than 100
countries and hold the No. 1 or No. 2 position in virtually every category in which we compete.
On average, U.S. shoppers place at least one General Mills product into their shopping cart each
time they visit the grocery store.
A brief overview of our businesses:
Baking Products
We market global brands such as Green Giant vegetables, Old El Paso Mexican food and
Häagen-Dazs ice cream. Our U.S. portfolio includes Yoplait yogurt, Cheerios, Wheaties and
other Big G cereals.
We also market strong local brands, such as Diablitos meat spread in Venezuela, Latina pasta in
Australia and La Salteña dough in Argentina.
General Mills markets great-tasting baking solutions that feature Betty Crocker dessert mixes,
cakes and frostings, Bisquick baking mixes and Gold Medal flour.
Big G Cereals

A leader in the U.S. ready-to-eat cereal category, Big G offers consumer favorites such as
Cheerios, Wheaties and Lucky Charms.
Meals
General Mills provides convenient dinner options with a line of Helper dinner kits, Betty
Crocker potato mixes, Progresso soups, Green Giant vegetables and meal starters, and Old El
Paso Mexican foods.
Organic
Small Planet Foods features Cascadian Farm and Muir Glen, which hold top positions in nine
organic food categories.
Pillsbury
With a clear leadership share of the U.S. refrigerated dough category, Pillsbury products include
Pillsbury Home Baked Classics frozen dough, Pillsbury frozen breakfast items, and Totino's
frozen pizza and snacks.
Snacks
General Mills features brands such as Fruit Roll-Ups fruit-flavored snacks, Chex Mix snacks,
Pop Secret microwave popcorn, Nature Valley granola bars and Bugles corn snacks.
Yogurt
Yoplait is a leader in the U.S. yogurt category, with products such as Yoplait Original, Yoplait
Light, Go-GURT, Colombo yogurts.
Bakeries & Foodservice
General Mills markets unbaked, partially baked and fully baked dough products and mixes to
foodservice operators and retail and wholesale bakeries. Our market-leading branded products
also are available through outlets such as school cafeterias, restaurants and convenience stores.
International
The portfolio includes Häagen-Dazs ice cream, Pillsbury dough-based products, Betty Crocker
desserts and mixes, Green Giant vegetables, Old El Paso Mexican foods and leading local
brands.
Joint Ventures
General Mills and Nestlé formed Cereal Partners Worldwide, which markets ready-to-eat cereal
brands in more than 130 international markets. Teaming with DuPont, 8th Continent competes in

the $400 million refrigerated soymilk market. Among our Häagen-Dazs joint ventures in Asia,
our largest is with Suntory
Genimax Inc.
95 Rue Cherbourg | Candiac QC J5R 6S1 | Canada

Phone: (514) 666-0123 | Fax: (514) 666-1033
Contacts
Mr. Jerome Samson | Partner in Technology Management
Organization Type
Consulting Firm
Company Overview
Genimax optimizes tax incentives from the government for manufacturers and engineering
firms.
The knowledge of our experts and the expertise of more than 400 files in SR&ED contribute to
the success of our services and to the maximization of your tax credit.
Genimax creates tangible assets maximizing the market opportunity for your technologies with
valuable license agreements.
 Summery due diligence of the intellectual property;

 Valuation of the technology;
 The preparation for the deal, wants and needs;
 Search for potential partners;
 Development of a strategic market approach;
 Negotiation of the licensing deal;
 Writing and revision of the license agreement;
 Follow up on payments and royalties;
WE ARE ALSO INTERESTED FINDING COMPANIES FOR TECHNOLOGY TRANSFER

TO CANADA, MOSTLY IN QUEBEC REGION.
ALSO, we look for valuation partners for US Market as well as Patent Mapping tools (software).

TECHNOLOGY BUYERS IN INDUSTRIALS AREAS SUCH AS:
ENVIRONMENT
ENERGY (WIND POWER)
ELECTRICAL UTILITY VEHICLE
MEDICAL EQUIPEMENT
Find some business match for our technology portfolio.
Available:
1- Environmental wood treatment process (without the use of any chemical)
2- In-Wheel Motor Concept using to of the edge nanomaterials
3- Power Wheelchair concept
Genome Therapeutics Corporation
100 Beaver Street | Woltham MA 2453 | United States

Phone: (781) 398-2357 | Fax: (781) 398-2607
Contacts
Mr. Hugh Cole | Senior Director, Corporate Development
Genpharm Inc.
85 Advance Road | Etobicoke ON M8Z 2S6 | Canada

Phone: (416) 207-1211 | Fax: (416) 236-9022 | Website: www.genpharm.ca

Contacts
Mr. Vidar Bentzen | Vice President Business Development
Organization Type
Industry Sector
Health Care
Company Overview
Genpharm is one of Canada's leading generics companies and a part of Mylan Inc., the third
largest generics group in the world.
Genpharm also operates a small branded speciality business under the name Prempharm.
Genpharm is interested in commercial Rx product deals in all therapeutic categories, whether

generics or proprietary drugs. We are not interested in early stage developments.
Genzyme Corporation
500 Kendall Street | Cambridge MA 02142 | United States

Phone: +1 617 252 7500 | Fax: +1 617 252 7600
Contacts
Mr. Constantine Chinoporos | Vice President . Corporate Development
Ms. Jennifer A. Tegfeldt | Director, Business Initiatives and Strategy
Organization Type
Industry Sector
Health Care
Company Overview
Founded in 1981, Genzyme today is one of the largest and most well established biotechnology
companies in the world. With more than 14 major products and services helping patients in
nearly 90 countries, Genzyme is a global leader in the effort to develop and apply the most

advanced capabilities in biotechnology to address a range of unmet medical needs. Genzyme-

sponsored research and development has led to the introduction of new treatments for many
serious health problems, from rare and debilitating genetic diseases to renal disease, orthopedic
injuries and surgical scaring. The company’s international R&D team is continually at work
identifying new opportunities to meet the health care challenges of the future.
With headquarters in Cambridge, Massachusetts, Genzyme has over 9,500 employees working in
90 countries and 2007 annual revenues of $3.8 billion.
Genzyme’s clinical focus revolves around the following areas of medicine: lysosomal storage
disorders, renal disease, biosurgery/orthopaedics, transplant and immune diseases and
endocrinology/oncology in addition to its presence in the genetics/diagnostics arena.
Clinical Focus
Lysosomal Storage Disorders - These inherited diseases, which typically affect fewer than
10,000 people worldwide, are caused by enzyme deficiencies. Genzyme markets four enzyme
replacement products to treat these diseases, which can be life-threatening. Cerezyme®
(imiglucerase for injection) – for Type 1 Gaucher disease. Fabrazyme® (agalsidase beta) – for
Fabry disease. Aldurazyme® (laronidase) – for Mucopolysaccharidosis I. Myozyme®
(alglucosidase alfa) – for Pompe disease.
Renal Disease
Renagel® (sevelamer hydrochloride) is Genzyme’s calcium-free, metal-free phosphate binder
that reduces phosphorous levels in chronic kidney disease patients who are on dialysis.
Renvela® (sevelamer carbonate) is a next-generation version of Renagel, currently approved in
the U.S. for use in dialysis patients. Genzyme is pursuing worldwide approvals and seeking to
expand Renvela's indication to include patients with earlier stages of chronic kidney disease.
Hectorol® (doxercalciferol) is a vitamin D2 treatment for secondary hyperparathyroidism in
chronic kidney disease patients.
Orthopaedics / Biosurgical Specialties

Synvisc®, Synvisc-One™ (hylan G-F 20) Synvisc is one of the world’s top therapies to treat the
pain of osteoarthritis of the knee; Synvisc-One offers a new, single-injection treatment option.
Carticel® (autologous cultured chondrocytes) is a cell-based therapy to help repair damaged
knee cartilage currently marketed in the U.S. MACI® (Matrix-induced Autologous Chondrocyte
Implantation) is a cell-based therapy to help repair damaged knee cartilage currently marketed in
Europe and Australia. Seprafilm® is designed to prevent painful and potentially debilitating
adhesions following surgical procedures. Epicel® (cultured epidermal autografts) is a cell-based
therapy for treating patients with severe, life-threatening burns.

Transplant and Immune Diseases

Thymoglobulin® (anti-thymocyte globulin, rabbit) treats acute rejection in kidney transplant
patients by suppressing the body’s natural immune response. It is also being studied for liver
transplant. Genzyme has several products in development for immune diseases such as multiple
sclerosis and pulmonary fibrosis.
Oncology
Campath® / Mabcampath® (alemtuzumab), is approved in the U.S. and Europe as a first-line
treatment for B-cell chronic lymphocytic leukemia (B-CLL). Clolar® / Evoltra® (clofarabine),
is approved in the U.S. and Europe for the treatment of children with refractory or relapsed acute
lymphoblastic leukemia. Thyrogen® (thyrotropin alfa for injection), is used in thyroid cancer
follow-up, allowing patients to be screened without having to suspend thyroid hormone therapy.
It is also approved in the U.S. and Europe for use in remnant ablation, a procedure patients
commonly undergo when being treated for thyroid cancer.
Genetics / Diagnostics
Genzyme is one of the largest providers of diagnostic testing services in the world, with expertise
in reproductive and oncology testing. Genzyme is also a major supplier of point-of-care
diagnostic products, with a focus on infectious diseases, diabetes and cardiovascular disease.
The company is playing an important role in the movement toward personalized medicine by
developing tests that can help physicians identify how patients are likely to respond to targeted
therapies.
Research and Development

Genzyme's research and development efforts are focused on the areas of medicine where it
markets commercial products. The company also conducts research in cardiovascular disease,
neurodegenerative diseases, and other areas of unmet medical need. In 2007, Genzyme invested
approximately $640 million in this work, or about 17 percent of its revenues.
Genzyme continues to build its pipeline through both internal research and licensing and
acquisitions, focusing on product candidates with the potential to change the standard of care for
serious diseases. The company’s pipeline is concentrated on programs in mid- to late-stage
development and includes approximately 25 phase 2 studies and several major pivotal studies.
Therapies in late-stage development include: alemtuzumab for multiple sclerosis;

Mozobil™(plerixafor), which is designed to improve the outcome of stem cell transplantation in
patients with blood cancers; Clolar, for adult acute myeloid leukemia; and mipomersen for
familial hypercholesterolemia and other high risk, high cholesterol patients.
Corporate Responsibility

Corporate responsibility is a priority at Genzyme. The company’s commitment to patients

extends beyond the development of new treatments and the services needed to deliver them.
Genzyme has a strong presence in developing countries, where it provides free medicine to
patients and helps to build sustainable health care systems. The company in 2006 launched an
initiative to support the development of treatments for neglected diseases that affect hundred of
millions of people in the developing world. Genzyme’s headquarters is one of the most
environmentally responsible office buildings in the world, and the company is a leader in waste-
reduction and recycling efforts.
In addition, Genzyme supports science education and health initiatives in the communities in
which it operates. For these and other efforts, Genzyme has been included for the past three years
in the Dow Jones Sustainability World Index, which consists of companies that excel in
economic, environmental and social performance. In 2007, Genzyme was named one of the
"Global 100 Most Sustainable Corporations in the World" by Innovest Strategic Value Advisors.
BusinessWeek has ranked Genzyme as one of the top corporate givers, and the company has also
been recognized by the U.S. Environmental Protection Agency, the American Association for the
Advancement of Science, and many other organizations.
George Mason University
4400 University Drive | Fairfax VA 22030 | United States

Phone: (703) 993-4103 | Fax: (703) 993-9710
Contacts
Mr. David Grossman | Assistant Director, Office of Technology Transfer
Gilbert + Tobin
Level 37 | 2 Park Street | Sydney NSW 2000 | Australia

Phone: +61 2 9225 5000 | Fax: +61 2 9322 4000
Contacts
Mr. Anthony Muratore | Partner
Global Intellectual Strategies
120 Iber Road | Unit 101 | Stittsville ON K2S 1E9 | Canada

Phone: (613) 592-2693 ext 222 | Fax: (613) 592-0784 | Website: www.gistrategies.com

Contacts
Ms. Pierrette M. Breton | President
Dr. Marc Pepin | Patent Analyst
Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
Global Intellectual Strategies (GIS) works together with law firms and companies to derive
greater value from a company’s patent assets. We are a company of IP professionals and
engineers that provides patent and technical analysis in support of licensing and litigation. Some
of our most requested services are portfolio evaluation and infringement analysis.
Our portfolio evaluation service consists of a review of a company’s patent assets to group
patents by technology, to identify the likelihood of those technologies being commercially
implemented by a third party, to identify potentially infringing products, and to identify a method
of analysis necessary to show infringement. The deliverable from our portfolio evaluation is
typically a patent/product map indicating patents and products that should be considered for
infringement analysis. The patent/product map also identifies products that fail to meet the
requirements of patent claims and the reasons they failed, which is very useful in deciding if a
patent or a product type should be removed from future consideration.
Our infringement analysis service involves applying a patent claim against an accused product.
We collect evidence needed to build a definitive case for infringement through any combination
of literature, product inspection, software/circuit reverse engineering, real-time testing, and
materials analysis. Our infringement reports typically include a claim chart mapping claim
elements onto the accused product.
Our areas of expertise include analog & digital circuits, microprocessor architecture,
semiconductor processing, microwave architecture, RF design, broadcast, networks, wireless
communication, imaging, video, multi-media, electronic commerce, pharmaceuticals,
nutraceuticals, agrochemicals, petrochemicals, polymers, industrial chemical processes and
materials science.
IP Licensing Support, IP Litigation Support (Offensive and Defensive), Prior Art Searches,
Reverse Engineering


Technology Companies, IP Law Firms
Global Royalty Audits, Inc.
218 King Street | Englewood NJ 07631 | United States

Phone: (201) 694-8109 | Fax: (201) 541-5627 | Website: www.graudits.com
Contacts
Mr. Michael W. Swan | President
Mr. Glenn Tautrims | Director
Organization Type
Financial Services
Company Overview
Global Royalty Audits, Inc. ("GRA") is a firm of accountants and attorneys that specializes in
the performance of royalty audits. GRA's principals, Mike Swan and Glenn Tautrims, have
over 20 years combined experience performing royalty audits through out the world (e.g., Asia,
Middle East, Europe, North America) and in nearly every industry, including but not limited to
pharmaceuticals, telecommunications, agriculture, telecommunications, computer hardware and
software, etc.

Licensors who have existing license agreements and need assurance of royalty payments.

To discuss our services with Licensors contemplating the performance of royalty audits or have
concerns about the reportings submitted by their licensees.
Global Strategic Connection
44125 Deep Hollow Circle | Northville MI 48168 | United States

Phone: (734) 622-7653
Contacts
Mrs. Mi Dong | Chief Scientific Officer

Golden Pine Ventures, LLC
2530 Meridian Parkway | Suite 200 | Durham NC 27713 | United States

Phone: (919) 806-4480 | Fax: (919) 806-4770 | Website: www.goldenpineventures.com
Contacts
Dr. Ian J. Mehr | Managing Director
Mr. Christopher Meldrum | Managing Director
Organization Type
Financial Services
Industry Sector
Health Care
Company Overview
Golden Pine Ventures is a venture capital company that seeks out biotechnology and
biomedical opportunities developed by leading researchers and grows them into valuable
businesses. We focus on academic research, forming partnerships and founding companies with
professors, subsequently licensing the underlying patent(s) on their discoveries. Golden Pine is
most interested in therapeutic and medical device opportunities, although diagnostic and
platform/tool technologies will also be considered. Golden Pine is essentially a seed-stage
venture fund, advancing relatively modest amounts of capital to portfolio companies; larger,
multi-million dollar (e.g. Series A) funding is garnered from other investors, the raising of which
is a primary function of GPV on behalf of our portfolio companies.
Patents
Technology transfer
Valuation
Licensing
University research

Golden Pine Ventures would be most interested to meet with university representatives to
describe Golden Pine's mission and operations, and to learn of potential technologies which
could form the basis of new GPV portfolio companies.
Golden Pine would also be interested to meet with representative of companies wishing to learn
more about partnering opportunities with its current porfolio companies:
Catena Pharmaceuticals, Inc.
Catena Pharmaceuticals is focused on the development and commercialization of novel GPCR

antagonists, particularly in the areas of cancer and fibrotic disease. Catena's proprietary
chemistry is uniquely capable of affecting a specific class of GPCRs known to be relevant in a
variety of disease states.
http://www.catenapharma.com/
Exigent Pharmaceuticals, Inc.

Exigent Pharmaceuticals is a new biopharmaceutical company focused on the development and
commercialization of anti-infectives. Exigent is currently developing new pharmaceuticals to
treat drug-resistant bacterial infections, using its proprietary technology platform.
http://www.exigentpharmaceuticals.com/
Kylin Therapeutics, Inc.

Kylin Therapeutics, a cutting-edge biotechnology company, employs a revolutionary RNA
nanoparticle technology platform called “pRNA” to exploit the enormous potential of RNA
interference (RNAi) for treatment of many common diseases. The visionary platform has
enormous potential to meet the huge market opportunity for treating cancer and other diseases
with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to
overcome the most significant challenges in the development of RNA-based therapies.
http://www.kylintherapeutics.com/
Pique Therapeutics, Inc.

Pique Therapeutics is a biotechnology company seeking to become the leader in therapeutic
vaccines, focused initially on the treatment of cancer. Pique’s lead product is a first-in-class
therapeutic vaccine for non-small cell lung cancer in Phase 2 clinical trials. Pique is also utilizing
its novel therapeutic vaccine technology in additional areas of oncology, with products in pre-
clinical stage for pancreatic, colorectal, and head and neck cancers.
http://www.piquetherapeutics.com/

At the LES Annual Meeting, Golden Pine Ventures would like to:
1. Meet with university technology transfer and licensing professionals to cultivate

relationships and learn of technologies that may grow into new porfolio companies
2. Meet with potential corporate collaborators for current portfolio companies
Country(s)
Partnering
Novel Anti-
cancer, AMD, inflammation,
Angiogenic GPCR Not Applicable Worldwide
fibrosis, COPD, asthma, pain
Antagonists
Novel Antibacterial Anti-bacterial, Anti-infective,

Not Applicable Worldwide
Therapies Antibiotic
PT 107 for the NSCLC, pancreatic cancer,

treatment of lung colorectal cancer, head & Not Applicable Worldwide
cancer neck cancer
RNAi Delivery
Technology & Cancer Oncology, Anti-virals, Other Not Applicable Worldwide
Therapy
Goudreau Gage Dubuc LLP
2200 - 2000 McGill College | Montreal QC H3A 3H3 | Canada

Phone: (514) 397-7602 | Fax: (514) 397-4382 | Website: www.ggd.com
Contacts
Mr. Greg Moore | Partner
Organization Type
Law Firm
Company Overview

Goudreau Gage Dubuc LLP is one of Canada's most highly-regarded intellectual property firms.
We are a dedicated group of scientific and legal experts whose combined experience and
interests bring a strategic approach to this highly specialized area.
Goudreau Gage Dubuc's services and expertise address all intellectual property matters,
particularly in the fields of patents, trade-marks and domain names, industrial designs, copyright,
trade secrets, and litigation.
From chemistry, electronics, mechanical and electrical engineering to biotechnology and

pharmaceuticals, computer technology, telecommunications and genetic engineering, we
continuously define and redefine our expertise to meet the challenges presented by new and
emerging technologies.
Since 1966, GGD's success in the protection and enforcement of intellectual property rights has
earned us an enviable international reputation. We work with an international network of
intellectual property firms to stay abreast of, and react swiftly to, changes in international law
and practice.
Government of Canada
111 Harrington Street | Level 5, Quay West | SYDNEY NSW 2000 | Australia
Phone: 02 9364-3027 | Fax: 02 9364 3097 | Website: www.nrcan.gc.ca
Contacts
Mr. Bruce Faiers | Sr. Technology Transfer Officer/Business Advisor
Gowling Lafleur Henderson LLP
Barristers & Solicitors | Patent & Trade Mark Agents | Suite 2600, 160 Elgin
Street | Ottawa Ontario K1P 1C3 | Canada
Phone: +1.613.233.1781 | Fax: +1.613.563.9869
Contacts
Ms. Jane E. Clark | Partner
Mr. Michael J. Crichton | Associate
Mr. Keith T. Desjardins | Partner
Mr. John Ramsay | Partner
Ms. Shelley Samel | Partner
Company Overview

For more than 100 years, Gowlings has provided a broad range of expert legal services. Today,
as one of Canada's largest national law firms, with more than 700 lawyers, patent and trade mark
agents, Gowlings has offices in all major business and technology centres across Canada –
Montréal, Ottawa, Kanata, Toronto, Hamilton, Waterloo Region, Calgary and Vancouver.
Internationally, Gowlings has an office in Moscow to serve clients' IP needs in Russia and the
CIS. The Firm's London office supports clients from around the world with an emphasis on
energy, resources and infrastructure.
Our professionals work together in cross-disciplinary industry groups or client-dedicated teams

to give our clients timely access to our best advice. In addition to its pre-eminence in IP,
advocacy, corporate and business law, Gowlings is recognized for its expertise in information
technology, energy and infrastructure, international trade, advertising and media, professional
liability and the environment. Gowlings is also one of Canada’s leading providers of government
relations and regulatory affairs at both federal and provincial levels of government.
Gowlings professionals appear regularly before the Supreme Court of Canada. They have acted
for the U.S. and Mexican governments regarding the Canada-U.S. Free Trade Agreement and
the North American Free Trade Agreement, respectively. They have been leaders in the
development of landmark Canadian legislation such as the Protection of Personal Information
and Electronic Documents Act (C-6) and they continue to provide public policy advice to
governments around the world on legislation relating to insolvency and the regulation of
financial institutions.
Business Law
At Gowlings, our professionals provide responsive, timely recommendations on business law

issues on everything from individual contracts to public offerings.
Recognized as a leading, national firm in business law, we draw on extensive experience across a
number of industry sectors including automotive, manufacturing, mining, high technology, oil
and gas, finance and investment, venture capital, healthcare and advertising. By understanding
the dynamics of various industries, this group provides its clients the best service possible.
Since the early 1900s, Gowlings has been recognized as a leader in intellectual property law. The
IP group provides representation on all matters relating to the enforcement of patents, trade
marks, copyrights, industrial designs, trade secrets and other rights, and the full range of
litigation services before federal and provincial courts at both trial and appeal levels.
Many of our IP professionals are ranked as Canadian and world leaders in surveys published by
Mondaq, Euromoney, and Lexpert.
In 2006, Gowlings was named by Managing Intellectual Property as “Canadian IP Law Firm of
the Year,” and ranked in the top-tier of MIP’s World IP Survey in trade mark and copyright law
for the tenth consecutive year, while also achieving top-tier status in patent law.

Advocacy
The Gowlings advocacy professionals have expertise in civil and commercial disputes,
insurance, employment and labour relations, administrative and regulatory matters, including
competition law, and professional and product liability claims and related matters.
They provide top-level advocacy services within and outside the business community, sharing
their expertise with skilled professionals in the firm’s other practice areas. They appear at all
levels of the federal and provincial courts and participate in dispute resolution proceedings such
as mediations and arbitrations.
Greenblum & Bernstein, PLC
1950 Roland Clarke Place | Reston VA 20191 | United States

Phone: (703) 716-1191 | Fax: (703) 716-1180
Contacts
Mr. Branko Pejic | Attorney
Company Overview
Greenblum & Bernstein ("G&B") is a U.S. law firm providing services in all aspects of
intellectual property law, including: Client Counseling, Patent Procurement, Litigation (including
ANDA/Orange Book Litigation), Licensing, and Technology Transfer, Petitions, Appeals and
Special Procedures, Trademarks and Copyrights.
The professionals of G&B have backgrounds in all major technical disciplines, including
biotechnology, pharmaceuticals and chemistry (several professionals hold PhD degrees).
G&B has many European clients and is experienced in both European and U.S. laws and
regulations.
Firm members worked cumulatively for more than 150 years inside the U.S. Patent and
Trademark Office (the firm is located close to the U.S. Patent and Trademark Office).

Greene, Tweed & Co.
2075 Detwiler Road | P.O. Box 305 | Kulpsville PA 19443-0305 | United States
Phone: (215) 256-9521 ext 1801 | Fax: (215) 256-0925 | Website: www.gtweed.com
Contacts
Mr. Glenn J. Doell | Technology Transfer Director
Gruenecker Kinkeldey Stockmair & Schwanhaeuser
Maximilianstrasse 58 | Muenchen 80538 | Germany

Phone: -212390 | Fax: -220327
Contacts
Dr. Heike Vogelsang | Patent Attorney
Grunecker & Koll., Law Firm
Leopoldstrasse 4 | Munich 80802 | Germany

Phone: +49-89-212 350 | Fax: +49-89-220 287
Contacts
Dr. Udo Weigelt | Patent Attorney/Partner
Gulliksson Advocates Ltd.
Box 739 | Lund SE-220 07 | Sweden

Phone: +46 46 19 05 20 | Fax: +46 46 19 05 25
Contacts
Mr. Per Ericsson | LL.M. Attorney-at-Law
Mr. Jonas Gulliksson | Advocate

Company Overview
Standing out from the crowd
We are a Swedish law firm that helps our clients to maximize the potential of their ideas. We
distinguish ourselves from many law firms in the Nordic countries by offering expertise in areas
relating to both intellectual property law and commercial law. Our services cover everything
from the handling of trademark and design rights to advising in business matters and negotiating.
Thanks to our unique cooperation with the patent attorneys of Ström & Gulliksson we also
handle matters concerning inventions and other innovations within all areas of technology.
Clients
In our relations with our clients we always strive for top quality. It is thus our aim to offer all the
professional support they need and to accomplish our commissions in such a way that they will
be able to maximize the long-term value of their ideas. Our clients range from small and
medium-sized companies right up to global groups of companies within a wide spectrum of
business areas. Some of them seek advice from us in specific legal matters while others consult
us on a daily basis.
Our team
Among our professionals you find advocates and attorneys-at-law as well as paralegals and
assistants with long experience. Our team offers not only specialist knowledge in intellectual
property law and related legal areas. We also have substantial knowledge within the field of
commercial law. Since many of our attorneys also have extensive experience in legal
proceedings we are often engaged as legal advisors or attorneys in everything from infringement
investigations and negotiations to international dispute resolutions.
Network
We are a correspondent law firm of the Arator Group – one of the major intellectual property
consultancy groups in the Nordic region with representatives in Denmark, Germany, Norway,
Sweden, and USA. One of the subsidiaries of the Arator Group is Ström & Gulliksson with
which we share offices on the same premises at several locations in Sweden. We have also a
continuous cooperation with other law firms and patent attorneys around the world. Furthermore,
we are affiliated to various Swedish and international organizations that give us access to an
extensive base of knowledge and open the doors to lines of businesses and companies both
within and outside the borders of Sweden.
Contact
Please feel free to contact any of our advocates, attorneys, paralegals or assistants. You will find
further information and contact details on our website, www.gulliksson.se.
Uniting Innovative Minds®

We always emphasize the importance of cooperation – both between our professionals and in our
client relations. Through cooperation we can accomplish a dynamic fusion, contributing not only
to the development of existing ideas but also to the creation of brand new ideas and good
business opportunities. In this context we will consistently encourage our clients to choose the

right paths to ensure the commercial success of their ideas.
H. Lee Moffitt Cancer Center and Research Institut
12902 Magnolia Drive | MRC TTO | Tampa FL 33612-9497 | United States

Phone: (813) 745-6902 | Fax: (813) 745-1398
Contacts
Mr. Ray Carpenter | Sr. Intellectual Property Associate

Partnering
BioMarkers- Diagnosis Oncology Not Applicable
BioMarkers- Predicting
Oncology Not Applicable
Response
BioMolecule Oncology Not Applicable
Small Molecules Oncology Not Applicable
STAT3 Inhibitors Oncology Not Applicable
H.K. Acharya & Co.
H K Avenue, 19 Swastik Society | Navrangpura | Ahmedabad 380 009 | India

Phone: 91 79 27545255 | Fax: 91 79 27545257
Contacts
Dr. Malla Reddy | Technical Expert Associate
Organization Type
Law Firm
Company Overview

H. K. Acharya & Company is a Law Firm having specialization in Intellectual Property

Laws based at Ahmedabad in India and also having its offices in Mumbai, Rajkot and
Morvi in India and a representative office at Los Altos, CA, USA.
You may get more details from our website www.markpatent.com
Hewlett-Packard Sg Pte Ltd
61 Alexandra Terrace #05-01/14 | Singapore Singapore

Phone: 63131635 | Fax: 62782452
Contacts
Mr. Peter Tay |
High Tech Intellectual Property Consulting LLC
13612 Country Lake Drive | Austin TX 78732 | United States

Phone: (512) 917-5526 | Fax: (512) 266-0082
Contacts
Dr. Ronald E. Pyle | Intellectual Property Consultant
HighTech-Solutions
PO Box 51024 | Colorado Springs CO 80949 | United States

Phone: (303) 775-7740
Contacts
Mr. Jeffery Carter |
Mr. Seamus Gilchrist | Principal
Mr. Kazimierz Siwiak |
Organization Type
Consulting Firm

Industry Sector
High Technology
Company Overview
We provide intellectual property consulting services to technology companies and law firms
worldwide. Utilizing our extensive knowledge and expertise in IP and a substantial number of
technical fields, we deliver high quality solutions to a wide variety of clients.
Our services include patent evaluation, claim charting, technical opinions, reverse engineering,
transfer pricing, digital discovery, expert witnesses, and IP portfolio valuation, strategy, and
marketing.
All of our experts have advanced degrees in their areas of expertise, and all have intellectual
property experience.
Hoffmann & Baron LLP
6900 Jericho Turnpike | Syosset NY 11791 | United States

Phone: (516) 822-3550 | Fax: (516) 822-3582 | Website: www.hoffmannbaron.com
Contacts
Mr. James F. Harrington | Attorney at Law
Organization Type
Law Firm
Company Overview
Hoffmann & Baron, LLP is a full-service intellectual property law firm which specializes in
prosecution, counseling, licensing, and litigation of patent, trademark, and copyright-related
issues worldwide. The firm’s practice also includes unfair competition, trade secrets, licensing,
technology-related agreements, and due diligence.
With offices in Syosset, New York and Parsippany, New Jersey, Hoffmann & Baron, LLP serves
clients throughout the United States and internationally. Clients include individuals,
entrepreneurial firms, universities, national research laboratories, and multinational corporations.
Several qualities enable us to provide clients with a distinguished level of service. In addition to
the exceptionally strong technical and academic credentials of the partners and associates, most

of our attorneys have held research or engineering positions in industrial or academic

environments. Our role as legal advisors is enhanced and expanded by this immersion in the
technology of the fields we serve. Such experience also provides us with insight into a client’s
legal challenges and opportunities. The firm can readily tailor its services to fit the intricacies
and challenges of your industry.
In addition to enforcing and defending our clients’ rights in the areas of patents, trademarks, and
copyrights, we provide counseling regarding a variety of other legal issues associated with
technology development. For example, the firm’s attorneys counsel clients concerning
technology licensing, technology transfer, patent infringement, patent validity, and software
protection and licensing. The firm is also experienced in all phases of intellectual property
litigation, opposition, and interference in the United States and abroad.
Hoffmann & Baron, LLP serves clients in all major fields of technology which include
aeronautics and aerospace, artificial intelligence, automotive systems, bio-affecting agents and
delivery systems, biochemistry, bioinformatics, biopolymers, biotechnology, business methods,
chemical processes and systems, computers, consumer products, cosmetic chemistry, dietary
supplements, drug delivery systems, e-commerce, electrical processes and systems,
electromechanical processes and systems, electronics, fiber optics, food and food processing,
genomics, health and beauty products, lasers, manufacturing and materials, mechanical processes
and systems, medical and dental devices, microarrays, microbiology, molecular biology,
nanotechnology, nutraceuticals, optics, organic and inorganic chemistry, packaging, petroleum
processing and products, pharmaceuticals, plastics, polymers, proteomics, software, and
telecommunications, among others. For additional information, visit www.hoffmannbaron.com.
Honeywell Aerospace
21111 N 19th Avenue | Phoenix AZ 85027 | United States

Phone: (602) 436-5577 | Fax: (602) 822-7000 | Website: www.honeywell.com/licensing
Contacts
Mr. Don Shell | Manager Technology Licensing
Organization Type
Industry Sector
High Technology

Company Overview
Honeywell Aerospace is the leading developer and supplier of electronic and mechanical
products and systems, along with related software, for the aviation and space industry. With
annual revenues of over $12B, Honeywell Aerospace is a business unit of Honeywell
International Inc., a $37B Fortune 50 corporation.
Technology and product development drivers include:
 Priority given to safety critical applications

 Customer requirements for extremely reliable products
 Highly regulated environment
Honeywell Aerospace seeks to license intellectual property to those markets with similar drivers.
Primary interest is identifying and engaging with companies outside of aerospace that have IP
needs that Honeywell can fulfill. Particular interest in medical, automotive, surface
transportation, and nuclear industries.
Secondary interest is supporting in-bound IP licensing where internal needs and external
solutions have been identified by Engineering and Marketing teams.

Making solid contacts with companies that are looking for IP to reduce development and
schedule risk, or gain advantage over competition.
Hooper & Associates
229 Brannan Street | Suite 9E | San Francisco CA 94107 | United States

Phone: (650) 255-1446 | Fax: (415) 495-6476
Contacts
Mr. Gary Hooper | President

Huron Consulting Group
1120 Avenue of the Americas | 8th floor | New York NY 10036-6700 | United States
Phone: 212-785-1900 | Fax: 212-785-1313 | Website: www.huronconsultinggroup.com
Contacts
Ms. Laura Connor | Manager
Mr. David Leathers | Managing Director
Organization Type
Consulting Firm
Company Overview
Huron Consulting Group helps clients effectively address complex challenges that arise in
litigation, disputes, investigations, regulatory compliance, procurement, financial distress, and
other sources of significant conflict or change. The Company also helps clients deliver superior
customer and capital market performance through integrated strategic, operational, and
organizational change. Huron provides services to a wide variety of both financially sound and
distressed organizations, including Fortune 500 companies, medium-sized businesses, leading
academic institutions, healthcare organizations, and the law firms that represent these various
organizations. Learn more at www.huronconsultinggroup.com.

patent, trademark, and copyright litigation
Hutchison Law Group PLLC
5410 Trinity Road | Suite 400 | Raleigh NC 27607 | United States

Phone: 919.829.9600 | Fax: 919.829.9696
Contacts
Ms. Caroline H. Rockafellow | Attorney
Mr. Bill Wofford | Partner
Company Overview

Hutchison Law Group is the leading provider of strategic business and intellectual property
counsel to the Southeast's technology community. We partner with our clients to provide
responsive quality service, strategic advice, creative problem-solving and connections to
investors. We understand our clients’ technologies and the unique opportunities and challenges
they face. Our attorneys play a key role creating an environment and infrastructure that breed
success. hutchlaw.com
IAM Magazine
New Hibernia House | Winchester Walk, London Bridge | London ENGLAND HC SE1
9AG | United Kingdom
Phone: +44 20 7234 0606 | Fax: +44 20 7234 0808
Contacts
Mr. Gavin Stewart | Publisher
Mr. Joff Wild | Editor
IBM
12902 Federal Systems Park Dr | Fairfax VA 22033-4421 | United States

Phone: +1.203.486.4587 | Fax: +1.203.486.4587
Contacts
Mrs. Kathy Rosa |
Company Overview
IBM has created the Center for Business Optimization with a unique mission: to enhance
organizational performance by applying advanced analytical methods and optimization
techniques to solve some of the most complex problems facing business and government. The
Center for Business Optimization leverages IBM’s global resources and capabilities which
include business consultants, mathematicians and operations research specialists from IBM
Research and advanced technologies and services from deep computing power to hosted
offerings. In addition, the Center for Business Optimization has developed business partner
relationships with major industry application software vendors and leading universities and
operations research organizations.

All of these resources are brought together to help our clients deliver bottom-line results and
assist in making the difficult decisions that are required every day — from optimizing the use of
capital and human assets, to better scheduling, to more effective financial management.
The Center currently has solutions in the areas of risk management optimization, complex supply
chain optimization, marketing investment optimization and crime analytics.
Icagen Inc.
PO Box 14487 | Research Triangle Park NC 27709 | United States

Phone: +1.919.941.5206 | Fax: +1.919.941.0813 | Website: www.icagen.com
Contacts
Dr. Gregory S. Shotzberger | Vice President
Organization Type
Industry Sector
Health Care
Company Overview
Icagen, Inc. is a public biopharmaceutical company focused on the discovery, development

and commercialization of novel, orally-administered, small-molecule drugs that act on ion
channel targets. Utilizing its proprietary know-how and integrated scientific and drug
development capabilities, Icagen has identified multiple drug candidates that modulate specific
ion channels. The Company is conducting research and development activities, in some cases in
collaboration with leading pharmaceutical companies, in a number of therapeutic areas,
including pain, epilepsy, inflammation and asthma.

Patents, tech transfer and university research related to ion channels.

 Companies interested in discussing an exclusive worldwide collaboration on our novel T-

type calcium channel or TRPA1 discovery programs for pain.
 Companies interested in learning more about senicapoc, a first-in-class oral treatment for
asthma currently in Phase II clinical trials and available for licensing/co-development.
 Companies seeking to out-license attractive, clinical-stage candidates in Phases I or II
(preferred therapeutic areas: pain, epilepsy, inflammation, respiratory diseases and
hospital products).

To meet with prospective partners to discuss opportunities for research collaborations and
licensing.

Partnering
Respiratory,
Senicapoc Not Applicable
inflammation
ICAP North America
Harborside Financial Center | 1100 Plaza 5, 12th Floor | Jersey City NJ 7311 | United States
Phone: (212) 815-9092 | Fax: (212) 815-9596
Contacts
Mr. Donald Boreman | Executive Vice President
Idaho Technology Inc.
390 Wakara Way | Salt Lake City UT 84108 | United States

Phone: 801.736.6354 x423 | Fax: 801.588.0705 | Website: www.idahotech.com
Contacts
Ms. Jill T. Powlick | Corporate Intellectual Property Counsel

Organization Type
Company Overview
Idaho Technology, Inc. is a privately held biotechnology company based in Salt Lake City, UT.
Founded in 1990, Idaho Technology licensed the rapid PCR technology from the University of
Utah. Through funds from the United States Department of Health and Human Services and the
Department of Defense, the company has created many commercial instruments and reagents for
use in research and applied fields. Several of these products, including the LightCycler®
Instrument, have been sublicensed to Roche Diagnostics GmbH. Researchers, medical
technicians, law enforcement officers, and soldiers in the field use the company's devices to
detect or study disease-causing organisms.
IdeaPoint Inc.
300 Congress Street | Suite 404 | Quincy MA 2370 | United States

Phone: (617) 729-3110 | Website: www.idea-point.com
Contacts
Mr. Frank D.J. Haines | Director of Business Development
Idexx Laboratories Inc.
2825 KOVR Drive | West Sacramento CA 95605 | United States

Phone: 916-731-4017 | Website: www.idexx.com/preclinicalresearch
Contacts
Mr. Lalit Gaur | Sr. Manager, Licensing and Strategic Partnerships
Organization Type
Industry Sector
Health Care
Company Overview

IDEXX Preclinical Research Services is part of a national network of laboratories that provide
testing and consultation services for the biotechnology and pharmaceutical industries. High-
capacity, fast turnaround times, excellent customer service, and high quality testing services are
our unique trademarks. IDEXX has experienced pathologists and a qualified research support
team to help plan, schedule, receive, monitor and deliver accurate results for your studies. We
offer testing in the areas of
37. Biochemistry
38. Hematology
39. Immunology
40. Microbiology
41. Histology
42. Anatomic Pathology
We also provide electronic results, free courier service and free sample collection tubes as part of
our comprehensive range of services.

Interested in meeting companies with diagnostic and pharmaceutical technologies for animal
health
IgniteIP, LLC
105 Lock Street | Suite 407 | Newark NJ 07103 | United States

Phone: (973) 624-1555 | Fax: (973) 624-1444 | Website: www.igniteip.com
Contacts
Mr. Brandon Williams | Managing Director
Organization Type
Financial Services
Company Overview
IgniteIP is a private equity investor that funds innovation: we partner with inventors, universities,
and corporations to fund and manage the protection, development, productization and
commercialization (through licensing). Founded in 2005, we have invested over $10M in
promising new technologies and have already achieved results. We are looking for technologies
to fund, sources of new deals, resources for evaluating new technologies, and corporations

looking for sources of innovation. We have been called an Innovation Capitalist by the Harvard
Business Review and Technology Transfer Tactics journal.

We are looking for technologies to fund, sources of new deals, resources for evaluating new
technologies, and corporations looking for sources of innovation.
ImClone Systems
33 ImClone Drive | Branchburg NJ 8876 | United States

Phone: (908) 243-9996 | Fax: (908) 575-2158
Contacts
Dr. John S. Zawad | Vice President, Business Development
Company Overview
ImClone Systems Incorporated is a fully integrated global biopharmaceutical company

committed to advancing oncology care by developing and commercializing a portfolio of
targeted biologic treatments designed to address the medical needs of patients with a variety of
cancers. The Company's research and development programs include growth factor blockers and
angiogenesis inhibitors. ImClone Systems' headquarters and research operations are located in
New York City, with additional administration and manufacturing facilities in Branchburg, New
Jersey. For more information about ImClone Systems, please visit the Company's web site at
http://www.imclone.com.
Immatics Biotechnologies GHBH
Frauenhoterstrasse 186 | Martinsried 82152 | Germany

Phone: 498930904156 | Fax: 498930904155
Contacts
Mr. Wolfgang Flasche |
Inflexion Point Strategy, LLC
1037 Ramona Street | Palo Alto CA 94301 | United States

Phone: (650) 814-5600 | Fax: (650) 745-1170 | Website: www.ip-strategy.com

Contacts
Mr. Ronald Laurie | Managing Director
Organization Type
Financial Services
Industry Sector
High Technology
Company Overview
Inflexion Point Strategy, LLC is an intellectual property investment bank based in Silicon Valley
and founded by Ron Laurie in January 2004. Inflexion Point represents technology companies
and institutional investors in buying, selling or investing in patent portfolios having significant
strategic value and in sourcing and facilitating IP-intensive M&A transactions such as corporate
spin-outs of "stranded" technologies and associated IP. More information is at http://www.ip-
strategy.com
Inhibitex, Inc.
9005 Westside Parkway | Alpharetta GA 30004 | United States

Phone: 678-746-1144 | Fax: 678-746-0624 | Website: www.inhibitex.com
Contacts
Dr. Joseph M Patti | CSO
Company Overview
A biopharmaceutical company focused on the development of products to treat serious infectious

diseases.
for Partnering
Antiinfective, primary
FV-100 Not Applicable
care

HCV Nucleoside HCV, antiviral,

Not Applicable
Polymerase Inhibitor antiinfective
HIV, antiviral,
HIV Integrase Inhibitor Not Applicable
antiinfective
Innography
6300 Bridgepoint Parkway | Building 1, Suite 500 | Austin TX 78730 | United States
Phone: (512) 415-3469 | Fax: (866) 827-4105
Contacts
Mr. Robert C. Busch | VP Business Development
Mr. Doug Miller | Vice President, Marketing
Innovation Development Institute
45 Beach Bluff Avenue | Suite 300 | Swampscott MA 01907-1542 | United States

Phone: (781) 595-2920 | Fax: (781) 593-4660 | Website: www.inknowvation.com
Contacts
Ms. Ann Eskesen | President
Innovation Edge
20 Diane Lane | Appleton WI 54915 | United States

Phone: 920-428-1878
Contacts
Dr. Jeff Lindsay | Director of Solution Development

Inrea Research Solution Pvt Ltd
B-4084, Oberoi Garden Estate, | Chandivali, Andheri (E) | Mumbai IN 400072 | India
Phone: 91-22-40154282 | Fax: 91-22-28575655 | Website: www.inrea.co.in
Contacts
Mr. Nalin Agrawal | Director
Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
Inrea Research provides patent research, patent analytics, business technology analysis and
licensing support services to Fortune 500 companies, SMEs, Start-ups, Venture capitalists, IP
consultants, business development executives and law firms in Electronics, Communications,
Mechanical, Biomedical Devices, Life Sciences, Consumer goods, Chemical, Chemistry and
Materials Science industries.
Through our subject matter expertise and extensive information coverage we help our clients
strategize their R&D, their business development efforts and in/ out licensing plans. Further,
through our proprietary software and collaboration platforms we help our clients extract insights
from formidable patent thickets and drive key business decisions.
Our services include:
Research Services (Prior-art Searches):

· Patentability/ Novelty
· Validity/ Invalidity/ Opposition
· Freedom-to-operate/ Clearance
· State-of-the-art/ Collection
· Structure/ Sequence/ Reaction
· Non-patent Literature
Patent Analysis Services:

· Industry Intelligence and Forecasts
· Competitive Intelligence
· Patent Landscaping and Mapping
· Portfolio Analysis
· In/ Out Licensing Support

· Legal Status Analysis

· Business & Technology (Biztech) Analysis
· Updates/ Watches
Institut National De La Recherche Scientifique
490, Rue de la Couronne | Quebec QC G1K9A9 | Canada

Phone: (418) 654-3874 | Fax: (418) 654-3858
Contacts
Mr. Stephen Fitzpatrick | Attorney
Institut Pasteur
28 rue du Docteur Roux | Paris 75015 | France

Phone: 45 68 81 87 | Fax: 40 61 37 32
Contacts
Mr. Vincent Charpentier | Licensing Manager
Mr. Fabrice Mouche | Project Manager
Organization Type
Industry Sector
Health Care
Company Overview
Institut Pasteur is a non-profit private foundation which contributes to the prevention and
treatment of disease, primarily infectious diseases, through research, education, and public
health activities.
The Institut Pasteur foundation has set itself the following objectives:
The study of infectious, parasitic and immune-system diseases, together with the means of
preventing and fighting such diseases;
The pursuit and development of research into micro-organisms, their role in natural, normal or
pathological processes, and the reactions that they induce;
The study and teaching of all aspects of microbiology, together with the training of scientific and
technical personnel, with a view to promoting research in fundamental and applied

microbiology;
The study of all theoretical or practical phenomena related to microbiology, immunology or,
generally, fundamental or applied biology, and research in these fields.
Our Values
Institut Pasteur is led by:
An ideal: helping to fight against disease - primarily infectious diseases - through research,
education, and public health activities
High expectations: striving for excellence in every one of our missions
A humanist vision of the world and generosity to others.
Three spheres of activity
The Institut Pasteur brings together three fields of activity -which are : research, education and
public health- on its Parisian campus with almost 2500 individuals, within an independent
international network of Pasteur institutes, which constitutes an original and autonomous body,
the only one of its kind in the world.
Research in biology, with a priority for the fight against infectious diseases (microbiology)
Viral diseases (hepatitis, influenza, AIDS, rabies, poliomyelitis, haemorrhagic fever etc.)
Bacterial diseases (tuberculosis, whooping cough, meningitis, cholera, diarrhoea etc.)
Parasitic diseases (malaria etc.)
Our researchers also study other diseases such as:certain types of cancer, genetic diseases,
neurodegenerative diseases, and allergy.
Main fields of research: microbiology, immunology, molecular biology, neurobiology, genomics
and post-genomics.
Education
Every year, approximately 250 young scientists from all over the world follow high-level courses
in microbiology and immunology as part of the institute's teaching programme, and over 800
trainees belonging to 60 different nationalities come to perfect their skills in the institute's
laboratories.
Public health activities
Our medical centre provides to the population the following services :
Vaccinations and advice to travellers (influenza, tetanus, hepatitis, diphtheria, etc.)

Infectious and tropical diseases
Travel medicine
Allergy

Rabies centre
Screening centre (AIDS, hepatitis C)
Analysis laboratory
The International Network of Pasteur Institutes provides similar services, specific to the
countries in which they are located. 22 National Reference Centres and 8 World Health
Organization Collaborating Centres efficiently monitor infectious diseases in France and
throughout the world. In order to enable the results of its research to be of rapid benefit to the
general public, in the form of new products, technologies or services, the Institut Pasteur has
established close partnerships with industry in a number of fields including :
human health, by improving and developing medicinal products, vaccines (against tuberculosis,
whooping cough, malaria, gastric ulcers etc.), and diagnostic tests (for dengue, listeriosis,
tuberculosis etc.)
the environment
the food industry
hygiene.
This valorisation of its research also represents a source of financing enabling the Institut
Pasteur to pursue its missions.

Big Pharma, Start-up in the field of biotechnology.
Intellectual Asset Management Associates, LLC
515 King Street, Suite 420 | Alexandria VA 22314 | United States

Phone: (703) 548-8213 | Fax: (703) 684-6048 | Website: www.iama-hq.com
Contacts
Mr. Donald Grant Kelly | Principal
Intellectual Assets, Inc.
14606 Horseshoe Drive | Saratoga CA 95070 | United States

Phone: (408) 314-5896 | Fax: (408) 868-9462
Contacts
Dr. Paul Germeraad | President

Organization Type
Consulting Firm
Company Overview
IntellectualASSETS, Inc. is a professional advisory services firm, specializing in integrated
business, R&D, and IP processes.
We distinguish ourselves by using cutting edge IP assessment tools and proprietary software
to enhance our productivity. Furthermore, we offer invaluable insights based on our depth and
breadth of executive level management experience and industry coverage.

Patents, trademarks, technology transfer, evaluation, intellectual assets management

Anyone we can help

Helping members find LES Education opportunities
for Partnering
Integrated Intellectual Asset
n/a Not Applicable
Management
Intellectual Property Insurance Services Corporation
9720 Bunsen Parkway | Louisville KY 40299 | United States

Phone: (502) 491-1144 | Fax: (502) 491-4888 | Website: www.ipisc.com
Contacts
Mr. Charles Baxter | General Counsel
Organization Type
Financial Services
Company Overview
IPISC is the industry leader in the assessment and transfer of intellectual property (IP)
infringement risk. We are an IP insurance and risk management services company who wrote
the first-ever IP infringement enforcement insurance policy. We provide IP insurance policies
and professional services to help reduce IP exposure, and mitigate the cost and consequences of

litigating IP cases. In addition to enforcement and defense patent insurance, we offer trademark
and copyright insurance. We also offer insurance to cover business interruption in the event of
an adverse IP lawsuit, insurance to cover the unauthorized disclosure of a company's
confidential information and insurance which backs IP to make it available as an asset.

IPISC provides insurance policies to enforce patents, trademarks or copyrights, or to defend
against allegations of infringement of patents, trademarks, copyrights or trade secrets. IPISC
further provides services to the IP community including searches, valuations and litigation
management.

We would like to meet with anyone interested in managing IP risk through insurance, as
described on www.ipisc.com.

Partnering
Indsurance for intellectual
Insurable risk Not Applicable United States, Worldwide
property
Intellectual Property International, Ltd.
3766 Brookdale Blvd | Castro Valley CA 94546-2014 | United States

Phone: (510) 888-1998 | Fax: (510) 538-5200
Contacts
Mr. Lawrence J. Udell | Executive Director
Organization Type
Consulting Firm
Industry Sector
Company Overview
IPI serves as an educational organization in all areas of technology commercialization.
We work with inventors throughout the world in assisting to license their IP.

We also serve as intermediary in M&A plus valuations of new technologies and markets.
Over 50 years of new venture experience with a team of 42 diversified experts.
We assemble the management team and funding for new technology opportunities.

Any firm with technology or IP portfolio that is seeking commercialization or licensing.
Intellectual Ventures
1756.114 Avenue, SE | Suite 100 | Bellevue WA 98004 | United States

Phone: (425) 467-2300 | Fax: (425) 467-2350
Contacts
Mr. Kevin Barhydt | Director of Acquisitions
Mr. Cash Elston | Acquisitions Manager
Ms. Elizabeth Holohan | Director of University Programs
Mr. Gaby Khouri | Portfolio Architect, Licensing
Dr. Donald Merino | General Manager Acquisitions
Industry Sector
High Technology
Company Overview
Intellectual Ventures is an invention company. We conceive and patent our own inventions in-
house through a world-renowned staff of internal and external scientists and engineers. We also
acquire and license patented inventions from other inventors around the world. Our network of
invention sources includes: large and small businesses, governments, academia, and individual
inventors. These inventions span a diverse range of technologies including: software,
semiconductors, wireless, consumer electronics, networking, lasers, biotechnology, and medical
devices. Our current focus is on developing our invention portfolio. Over time, we intend to
market our portfolio on a broad and non-exclusive basis through a variety of channels including
spin-out companies.
Our acquisition and partnering model has been embraced by a wide range of organizations (large
and small, private and public, commercial and not-for-profits, academic and research
institutions) and individuals. For some, they view working with Intellectual Ventures as a way to
commercialize their R&D efforts. For others, they look at it as a way to fund additional R&D
and ongoing patenting efforts. Regardless of the purpose, they are pleased that we are developing
a market for inventions and a commercial outlet for their inventive efforts.

Like other early stage companies, much of the initial work is dedicated to building the first
product. For us, this means building our initial portfolio. We are not focused on marketing or
distributing our portfolio at the moment. When we do reach that point, however, our intent is to
market our portfolio on a broad and non-exclusive basis. Like any product, it is likely that our
portfolio will be segmented according to customer needs and offered through a variety of
channels, which could include spin-out companies, marketplace exchanges, etc.
IntelliPharm Inc.
94 Acres | Kirkland QC H9H 4Z4 | Canada

Phone: (514) 236-7340
Contacts
Mr. Mark Lackovsky | President
Organization Type
Consulting Firm
Industry Sector
Health Care
Company Overview
IntelliPharm is focused on searching, evaluating and concluding licensing agreements for the
Canadian market

Seeking late stage products for licensing in Canada. Phase III, pending registration and approved
products are being sought.
Manufacturers
Distributors

In-licensing products for the Canadian market

InterDigital Communications LLC
781 Third Avenue | King of Prussia PA 19406 | United States

Phone: (610) 878-7857 | Fax: (610) 878-7843
Contacts
Mr. Donald Boles | Sr. VP/Chief Patent Strategist
Mr. Laurence J. Schroepfer | Senior Business Development Attorney
International Patent Licensing Company, LLC
5420 LBJ Freeway | Suite 660 | Dallas TX 75240 | United States

Phone: (972) 851-5993 | Fax: (972) 851-5991 | Website: www.iplcllc.com
Contacts
Mr. Charles Neuenschwander | Principal
Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
About IPLC
IPLC’s experienced licensors have brought more than $220 million of direct financial
benefit to clients over the past 15 years. Our management consulting and program
execution can help companies in the high tech industry:
43. Devise, implement or improve assertive out-licensing programs

44. Defend against demands for unreasonable royalties
45. Substantially increase the value of portfolios offered for sale
46. Eliminate or minimize all costs of monetizing a patent portfolio
Since the early years of assertive out-licensing in the high-tech industry, the principals of
IPLC have helped select clients realize royalty revenues from their patent portfolios. Some
small clients are not in a position to fund licensing or brokering services and we have
programs to suit their needs. Other clients are large international companies in
semiconductor, telecommunication, information technology and consumer electronics fields

located in Asia, the US and Europe. For them we provide an outsourcing alternative to
relieve manpower or budget constraints.
For all of our clients, we have provided programs custom tailored to objectives they set
forth. While there are methodologies that work well in many situations, no single program
performs best for everyone. Further, we do not hesitate to recommend other consultants
when a potential client is better served in other ways.
The three principals of IPLC combine project management skills, knowledge of high-tech
products and markets, expertise in patents under US law and business analysis &
negotiating know-how to develop programs that provide the client with the best chance to
meet critical objectives. We also have strong relationships with patent litigating law firms
in the US and Japan.

IPLC is a long time member of LES and regulary contributes to the planning and management of
meetings. We provide speakers for workshops and panels around the world and have contributed
to LES's journal les Nouvelles.

High tech individuals and companies involved in semiconductors, telecommunications,
information technology and consumer electronics.
First to give back and contribute to LES's mission to the licensing community as a whole. We
wish to be one of the leaders by speaking and publishing on behalf of LES.
LES meetings are a time for us to learn of issues confronting patent owners and the licensing
community and to meet with potential clients to give them an assessment of if and how we might
be of service.

Partnering
Assertive Licensing Worldwide, Asia, Europe,
n/a Not Applicable
Programs North America
Defensive Licensing Worldwide, Asia, Europe,
n/a Not Applicable

Expert Witnessing n/a Not Applicable North America

Patent Brokering Worldwide, Asia, Europe,
n/a Not Applicable
Intersouth Partners
406 Blackwell Street | Suite 200 | Durham NC 27701 | United States

Phone: 919.493.6640 | Fax: 919.493.6649 | Website: www.intersouth.com
Contacts
Mr. David L Pierson | Partner
Organization Type
Financial Services
Company Overview
Intersouth Partners is one of the most active and experienced early-stage venture funds in the
country, having invested in more than 95 entrepreneurial teams over the last two decades.
Founded in 1985 and based in Durham, North Carolina, Intersouth manages $780 million in
seven venture capital limited partnerships. Intersouth seeks a broad range of seed and early-
stage investment opportunities in the technology and life sciences sectors, including
biopharmaceuticals, materials, diagnostics and devices. Intersouth primarily invests in the
Southeast corridor between Baltimore and Florida and is focused on helping management teams
achieve the strategic objectives that enable outstanding companies to grow from seed stage
through successful exit.
IntraLinks
150 East 42nd Street, 8th Floor | New York NY 10017 | United States
Phone: 650-867-5493 | Website: www.IntraLinks.com
Contacts
Ms. Gemma Rastatter |
Organization Type
Industry Sector
High Technology
Company Overview

Businesses around the world rely on IntraLinks On-Demand Workspaces™ to help them share
sensitive information and documents safely and securely online — anywhere, anytime.
IntraLinks has been adopted by the mergers & acquisitions, syndicated loans, alternative
investments and life sciences communities and by the corporate legal, finance and operations
teams of global companies. We've facilitated projects with over 700,000 users, representing over
80,000 organizations. It's this industry experience and dedication to quality and consistency that
has helped us build loyal client relationships. The workspace is virtual. The trust is real.
for Partnering
IntraLinks On-Demand
n/a Not Applicable
Workspaces™
Invensys
36 Watchung Drive | Basking Ridge NJ 07920 | United States

Phone: (908) 470-4234 | Fax: (908) 470-4234
Contacts
Dr. Babu Rao Obilichetti | Management and Intellectual Property Consultant
Invention Law Group, PLLC
677 120th Avenue NE | Suite 2A-248 | Bellevue WA 98005 | United States

Phone: (425) 467-2291 | Fax: (425) 679-0591
Contacts
Mr. W. Ryan Clark | Acquisitions Associate
Invotex Group
1637 Thames Street | Baltimore MD 21231 | United States

Phone: (410) 824-0142 | Fax: (410) 824-0150
Contacts
Ms. Judy A. Byrd | Director
Mr. Mark J. Chandler | Managing Director

Ms. Debora R. Stewart | Managing Director

Mr. Scott Williams | Director
Organization Type
Consulting Firm
Company Overview
Invotex Group provides accounting, financial and
economic consulting services to the business and
legal communities, financial institutions, insurance
companies and governmental entities in matters
involving complex financial disputes, investigations,
reorganizations, insurance and valuations. In
addition, Invotex offers advisory services for
intellectual property owners, including licensing,
technology evaluation and valuation, license
compliance, asset management and enforcement
of IP rights. We offer clients a single source for
comprehensive financial consulting solutions.
Current and Prospective Clients
• Fortune 500
• Small-Mid Cap and Start-Up Companies
• Venture Capital Firms
• Universities

• Technology Transfer Offices
• Law Firms
• Individuals & Inventors
Objective: Develop relationships with people in organizations who wish to maximize the value
of their organizations intellectual property.
Invotex’s professionals provide financial and managerial consulting services to IP owners,

investors, corporations and their counsel.

Partnering
IP Sales and
Licensing
IP Valuation n/a Not Applicable Worldwide
Royalty Audit
Services
Technology
Evaluation
IP Bewertungs AG CIPB
Stephausplalz 10 | Hamburg 20534 | Germany

Phone: | Fax: 49.04087870122
Contacts
Mr. Ghesal Fahimi | Senior International Sales Manager

IP2 REVENUES, LLC
180 Thompson Drive | Hockessin DE 19707 | United States

Phone: (302) 252-5056 - Mobile | Fax: (302) 239-2113 | Website: www.IP2REVENUES.com
Contacts
Dr. Kewal K. Likhyani | President
Organization Type
Consulting Firm
Industry Sector
Consumer Products
Company Overview
As a "Freelance" hands-on business coach, my mission is to help clients develop and execute
actionable strategy to improve profitable top-line growth with intellectual property( IP ) tools,
including opportunity patenting, IP licensing, acquisition or commercialization in concert with
other business innovation initiatives.
The clients come to me because they want an experienced and highly credentialed "freelancing"
person to look at their business, R&D and IP portfolio(s) to 1) identify growth opportunities in
today's global open innovation environment and help execute them with our broad global reach
or 2) provide an independent assessment to improve reality check or 3) identify "blind spots".
I serve essentially all industrial segments in chemical, energy, materials, health care, consumer
products, high technology sectors.
As for background, a founding President, a Ph.D chemical engineer and a business coach, Dr.
Kewal K. Likhyani, is a former DuPont Director of Licensing & Joint-Ventures and a Patent
fellow at DuPont with over 37 years of hands-on experience in the area of R&D, market
development, competitive business analysis, manufacturing, intellectual property development
and monetization via licensing, commercialization or sale of IP portfolio(s). Dr. Likhyani is a
Certified Licensing Professional ( CLP ) by the Licensing Executive Society of USA and Canada
( LES ).

Company is interested in any of the following: business coaching, IP management or
monetization, patents, trademarks, tech transfer, valuation, intellectual asset management,
university research.

Companies who want an experienced and highly credentialed "freelancing" person to look at
their business, R&D and IP portfolio(s) to 1) identify growth opportunities in today's global open
innovation environment and help execute them with our broad global reach or 2) provide an
independent assessment to improve reality check or 3) identify "blind spots". Please contact Dr.
Likhyani directly at 302-252-5056 ( mobile ) or e-mail: Likhyani@IP2Revenues.com. web site:
http://www.IP2REVENUES.com

My goal is to meet with new clients face-to-face for further follow-up.
for Partnering
Business coaching Pain Management,
with IP tools consumer products
ipCapital Group, Inc.
400 Cornerstorne Drive | Suite 325 | Williston VT 05495 | United States

Phone: (802) 872-3200 ext212 | Fax: (802) 288-9465 | Website: www.ipCG.com
Contacts
Mr. Douglas J. Roth | Senior Manager
Mrs. Rachael S. Schwartz | IP Strategy Consultant
Ms. Katherine Shore | Consulting Manager
Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
Since 1998, ipCapital Group has delivered over 450 successful IP engagements to companies in
a wide range of industries. Our professional services maximize financial results for clients that
seek to develop and execute intellectual property (IP) strategies, strengthen and monetize IP
portfolios, and establish and implement Intellectual Asset Management (IAM) practices. We
have an interdisciplinary team trained in business, law, marketing, and product development that
provides a systematic and comprehensive view of the full lifecycle of IP, from creation to
monetization to retirement.

ipCapital Group provides services to support companies in solving IP crises, developing IP

strategies and executing processes, and other IAM-related project work.
ipCapital Group is seeking to meet with companies that are looking to solve important IP crises,
raise the level of IP awareness within their organizations, gather competitive intelligence to
support business goals, or improve internal IAM processes.
ipCapital's goals for attending the LES Annual Meeting 2008 are:
 Learn from thought leaders in IAM

 Spark new thinking about how to serve our clients better
 Catch up with familiar colleagues and acquaintances
 Network to meet new contacts in any industry or company size
 Discuss ipCapital's capabilities and services with companies that may have needs
IPEG- IP merchant banking
Bezuidenhoutseweg 350 | 2594 BE The Hague | The Hague 10023 | Netherlands

Phone: 3170335 05 22
Contacts
Mr. Severin de Wit | Partner
IPEngine LLC
20 William Street | Wellseley MA 2481 | United States

Phone: (617) 513-1403
Contacts
Mr. Russell Franks | CEO
ipernica ltd
Level 1, 16 Ord Street | West Perth WA 6005 | Australia

Phone: +61 8 94208503 | Fax: +61 8 94208547 | Website: www.ipernica.com

Contacts
Mr. Tim Jones | General Manager
Organization Type
Financial Services
Company Overview
ipernica is a business that realises value in good ideas, ideas being the source of all
intellectual property rights.
“We assist you to make your ideas a reality and unlock their potential value”
What We Do
ipernica is an Australian based public company (ASX code ‘IPR’) with extensive global
activities focussed on generating revenue from intellectual property (IP) rights. IP rights, such as
patents, trade marks and copyright, protect inventors and IP owners by preventing others from
using their ideas, creations and inventions without their consent.
ipernica has extensive IP expertise in the creation and exploitation of IP rights, and can assist
you to create and unlock the value in your IP. We also generate revenue from investing in and
commercialising our own IP portfolio.
What we Do
Innovate: Innovation and Commercialisation Services ipernica provides a range of professional

services aimed at addressing many of the key issues faced by you and/or your organisation in
seeking to commercialise your IP.
Protect: Assertion of IP Rights Preventing others from using your IP without your consent is
essential to preserve the value of your IP and to protect the investment you have made in its
creation.
Realise: Realising Revenue from IP Licensing and Venture Investments ipernica invests cash
and resources into commercialisation programs that realise revenue from intellectual property.
The Benefits
Our Stability: ipernica is a publicly listed company trading on the Australian Stock Exchange
(ASX code 'IPR')
Our Depth of Skill and Experience: experience that comes from working with clients such as
CSIRO, Telstra and the Australian Government Department of Defence and from the combined
experience of our team.

Our Strategic Partnerships: that provide clients with access to technical consultants, venture
capital firms, patent attorneys, IP commercialisations and business development companies
Our Extensive Global Networks and Activities: ipernica has extensive global industry and
professional networks and its activities extend throughout the world.
 Patents
 Patent enforcement funding and services
 Intellectual asset management
 Patent Owners
 Patent Attorneys
 Patent Agents
 Litigation Funders
 Trial Lawyers
 Portfolio Managers/CIPO's

We are looking to assist patent owners who are interested in monetising their patents, through
various means including assertion, licensing and securitization.
IPLC International Patent Licensing Co.
5420 LBJ Freeway | Suite 660 | Dallas TX 75240-2318 | United States

Phone: (972)670-8813 | Fax: (972) 479-0464
Contacts
Mr. Gerald Amen | Principal
Mr. Gregory Howison | Principal

IPotential, LLC
1400 Fashion Island Blvd | Suite 601 | San Mateo CA 94044 | United States
Phone: (650) 572-8825 | Fax: (650) 572-9507 | Website: www.ipotential.com
Contacts
Mr. Joe Chernesky | President & COO
Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
IPotential is the technology industry's premier provider of complete intellectual property strategy
and patent monetization services. IPotential, founded in late 2003, is dedicated to bring the same
level of experience and expertise in patent transactions and strategy as had previously been
available only to the largest technology companies. Our management team has more than 100
years of IP strategy and transaction experience at leading Silicon Valley companies and law
firms.
Its brokerage service is the leading market maker for technology patents. With experience in
buying, selling and licensing thousands of patents, IPotential helps its customers understand and
navigate the complicated legal, business and technical process required to generate the maximum
value of their patent portfolios.
IPSEVA
2828 Westshire Drive | Los Angeles CA 90068 | United States

Phone: (323) 465-0712 | Fax: (323) 465-3604
Contacts
Ms. Cynthia Cannady | Attorney at Law
IPVALUE Management Inc.
200 W Evelyn Ave, Suite 100 | Mountain View CA 94041 | United States
Phone: 650 230 4759 | Fax: 650 425 3384 | Website: www.ipvalue.com
Contacts
Mr. George Park | Director

Company Overview
IPVALUE Management is the leading provider of strategic IP advisory and transaction services,
serving the needs of the world’s premier patent creators and owners. IPVALUE’s singular
mission is to maximize return on invention for its partners.
Since its establishment in 2001, IPVALUE has successfully closed numerous transactions of
various types, including patent licensing and litigation settlement, sales, and technology transfer,
and delivered in excess of $350M in revenues to our partners. IPVALUE has also provided deal
critical advisory services at the intersection of IP law and technology business strategy in support
of several large private equity / M&A transactions.
IPVALUE serves its partners by bringing together a top-notch team of multidisciplinary

professionals, the resources to invest in developing opportunities, a unique success-based
partner-centric business model, and the highest standards of professionalism and integrity.
Providing leading global enterprises with ability to make appropriate risk-reward trade-offs
coupled with the highest level of transparency and compliance with corporate standards,
IPVALUE is the blue-chip IP partner of choice for many leading global technology firms.
IPVALUE is ideally positioned to partner with creators and owners of world-class IP to create
long-term value in the context of a shared risk-reward framework.
ISTA Pharmaceuticals, Inc.
15295 Alton Parkway | Irvine CA 92618 | United States

Phone: (949) 788-5302 | Fax: (949) 789-7744
Contacts
Mrs. Lauren P. Silvernail | CFO and VP Corporate Development
Mr. Craig R. Skenes | Director, Business Development
Organization Type
Industry Sector
Health Care
Company Overview
ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. The Company’s products

addressing the $3.2 billion U.S. prescription ophthalmic industry include therapies for
inflammation, ocular pain, glaucoma, allergy, dry eye, and vitreous hemorrhage. ISTA currently
markets three products: XibromTM (bromfenac sodium ophthalmic solution) for the treatment of
inflammation and pain following cataract surgery, Istalol® (timolol maleate ophthalmic solution)
for the treatment of glaucoma, and Vitrase® (hyaluronidase for injection) for use as a spreading

agent.
The Company also is developing a strong product pipeline to fuel future growth and market
share. ISTA’s product development and commercialization strategy is to launch a new product
every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic
pharmaceutical company in the U.S.

We are interested in licensing prescription products for the eye for the U.S. market.

Companies with prescription drug candidates that can be made into eye pharmaceuticals. Prefer
product candidates ready for human clinical study in the U.S.

In-Licensing
ITECS
608 Faulkner Street | New Smyrna Beach FL 32168 | United States

Phone: (404) 934-9161
Contacts
Dr. Susan K. Ward | President
Company Overview
ITECS Company Profile
Company Overview
ITECS is a technology development company that helps businesses, universities and nonprofits
successfully fund, develop and commercialize technologies by capitalizing on government
opportunities. We have a proven track record of helping our clients to establish funding streams,
achieve market access, and develop robust value propositions to quickly meet their growth
objectives with lower risk.
ITECS helps clients form partnerships to get their technology to market faster, easier and with
more success. We do this by combining our extensive experience in identifying, validating,
positioning, and securing funding for technology development with our network of government,
university, non-profit and corporate technology contacts.
Examples of Who We Work With:

 Corporations:
A.Schulman, Ashland Specialty Chemical, Archer Daniels Midland, Air Products, Arkema,
BASF, BP Amoco, Delphi, Degussa, CentriCare, Eastman Chemical, FMC, Folia Inc.,
Goodrich, Johns Manville, Kemira, MeadWestvaco, Meggitt Electronics, NASA, National
Composites Center, PPG Industries, Roche Diagnostics, Sappi LTD, Sherwin Williams,
Starfire Systems, US Gypsum, Valvoline
 Universities & Non-profits:

East Carolina University, Findley Economic Development, National Composites Center
(NCC), Ohio State University, Florida State University, Penn State University, Southern
Research Institute (SRI), University of Alabama, University of South Carolina, Wallace
Kettering Institute
Proven Track Record:

To date we have helped our clients secure over $100M in research funds and $500M in
additional sales by putting together partnerships between businesses, universities and
government agencies.
Itecs-Innovative, Inc.
102 Sequoia Drive | Lexington NC 27292 | United States

Phone: (336) 250-1446 | Fax: (336) 238-3697
Contacts
Ms. Sandra Kessler |
J.D. Franco & Company, LLC
300 East Lombard Street | Suite 840 | Baltimore MD 21202 | United States
Phone: (443) 552-3308 | Fax: (443) 583-1453
Contacts
Mr. Jeff Franco | Principal
Organization Type
Industry Sector
Health Care
Company Overview

J.D. Franco & Company is focused on launching new technologies resulting from University
based research. We focus on working with inventors and Universities to launch companies
around new inventions. This is done via standard out licensing agreements or JVs with the
University.

Presenting.
Also interested in meeting anyone associated with the medical device industry.

Medical companies focus on percutaneous cardiovascular technologies or that have an interest in
this space.

Present and network and potentially find a strategic partner for my percutaneous interventional
cardiology technology.
Country(s)
Partnering
interventional cardiology,
Tendon cardiovascular, structural heart Not Applicable
disease, mitral regurgitation
Japan Technology Group Inc.
Eight Penn Center, Suite 1300 | 1628 John F. Kennedy

Boulevard | Philadelphia PA 19103 | United States
Phone: (215) 701-6349 | Fax: (215) 751-0192 | Website: www.japantechnologygroup.com
Contacts
Ms. Konomi Takeshita | Vice President
Company Overview
Japan Technology Group, Inc. (JTG) is a technology transfer company, serving as an

international broker of technology-based intellectual property. It is a subsidiary of Keisen

Associates, a Tokyo-based intellectual property law firm with a liaison office in Philadelphia,
Pennsylvania. JTG serves as a link especially between North American companies and untapped
promising Japanese innovations. JTG and its affiliates also provide a one-stop solution for the
strategic management of international intellectual property rights, helping companies and
universities worldwide acquire and protect patents in Japan.
Jarden Consumer Solutions
2381 Executive Center Drive | Boca Raton FL 33431 | United States

Phone: (561) 912-4511 | Fax: (561) 912-4667
Contacts
Mr. Carlos Coroalles | Vice President, Licensing
JARO Biosciences LLC
575 High Street, Suite 201 | Palo Alto CA 94920 | United States
Phone: +1.215.794.7721 | Fax: +1.215.794.7721 | Website: www.jarobiosciences.com
Contacts
Mr. Roberto Cetrullo | Managing Director
Company Overview
JARO Biosciences is a company affiliated with VIVO Ventures, a venture capital firm that
specializes in investments in biopharmaceutical companies. JARO Biosciences was established
in 2007 and is focusing its efforts on the creation of new businesses in China by combining its
entrepreneurial activities with the venture capital experience and capabilities of the VIVO team.
JARO Biosciences was founded by James Huang and Roberto Cetrullo, with the purpose of
creating new businesses through the in-licensing, development and commercialization of
biopharmaceuticals.
James Huang and Roberto Cetrullo are veterans of the pharmaceutical industry who offer more
than four decades of global commercial management and corporate development experience with
leading multinational pharmaceutical companies and small to mid-sized biotechnology
companies.
JARO collaborates with a vast network of world class professionals and leading pharmaceutical
and biotechnology companies in China, North America, Europe and Japan. It performs due
diligence on a broad range of potential Chinese partners with strong therapeutic area expertise,

and it is currently engaged in the negotiation of multiple in-licensing and partnership

collaborations.
John Wiley & Sons, Inc.
111 River Street | Hoboken NJ 7030 | United States

Phone: (201) 748-6090 | Fax: (201) 748-6566 | Website: www.wiley.com
Contacts
Ms. Susan McDermott | Senior Editor
Company Overview
John Wiley & Sons, Inc. is a leading publisher providing a full array of valuable licensing and
intellectual property books. Successful titles such as Einstein in the Boardroom by Suzanne S.
Harrison and Patrick Sullivan, Sr., Intellectual Property: Valuation, Exploitation, and
Infringement Damages by Gordon V. Smith and Russell L. Parr, The Art & Science of
Technology Transfer by Phyllis L. Speser, and Licensing Best Practices edited by Robert
Goldscheider and Alan Gordon and written by LESI members have made Wiley an essential
resource for IP professionals. Our expert authors incorporate the most up-to-date information and
provide insight on how cutting-edge topics impact the intellectual property field.
Johns Hopkins University - Applied Physics Laboratory
Applied Physics Laboratory | Laurel MD 20723-6099 | United States

Phone: (443) 778-8680 | Fax: (443) 778-5882 | Website: www.jhuapl.edu
Contacts
Dr. Teresa Colella | Technology Manager
Organization Type
Industry Sector
Company Overview
The Applied Physics Laboratory (APL) is a research and technology division of The Johns
Hopkins University, located halfway between Washington and Baltimore in Laurel, Maryland.

APL, a University Associated Research Center (UARC), supports the Department of Defense
and other government agencies through innovative applied research, technology development,
and problem solving.
The Laboratory maintains specialized research and test facilities, employs approximately 4,000
staff (68% scientists and engineers), and receives more than $780 million of annual funding.
APL's interdisciplinary teams of physicists, engineers, and mathematicians have been
successfully applying military and space-derived expertise to solve problems in transportation,
biomedical engineering, health care, the environment, and other fields for over 60 years. Many
of APL's proven and emerging technologies present opportunities for transfer to the private
sector to develop new and improved products. To obtain more information about APL, go to
www.jhuapl.edu
APL’s portfolio of technologies available for licensing includes: Materials and Structures;
Electronics; Modeling and Simulation; Information Processing & Analysis; Communications and
Distributed Systems; Space and Environmental Physics; System Analysis, Test & Evaluation;
Vehicle Technology; Life Science Research Tools & Biomedical Devices; and Sensor
Technologies.
APL’s dedicated Office of Technology Transfer offers business and industry streamlined access
to APL technology. The OTT operates as a single point-of-contact for industry to identify the
available technologies and research capabilities at the Laboratory and to secure both licensing
and industry R & D agreements.

technology transfer, patents, trademarks, valuation, research collaborations

The Applied Physics Laboratory is seeking commercial partners in the areas of electronics;
nanotechnology; life science tools and biomedical devices; communications and distributed
systems; and sensors.
Please contact Teresa Colella, Technology Manager, for an introductory meeting.

out-licensing, research collaborations
Country(s)
Partnering
Method for the Simultaneous
Life Science Tools,
Purification of Nucleic Acids Not Applicable Worldwide
reduced to practice
and Proteins

Nucleic Acid Microarray Life Science Tool;

Sensor Reduced to Practice
Ultra Thin Flexible microelectronics;
Microelectronics reduced to practice
Johns Hopkins University - Technology Transfer
Johns Hopkins Technology Transfer | 100 North Charles Street | Baltimore MD 21201 | United
States
Phone: 410 516 4565 | Fax: 410 516 4411
Contacts
Mr. Wes Blakeslee | Executive Director
Ms. Julia Brill | Portfolio Director
Dr. Andrea Doering | Portfolio Director
Ms. Leigh A Penfield | Associate Director
Organization Type
Industry Sector
Company Overview
The Johns Hopkins University's mission is to educate its students and cultivate their capacity for
life-long learning, to foster independent and original research and to bring the benefits of
discovery to the world. The University was founded on the principle that knowledge and the
understanding of the intricacies of that knowledge are best sought through research.
The mission of Johns Hopkins Technology Transfer (JHTT) is to advance the mission of the
Johns Hopkins University to bring the benefits of discovery to the world, by implementing the
commercialization of university inventions for the public good. To achieve this vision, we will
engage strategically with our stakeholders - faculty, industry, sister institutions and funding
entities to become a vital component of the University's commitment to social responsibility and
public service.
technology transfer, patents, trademarks, valuation, research collaborations

Life sciences and physical sciences companies with applications in therapeutic, diagnostic,
device and research products. Areas of expertise include oncology, neurology, ophthamology,
nanotechnology, pathology, vaccines, dermatology, anesthesiology, urology, ob/gyn, radiology
and surgery.

out-licensing, research collaborations
Johnson & Johnson
One Johnson & Johnson Plaza | WH1212 | New Brunswick NJ 08933 | United States
Phone: +1.732.524.1147 | Fax: +1.732.524.6377
Contacts
Ms. Catherine Oyler | Sr. Director, Emerging Technologies
Dr. Robert A Zivin | Corporate Director
Company Overview
Improving the health and well-being of people around the world is a vital and important
business. It is perhaps the world's most meaningful business and, for that reason, attracts
exceptional people who are capable, skilled, and possess a genuine passion for making a
difference in people's lives. As the world's most comprehensive and broadly based health care
company, Johnson & Johnson is privileged to play a role in helping millions of people be
well...and stay well.
Our products and services bring high value; they are in increasing demand; and the progress of
science is opening new horizons for improving human health and well-being.
Johnson & Johnson is a unique company. And in a world in which change is the only constant,
Johnson & Johnson is an enduring company. Our uniqueness goes well beyond the exceptional
long-term financial results we have delivered for many decades. It derives from management
philosophies that define our unique business model and have guided us through extraordinary
changes in the science and economics of human health over much of the past century. We are:
 Founded on shared values embodied in Our Credo.

 Broadly based in human health care.
 Decentralized in the way we operate the business.
 Managed for the long term.

Followed over time, these strategic principles are the source of our enduring strength and our
ability to adapt and flourish in a dynamic, ever-evolving industry. They encourage successful
operation of our businesses for both the near and the long term.
While Johnson & Johnson continues to expand its portfolio, its pharmaceutical companies
currently conduct research and/or market products in the following therapeutic categories:
Analgesia, Inflammation, Anti-infectives, Central Nervous System, Cardiovasculars, Diabetes,

Obesity, Gastroenterology, Hematology, Immunology, Virology, Metabolism, Oncology,
Neurology, Psychiatry, Pain, Urology and Women’s Health.
Johnson & Johnson has more than 230 operating companies worldwide.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is discovering
and developing drugs in a variety of therapeutic areas to address unmet medical needs
worldwide. The company's worldwide capabilities include integrated drug discovery research
and early development facilities in La Jolla, California, Beerse, Belgium and Spring House,
Pennsylvania.
ALZA Corporation is the leader in drug delivery technology and addresses some of the most
complex problems in drug development, including the delivery of macromolecules, proteins and
poorly soluble compounds. ALZA has more than 35 years experience in oral, transdermal,
implantable and liposomal delivery technologies.
Centocor Inc. is harnessing the power of world-leading research and biomanufacturing to deliver
innovative biomedicines that transform patients' lives. Centocor has already brought innovation
to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic
arthritis, and ulcerative colitis. Centocor products have also saved lives in the treatment of heart
attacks and have been used to reduce risk of cardiac events in interventional cardiology.
Centocor seeks novel, innovative products and technologies to either enhance existing programs
or create new products.
Ortho Biotech Products, L.P. is a leading biopharmaceutical company dedicated to improving the
lives of patients with cancer, anemia and kidney disease. Ortho Biotech also developed and
commercialized the first monoclonal antibody. With one of the largest oncology sales forces in
North America and access to cutting-edge research through the Johnson & Johnson
biopharmaceutical research and development companies, Ortho Biotech seeks partners with late-
stage oncology, supportive care and anemia products and is interested in co-promotion and co-
commercialization opportunities.
Ortho McNeil, Inc. provides innovative prescription medicines for primary care providers,
hospitals and other health care facilities. PriCara, a Unit of Ortho McNeil, Inc., is fully
dedicated to serving the needs of primary care providers and their patients. Areas of focus
include anti-infectives and treatments for acid reflux and pain.

Ortho McNeil Neurologics, Inc. focuses on providing solutions that improve neurological
health. The company currently markets products for Alzheimer's disease, epilepsy, and migraine
prevention and treatment.
Scios, Inc. operates as part of the Pharmaceuticals Group of Johnson & Johnson. It is a
biopharmaceutical company developing novel treatments for cardiovascular conditions. The
company’s disease-based technology integrates expertise in protein biology with computational
and medicinal chemistry to identify novel targets for research.
Tibotec Pharmaceuticals Ltd. is dedicated to the discovery, development and delivery of

innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need.
TransForm Pharmaceuticals, Inc. identifies new product opportunities by optimizing drug form
and/or formulations to increase the clinical and commercial value of pharmaceutical products
across the entire spectrum of pharmaceutical development from early stage to lifecycle
management. Transform is leveraging their expertise into biologics, vaccines and medicated
devices.
Johnson & Johnson Consumer Products
199 Grandview Road | Skillman NJ 8558 | United States

Phone: (908) 874-1809 | Fax: (908) 874-2595
Contacts
Mr. Randall G. Goodreau | Vice President
Johnson & Johnson Healthcare Products Division of McNEIL .PPC , Inc
201 Tabor Road | Morris Plains NJ 07950 | United States

Phone: (973) 385-0709 | Fax: (973) 385-5542
Contacts
Ms. Robin S. Sitver | Executive Director, Business Development
Organization Type
Industry Sector
Health Care

Patented products or technologies suitable for over- the- counter pharmaceuticals or consumer
products.


Companies interested in pursuing licensing discussions for products or technologies for the over
the counter eye care or topical segments. Products or technologies that could be marketed under
brands such as Visine, Band-Aid Brand Adhesive Bandages, Neosporin, Cortaid, BenGay or
Purell are of particular interest.

In-licensing products or technologies suitable for over-the-counter pharmaceuticals or consumer
products.
Jones & Co.
365 Bay Street | 2nd Floor | Toronto ON M5H 2V1 | Canada

Phone: (416) 703-5716 | Fax: (416) 703-6180 | Website: www.jonesco-law.ca
Contacts
Mr. Paul Jones | Principal
Organization Type
Law Firm
Company Overview
Jones & Co. is a mullti-lingual law firm in Toronto, Canada. It provides legal advice to
buisnesses regarding the protection and distribution of their goods and services in Canada and in
the international marketplace. It is particularly well-known for its work in intellectual property,
licensing and franchising, and international law.
Experienced in both common law and civil law jurisdictions, the firm works for clients from
Asia, Europe and the Americas, often coordinating work in several jurisdictions.
We have a particular focus on China, Russia and Eastern Europe. We have provided advice to
the Chinese Ministry of Commerce on American law, and have been consulted by members of
the U.S. Departments of Justice and Commerce, and the Federal Trade Commisssion, on Chinese
law. We have been invited to China several times to speak on Chinese law in a comparative
setting.

We have assisted clients with intellectual property protection and licensing strategies in China
and have familiarity with Russia and other jurisdictions. We have experience in the
pharmaceuticals and biotechnology, mining and smelting, high technology and consumer goods
sectors. Our interests focus on international licensing and intellectual asset management.


We are interested in meeting with companies either doing business in China, Russia or Eastern
Europe, or seeking to do business in these areas.
JRG Ventures, LLC
205 Powell Place | Brentwood TN 37027 | United States

Phone: (615) 312-8233 | Fax: (615) 312-8234 | Website: www.jrgventures.com
Contacts
Mr. Keith A. Gregg | Chairman & CEO
Organization Type
Consulting Firm
Industry Sector
Health Care
Company Overview
JRG Ventures, LLC is a multinational retained business development and growth strategy firm
specializing in Life Sciences, Health Care IT, and novel corporate Information Technology.
JRG’s client portfolio encompasses start-up ventures to multinational corporations. We offer our
clients an extensive list of services including: business development and licensing, valuations,
corporate strategy, domestic/foreign distribution and sales, regulatory and manufacturing
challenges, reimbursement, interim management, access to capital, and the negotiation/execution
of growth avenues.

High growth companies with products/technologies in:
- Life Sciences (Pharmaceutical, Biotechnology, Device, Diagnostics)
- Health Care Information Technology

To meet with existing Clients and expand our network of new high growth companies.
Jubilant Innovation
1740 South Morgantown road | Greenwood, IN | Indianapolis 46143 | United States

Phone: 3175342540 | Fax: 3173000782 | Website: www.jubilantbiosys.com
Contacts
Mr. Jonathan Northrup | COO

Organization Type
Industry Sector
Health Care
Company Overview
Jubilant is a $2.5 Bil market cap Indian healthcare company based entirely on collaborative
efforts in pharmaceuticals and health care. The company has a number of service companies
which do drug discovery, clinical development, drug development, and drug substance and drug
product manufacturing and scale up. Jubilant is focused on small molecules and especially the
therapeutic areas of oncology, Neuroscience, Metabolic disorders, and CV.
Jubilant Innovation (JI) is the drug development group of the companies. JI also has a small
venture fund which allows it to participate in drug development financing with its partner. JI is
interested in finding biotechnology and pharmaceutical companies that would like to collaborate
to develop pharmaceutical products in its therapeutic areas from as early as optimized lead
through phase II proof of concept. At that time JI would like to participate with its partner in a
monetization event. JI will coordinate and harness, as appropriate, the abilities of the Jubilant
network for its partner and for the drug development effort.

JI is interested in finding biotechnology and pharmaceutical companies that would like to
collaborate to develop pharmaceutical products in its therapeutic areas from as early as
optimized lead through phase II proof of concept.

JI is interested in meeting with companies that have small molecules that have been or are close
to being optimized, and are interested in help from a partner to develop these molecules to phase
II Proof of Concept. For that effort, the partner would be willing to provide JI an exit at phase II
or phase II POC.

JI is interested in meeting with companies that have small molecules that have been or are close
to being optimized, and are interested in help from a partner to develop these molecules to phase
II Proof of Concept. For that effort, the partner would be willing to provide JI an exit at phase II
or phase II POC.
Kangxin Partners, P.C.
Floor 16, Tower A, InDo Building | A48 Zhichun Road, Haidian

District | Beijing 100098 | China

Phone: +86 10 5873 1888 | Fax: +8610 5873 1999
Contacts
Mr. Samson Yu | Managing Partner
Mr. Shegao Zhang | Partner and Chinese Patent Attorney
Kauffman Foundation
4801 Rockhill Road | Kansas City MO 64110 | United States

Phone: (816) 932-1106 | Fax: (816) 751-6815 | Website: www.iBridgeNetwork.org
Contacts
Mrs. Laura Paglione | Director
Industry Sector
Company Overview
The iBridgeSM Network, a program of the not-for-profit Kauffman Innovation Network, Inc.,
provides transparency and access to university developed innovations through a Web site,
www.iBridgeNetwork.org. The site aggregates research materials, technologies, and discoveries
in an easy-to-search forum.
Through the collaborations created via the site, unexpected advances may take place that lead to
next-generation solutions across every field. As the site continues to develop, relationships will
be enabled on a one-to-one basis or through communities focused on a specific subject matter in
which colleagues may discuss innovations, compare ideas and notes, and, potentially, find
unforeseen commonalities and synergies.

iBridgeSM Network is interested in meeting with non-profit organizations that are interested in
posting innovations on the Network's Web site, www.iBridgeNetwork.org, including
universities, foundations, membership associations, etc. Additionally, those who are interested in
learning more about searching for and/or liscensing innovations on the iBridge Web site.

Continue to grow and build those who are iBridgeSM Network members as well as those
interested in learning more about using the iBridge Web site's search capabilities and potential
for partnerships.

Kauffman Innovation Network Inc.
4801 Rockhill Road | Kansas City MO 64110 | United States

Phone: (816) 932-1155 | Fax: (816) 932-1430
Contacts
Ms. Katie Petersen | Membership Services Manager
Organization Type
Industry Sector
Company Overview
The iBridgeSM Network, a program of the non-profit Kauffman Innovation Network, Inc.,
provides the transparency and access to university developed innovations that will lead to further
advances and next- generation products. The Network aggregates research materials,
technologies, and discoveries in an online, easy-to-search forum—the iBridge Web site.
Through the site, www.iBridgeNetwork.org, researchers and commercial end-users can easily
search for and obtain what they need. Users can bookmark pages and make notations for
personal reference at a later date. Additionally, some purchases can be made on the site.

Partnering
iBridge
n/a Not Applicable
Network
Kellogg Company
2 Hamblin Avenue East | W.K.K.L | Battle Creek MI 49017 | United States

Phone: (269) 961-2782 | Fax: (269) 660-3355
Contacts
Ms. Ellen Harvath | Corporate Counsel

Kelsan LLC
6801 Van Fleet Drive | McLean VA 22101 | United States

Phone: (703) 623-1247 | Website: www.cpaglobal.com
Contacts
Mr. Mark G. Hower |
Kimberly-Clark Corporation
1400 Holcomb Bridge Rd | Roswell GA 30076 | United States

Phone: 678-352-6263 | Fax:
Contacts
Ms. MaryJo Meyer |
Kirkland & Ellis LLP
200 East Randolph Street | Suite 4800 | Chicago IL 60601-6436 | United States
Phone: (312) 861-2466 | Fax: (312) 861-2200
Contacts
Ms. Amanda Hollis | Associate
Mr. Vladimir Khodosh | Associate
Mr. Russell Levine | Partner
KLEE Business Consulting LLC
575 Totavi Street | Los Alamos NM 87544 | United States

Phone: (505) 695-9689 | Fax: (505) 662-6996
Contacts
Dr. Kenneth Lee |
Knobbe, Martens, Olson & Bear, LLP
550 West C Street | Suite 1200 | San Diego CA 92101 | United States
Phone: (619) 525-8301 | Fax: (619) 235-0176
Contacts

Mr. Arthur Rose | Partner

Dr. Rose M. Thiessen | Partner
Organization Type
Law Firm
Company Overview
Knobbe Martens Olson & Bear LLP was founded in 1962. Today, with over 200 lawyers and
other professionals specializing in intellectual property law, the firm is one of the largest
specialty firms in the United States. Knobbe Martens serves clients around the globe, including
public and private companies at various stages of growth from start-up to Fortune 500.
Knobbe Martens’ practice covers all aspects of intellectual property law, including patents,
trademarks, copyrights, unfair competition, trade secrets and rights of publicity. The firm assists
clients in identifying, procuring and litigating their intellectual property throughout the world.
These services include obtaining patents, trademark registrations and copyright registrations;
handling contested proceedings before the ITC, the Patent Office and the Trademark Trial and
Appeal Board; preparing the entire spectrum of agreements relating to the use and licensing of
intellectual property; and advising and preparing opinions for clients on all aspects of intellectual
property. The firm also litigates intellectual property matters in federal and state courts across the
country, and handles appeals in all U.S. jurisdictions.
Knobbe Martens’ lawyers are highly qualified to address all of their clients’ intellectual property
needs. Most of the firm’s lawyers have undergraduate degrees in science or in one of the
engineering disciplines. Many also have prior professional experience as engineers or scientists
in high-tech industries. More than 25 lawyers, agents and scientists at the firm have Ph.D. or
M.D. degrees.
Both litigation and prosecution at the firm are supported by lawyers and scientists with strong
technical degrees. These highly knowledgeable professionals enable the firm to handle
intellectual property cases of all sizes, regardless of the technology at issue.
The firm also has a number of non-technical lawyers who specialize in the worldwide protection
of trademarks and copyrights. Knobbe Martens’ international practice is supported by several
lawyers and patent attorneys who formerly practiced in Europe or Asia.

for Partnering
Legal services in all areas of
n/a Not Applicable
intellectual property law
Kowa Pharmaceuticals America, Inc
530 Industrial Park Blvd | Montgomery AL 36117 | United States

Phone: (334) 288-1288 ext 146 | Fax: (334) 288-2788 | Website: www.kowapharma.com
Contacts
Dr. Roger D. Graben | Vice President
Organization Type
Industry Sector
Health Care
Company Overview
Kowa Pharmaceuticals America, Inc. is a specialty pharmaceutical company focused primarily in

the areas of cardiology, pain and migraine. A privately held pharmaceutical company
headquartered in Montgomery, Alabama, we are focusing our efforts on the acquisition,
development, licensing, and marketing of pharmaceutical products.
In July of 2008, Kowa Company, Ltd., of Nagoya, Japan, acquired ProEthic Pharmaceuticals,
Inc., and Kowa Pharmaceuticals America, Inc. (KPA) was born.
Kowa’s step into the U.S. pharmaceutical market represents a significant step towards its vision
of creating a global pharmaceutical organization. KPA is a specialty pharmaceutical company
focused primarily in the areas of cardiology, pain and migraine. The privately held company
focuses its efforts on the acquisition, development, licensing, and marketing of pharmaceutical
products.
The first Kowa pipeline pharmaceutical product to be launched by the new company will be
pitavastatin, a novel HMG CoA reductase inhibitor for the treatment of hyperlipidemia.
Pitavastatin is sold in Japan, Korea and Thailand under the brand Livalo(R). Pitavastatin has
recently completed Phase 3 clinical development in Europe and the United States. An NDA war
submitted in October, 2008.
KPA also has a PDUFA date of October 27, 2008 on PRO-513, a rapid acting migraine
treatment.

Pipeline
For a complete overview of Kowa Company, Ltd.'s drug candidates currently in Phase I or later
clinical development, please click on the following link:
http://www.kowa.co.jp/eng/g/rd/pipeline.htm
Candidate Phase Indication Target NDA

PRO-513 NDA Submitted Migraine 2008
NK-104 (Pitavastatin) Phase III Hyperlipidemia 2008
Interested in:
 Neurology co-promotion partner for PRO-513, KPA's rapid acting migraine product with
a PDUFA date of October 27, 2008.
 Canadian marketing partner for PRO-513, KPA's rapid acting migraine product with a
PDUFA date of October 27, 2008.
 In-license or co-promote opportunities for late stage cardiovascular/metabolic products.
 In-license or co-promotion of topical NSAIDs.
Neurology
Cardiovascular
Metabolic
Type 2 diabetes
Pain

 Neurology co-promotion partner for PRO-513, KPA's rapid acting migraine product with
a PDUFA date of October 27, 2008.
 Canadian marketing partner for PRO-513, KPA's rapid acting migraine product with a
PDUFA date of October 27, 2008.
 In-license or co-promote opportunities for late stage cardiovascular/metabolic products.
 In-license or co-promotion of topical NSAIDs.
Country(s)
Partnering
Cardiovascular,
Cardiovascular/Metabolic In-
Metabolic, Type II Not Applicable United States
license or co-promote
diabetes
migraine, pain, United States,
PRO-513 Migraine Product Not Applicable
neurology Canada
Pain, musculoskeletal,
Topical NSAID Not Applicable United States
orthopedic
KrolPharma Resources
10901 Granada Lane | Suite 101B | Overland Park KS 66211 | United States
Phone: (913) 906-0037 | Fax: (913) 906-9079
Contacts
Dr. Thomas F. Krol | President
Kuhnen & Wacker
Patent- und Rechtsanwaltsbuero | Prinz-Ludwig-Str. 40A | Freising Freising 85354 | Germany

Phone: +49-8161-608 0 | Fax: +49-8161-608 100 | Website: www.kuhnen-wacker.com
Contacts
Dr. Mark Andre May | Patent Attorney

Organization Type
Law Firm
Company Overview
Continuity, Quality and Strategy...
... are the three pillars of one of the major Intellectual Property Firms in Germany.
During 30 years of activity in Intellectual Property our firm acquired a world-wide reputation.
Our professional staff is specialized in intellectual property matters. Our target is our clients'
successful exploitation of industrial property rights world-wide. We offer the regular services in
patents, utility models, designs and trade marks but also specialize in IP evaluation and in IP
litigation including Cross-Border-Injunction and licencing.
LABORATORIO DAUDT
Rua Simoes Da Mota 57 | Rio de Janeiro 21540100 | Brazil

Phone: 55 21 33698529
Contacts
Mr. Gustavo Daudt Oliveira |
Organization Type
Industry Sector
Health Care
Company Overview
Daudt is a pharmaceutical company with the mission to develop, produce and comercialize
inovative products to promote health, well being and a better life quality for people.
Daudt is the most traditional pharmaceutical company of Brazil, present since 1882, focused on
products for health and oral care, in these two divisions. The operation is mainly in
brazilian market, one of the 10 biggest pharmaceutical markets in the world.
The manufacturing capacity is Liquid, Solid and Semi-Solid, in large scale.

Daudt is interested in licencing Patents, Tech Transfer and University Research.
We are looking for new technologies to launch in brasilian market, whether it is a total new
technology or a variation of an existed one, with some kind of advantage among competitors.
Our missoin is to bring inovation and improve health care.
We are interested in meeting:
- Health care technolgy developers.
- Pharmaceutical companies interested in licensing health care products.
- University developing and licensing new health care technologies.

Our goal is to license health care products or technologies.
Laboratorios Dermatologicos Darier
Insurgentes Sur 3579 | Torre 3 Piso 8, Col. Tlalpan | Mexico D.F. México City 14020 | Mexico
Phone: +52 55 5350 5542 | Fax: +52 55 53 50 5555
Contacts
Mr. Juan C. Lozano | Business Development Director
Mr. Francisco Padilla |
Organization Type
Industry Sector
Health Care
Company Overview
Mission:

47. Consolidate Darier as the Dermatologic company leader in Mexico, providing

innovative products with high quality to satisfy patients and physicians needs,
giving development opportunities to the employees, and fair return of investment
to shareholders.
Background:
48. Company founded in 1982 by Dr. Miguel Ahumada†, an entrepreneurial

dermatologist who established the first specialized dermatology pharmacy and
masterly formulas. Later on, Darier grew the interest for patent medicine,
developing research and development own capabilities.
49. The development of products started in a small modest factory, with basic tools
and only eight workers. “Fórmula Dérmica” was the first product under
Laboratorios Dermatológicos Darier.
50. Facilities were improved, and then Dermakeri 20® & Dermakeri 30®,
Dermocare®, Skin Care® and Dermacid® products were developed and
launched . Nowadays, Darier has 205 products in its current portfolio.
Manufacturing capabilities:
 In 1992 a modern and functional pharmaceutical plant located to 80 km from

Mexico city, in “CIVAC” was inaugurated.
 The Manufacture plant has an extension of 20.200 m2. Our corporative facilities
are located to the south of Mexico City, and we have partners in the field of
logistics, distribution and storage.
 Ferrand Pharma, a Darier´s group company specialized to produce steroids, was

opened in 2006.
Technologies:
1. Darier applies different “state of the art” technologies to the manufacturing

processes and products, which come from agreements developed with
international partners, providing to customers differentiated brands.


Darier Interests:
51. To get new dermatologic products to be launched

52. To get partners to export current and future Darier products
53. Establish contact with research companies and universities to find out new
compounds in Dermatology
54. Establish contact with research companies and universities to find out new
technologies
55. Explore possibilities of doing commercial partnerships out of Mexico

Companies to contact (mainly within the Dermatology field):
56. Healthcare
57. Research
58. Consumer
59. Technology developers
Darier delagation:
Juan Carlos Lozano

Business Development Director
Laboratorios Dermatológicos Darier, S.A. de. C.V.
Insurgentes Sur 3579
Torre 3 Piso 8 Col. Tlalpan Del. Tlalpan
C.P. 14020 México D.F.
Phone: +52 (55) 53505555 Ext. 4230
Celluar: +52 (55) 4099 3077
Fax: +52 (55) 53505555 Ext. 4130
juanlozano@darier.com.mx

Raúl Galván
Business Development Manager
Laboratorios Dermatológicos Darier, S.A. de. C.V.
Insurgentes Sur 3579
Torre 3 Piso 8 Col. Tlalpan Del. Tlalpan
C.P. 14020 México D.F.
Phone: +52 (55) 53505542
Cellular: +52 (55) 4080 4232
Fax: +52 (55) 53505555 Ext. 4030
raulgalvan@darier.com.mx

Darier Goals:
 Establish relations for:
o In-licensing & out-licensing dermatologic products

o To get new technologies to be applied for current and future portfolio
o To establish contact with American, Canadian, and European companies
to develop different marketing/commercial partnerships
o Contact companies which are making research in Dermatology
Landon IP, Inc.
1700 Diagonal Road | Suite 450 | Alexandria VA 22314 | United States

Phone: (703) 486-1150 | Fax: (703) 892-4510 | Website: www.landon-ip.com
Contacts
Mr. Robert Cantrell | Director of Consulting
Organization Type
Consulting Firm
Company Overview
Landon IP conducts professional patent and trademark searches. We analyze patents and

scientific articles, conduct technical intelligence, and consult to corporations and law firms
worldwide. Our information group sells patents, file histories, and other documents on
paper, on CD ROM, and on the Web.

Networking and education

Law firms and companies with active R&D programs
Lawrence Livermore National Laboratory
7000 East Avenue | P.O. Box 808, L-795 | Livermore CA 94550 | United States
Phone: (925) 422-9839 | Fax: (925) 423-8988
Contacts
Ms. Catherine Elizondo | Business Development Executive
Ms. Annemarie Meike |
Mr. Genaro E Mempin | Business Development Executive
Ms. Ida Shum | Business Development Executive
LECG, LLC
1603 Orrington Avenue | Suite 1500 | Evanston IL 60201 | United States

Phone: (847) 475-1566 | Fax: (847) 475-1031 | Website: www.lecg.com
Contacts
Dr. Mohan P. Rao | Director
Leger Robic Richard, LLP
1001 Victoria Square | Bloc E, 8th Floor | Montreal QC H2Z 2B7 | Canada
Phone: (514) 987-8881 | Fax: (514) 845-7874
Contacts
Ms. Panagiota Koutsogiannis | Partner
Mr. Adam Mizera | Lawyer
Mr. Francois Painchaud | Lawyer/Partner
Organization Type
Law Firm

Leiden University Medical Center
Albinusdreef 2, P.O. Box 9600 | Leiden NL-2300 RC | Netherlands

Phone: +31 71 526 52 71 | Fax: +31 71 526 69 63
Contacts
Mrs. Hester Tak |
Organization Type
University
Industry Sector
Health Care
Company Overview
Leiden University is the oldest in the Netherlands. It was founded in 1575 and later was granted
the motto Praesidium Libertatis or "Bastion of Liberty". Furthermore the Medical Centre
(LUMC) has acquired an international reputation for the transfer of laboratory findings to the
clinic and market. The Mission statement of the LUMC is: Leiden University Medical Center
(LUMC) is committed to ongoing improvement in health care quality and intends to continue to
play a leading role in this field at both national and international level.
The region has become a successful spawning ground for biotechnological and biomedical
companies located in the Bio Science Park in close vicinity of LU and LUMC.
New innovative technologies arising from top research groups of the LUMC are now available
for collaboration or licensing to commercial partners:
60. Medical Devices for diagnosis and treatment in the fields of urological disorders, lung
diseases and cardiovascular diseases.
61. Novel drug targets opening new therapeutic opportunities in treatment of cancer,
inflammatory diseases or transplant rejection
62. New molecular markers providing diagnostic opportunities for cancer, infectious diseases
or cardiovascular conditions
63. Immunological strategies to treat cancer, diabetes, transplant rejection and auto-immune
diseases.
64. New ways to harvest and treat stem cells.
Companies or other end-users interested to innovate using this scientific knowledge and
discoveries can liaise with Leiden University Research & Innovation Services (LURIS) or the
LUMC to negotiate agreements (respectively luris@luris.leidenuniv.nl or h.s.tak@lumc.nl ).


Technology Transfer of Universities, Patents, Life Sciences, Research, Licensing.
Pharmaceutical and Biotechnological Companies, Suppliers of Research Tools and companies

specialized in Medical Devices.
LES (USA and Canada), Inc.
1800 Diagonal Road | Suite 280 | Alexandria Virginia 22314 | United States
Phone: 703.836.3106 | Fax: 703.836.3107 | Website: www.usa-canada.les.org
Contacts
Ms. Eleanor de Leon | Meetings Director
Ms. Christine L. Mercado | Membership Director
Mr. Ken Schoppmann | Executive Director
Company Overview
LES is the leading professional association for intellectual property experts worldwide.
Established in 1965, LES has more than 6000 members in the US and Canada from a wide
variety of industries including biotechnology, pharmaceuticals, medical devices and diagnostics,
high technology, and universities. Through its local chapters, LES offers members opportunities
to connect locally to find new contacts and sustain ongoing relationships. LES is also a member
of the Licensing Executives Society International, which has 32 member societies with more
than 12,000 members in over 90 countries worldwide.
LES offers a full calendar of meetings and education programs designed to advance the
understanding and practice of licensing to improve the return on investment for intellectual
property. LES members are united in their commitment to professionalism, ethical standards,
and best practices in technology commercialization.
To find out more about LES, visit www.usa-canada.les.org or email info@les.org
LFB
3 avenue des Tropiques | BP 80097 | Courtaboeuf Cedex 91943 | France

Phone: 1 69 82 17 25 | Fax: 1 69 82 71 64
Contacts
Mr. Marc Koquely | Licensing Manager

LES Foundation
P.O. Box 329 | Lake Forest IL 60045 | United States

Phone: (847) 323-3893 | Fax: (847) 234-2768
Contacts
Ms. Lydia Steck |
Licensing International, Inc.
818 Solar Lane | Glenview IL 60025-4465 | United States

Phone: (847) 724-0265 | Fax: (847) 724-0267
Contacts
Dr. James Vlazny | President
Organization Type
Consulting Firm
Industry Sector
Health Care
Company Overview
Licensing International, Inc (LINC), a pharma/biotech consulting company, was founded

in 1991 by Dr. James Vlazny, former Director of Corporate Licensing at Abbott
Laboratories. LINC provides a full range of licensing services for its clients around the
world. LINC's primary client at this LES Meeting is Cook Biotech. LINC is fully retained
by Cook to help them find partners for two licensing opportunities, as described below.
UNIQUE LICENSING OPPORTUNITIES FROM COOK BIOTECH
Cook Biotech is seeking licensing partners to develop, register, and market their unique new
Tissue Vaccines (TVs) for treating and preventing cancer, and for their novel ExtraCellular
Matrix (ECM) Adjuvants for improving the efficacy of vaccines. Proof of principle for TVs
has been shown in a well known animal model, and the biomaterials in Cook's ECM Adjuvants
have a strong safety record since they have been used in surgical and medical devices by millions
of patients around the world. Both opportunites have strong patent protection. Details on Cook
and on their two licensing opportunities are given below.
ABOUT COOK BIOTECH

Cook Biotech, Inc., located in West Lafayette, Indiana, is a unit of the Cook Group, the 2nd
largest privately held medical device company in the world. Cook Biotech develops and
manufactures biomaterials from natural tissue sources for use in medical products. The company
conducts research, development and manufacturing operations in a state-of-the-art facility, and
operates its own processing and production line where natural tissues are transformed into
proprietary ExtraCellular Matrix (ECM) biomaterials that are used in numerous medical
products around the world.
Dr. Mark Suckow of the University of Notre Dame, has utilized Cook's ECM biomaterials in
his work on novel Tissue Vaccines for treating and preventing cancers, and the University has
filed patent applications on his work. Cook Biotech has an exclusive worldwide license, with
rights to sublicense, to Dr. Suckow's work and we are now seeking partners to develop, register,
and market Tissue Vaccines and ECM Adjuvants based on his work.
ABOUT TISSUE VACCINES and ECM ADJUVANTS
Cancer vaccines so far have met with limited success because these vaccines have relied on the
use of a single antigen or a single cultured cell type. Dr. Suckow has found that harvesting a
mixture of cells from tumor tissue results in a "Tissue Vaccine" that presents the immune system
with an enormous menu of antigens. He has also discovered that using Cook's ECM biomaterials
to grow tumor tissue cells results in an improved vaccine. He has tested these Tissue Vaccines
and these ECM Adjuvants in several in vivo experiments on Lobund Wistar rats, a well
established animal model of prostate cancer, and found them to be effective in treating, reducing
metastasis, and preventing cancer in this model. In addition, he has tested a xenogeneic (cross
species) rat Tissue Vaccine in this model and has found it to be effective in treating a
human cancer line. And he has combined his Tissue Vaccine with a standard treatment of
prostate cancer and found the combination to be more effective than either modality used alone.
Dr. Suckow's work is covered by 5 patent applications, plus Cook's ECM biomaterials used in
his work are approved for human use and are covered by numerous patents.
Nonconfidential information will be made available in partnering sessions, and confidential

information is available under terms of a confidentiality agreement.
Company Description
Mid-Sized Biotech
Therapeutic Areas
Oncology and Vaccines
Contact Information
Email: jamesvlazny@aol.com
Telephone: 847-724-0265

Fax: 847-724-0267

I am interested in all aspects of pharma and biotech licensing, and am especially interested in the
LES Education work and in LES Mentoring work. (I am on the Ed Committee, and am Co-Chair
of the Mentoring Committee.)
I would like to meet with Oncology companies and tell them about Cook's new Tissue Vaccines
for treating and preventing cancer.
And I would like to meet with Vaccine companies to tell them about Cook's new ECM
ADjuvants for increasing the efficacy of vaccines.

I would like to meet companies/organizations that are interested in finding partners to market
their products in Brazil through my client EMS Sigma Pharma, or in Korea through my client
LG Life Sciences.
for Partnering
ExtraCellular Matrix
Adjuvants
Tissue Vaccines for treating
and preventing cancer
Life Science Analytics, Inc.
800 James Avenue | Scranton PA 18510 | United States

Phone: +1.570.504.1402 | Fax: +1.570.961.2324 | Website: www.medtrack.com
Contacts
Mr. David M. Bialkowski | Account Manager
Mr. Brian Bialkowski | Key Account Manager
Mr. Primo Sagliocco | Account Manager

Company Overview
MedTRACK accelerates the business development and competitive intelligence process by
providing a leading edge technology platform which enables its users to research companies,
their respective products and the people involved by therapeutic or industry focus.
Over 13,700 global companies with over 55,000 products classified and tracked.
MedTRACK also makes meetings more efficient by filtering out those companies attending the
premier partnering meetings, not limiting any company details to what is posted on the
conference-partnering platform.
MedTRACK is a fully integrated research and information resource that can track product
pipeline progression by therapeutic indication or disease, product, clinical phase, trial details, and
financial information.
The database is designed to enable industry professionals to look at public and private companies
that are working in a particular therapeutic area and quickly determine where they rank clinically
as well as financially.
MedTRACK provides extensive research tools that allow you to customize your inquiries; select
individualized search criteria, merge information on the financial statements and pipelines of two
or more companies, and conduct searches of companies and their respective products by
geography, mechanism of action, or by patent expiration.
MedTRACK Deals & Alliances database gives you the latest information and analysis of deal
making in the Life Sciences Industry.
We have reviewed and analyzed annual reports, regulatory filings, press releases, news articles,
websites, and research reports for the Life Sciences Industry and filtered, classified and
formatted them for your convenience and analysis--providing you with over 37,000 deals.
In addition to our convenient classification we have added our powerful Keyword Search that
will allow you to search the entire database of deals for your specific needs. We have also
provided the SEC document where available so you can conveniently and thoroughly analyze the
transaction without having to spend your valuable time navigating the web!
Life Sciences Partners
Johannes Vermeerplein 9 | Amsterdam 1071 DV | Netherlands

Phone: +31.20.664.5500 | Fax: +31.20.676.8810
Contacts
Ms. Mary Tanner |

Company Overview
Life Sciences Partners (LSP) is a leading independent European venture capital firm, providing
private equity financing to early- to mid-stage life-science companies. Since the late 1980s,
LSP’s management has invested in a large number of highly innovative enterprises, many of
which have grown to become leaders of the global life-science industry. With USD 450 million
under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s
largest and most experienced specialist life-science investors.
LifeCycle Pharma, Inc.
Kogle Allé 4 | Hørsholm 2970 | Denmark

Phone: +45 3613 2932 | Fax: +45 3613 03 19 | Website: www.lcpharma.com
Contacts
Mr. Ira Weisberg | Vice President, Business Development
Organization Type
Industry Sector
Health Care
Company Overview
LCP is an emerging specialty pharmaceutical company, focused on organ transplantation and its
associated co-morbidities. The intention is to enter the transplantation market through our own,
hospital-based specialty sales force. We currently have seven products involving nine indications
in development.
Our first commercialized product, LCP-FenoChol, has received FDA approval for sale in the
U.S., under the brand name Fenoglide™, for the treatment of dyslipidemia as an adjunct to diet
in adult patients. Launched in February 2008, Fenoglide™ is marketed in the U.S. by our partner
Sciele Pharma.
LCP’s lead product candidate in immunosuppression for transplant patients, LCP-Tacro, was
developed in-house using our proprietary MeltDose® technology platform. LCP-Tacro is
currently in Phase III clinical trials and will be the first product that LCP expects to fully develop
and commercialize itself in selected markets.

Our proprietary MeltDose® technology platform is designed to enhance the release and
absorption of drugs in the body by incorporating the drug in a solubilized form in a tablet matrix.
By applying our MeltDose® technology to create new versions of existing drugs, we believe we
are able to develop products with differentiated characteristics significantly faster and cheaper
and with a higher success rate as compared with traditional drug development.
LCP is an international company with headquarters in Copenhagen, Denmark along with a

wholy owned subsidiary in New York. The Company was founded in June 2002 as a spin-off
from Lundbeck A/S and is listed on the OMX Nordic Exchange (OMX: LCP). LCP is a member
of the MidCap+ index.
For more information see: www.lcpharma.com

LCP's partnering strategy is based upon two key areas where we believe we can bring value to
our partners.
1.) LCP is actively seeking to build long-term relationships with partners through in-licensing,
out-licensing and collaboration in the transplantation and immunosuppression areas.
2.) LCP is actively seeking to build partnerships by applying its drug delivery platform,
MeltDose®, which has proven both clinically and commercially to enhance bioavailability of
poorly soluble drugs.
We plan to advance our product portfolio internally and when appropriate enter into
collaborative agreements with respect to some of our products.
Our goal is to maximise the value of our business by retaining substantial commercial rights or
profit sharing opportunities to our products and developing them through a combination of in-
house clinical development and out-licensing of both early- and late-stage programs.

We would be intersted in meeting with companies who are either looking for a drug delivery
technology that allows for improved bioavailability and for a controlled release profile. In
addition, we would welcome meetings with companies looking to out-license products for the
transplant or immunosuppression market.

for Partnering
Oral drug delivery technology
MeltDose(R) Lead Series
applicable to most areas.
Ligand Pharmaceuticals, Inc.
10275 Science Center Drive | San Diego CA 92121 | United States

Phone: (858) 550-7515 | Fax: (858) 550-7581
Contacts
Dr. Syed Kazmi | Senior Director, Business Development & Strategic Planning
LigoCyte Pharmaceuticals, Inc.
2155 Analysis Drive | Bozeman MT 59718-6831 | United States

Phone: +1.406.585.2733 | Fax: +1.406.585.2766
Contacts
Dr. Robert Goodwin | President & COO
Mr. James Grenzebach | Manager, Business Development
Company Overview
LigoCyte is a biopharmaceutical company developing vaccines and therapeutic monoclonal

antibodies targeted at important respiratory and gastrointestinal markets. The Company initiated
its first Phase I safety trial for its norovirus vaccine in April 2007.
The Company's product candidates include next generation virus-like particle (VLP) vaccines
against norovirus, influenza and other respiratory viruses. LigoCyte is also developing
monoclonal antibodies for chronic inflammatory indications in collaboration with Biogen Idec
and the National Institutes of Health.
LigoCyte’s norovirus and influenza vaccines are based on its widely applicable proprietary VLP
technology. In important respects, VLPs resemble viruses as they are seen by the immune system
and may be more immunogenic and have the potential to provide broader immune protection
than other recombinant vaccine approaches. VLPs are self-assembling recombinant protein
products that are easily manufactured. As purified recombinant products, VLPs contain no viral
nucleic acids and they can therefore induce protection without risk of infection.
LigoCyte has shown advantages from nasal delivery of its vaccines for respiratory and
gastrointestinal applications and has developed considerable expertise in highly immunogenic
dry powder formulations. Nasal delivery more closely mimics the immunization of natural

infection at a mucosal site and induces additional protective responses compared to injection.
Dry powder vaccines have numerous potential advantages including needle-free delivery,
improved stability, and potential for self-administration. The Company believes that these
features will provide distinct advantages in the norovirus and other vaccine programs.

Partnering
CD103 MAb MAb Therapeutic Preclinical Testing
CD62E&L MAb MAb Therapeutic Preclinical Testing
Influenza Vaccine Vaccine Preclinical Testing
Norovirus
Vaccine Phase I
Vaccine
Lockheed Martin Missiles and Fire Control
P.O. Box 650003 | Mail Stop PT.09 | Dallas TX 75265-0003 | United States
Phone: (972) 603-9207 | Fax: (972) 603-3345
Contacts
Mr. Timothy D. Stanley | Associate General Counsel IP
Mr. R. Allen Vaughn | Manager, Intellectual Property Stategy & Licensing
Organization Type
Industry Sector
High Technology
Company Overview
Lockheed Martin Corporation, an advanced technology company, was formed in March 1995
with the merger of two of the world's premier technology companies, Lockheed Corporation and
Martin Marietta Corporation.
Headquartered in Bethesda, Maryland, Lockheed Martin employs about 140,000 people

worldwide and is principally engaged in the research, design, development, manufacture and
integration of advanced technology systems, products and services.

CUSTOMER BASE: As a lead systems integrator and information technology company, the
majority of Lockheed Martin's business is with the U.S. Department of Defense and the U.S.
federal government agencies. In fact, Lockheed Martin is the largest provider of IT services,
systems integration, and training to the U.S. Government. The remaining portion of Lockheed
Martin's business is comprised of international government and some commercial sales of our
products, services and platforms.
FINANCIAL PERFORMANCE: The Corporation reported 2006 sales of $39.6 billion, a

backlog of $75.9 billion, and free cash flow of $3.8 billion.
ORGANIZATION: Lockheed Martin's operating units are organized into broad business areas.
 Aeronautics, with approximately $11.4 billion in 2006 sales, includes tactical aircraft,
airlift, and aeronautical research and development lines of business.
 Space Systems, with approximately $7.9 billion in 2006 sales, includes space launch,
commercial satellites, government satellites, and strategic missiles lines of business.
 Systems & IT Group, with approximately $20.3 billion in 2006 sales, will leverage our
existing and emerging capabilities to address customers' growing needs for highly
integrated systems and solutions. This includes missiles and fire control, naval systems,
platform integration, C4I, federal services, energy programs, government and commercial
IT and aeronautical/aerospace services lines of business.
L'Oreal
25-29 quai Aulagnier | Asnières 92600 | France

Phone: 01 47 56 41 13
Contacts
Mr. Frédéric Caillaud | Licensing & Business Development department director
Lowenstein Sandler, PC
65 Livingston Avenue | Roseland NJ 07068 | United States

Phone: (973) 597-2574 | Fax: (973) 597-2575 | Website: www.lowenstein.com
Contacts
Mr. Raymond P. Thek |
LSI Corporation
1110 American Parkway NE | Room 12L-306 | Allentown PA 18109-9138 | United States

Phone: (610) 712-1363 | Fax: (610) 712-3467

Contacts
Mr. Rick A. de Pinho | Senior Licensing Manager
LTS Lohmenn Therapy Systems Inc.
21 Henderson Drive | West Caldwell NJ 70076 | United States

Phone: (973) 244-2026 | Fax: (973) 575-5174
Contacts
Mr. Patrick Walters | Senior Vice President
LURIS
Rijnsburgerweg 10 | Leiden 2333 AA | Netherlands

Phone: +31 71 526 5560 | Fax: +31 71 526 6921 | Website: www.LURIS.nl
Contacts
Dr. Robert Smailes | Director
Organization Type
University
Industry Sector
Company Overview
Leiden University is the oldest in the Netherlands. It was founded in 1575 and later was granted
the motto Praesidium Libertatis or "Bastion of Liberty". Nowadays Leiden University (LU) has a
firmly established position among the top research institutes of Europe in many fields including
natural sciences, medicine, social and behavioural sciences. Furthermore the Medical Centre
(LUMC) has acquired an international reputation for the transfer of laboratory findings to the
clinic and market. Therefore, the region has become a successful spawning ground for
biotechnological and biomedical companies located in the Bio Science Park in close vicinity of
LU and LUMC.
New innovative technologies arising from top research and collaborations between departments
of life sciences, physics, chemistry and informatics are now available for collaboration or
licensing to commercial partners:
 Small molecules allowing development of new drugs for cardiovascular, neurological or

autoimmune disorders

 Novel drug targets opening new therapeutic opportunities in treatment of cancer,

inflammatory diseases or transplant rejection
 Biosensor technologies enabling development of new diagnostic tools in medical,
environmental and industrial applications
 New molecular markers providing diagnostic opportunities of infectious diseases or
cardiovascular conditions
 Monitoring or surgical devices designed for assessing respiratory, cardiovascular or
genitourinary disorders
 Drug screening technologies allowing identification of new biologics or membrane
protein ligands and new design method of microfluidic chips
 Novel materials for use in luminescent lighting technology or novel architectural
software component are also available.
Companies or other end-users interested to innovate using this scientific knowledge and
discoveries can liaise with Leiden University Research & Innovation Services (LURIS) to
negotiate agreements (luris@luris.leidenuniv.nl).
Marshall, Gerstein & Borun
6300 Sears Tower | 233 South Wacker Drive | Chicago IL 60606-6402 | United States
Phone: (312) 423-3451 | Fax: (312) 474-0448
Contacts
Mr. Paul Brown | Attorney
Ms. Pamela L. Cox | Partner
Martek Biosciences Corporation
6480 Dobbin Road | Columbia MD 21045 | United States

Phone: 1.410.740.0081 | Fax: 1.410.470.2985
Contacts
Mr. Matthew Kiser | Executive Director, Pharmaceutical Business Development
Mr. Christopher Lindsay | VP Pharmaceutical & Dietary Supplements
Marval O'Farrell & Mairal
Av. Leandro Alem 928 | Buenos Aires 1001 | Argentina

Phone: 54 114310000 | Fax: 54 1143100200
Contacts
Ms. Veronica Canese Mendez | Associate

Matsushita Electric Industrial, Co., Ltd.
8th Floor Twin 21 OBP Panasonic Tower | 2-1-61 Shiromi, Chuo-ku | Osaka 540-6208 | Japan
Phone: 81-6-6949-4532 | Fax: 81-6-6949-4545
Contacts
Ms. Kyoko Hamakawa |
Organization Type
Industry Sector
High Technology
Company Overview
We, Matsushita Electric Industrial Co., Ltd., changed our company name to Panasonic
Corporation on October 1, 2008.
Panasonic, since our establishment in 1918, has been developing and manufacturing a wide
range of electronics products in various fields, including Audio-Visiual, Communications, Home
Appliances, and Components/Devices.
Mayo Clinic
200 First Street, SW | Centerplace 4 | Rochester MN 55905 | United States

Phone: 507-284-8878 | Fax: (507) 284-5410
Contacts
Mr. Tim Argo | Licensing Professional
Ms. Bernadette Cusack | Office of Intellectual Property
Ms. Barbara Gamez Sims | Technology Licensing Manager
Ms. Julie Henry | Technology Licensing Manager
Mr. Bruce R. Kline | Tech. Lic. Manager
Mrs. Catherine Koh | Technology Licensing Manager
Mr. Steven T. McMaster | Technology Licensing Manager
Ms. Susan Stoddard | Technology Licensing Manager
Industry Sector
Health Care
Company Overview

Mayo Clinic's Office of Intellectual Property is dedicated to converting Mayo Clinic ideas,
ingenuity and expertise into healthcare products and services which are consistent with Mayo
Clinic's image and reputation. Because Mayo Clinic integrates their clinical practice, medical
education and medical research, it is a rich resource of medical technology.
MBM Intellectual Property Law
200 Granville Street | 22nd Floor | Vancouver BC V6C 1S4 | Canada

Phone: +1.604.669.4350 | Fax: +1.604.669.4351
Contacts
Ms. Diana Mansour | Associate
Company Overview
MBM Intellectual Property Law is a dynamic and progressive law firm that practices exclusively
in the area of intellectual property, including the commercialization of technology and the
exploitation of knowledge. MBM & Co. is a patent and trademark agency sister firm to our law
firm Marusyk Miller & Swain LLP. Our firms and our professional teams have a wide range of
services to offer in the intellectual property arena. With offices throughout Canada, MBM
Intellectual Property Law coordinates clients’ intellectual property portfolios with the expertise
available nationwide. All of our offices work closely together on clients’ portfolios, allowing for
a fully integrated team approach to intellectual property portfolio development, management and
protection.
McDonald Hopkins, LLC
640 N. LaSalle Street | Suite 590 | Chicago IL 60654 | United States

Phone: (312) 280-0111 | Fax: 312-280-8232 | Website: www.mcdonaldhopkins.com
Contacts
Mr. Michael J. Femal |
Organization Type
Law Firm
Company Overview
McDonald Hopkins LLC has more than 130 attorneys focused on a winning strategy: To help
clients achieve their missions. The firm has a more than 75-year track record of creating
insightful legal solutions that work. We apporach every day with an entrepreneurial spirit
focused on finding cost-effective and practical resolutions to our clients' greatest challenges.

With offices in Chicago, Cleveland, Columbus, Detroit, and West Palm Beach, McDonald
Hopkins is a full service law firm-- business law, litigation, business restructuring, and estate
planning.
The intellectual property matters we have litigated include patent, copyright, licensing,
trademark, and trade secret issues, representing Fortune 500 companies. Our attorneys have
participated in actions in federal and state court, as well as proceeding and appeals before the
Trademark Trial and Appeal Board.

Procuring and managing intellectual property is critical in today’s technology-driven, global
marketplace. Our clients rely on us to provide prompt, thorough and efficient counsel on matters
involving patents, copyrights, trademarks, intellectual property procurement, trade dress and
trade secrets. The group focuses on, management, and enforcement for Fortune 500 companies,
mid-cap companies, and start-ups. Supported by the talents of our Litigation and Business Law
attorneys, our IP attorneys deliver a complete range of innovative and comprehensive solutions,
as well as insightful industry expertise. Our in-depth approach enables us to meet the business
goals of our diverse client base. In fact, the hallmark of our IP practice is to dovetail our clients’
intellectual property needs with their business plans and strategies, presenting a cohesive and
comprehensive outcome.
Patent Expertise
We perform patent searches and prepare, file, and prosecute patent applications through the U.S.
Patent and Trademark Office. We perform patent infringement and validity studies, non-
infringement/clearance opinions and patentability studies.
Presently, we have six attorneys admitted to practice before the U.S. Patent Office. Our patent
attorneys have a variety of engineering and science backgrounds as well as a variety of industry
experiences. Our attorneys have significant patent preparation and prosecution experience in the
metallurgical fields. We have experience in securing patent protection for clients in the fields of
powder metals, die casting, forging and tubular fabrication, among others. One of our clients,
Metaldyne, is a leader in the powder metal field.
Transactions
Our attorneys are experienced and participate in a broad range of IP transfer and licensing
transactions. We provide substantial support to our corporate and merger and acquisition
attorneys in performing IP due diligence, drafting of key IP provisions, and negotiations in
merger and acquisition settings.

International
Our practice is international in scope. We have relationships with associates in jurisdictions

throughout the world with whom we file and maintain intellectual property rights on behalf of
our clients. Our foreign associates also assist us in resolving intellectual property disputes on
behalf of our clients.
Litigation
We regularly provide counsel, representation, and legal opinions on matters involving

intellectual property disputes and litigation. Our litigation experience includes participation in
hearings, arbitrations, mediations, and trials involving intellectual property disputes. We have
litigated matters including patent, copyright, licensing, trademark and trade secret issues. Our
attorneys have participated in appellate proceedings and arguments before the United States
Court of Appeals for the Federal Circuit, as well as for the Trademark Trial and Appeal Board.
IP Maintenance
We utilize a sophisticated computerized docket system that centers on the “CPI” or Computer
Packages, Inc. docket platform. We employ an experienced, full-time docket clerk to maintain
our docket and to help us with annuity payments for clients, typically with paralegal assistance
and minimal lawyer involvement.
Representative Matters
Our Intellectual Property Practice Group is comprised of individuals with extensive experience
in Intellectual Property counseling, prosecution, licensing, dispute resolution, and litigation.
Throughout our careers, we have:

1. · Successfully managed significant intellectual property litigation through trial.
2. · Advised significant clients with regard to technology licenses and business
franchise agreements.
3. · Negotiated agreements to resolve Intellectual Property disputes in the U.S. and in
foreign countries.
4. · Managed trademark and patent portfolios for clients with hundreds of active matters
worldwide.

We typically work with companies ranging in size from middle market up to significant multi-
national corporations.
Please contact:
Michael J. Femal
mfemal@mcdonaldhopkins.com
312.642.1902

Goals include: in-licensing, research collaborations, marketing agreements, finding customers or
services.
McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive | Chicago IL 60606 | United States

Phone: (312) 913-2122 | Fax: (312) 913-0002
Contacts
Mr. Patrick Gattari | Partner
Mr. Bradley Hulbert | Founding Partner
Mr. Robert J Irvine | Partner
Dr. Paul S Tully | Partner - Patent Attorney
Organization Type
Law Firm
Company Overview
McDonnell Boehnen Hulbert & Berghoff LLP is an intellectual property law firm devoted to the
needs of technology-driven companies. Our clients range from Fortune 100 companies to
entrepreneurial start-ups. Our work includes all facets of intellectual property litigation,
prosecution, and counseling.
up to speed
More than half of our professionals have advanced technical degrees. Many of our attorneys
have worked and published in their respective industries. MBHB attorneys represent clients
before the U.S. Patent and Trademark Office and throughout the federal court system, including
the U.S. Supreme Court, the U.S. Court of Appeals for the Federal Circuit, U.S. District Courts,
and the International Trade Commission.

down to earth
Royalty Investigation Services
Our Royalty Investigation Will Help You Identify What Is Rightfully Yours
Despite unsurpassed legal and technical skill, our focus remains on clear communication to
judges, juries, patent examiners, other lawyers and, most importantly, our clients. Our attorneys
provide practical and understandable advice to clients throughout the world.
McGladrey & Pullen, LLP
20 N. Martingale Road | Suite 500 | Schaumburg IL 60173 | United States

Phone: (847) 413-6339 | Fax: (847) 517-7067
Contacts
Ms. Debora A. Larson | CPA
Mr. Sidney Rattner | Partner
Organization Type
Financial Services
Company Overview
Mathematical errors and misinterpretation of license agreement language can mean thousands to
millions of additional royalty dollars are owed. Intentional understatement of sales subject to
royalty is less easy to detect, but it does occur, and it can also mean significant additional royalty
dollars are owed.
Our contractual compliance group focuses on performing royalty investigations on a worldwide

basis for licensors of intellectual property, copyright or trademark licenses. Our job is to help
you identify the royalty income owed you. Through mutually agreed-upon procedures
(commonly referred to as "royalty audits"), we assist you in determining whether your licensee is
reporting sales and their applicable royalties according to the terms of your license
agreement. Additionally, we are able to assist you in putting in place the right compliance
monitoring programs.
Our Approach

During our royalty engagement, we perform agreed-upon procedures, including one designed to
determine if:
 You have procedures and controls for monitoring when royalty payments should be received
and if the amount is within an expected or given range.
 Your system has "red flags" notifying you if there is a deviation from last month's/year's
payment or the average payment to date.
 Your licensee reports its royalty data in the format and detail mandated by the terms of the
license agreement.
Our Experience
We have more than 40 years of cumulative experience in conducting royalty investigations. We
assist our clients on internal royalty monitoring systems and license agreement language as it
relates to accounting terms and definitions, as well as audit paragraphs, all of which afford the
licensor greater protection of royalty streams.
During the past 10 years our experience has shown that the most common reasons for
underpayment of royalties are due to:
 Clerical error
 Misinterpretation of license agreement language
 Development and sales of new products that utilize the licensed technology, not being
included in the royalty reports
 Intentional understatement
How You Will Benefit

The benefits of our royalty investigations come to you in dollars and cents. Over the past 10
years we have helped our clients identify millions of dollars of unpaid royalties. Based on our
experience, we believe that it is good business practice to conduct royalty investigations, the
rewards of which many times exceed the costs of doing so. In many cases, based on our findings,
the burden of the audit cost has been shifted to the licensee.
Additional Support
If the need arises, we have experienced professionals to handle your Intellectual Property
Valuation and Litigation needs. These services include providing expert testimony, determining
lost profits, evaluating financial strategies, and determining the value of various types of
intellectual property assets.
Contact information:
Sid Rattner
Partner
847.413.6217
sid.rattner@rsmi.com

It is McGladrey & Pullen's goal to make LES attendees aware of our Royalty and Contractual
Compliance Audit Services and the benefits of conducting audits of their contractual partners
(licensees).
for Partnering
Royalty and Contractual
Compliance Audit Services
McKee, Voorhees & Sease, PLC
801 Grand Avenue | Suite 3200 | Des Moines IA 50309 | United States
Phone: (515) 288-3667 | Fax: (515) 288-1338
Contacts
Ms. Jill Link | Attorney
Mr. Steven Smith | Attorney
Mr. Kurt Van Thomme | Attorney
Organization Type
Law Firm
Company Overview
Our attorneys in the licensing specialty area serve the diverse licensing needs of our clients. Our
clients include corporations, small businesses, individuals, and universities. While our attorneys
have experience in a vast array of technological fields, our attorneys have a unique level
of experience in drafting and negotiating complex intellectual property agreements in the field of
biotechnology. We advise clients and prepare and negotiate agreements for all types of
intellectual property, such as:
 Patent licenses and assignments, including in-licensing and out-licenses

 Trademark, Trade Secret and Copyright licenses and assignments
 Consulting agreements
 Confidentiality and non-disclosure agreements
 Entertainment agreements, such as product placement and promotion agreements
 Technology collaboration agreements

 Employee agreements relating to intellectual property

 Material transfer and other research agreements
 Software and related agreements, such as EULAs
In addition, we work closely with our clients' general attorneys in reviewing, drafting and
negotiating intellectual property provisions for various types of agreements, such as distribution
agreements, merger and acquistion agreements, sales representative agreements, purchase
agreements, and other general commercial agreements.
Our attorneys blend a wide array of technical expertise with proven legal experience. We keep
abreast of the latest trends, developments and legal issues to ensure that we give our clients the
highest level of legal services. These competencies allow us to provide comprehensive
intellectual property counseling services, which include:
 Preparation and filing of national and international intellectual property applications

 Preparation and filing of interferences and arbitrations
 Evaluation of patent portfolios and technology transfers
 Complex litigation that may be required to enforce our clients' rights or insulate them
from challenges and attacks

Biotechnology, Networking and other High Technology, Pharmaceutical, Educational and other
entities that desire loyal, dedicated, sophisticated and energetic legal professionals to represent
them in their licensing and other intellectual property matters in an efficient, effective and cost
sensitive manner.
McKool Smith, P.C.
300 Crescent Court | Suite 1500 | Dallas TX 75201 | United States

Phone: (214) 978-6335 | Fax: (214) 978-4044 | Website: www.mckoolsmith.com
Contacts
Mr. Thomas L. Crisman | Patent Attorney
Mr. Bryan Yearwood | Director of Licensing
Organization Type
Law Firm
Company Overview
McKool Smith is one of the nation’s leading pure trial firms. Our practice encompasses a broad
range of commercial disputes including antitrust, intellectual property, technology, contract,
securities, environmental, pharmaceutical sciences, class action, and business torts. We can be
found in state and federal courtrooms, including appellate courts, across the United States.


We are looking to meet with prospective clients interested in finding attorneys to enforce their
patent rights.
MDC - Thomson Scientific
29100 Northwestern Hwy | Suite 300 | Southfield MI 48034 | United States

Phone: (813) 792-8898 | Fax: (813) 792-8793
Contacts
Mr. Michael Flannery | Sales Manager
Mead Johnson Nutritionals
2400 W. Lloyd Expressway | Mail Code B115 | Evansville IN 47721 | United States
Phone: (812) 429-5889 | Fax: (812) 429-5945
Contacts
Ms. Susan Vaughn | Director, External Development
MedicineLodge, Inc.
180 South 600 West | Logan UT 84321 | United States

Phone: (435) 753-7675 | Fax: (435) 753-7698 | Website: www.medicine-lodge.com
Contacts
Mr. David W. Meibos | Director
Organization Type
Industry Sector
Health Care
Company Overview
MedicineLodge is part of the iMDs family. IMDs stands for Innovative Medical Device
Sourcing; our intention is to be the preferred partner for companies in the development and
manufacturing of orthopedic implants.


We are interested in patents, technology transfer, intellectual asset management, and university
research.

We would like to meet with inventors, universities, and orthopedic companies that are looking
for partnerships in medical device manufacturing, research & development, or licensing.

Our goals for the LES meeting are to stay current with IP and licensing trends, connect with
orthopedic companies that have manufacturing or research and development needs, and connect
with inventors, companies, and universities that need help developing or licensing medical
device technologies.
Medicis Pharmaceutical Corporation
8125 North Hayden Road | Scottsdale AZ 85258-4343 | United States

Phone: (480) 291-5931 | Fax: (480) 291-8931 | Website: www.medicis.com
Contacts
Ms. Carla Brenner | Business Research , Corporate Development
Mrs. Diana Harbort | VP, Corporate Development
MedImmune Ventures
One MedImmune Way | Gaithersburg Maryland 20878 | United States

Phone: 301-398-0000 | Website: www.medimmune.com
Contacts
Ms. Eva M Jack | Managing Director
Company Overview
MedImmune's new state-of-the-art R&D facility and worldwide corporate headquarters is

located in Gaithersburg, Maryland.
MedImmune Ventures Overview

MedImmune Ventures, a wholly owned venture capital fund within the

AstraZeneca/MedImmune group of companies, fosters creativity and entrepreneurship through
investment in cutting-edge science as a means to enable AstraZeneca and MedImmune to remain
at the forefront of drug development. It was created in 2002 to leverage both MedImmune’s
expertise in discovering, developing and commercializing biotechnology products, as well as its
financial resources to help transform new ideas in biotechnology into successful products and
companies. With the acquisition of MedImmune by AstraZeneca in June 2007, MedImmune
Ventures has broadened its charter to include all therapeutic areas of interest for the combined
companies as indicated below.
With $300M under management, MedImmune Ventures may invest up to $30M per company —
from seed stage to PIPEs. While primarily seeking investments in North America, MedImmune
Ventures may opportunistically consider European investments.
Investment Strategy
We consider investments in areas strategic to MedImmune and AstraZeneca, including

cardiovascular/gastrointestinal disease, neuroscience, oncology, infection, respiratory disease
and inflammation. We are modality agnostic, investing in biologics, small molecules and
vaccines. In addition, we will also examine investment opportunities related to new technologies
and programs related to translational sciences, and the intersection between diagnostics and drug
development. While strategic investments are the first priority, solid financial investments are
also considered.
What makes MedImmune Ventures unique?

65. Focus on strategic and financial returns – top quartile returns
66. Ability to leverage extensive internal domain expertise of R&D, commercial and
manufacturing organizations for due diligence evaluations which leads to quick decision
making
67. Commitment to our portfolio companies - senior leaders with the relevant operational
expertise from AstraZeneca and MedImmune serve on the Boards of our portfolio
companies
The MedImmune Ventures Team
Dave Mott, President and Chief Executive Officer, MedImmune

Ed Mathers, Executive Vice President, Corporate Development and Venture, MedImmune
Frank Top, M.D., Senior Vice President, MedImmune Ventures
Joe Amprey, M.D., Ph.D., Managing Director, MedImmune Ventures
Eva M. Jack, Managing Director, MedImmune Ventures
Maggie LeFlore, Ph.D., Managing Director, MedImmune Ventures

MedImmune, LLC
One MedImmune Way | Gaithersburg MD 20878 | United States

Phone: (301) 398-4156
Contacts
Mr. Jonathan Klein-Evans | Vice President, Intellectual Property
Medtronic, Inc.
710 Medtronic Parkway NE | Minneapolis MN 55432 | United States

Phone: 1.763.514.4000
Contacts
Mr. Charles Dennis | Vice President, CRDM Business Development
Company Overview
Company Description
Medtronic is the global leader in medical technology- alleviating pain, restoring health, and
extending life for millions of people around the world. Medtronic develops and manufactures a
wide range of products and therapies with emphasis on providing a complete continuum of care
to diagnose, prevent and monitor chronic conditions. Every five seconds, somewhere in the
world, a person’s life is saved or improved by a Medtronic product or therapy.
Founded
April 29, 1949 in Minneapolis, Minnesota, USA, by Earl E. Bakken and Palmer J. Hermundslie.
Financial
Revenue for the year ended April 27, 2007: $12.3 billion. New York Stock Exchange ticker:
MDT.
Key Businesses
 Cardiac Rhythm Disease Management manages the full spectrum of cardiac rhythm
disorders to improve long-term patient care. The solutions developed at Medtronic allow
physicians to monitor and treat their patients' changing cardiac conditions throughout a
lifetime. These developments include pacemakers to treat patients with bradycardia (too-
slow heartbeat); implantable defibrillators to help patients with tachyarrhythmia (too-fast

heartbeat); and diagnostic and monitoring innovations that diagnose heart-related

syncope (unexplained fainting), just to name a few.
 Neuromodulation offers innovative therapies for chronic pain, movement disorders,

spasticity, overactive bladder and urinary retention, benign prostatic hyperplasia, and
gastroparesis. Medtronic developed and leads the field of neuromodulation, the targeted
and regulated delivery of electrical pulses and pharmaceuticals to specific sites in the
nervous system.
 Spinal and Biologics offers products that treat a variety of disorders of the cranium and
spine, including traumatically induced conditions, deformities and tumors. Through the
introduction of INFUSE® Bone Graft and Minimal Access Spinal Technologies, the
business has distinguished itself as a global leader in less-invasive surgical techniques. It
also develops a variety of image-guided surgical navigation systems.
 Diabetes offers insulin pump therapy, continuous glucose monitoring systems, related
disposable products and diabetes management software, making Medtronic a world
leader in diabetes management.
 CardioVascular develops products that are used throughout the vascular system and
those used for arrested and beating heart bypass surgery. The business markets the
industry’s broadest line of heart valve products for replacement and repair, plus auto-
transfusion equipment and disposable devices for handling and monitoring blood during
major surgery, as well as cardiac ablation devices to treat a variety of heart conditions.
The business also offers products and therapies that treat a wide range of vascular
diseases and conditions. These products include coronary, peripheral and neurovascular
stents, stent graft systems for diseases and conditions throughout the aorta, and distal
protection systems.
 Ear Nose & Throat (ENT) develops and manufactures minimally invasive products and
techniques that treat a wide range of ENT conditions. The business markets powered
tissue-removal systems and other micro-endoscopy instruments, nerve monitoring
systems, disposable fluid control products, image-guided surgery systems and a
Ménière's disease therapy device.
 Physio-Control, a Medtronic company, makes external defibrillator/monitor/pacemaker

products for in-hospital and out-of-hospital use. The wholly-owned subsidiary offers a
range of products and services including LIFEPAK® defibrillators used by hospital and
emergency services personnel as well as trained responders who have minimal training in
CPR and use of an automated external defibrillator. On Dec. 8, 2006, Medtronic
announced plans to spin off the Physio-Control business.
Global Presence
Medtronic does business in more than 120 countries. Medtronic World Headquarters is located in
Minneapolis, Minnesota. Regional Headquarters include Switzerland and Japan.

Workforce
Medtronic employs more than 37,000 people worldwide.
Merck & Co., Inc.
One Merck Drive, WS 2A-51 | P.O. Box 100 | Whitehouse Station NJ 08889-0100 | United
States
Phone: +1.908.423.6940 | Fax: +1.908.735.1201
Contacts
Ms. Pamela Demain | Executive Director, Corporate Licensing
Organization Type
Industry Sector
Health Care
Company Overview
Merck & Co., Inc., Whitehouse Station, NJ, USA, is a global research-driven pharmaceutical
company dedicated to putting patients first. Merck discovers, develops, manufactures, and
markets vaccines and medicines in over 20 therapeutic categories directly and through its joint
ventures. Our mission is to provide society with superior products and services by developing
innovations and solutions that improve the quality of life.
At Merck, our strategy for growth is based on breakthrough research — both internal and
external through partnerships — and demonstrating the value of our medicines to patients,
payers, and providers. Worldwide sales in 2007 were $24.2 billion and Merck continues to invest
heavily in research and development.
Merck’s product line includes a broad portfolio of highly innovative prescription products in
important therapeutic areas. Human health products include medicines to treat high blood
pressure, elevated cholesterol levels, diabetes, cancer, osteoporosis, asthma, benign prostatic
hypertrophy, arthritis, pain, migraine, glaucoma, infectious diseases (antibiotic, antifungal, and
antiviral agents), and vaccines (to prevent childhood diseases, human papilloma virus, rotavirus,
shingles, and hepatitis A and hepatitis B).
To contact Merck about a licensing opportunity, please contact Chief Licensing Officer, Merck
& Co., Inc.,
One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889 USA; Tel: 908–423–4350; Fax:
908–735–1201. Please provide a brief, non-confidential overview of your discovery with
sufficient data to allow a preliminary scientific review. For further information, please visit our
Web site at http://www.merck.com/licensing/


Negotiations, university tech transfer, etc

Biotechs, academic institutions, large pharma.
To meet other companies and institutions with technologies or products in development of

interest for licensing, research collaborations, etc.
To meet other licensing and tech transfer professionals in the healthcare area.
Merial Limited
3239 Satellite Blvd. | Duluth GA 30096 | United States

Phone: 678-638-3903 | Fax: 678-638-3680 | Website: www.merial.com
Contacts
Mr. Peter Selover | Head of Business Development
Mesa Therapeutics
261 Forest Ave | Glen Ridge NJ 07028 | United States

Phone: (908) 764-4467 | Website: www.mesatherapeutics.com
Contacts
Mr. John D. Peck | President
Organization Type
Industry Sector
Health Care
Company Overview
Mesa Therapeutics is an emerging specialty pharmaceutical company focused on acquiring

branded prescription products with additional market potential.

Mesa’s goal is to maximize the value of these brands to patients, the medical community, and all
stakeholders.
Mesa is leveraging its experience and core competency to acquire and market products in acute
care, oncology, CNS, and other specialty therapeutic classes.
Mesa Therapeutics is interested to meet pharmaceutical companies that are looking to out-
license any non-strategic prescription product assets that are at or close to marketing approval,
especially in areas of acute care, oncology, immunology, CNS. In-license of ANDA
opportunities could also be of interest.
Mesa is seeking in-license opportunities for prescription pharmaceuticals, both branded and
generic. For branded products, the company is positioned to in-license specialty pharmaceuticals
with marketing authorization or ready for NDA submission that are not a strategic fit for the
brand owner. Key areas of interest are oncology, CNS, infectious disease, injectable products
and other specialty therapeutic classes.
For generic pharmaceuticals, the company is interested and able to acquire formulations and
ANDAs that are non-strategic to the current owner.
With the company's diversified management team, Mesa’s goal is to maximize the value of these
brands to patients, the medical community, and all stakeholders.
Metroconsult S.r.l.
Via Sestriere, 100 | None Torinese 10060 | Italy

Phone: +39 0119904174 | Fax: +39 011 9863725 | Website: www.metroconsult.it
Contacts
Mr. Roberto Dini | CEO
Organization Type
Law Firm

Industry Sector
High Technology
Company Overview
Metroconsult deals with all the aspects of Intellectual and Industrial Property.
Metroconsult acquired a considerable experience in the fields of consumer electronics and

household appliances. Thanks to this skill Metroconsult developed an amount of knowledge
concerning the value and the strategic importance of Patents, Trademarks and Design.
Metroconsult supports the owners of I.P. rights to develop and exploit the business around their
rights. To these aims, in addition to support the client in filing and prosecuting the Patent,
Trademarks and Design applications till their granting, the firm invites IP rights owners to think
of them as a real competitive instrument.
Special Metroconsult skills:
Assistance in patents and trademarks enforcement, comprising Border Seizure

actions
Assistance in judicial and extra-judicial actions for infringement and nullity
Expert opinions on validity and infringement of patents
Expert opinions on validity and infringement of trademarks
Supporting clients in negotiating and drafting license and assignment agreements

Metroconsult is interested in meeting potential clients/partners who are interested in developing
business in Europe, in particular first filing and prosecuting patents and trademarks in Europe
and then protecting them from infringment cases and eventually licensing them.
Metroconsult is interested to meet with any type of Industry or University who are planning to
develop business in Europe, based on the exploitation of I.P.Rights.


Partnering
IP Services n/a Not Applicable
IP Services n/a Not Applicable Worldwide
Microsoft Corporation
1 Microsoft Way | Redmond WA 98052 | United States

Phone: (425) 706-2016 | Fax: (425) 936-7329
Contacts
Mr. Sean Clark | Senior Licensing Executive
Ms. Debbie Donaty | Sr. Paralegal
Dr. Scott Forbes | Senior Licensing Executive
Mr. Richard Greeley | Director, Licensing
Mr. Geoffrey Hoggard | Senior Licensing Executive
Ms. Simmone Misra | Licensing Executive
Ms. Tatiana Moore | Senior Director, IP Licensing, Corporate IP&L
Mr. Robert Morris | Director, Strategic Licensing
Ms. Joy Murray | Director IP Licensing
Mr. Marshall Phelps | Corporate Vice President and Deputy General Counsel
Mr. Robert Tenczar | Director
Midas Pharma GmbH
Rheinstrasse 49 | Ingelheim 55218 | Germany

Phone: +49-6132-990 572 | Fax: +49-6132-990 672 | Website: www.midas-pharma.com
Contacts
Ms. Antje Deichmann | Project Manager International Licensig
Organization Type
Industry Sector
Health Care
Company Overview
Midas Pharma is an independent marketing and sales company providing services to the health
care industry and bringing together companies with different interests and capabilities. Midas
Pharma is based in Germany with subsideries in USA, France, Denmark, Poland, Italy, Japan,
India and China.

Our objective: To be the partner of first choice in all questions concerning Active Pharmaceutical
Ingredients, Custom Synthesis and Biotech Products, Pharmaceutical Contract Manufacture,
International Licensing or Registration Dossiers and Regulatory Affairs. Pharmaceutical
development partners make use of our company in order to market their registration dossiers and
special development projects.
The key elements in our offer are as follows:
- International Licensing
Licensing in or licensing out (preferable late stage or ready to use products) – we provide you
with all the information needed about international markets, competitors, patents and regulatory
issues. We help you to identify suitable license partners in our markets and assist you in
developing the right regulatory and licensing strategies. We will further support the negotiations
to the benefit of the parties involved.
- Custom Synthesis and Biotech Products
We are able to offer a wide range of chemical reactions and technologies in accordance with
cGMP guidelines– including key technologies such as phosgenation and cryogenic reactions as
well as classical fermentation. We cover the whole spectrum of biotechnology, from vector strain
construction over process development up to production of proteins and antibodies. We offer
fermentation from bacteria and yeast as well as from mammalian cells.
- Contract Manufacture of Finished Dosage Forms
We offer a wide range of contract manufacturing opportunities for pharmaceuticals etc. We also
promote patented platform technologies which can be used for life cycle management or generic
applications.
- Regulatory Support
Our experts will always be ready to give their advisory service on regulatory affairs and offer
their expertise in preparing registration strategies or in the filing of application or certification
procedures, implementation of new variation procedures, etc
- Active Pharmaceutical Ingredients

We can help you to find high-performing API-suppliers. Auditing production facilities to assure
cGMP compliance, searching for patent circumventing manufacturing processes or developing
niche products that are not generally available belong to Midas´ core activities.


We are presenting partners looking for licensees fort he following kind of products and
technologies:
68. oral dissolving, taste masking products

69. topical presentations based on unique technologies
70. products/devices in the gynecology field
71. Nutraceuticals with unique presentations or concepts
72. If you should look for something particular, please ask us…
Development, Marketing and Sales Companies who:
73. are looking for product and/or technologies as described above

74. would like to licence out the proprietary products/developments
We would like to meet companies with unique products or technologies, interested in our service
to find transatlantic licensing opportunities.
Milde & Hoffberg, LLP
10 Bank Street | Suite 460 | White Plains NY 10606 | United States

Phone: (914) 949-3100 | Fax: (914) 949-3416
Contacts
Mr. Steven Hoffberg | Partner
Organization Type
Law Firm
Industry Sector
High Technology


Milde & Hoffberg assists companies in monetzing patents and brokering deals. We have
relationships with a number of organizations that specialize in acquiring, licensing, and selling
portfolios, and and also specific skills and experience that permit us to understand and analyze,
and in some cases enhance the portfolios we work with. As patent attorneys, we can also
consider legal alternates to voluntary transactions, and provide guidance. While we do consider
litigation as a failure of the preferred negotiations route, in some cases it is difficult to avoid.
When assisting clients with IP portfolio transactions, we generally do not displace existing IP
counsel, and rather work with them to efficiently determine the best strategy and
implementation.
In some cases we are able to work on an exclusive or non-exclusive basis, compensated only
when a transaction closes. In other cases, we represent the seller throughout the process,
regardless of whether a licesing or sale transaction is the desired conclusion.
We work with a number of startups and entrepreneurial interests, to develop concepts into
marketable portfolios or operating companies, as well as large, established entities.

We wish to meet those who have IP, and especially patents, for sale or exclusive license, as well
as entities which are seeking to develop strategic portfolios of any type. Our breadth of
experience ranges from high tech, to biotech and pharma, MEMS, nanotechnology, and
everything between.
for Partnering
Automatic Doorstop n/a Not Applicable United States
Electronic Medical Records
IT Technology
Electronic Sneakers n/a Not Applicable United States
Millipore Corporation
28820 Single Oak Drive | Temecula CA 92590 | United States

Phone: (951) 676-8080 | Fax: (951) 506-0942 | Website: www.millipore.com
Contacts

Mr. Matthew G. Brown | BioScience Licensing Manager

Mr. J. Hubbard | Chief Patent Counsel
Organization Type
Industry Sector
High Technology
Company Overview
Millipore is a leading provider of products and services that improve productivity in
biopharmaceutical manufacturing and in clinical, analytical and research laboratories. The
Company is organized in two operating divisions. Its Bioprocess Division enables
pharmaceutical and biotechnology companies to optimize their manufacturing productivity,
ensure the quality of drugs, and scale up the production of difficult-to-manufacture biologics. Its
Bioscience division helps to optimize laboratory productivity and workflows by providing
reagents, kits and other enabling technologies and products for life science research and
development. Millipore has a deep understanding of its customers' research and manufacturing
process needs, and offers reliable and innovative tools, technologies and services. The Company
is part of the S&P 500 index and employs approximately 5,800 employees in more than 47
offices worldwide.

Patents, technology transfer, valuation, intellectual asset management, licensing, royalty
reporting, royalty audits, intellectual property enforcement
Mississippi State University
P.O. Box 5282 | Mississippi State MS 39762-5282 | United States

Phone: (662) 325-3521 | Fax: (662) 325-0667
Contacts
Mr. Charles Rivenburgh | Director Technology Licensing
Mologen AG
Fabeckstrasse 30 | Berlin 14195 | Germany

Phone: +49 30 8417 880 | Fax: 349 30 8417 8850 | Website: www.mologen.com
Contacts
Mr. Joerg Petrass | Chief Financial Officer
Organization Type

Industry Sector
Health Care
Company Overview
MOLOGEN AG is a biotechnology company researching and developing innovative DNA-

based drugs to fight diseases that require a high degree of medical treatment.
The company’s activities are concentrated on creating new immunological drugs and therapies to
combat cancer and on developing state-of-the-art vaccines for the prevention and the treatment
of serious infectious diseases in humans as well as animals.
In the field of cancer, MOLOGEN is developing a novel cancer medicine MGN1703. It is based
on a new type of TLR9 agonist called dSLIM®. The use of the
DNA immunomodulator dSLIM® activates the immune system by targeting the Toll-like
Receptor 9 (TLR9) on certain immune cells. The immune system activated and modulated by
dSLIM® is in a position to overcome its fatal tolerance towards cancer cells and advance against
them strategically. Mologen's cancer medicine MGN1703 is currently being investigated in a
phase I clinical trial in Europe.
In the field of infectious diseases, MOLOGEN’s primary focus is the application of its highly
promising MIDGE® and MIDGE®-Th1 gene expression vectors. With these DNA-based
vectors in particular, specific cellular and humoral immune responses to viruses, bacteria or
parasites can be generated. Previous experiments have shown that through the use of MIDGE
vectors the amount of vaccine to be administered can be reduced and the quality of the immune
reaction can be improved. The most advanced area here is the development of vaccines and
therapeutic agents against leishmaniasis, a serious parasitic disease. In addition, more extensive
studies on the treatment of feline leukemia virus (FeLV, also known as cat leukemia) are
currently ongoing.
MOLOGEN was founded in 1998 and was one of the first German biotechnology companies to
go public. MOLOGEN AG shares are listed at the Frankfurt Stock Exchange (ISIN DE
0006637200).
Fore more information please visit www.mologen.com

Partnering
FeLV (Feline Leukemia
MGN1225 Not Applicable Worldwide
Virus)

colorectal cancer, various

MGN1703 Not Applicable Worldwide
other cancers
Momsen, Leonardos & Cia
Rua Teofilo Otoni, 63 - 10 Andar | Centro | Rio de Janeiro 20090-080 | Brazil

Phone: +55 21 2518-2264 | Fax: +55 21 2518-3152
Contacts
Ms. Marcela de Souza | Attorney
Morgan & Finnegan
3 World Financial Center | New York NY 10281-2101 | United States

Phone: (212) 415-8500 | Fax: (212) 415-8701
Contacts
Mr. Alan Sack | Of Counsel
Morrison & Foerster
425 Market Street | San Francisco CA 94105 | United States

Phone: 415 268-7000 | Fax: 415 268-7522 | Website: www.mofo.com
Contacts
Mr. Rory J. Radding | Partner
Company Overview
MORRISON & FOERSTER -- WE UNITE IDEAS, PEOPLE AND THE LAW IN THE
RELENTLESS PURSUIT OF SUCCESS FOR LIFE SCIENCES CLIENTS
Scope and Focus: With life sciences professionals who have literally shaped our industry,
Morrison & Foerster is one of the world’s largest full-service law firms with over 1,000
attorneys located in 19 key financial and biotechnology centers around the world. The Firm
has represented pioneers and entrepreneurs for over 120 years without ever losing its focus
on excellent lawyering and superior client service. We are driven to achieve our clients’
business objectives and deliver success.
Client Resources: The resources available to our life sciences clients are unmatched:
 Dedicated life sciences licensing, strategic alliance and corporate partnering transactional
expertise, with sophisticated industry, business and scientific experience.

 VIP group marries patent and licensing expertise in a team-oriented approach to provide
efficient, strategic advice in diligencing life sciences patent and deal portfolios, to support
fast-faced corporate partnering.
 Intellectual Property Group provides cutting-edge patent strategy, prosecution and
litigation services (with over 300 attorneys, the largest IP group of any full-service firm).
 Extensive experience representing life sciences companies -- and the venture funds and
investment banks that finance and diligence them -- in corporate matters, with over 250
lawyers in our corporate group.
 Our Litigation Practice Group (with over 400 trial and appellate lawyers) was recently
named one of the top 10 litigation practices in the country by the American Lawyer.
 Largest law firm in California with over 600 attorneys located in the state.
Global Reach: We provide global reach in the world’s life sciences and financial centers:
Palo Alto Beijing Orange

County
San Francisco Brussels Sacramento
San Diego Century City Shanghai
Denver Hong Kong Singapore
No. Virginia Los Angeles Tokyo
Washington New York Walnut Creek
London
International Practice: Our extensive international practice includes life sciences, finance,
trade and dispute resolution across the Americas, Asia and Europe, with particular strength
in Asia.
 Dominant life sciences team in London market, including corporate partnering and
general corporate attorneys whose experience dates back to the inception of UK
involvement in biotech.
 Largest U.S. law firm in Japan with over 50 attorneys in our Tokyo office, which was
established in 1987 and enjoys a highly sophisticated corporate and capital market
practice.
 Significant and expanding China platform with over 30 attorneys in our Beijing and
Shanghai offices, along with well-established offices in Hong Kong and Singapore.

MOSAID Technologies Incorporated
11 Hines Road | Ottawa ON K2K2X1 | Canada

Phone: (613) 599-9539 | Fax: (613) 591-8148 | Website: www.mosaid.com
Contacts
Mr. Vinod Kumar | Director, Patent Portfolio Development
Industry Sector
High Technology
Company Overview
Founded in Ottawa, Ontario, Canada in 1975 as a DRAM chip design and reverse engineering
services company, today MOSAID Technologies Inc. is a global leader in the development and
licensing of Intellectual Property (IP) for semiconductor and communications technologies.
MOSAID is a pure-play IP company focused on a single core business: patent licensing with
memory technology research and Development (R&D).
Mpex Pharmaceuticals, Inc.
11535 Sorrento Valley Road | San Diego CA 92121 | United States

Phone: (858) 875-6662 | Fax: (858) 875-3143 | Website: www.mpexpharma.com
Contacts
Mr. Neil Berkley | Director of Business Development
Organization Type
Industry Sector
Health Care
Company Overview
Mpex Pharmaceuticals is a biopharmaceutical company developing new therapies to combat the
growing issue of antibiotic resistance, with a particular focus on gram negative organisms. The
Company’s internal development pipeline focuses on combining proprietary formulations,
PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly
inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance. Mpex's lead
product candidate, MP-376, is a novel aerosol formulation of an approved antibiotic that recently
achieved proof-of-concept in a Phase 1b study in 40 cystic fibrosis (CF) patients. MP-376 is
currently in a Phase 2b clinical trial for the treatment of chronic infections due to Pseudomonas
aeruginosa in patients with CF and is slated to begin a Phase 2 trial in Q3 2008 in patients with

severe chronic obstructive pulmonary disease (COPD). This novel formulation, coupled with a
high-efficiency nebulizer, is projected to enable delivery of drug directly to the lungs to produce
greater antibacterial effects with a lower propensity for drug resistance, and a shorter
administration time. The Company is also developing inhibitors of bacterial multi-drug resistant
efflux pumps. Efflux pumps are a major source of drug resistance in many gram-negative
pathogens and there are currently no approved treatments which can block this resistance
mechanism. In preclinical studies, Mpex’s Efflux pump inhibitors (EPIs) have been shown to
restore the potency of numerous antibiotics against drug-resistant gram-negative organisms.
These EPIs are now being optimized for potential clinical development. In June 2008, Mpex
entered into a worldwide strategic alliance with GSK to develop novel EPIs in combination with
a variety of existing and development stage antibiotics.

Mpex’s LES goal is to identify new pharmaceutical licensing opportunities. Mpex is actively
seeking pharmaceutical in-licensing opportunities with clear completive advantages in both the
anti-infective space (including antibacterials, antifungals, and antivirals) and the pulmonary
space (specifically agents that are suitable for or provide an advantage when delivered topically
to the lung vial inhalation). Development stage of the opportunity is not critical, but would
prefer early stage assets that are in lead optimization through pre-clinical development.

Mpex is interested in meeting with any pharmaceutical company or university who has anti-
infective agents (including antibacterials, antifungals, and antivirals) and/or pulmonary agents
(specifically agents that are suitable for or provide an advantage when delivered topically to the
lung vial inhalation) available for licensing. The contact person for Mpex is Neil Berkley
(Director of Business Development).

In-licensing
Mr. Dwight Olson
2807 Curie Place | San Diego CA 92122 | United States

Phone: (858) 452-4136 | Fax: (858) 452-4136
Contacts
Mr. Dwight Olson |
Mr. Eric Erickson
13400 E. Shea Blvd. | Scottsdale Arizona 85259 | United States

Phone: 480-301-6180
Contacts
Mr. Eric Erickson |

Organization Type
Industry Sector
Health Care
Company Overview
Mayo Clinic Health Solutions, Office of Intellectual Property
The Office of Intellectual Property is responsible for finding business opportunities for
discoveries and inventions made by Mayo Clinic physicians and employees.
Mr. Russell Barron
1224 North Prospect Avenue | #7T | Milwaukee Wisconsin 53202 | United States
Phone:
Contacts
Mr. Russell J Barron | Partner
Mr. Theodore Galanthay
8429 E. Cactus Wren Circle | Scottsdale Arizona 85266 | United States

Phone: (480) 575-0744
Contacts
Mr. Theodore Galanthay | Attorney at Law
MUSC Foundation for Research Development
221 Ft. Johnson Road | CHARLESTON SC 29412 | United States

Phone: 843-953-0773
Contacts
Mr. Chip Hood | Executive Director

Myriad Genetic Laboratores
320 Wakara Way | Salt Lake City UT 84108 | United States

Phone: (801) 505-5065 | Fax: (801) 883-3256
Contacts
Dr. Michael Hansen | Vice President Business Development & Licensing
NanoGram Corporation
165 Topaz Street | Milpitas CA 95035 | United States

Phone: (408) 719-5307 | Fax: (408) 262-6290
Contacts
Ms. Andrea Cohen | IP Licensing Counsel
NASA Goddard Space Flight Center
Mail Code 504 | 8800 Greenbelt Road | Greenbelt MD 20771 | United States
Phone: (301) 286-2198 | Fax: (301) 286-0301
Contacts
Mr. Alfred T. Mecum | Aerospace Eng, Technology Transfer
Mr. James Nichols | Technology Manager
Ms. Enidia Santiago-Arce | Technology Transfer Manager
National ICT Australia (NICTA)
Level 5 | 13 Garden St | Eveleigh NSW 2015 | Australia

Phone: 61.2.93762095 | Fax: 61.2.93762025 | Website: www.nicta.com.au
Contacts
Ms. Diana Nguyen | Junior Counsel
Organization Type
Industry Sector
Company Overview

NICTA's mission is to create an enduring world-class research institute in Information and

Communications Technology (ICT) that generates national benefit.
Our research themes are embedded systems, networked systems, making sense of data and
managing complexity. These are intertwined with our business areas of biomedical and life
sciences, intelligent transport systems, safety and security, environmental management, mobile
systems and services and software infrastructure.

NICTA is interested in various methods of effectively maintaining its intellectual property
portfolio (mainly patents), as well as ideas on how to effectively value its technology in order to
commercialise it.

A broad range, from private sector to university research institutes.
National Institute of Diabetes
12 South Drive | Room 3011 | Bethesda MD 20892 | United States

Phone: (301) 451-3636 | Fax: (301) 402-7461
Contacts
Ms. Rochelle Blaustein | Director, Technology Transfer & Development
National Institutes of Health
NHGRI Technology Transfer Office | 5626 Fishers Lane, MSC

9418 | Bethesda MD 20852 | United States
Phone: 301-402-2537 | Fax: 301-402-9722 | Website: genome.gov
Contacts
Ms. Felicia Bass | Technology Transfer Specialist
Dr. George H. Keller | Monitoring & Enforcement Specialist
Organization Type
National Renewable Energy Laboratory
1617 Cole Blvd. | MS 1635 | Golden CO 80401 | United States

Phone: (303) 275-4485 | Fax: (303) 275-3040

Contacts
Mr. Thomas A. Williams | Deputy Director
National Research Council Industrial Research Assistant Program
2655 North Sheridan Way | Suite 135 | Mississauga ON L5K 2P8 | Canada
Phone: (905) 829-5243 | Fax: (905) 829-8436 | Website: www.ocean-nutrition.com/
Contacts
Mr. Andrew G. Bauder | Business Analyst
National Research Council of Canada
Institute for Biodiagnostics | 1200 Montreal Road, Bldg. M-58 | Ottawa Ontario K19
0R6 | Canada
Phone: 613.993.9101 | Fax: 613.952.9907
Contacts
Mr. Clement J. Langemeyer | Director, Business Portfolio Office
Natural Resources Canada
580 Booth Street | 16th Floor | Ottawa ON K1A 0E4 | Canada

Phone: (613) 995-6196 | Fax: (613) 952-2587
Contacts
Ms. Elizabeth Blackburn | Manager - IP Management Office
Navigant Consulting, Inc.
30 South Wacker Drive | Suite 3100 | Chicago IL 60606 | United States

Phone: (312) 583-2626 | Fax: (312) 583-5701
Contacts
Mr. Brent Bersin | Director
Ms. Kathleen M. Kedrowski | Managing Director
Mr. J. Shawn McGrath | Associate Director
Ms. Jill M. Rusk | Director
Mr. Barry Sussman | Director
Organization Type
Consulting Firm

Company Overview
Navigant Consulting (NYSE: NCI) is an international consulting firm, providing dispute,

investigative, operational, risk management and financial advisory solutions to legal counsel,
government agencies and companies experiencing regulatory or structural challenges.
NCI offers consulting services in Construction, Corporate Finance, Discovery Services,

Disputes, Energy, Financial Services, Government Contractor Services, Healthcare,
Insurance/Reinsurance Services, and Investigations.
NCI has approximately 1,800 full-time consultants, as of 12/31/2006. It has approximately

2,300 total employees, as of 12/31/2006. It is headquartered in Chicago with a geographical
presence in 42 cities (international presence in the Czech Republic, London, China and Canada).
Revenues for the full year of 2006 increased 18 percent, to $681.7 million, compared to $575.5
million in 2005. Full year EBITDA in 2006 increased 12 percent to $121.0 million, compared to
$108.0 million in 2005. It has been publicly traded since 1996 (NYSE: NCI).
Anything related to Intellectual Property:
 patents
 trademarks
 trade secrets
 trade dress
 false advertising
 corrective advertising
 unfair competition
 copyrights
 right of publicity
 royalty matters
 tech transfer
 valuation
 intellectual asset management
 licensing
 university research
Navigant Consulting's extensive experience in IP analysis and valuation combined with our IP
commercialization and transactional experience makes us uniquely qualified to provide the
highest level of service. Our IP consulting team provides the following:
 Extensive experience in the valuation and analysis of IP for a wide range of purposes

 Deep experience in developing and executing commercialization strategies for IP

 Complete "turn-key" IP commercialization services from identifying potential
technologies and markets to executing the transaction
 Significant Disputes & Investigations practice with considerable experience in IP
disputes
 Extensive knowledge of a broad range of industries, markets, and customers
 World-class professional team with national coverage
 Independent and objective consulting services
 Networking
 Business Development
 Education
NERAC, Inc.
Business Solutions | One Technology Drive | Tolland CT 6084 | United States

Phone: (860) 872-7000 | Fax: (860) 872-6026 | Website: www.scitechlicensing.com
Contacts
Mr. Scott A. Taper | Sr. Consultant
New Perspectives, Inc.
PO Box 688 | Huntsville AL 35804 | United States

Phone: (919) 641-8146
Contacts
Ms. Vicki L. Morgan | Vice President, Business & Market Development
New York Blood Center & L.F.K. Research Institute
310 East 67 Street | New York NY 10021 | United States

Phone: (212) 570-3215 | Fax: (212) 879-5922 | Website: www.osip.com
Contacts
Ms. Barbara A. Sawitsky | Director, Patents & Licensing/Business Development

Newell Rubbermaid
10 B Glenlake Parkway | Suite 600 | Atlanta GA 30328 | United States

Phone: (770) 407-3839 | Fax: (770) 407-3954
Contacts
Mr. Nat Milburn | V.P. Global Licensing
NextTechs Technologies
410 Pierce Street | Sutie 223 | Houston TX 77002 | United States

Phone: (832) 476-9310
Contacts
Mr. Michael E. Fitzgerald | President and CEO
Mr. Carlos Gorrichategui | Cheif Operations Officer
NextWave Pharmaceuticals
50 Lakeview Parkway | Suite 134 | Vernon Hills IL 60061 | United States

Phone: (847) 996-6200 | Fax: (847) 996-6195 | Website: www.nextwavepharma.com
Contacts
Dr. J. George Sarmiento |
Organization Type
Industry Sector
Health Care
Company Overview
Overview
NextWave is a Specialty Pharmaceutical Company with a broad line of prescription

pediatric products and over-the-counter products. NextWave develops uique products
that address many of the compliance, convenience, dosing and safety issues that
consumers face today.
NextWave Pharmaceuticals pediatric product development is guided by three simple
founding principles:

 Offer pediatricians the latest advancements in treatment options for children

 Provide parents with new and innovative medicines in order to care for their children
 And most importantly, help improve the health of all children
By listening to the needs of parents and children, and working closely with the pediatric
community, including pediatricians, physician assistants and nurse practitioners,
NextWave Pharmaceuticals is developing a broad line of products across several
therapeutic areas. With an unwavering focus on leveraging the next wave of
technologies for pediatrics, we will be able to provide unique products that address
many of the compliance, convenience, dosing and safety issues children and their
parents face today.
As we continue to move forward we welcome your input and understand that we all
share the common goal of a brighter tomorrow for our children.
Products
MyKidz IronTM , MyKidz Iron FLTM* and MyKidz Iron 10 are products currently available from
Pharmaceuticals. There are also numerous other products under development that will make a s
pediatric area, so check back often for the latest updates.
MyKidz Iron, MyKidz Iron FL and MyKidz Iron 10
MyKidz Iron and MyKidz Iron FL are liquid iron suspension dietary supplements fortified with
They have been specially designed to help meet the nutritional needs of growing infants and tod
vitamin supplements for breast-fed infants. They contain Vitamin D as recommended by the Am
Pediatrics (AAP) for exclusively breast-fed infants and for infants who consume less than 17 fl.
MyKidz Iron is a nonprescription iron supplement that is available behind the pharmacy counte
contains 0.25 of fluoride per dose for toddlers requiring fluoride supplementation and requires a
physician. See package insert for dosage and safety information.
MyKidz Iron 10™ is a liquid iron only suspension supplement. MyKidz Iron 10™ has been specially d
nutritional needs of growing infants and toddlers. One daily dose of MyKidz Iron 10™ provides an exce
iron.
MyKidz Iron 10™ is a non prescription iron supplement which contains 15mg/1.5mL Elementa
10™ is available behind the pharmacy counter at your local pharmacy. For more information or
10™ on-line please visit http://www.mykidziron.com/.
MyKidz Iron and MyKidz Iron FL offer unique benefits over other iron and vitamin supplemen
For more information on MyKidz Iron, visit http://www.mykidziron.com/.

If you are having problems locating MyKidz Iron or have questions about our product,
send us an e-mail at mykidziron@nextwavepharma.com or call us at 866-697-WAVE (9283).

* MyKidz Iron FL is available by prescription only.
NextWave Pharmaceuticals works with Stiefel Laboratories to bring you VERDESO™ Foam &
MimyX™ Cream for the treatment of Atopic dermatitis.
NextWave Pharmaceuticals also works with Fleet Laboratories to help in the promotion of the
Pedia-Lax™ line of laxative products.

Seek licensing opprtunities co-promotions and collaborations for products which serve the
Pediatric Patient population and the OTC consumers in the US.
NicOx SA
1681 route des Dolines - BP 313 | Les Taissounières - Bât HB4 | Sophia Antipolis cedex
06906 | France
Phone: +33 (0)4 97 24 53 00 | Fax: +33 (0)4 97 24 53 09 | Website: www.nicox.com
Contacts
Mr. Gavin Spencer | Senior Director Business Development
Organization Type
Industry Sector
Health Care
Company Overview
NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) a product-driven biopharmaceutical company
dedicated to the development and future commercialization of investigational drugs for unmet
medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an
internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and
cardio-metabolic disease.
Resources are focused on the development of naproxcinod, a proprietary NCE and the first
compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-
inflammatory agents, which is in phase 3 clinical studies for the treatment of the signs and
symptoms of osteoarthritis, with final phase 3 results anticipated in 2008.
Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs,
which are in development internally and with partners, including Pfizer Inc and Merck & Co.,

Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis,
hypertension, widespread eye diseases and Chronic Obstructive Pulmonary Disease (COPD).
NicOx S.A. is headquartered in France and is listed on the Euronext Paris Stock Exchange
(Compartment B: Mid Caps).
In-licensing: NicOx would like to meet companies with Phase 2 or later developments in the
cardiometabolic and rheumatology/inflammation therapeutic areas. Earlier stage developments
are also of interest for established mechanisms of action.
NicOx aims to build itself into a fully integrated biopharmaceutical company through focused
investment in in-house research and development programs and potentially through in-licensing
and by making select acquisitions in its core therapeutic domains of inflammation and
cardiometabolic disease.
NicOx has strategic partnerships, collaborative agreements and research alliances with some of
the world's leading pharmaceutical companies and specialist players, which allow it to maximize
the value of its technology and broad product portfolio, while allowing the Company to retain
commercialization rights in select areas.
NIH - Office of Technology Transfer
6011 Executive Boulevard, Suite 325 | MSC 7660 | Bethesda MD 20892-7660 | United States
Phone: (301) 435-4478 | Fax: (301) 402-0220 | Website: www.ott.nih.gov/
Contacts
Ms. Susan Rucker | Sr. Advisor for Intellectual Property Transactions
Organization Type
Industry Sector

NISTAC
2005 Research Park Circle | Manhattan KS 66502 | United States
Phone: (785) 532-3924 | Fax: (785) 532-3909 | Website: www.nistac.org
Contacts
Mr. Bret A . Ford | Director of Life Sciences
Organization Type
University
Industry Sector
Company Overview
Kansas State University and the State of Kansas formed the National Institute for Strategic
Technology Acquisition and Commercialization (NISTAC) to be the commercialization
company of K-State and to strengthen regional economies by facilitating the start-up and/or
expansion of technology-based, high growth enterprises, particularly via technology transfer
from research institutions and other sources.
NISTAC is partnered with the KSU Research Foundation to be the tech transfer arm of K-State.

Our company is interested in patents, tech transfer services, and partnering with commercial
entities.

NISTAC's goals for LES is to better help facilitate out-licensing of our portfolio of corporate
donated technologies, K-State technologies and to engage in research collaborations.
Nixon Peabody LLP
1300 Clinton Square | Rochester NY 14604-1792 | United States

Phone: (585) 263-1014 | Fax: (585) 263-1600

Contacts
Mr. Gunnar G. Leinberg | Partner
Organization Type
Law Firm
Company Overview
Nixon Peabody LLP is one of the largest multipractice law firms in the United States, with
offices in sixteen cities and approximately seven hundred attorneys collaborating across twenty-
five major practice areas. The firm’s size, diversity, and state-of-the-art information systems
enable us to offer a comprehensive, integrated range of legal services to individuals and
organizations of all sizes in local, state, national, and international matters.
The attorneys in our Intellectual Property practice help clients protect and exploit the full value
of their intellectual property, and our success on their behalf has placed us among the nation’s
top IP firms in the areas of litigation, patents, and trademarks.
We offer comprehensive IP services, bringing sharp legal skills, deep knowledge of engineering,
and excellent business judgment to every matter. Our aim is to offer consistently exceptional
service and maximize our clients’ competitive advantages while minimizing their risks. The
group’s services include:
 Litigating patent, trademark, copyright, unfair competition, and related antitrust matters
 Negotiating and drafting all agreements necessary to develop, license, obtain, transfer,
and commercialize technology
 Preparing and prosecuting patent applications
 Representing clients in patent interference proceedings before the U.S. Patent and
Trademark Office
 Providing comprehensive brand management services
 Providing infringement avoidance counseling
 Conducting intellectual property due diligence
 Providing alternative dispute resolution, including arbitration and mediation .
Our clients include:
 Fortune 500 companies

 Entrepreneurs
 Start-ups
 Leading academic institutions
 Individual inventors, in both cutting-edge and established technologies.
Our IP practice members are active in trade associations serving client industries, and we are
recognized legal authorities in many of them. Our patent attorneys have diverse technical
backgrounds, including degrees in chemical engineering, biotechnology, optical engineering,

microelectronics, mechanical engineering, electrical engineering, and computer science. Many

members of our group have substantial experience as U.S. patent examiners or as practicing
engineers in the commercial sector.
We would be interested in meeting companies, academic institutions, start-ups, and others

looking for legal assistance and counseling with protecting and exploiting the full value of their
intellectual property.
Noetic Technologies, Inc.
3610 Pearl Street | Hattiesburg MS 39401 | United States

Phone: (601) 261-1316 | Fax: (601) 261-1319
Contacts
Dr. Leslie Goff | President & CEO
Organization Type
Industry Sector
Materials
Company Overview
Noetic Technologies, Inc. is an innovation and commercialization company. Our leadership

team's experience includes technology development, commercialization, process engineering,
technical marketing and business start-ups.
Since 2004, Noetic has assisted professors and small businesses to create and focus their
business plans to rapidly move new and exciting technologies to market. As a result of our
unique business structure, we can accomodate a wide range of development structures including
licensing, joint venturing, joint development, and business start-ups.
Contact us to explore how Noetic can help connect your technology to the market!

Noetinger & Armando
25 de Mayo 489, 8o Piso | Buenos Aires C1002ABI | Argentina

Phone: +54 11 4315 9200 | Fax: +54 11 4315 9201 | Website: www.noetingeryarmando.com.ar
Contacts
Mr. Fernando Noetinger | Senior Partner
Nokia Corporation
Keilalahdentie 2-4 | Espoo 02150 | Finland

Phone: +358 7180 0800
Contacts
Mr. EKI KORPIOLA | SENIOR LEGAL COUNSEL
Organization Type
Industry Sector
Consumer Products
Company Overview
Nokia is the world leader in mobility, driving the transformation and growth of the converging
Internet and communications industries.

Patent analysis and valuation

Companies with SW reverse engineering and claim verification competence
Norgenix Pharmaceuticals
101 West Saint John Street | Suite 307 | Spartanburg SC 29306 | United States
Phone: (864) 680-6759 | Fax: (864) 580-2661 | Website: www.norgenixpharma.com
Contacts
Mr. Tom McLean | Senior Vice President
Company Overview

Norgenix Pharmaceuticals is a privately held pharmaceutical company that is seeking to acquire,

in-license or partner to commercialize, distribute, market and sell prescription medications or
unique medical devices. The experienced, professional Norgenix team can provide capitalization
and all aspects of commercialization, distribution and sales in the US market. Norgenix
Pharmaceuticals is funded by one of the largest privately held US healthcare corporations. Please
contact Tom McLean, Sr. VP and COO at 864-580-2660 Ext 302 or mobile 864-680-6759.
Norgenix Pharmaceuticals is seeking to acquire, in-license or partner to capitalize,

commercialize, distribute, market and sell prescription medications or unique medical devices in
the US market. Please contact Tom McLean, Sr. VP and COO at 864-580-2660 Ext 302 or
mobile 864-680-6759.

Companies looking to sell, out-license or partner late-stage or approved products in the US
market.
Nortel Networks
2221 Lakeside Blvd | Richardson TX 75082-4399 | United States

Phone: (972) 684-2761 | Fax: (613) 763-1552 | Website: www.nortel.com
Contacts
Mr. John P. Veschi | Chief Intellectual Property Officer
North Carolina Biotechnology Center
15 TW Alexander Dr. | P.O. Box 13547 | Research Triangle Park NC 27709-3547 | United
States
Phone: 919.541.9366 | Fax: 919.990.9544 | Website: www.ncbiotech.org
Contacts
Mr. John Richert | Vice President, Business & Technology Development

North Dakota State University
1735 NDSU Research Park Drive | Suite 124 | Fargo ND 58105 | United States
Phone: (701) 231-7886 | Fax: (701) 231-6661 | Website: www.ndsuresearchfoundation.org
Contacts
Mr. Jaideep Goswami | Licensing Associate
Mr. Jonathan L. Tolstedt | Licensing Associate/Patent Agent
Organization Type
University
Industry Sector
Company Overview
The NDSU RESEARCH FOUNDATION is an independent, not-for-profit organization
established to support North Dakota State University in achieving its instructional, research,
public service and academic goals.
The Foundation was developed to provide private support for the University by protecting,
adding value to, and commercializing intellectual property that is developed through research
activities at the University. By commercializing intellectual property, the Foundation is able
to create resources which are returned to the individual inventors and to the University to
promote continued research.
A vast array of technologies is currently available for licensing. General technology

categories are listed below, and information on specific technologies in each of these
categories is provided on our website, www.ndsuresearchfoundation.org. If you are
interested in any technology, or if you have any questions, please don’t hesitate to contact us.
Available Technologies
Agricultural Products - Crop varieties and related agricultural inventions developed by

NDSU plant breeders.
Biology and Medicine - Innovative biological and biomedical inventions, processes, and
compounds.
Chemistry and Materials - New chemicals and compounds, chemical sensor

technologies, and processes.

Electronics and Sensors - Advanced sensor technologies, innovative devices, and

methods pertaining to the manufacture of electronics and micro-electronics.
Horticulture - Plant species and cultivars developed by the NDSU Plant Sciences
Department.
Nanotechnology - Developments in nano-particles and micro-assembly techniques and

processes.
Paints and Coatings - Paints, polymers, and coatings developed by NDSU’s Coatings
and Polymeric Materials department, the country’s oldest paint research institution.
Software and Algorithms - Advanced software systems and algorithms.

The goals of the NDSU Research Foundation are to commercialize the intellectual property of
North Dakota State University and to promote continued research at the University. Therefore,
the interests of the NDSU Research Foundation are in Technology Transfer, Patents, Intellectual
Asset Management, and Sponsored Research.

Any company with an interest in the NDSU technologies listed above or at
www.ndsuresearchfoundation.org, or with an interest in sponsoring research at the University.

The goals for the NDSU Research Foundation for the LES Annual Meeting are primarily out-
licensing our available technologies, creating research opportunities, and working with industry
to develop solutions.
Country(s)
Partnering
Please see See individual
Not Applicable
www.ndsuresearchfoundation.org technologies.

Northeastern University
360 Huntington Avenue | 960 RN | Boston MA 2115 | United States

Phone: (617) 373-8809 | Fax: (617) 373-8866
Contacts
Mr. Jeffrey Kosiba | Intellectual Property Manager
Northrop Grumman Corp.
1840 Century Park East | Los Angeles CA 92886 | United States

Phone: (310) 201-1638 | Fax: (310) 201-1694
Contacts
Ms. Lori Morrison | Licensing Manager
Mr. Christian Orlowski | Corporate Director, Engineering & Technology
Northrop Grumman Corp., Electronic Systems
7323 Aviation Blvd, MS 1105 | Baltimore MD 21240 | United States

Phone: (410) 765-4105 | Fax: (410) 865-5040
Contacts
Mr. Robert F. Held | Director, Intellectual Property & Strategic Technology Agmts
Organization Type
Industry Sector
High Technology
Company Overview
Northrop Grumman Corporation (www.ngc.com) is a global defense and technology company

whose 120,000 employees provide innovative systems, products, and solutions in information
and services, electronics, aerospace and shipbuilding to government and commercial customers
worldwide.
Seven business sectors comprise Northrop Grumman. Below is a listing and description of each
sector by our four main business areas. To find out specific product, program or services
information, visit our Capabilities section, go to our A-to-Z List or click on one of the links
below.

Our Business Areas:
Information & Services

Northrop Grumman puts information to work. As a trusted partner, the company develops
systems and solutions that deliver timely, enabling information where it is needed most for its
military, intelligence, federal, state and local government, and commercial customers. More...
Electronics
Northrop Grumman’s electronic solutions span the spectrum. The company is a leading
developer, manufacturer, integrator and supporter of a variety of advanced electronic and
maritime systems for U.S. and international customers for national security and non-defense
applications. More...
Aerospace
Northrop Grumman’s aerospace systems operate from the high ground. The company is a
premier developer, integrator, producer and supporter of manned and unmanned aircraft,
spacecraft, high-energy laser systems, microelectronics and other systems and subsystems
critical to maintaining the nation’s security and leadership in science and technology. More...
Shipbuilding
Ships built by Northrop Grumman project power worldwide. The company is the nation’s sole
industrial designer, builder and refueler of nuclear-powered aircraft carriers and one of only two
companies that design and build nuclear-powered submarines. The business is also one of the
nation’s leading providers and life-cycle supporters of major surface ships for the U.S. Navy,
U.S. Coast Guard, international navies and commercial vessels. More...
NovaDel Pharma
25 Minneakoning Drive | Suite 101 | Flemington NJ 08822 | United States

Phone: +1.908.782.3431 ext. 2160 | Fax: +1.908.806.7624
Contacts
Dr. Deni Zodda | Senior Vice President, Chief Business Officer
Organization Type
Industry Sector
Health Care
Company Overview
NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations
for a broad range of marketed drugs. The Company’s proprietary technology offers, in

comparison to conventional oral dosage forms, the potential for faster absorption of drugs into
the bloodstream leading to quicker onset of therapeutic effects and possibly reduced first pass
liver metabolism, which may result in lower doses. Oral sprays eliminate the requirement for
water or the need to swallow, potentially improving patient convenience and adherence.
NovaDel’s oral spray technology is focused on addressing unmet medical needs for a broad array
of existing and future pharmaceutical products. The Company’s most advanced oral spray
candidates target angina, nausea, insomnia, migraine headaches and disorders of the central
nervous system. NovaDel plans to develop these and other products independently and through
collaborative arrangements with pharmaceutical and biotechnology companies.
The company's lead products are: NitroMist™ (nitroglycerin oral spray), approved for the
treatment and prophylaxis of angina; ZolpiMist™ (zolpidem oral spray), NDA filed for the
treatment of insomnia, and; Zensana™ (ondansetron oral spray), in Phase 3 for
nausea/vomitting. Earlier stage products include oral spray of sumatriptan (migraine),
midazolam (pre-procedure anxiety), sildenafil (erectile dysfunction) and fentanyl (breakthrough
cancer pain).

NovaDel is seeking partners for the commercialization of our NitroMist™ and ZolpiMist™
products.

We would like to meet with companies with sales/marketing capabilties in the United States,
Europe and Japan.
Open dialogues with companies meeting our need for a commercial partner for our most
advanced products.
for Partnering
NitroMist (Nitroglycerin
Acute Angina Not Applicable North America
Lingual Aerosol)
Zensana (Ondansetron Oral South America, Israel,
Anti-Nauseant Not Applicable
Spray) Japan, Austrialia

ZolpiMist (zolpidem oral

Hypnotic Not Applicable Worldwide
spray)
Novak Druce + Quigg, LLP
1300 Eye Street, N.W. | Suite 1000 West Tower | Washington DC 20005 | United States
Phone: (202) 659-0100 | Fax: (202) 659-0105
Contacts
Mr. Anthony Venturino | Patent Attorney
Organization Type
Law Firm
Industry Sector
Chemicals
Company Overview
A 40 attorney IP boutique providing quality patent prosecution, trademark prosecution and
patent reexamination services.
Patents, trademarks, IP due diligence

Companies seeking quality US IP counsel for obtaining patents and reexamining patents as well
as obtaining trademark registrations and opposing or filing cancellations against trademark
registrations.

Partnering
Legal services n/a Not Applicable

Novartis Consumer Health, Inc.
200 Kimball Drive | Parsippany NJ 07054 | United States

Phone: 973 503 8186
Contacts
Mr. Albert Ge | New Technologies and Product Innovation
Novartis Pharma AG
Lichtstrasse 35 | Postfach | Basel CH-4002 | Switzerland

Phone: +41-61-324-1111 | Website: www.novartis.com
Contacts
Ms. Carol A Finch | Head of Partnering General Medicines & Mature Products
Dr. Gerrard Terlouw | Head Search & Evaluation Infectious Diseases
Company Overview
The Novartis Pharmaceuticals Division is a world leader in the discovery, development,
manufacture, and marketing of prescription medicine. Our goals is to provide a broad portfolio of
innovative, effective and safe products and services to patients through healthcare professionals
around the world.
In 2006, the Pharmaceutical’s business posted sales of USD 22.6 billion. Our current product
portfolio involves over 130 projects – including potential new products as well as potential new
indications or formulations for existing products - in various stages of clinical development
The Pharmaceutical Division consist of the following therapeutic areas:
General Medicine
Cardiovascular & Metabolism
Neuroscience
Respiratory & Dermatology
ABGHI (Arthritis, bone, gastrointestinal, hormone replacement therapies, urinary
incontinence):
Infectious diseases
Specialty Medicines
Oncology & Hematology
Transplantation & Immunology
Ophthalmics

Novartis Pharmaceuticals Corp.
59 Route 10 | East Hanover NJ 07936-1080 | United States

Phone: +1.862.778.5309 | Fax: +1.973.781.6056
Contacts
Ms. Carolyne Zimmermann | Director, Business Development & Licensing
Organization Type
Industry Sector
Health Care
Company Overview
Our mission is to discover, develop and successfully market innovative products to prevent and
cure diseases to ease suffering and enhance quality of life.
Oak Ridge National Laboratory - Technology Transfer & Economic Development
P. O. Box 2008 | Oak Ridge TN 37831 | United States

Phone: 865/241-1948 | Fax: 865/241-4265 | Website: www.rctech.com
Contacts
Ms. Jennifer T. Caldwell | Senior Commercialization Manager
Company Overview
The Oak Ridge National Laboratory is the Department of Energy's largest science and energy
laboratory. ORNL's mission is to conduct basic and applied research that provides innovative
solutions to complex problems. The lab was founded in 1943 as part of the secret Manhattan
Project and has been managed since April 2000 by a partnership of The University of Tennessee
and Battelle Memorial Institute.
ORNL has a staff of more than 3,800 and approximately 3,000 guest researchers who spend two
weeks or more annually. The lab's budget exceeds $1 billion for FY05. ORNL is home to the
world's largest civilian science project, the $1.4 billion Spallation Neutron Source, and the first
DOE Center for Nanophase Materials Sciences is nearing completion adjacent to the SNS.
ORNL was also selected last year to build the fastest unclassified computer in the world.

Oakridge National Laboratory
1 Bethel Valley Road | Oak Ridge TN 37830-6196 | United States

Phone: (865) 574-8746 | Fax: (865) 574-9241
Contacts
Mr. Raymond Miller | Senior Commercialization Manager
Ocean Tomo
200 West Madison | Suite 3700 | Chicago IL 60606 | United States

Phone: 312-327-4857 | Fax: 312-327-4401
Contacts
Mr. Kevin Arst | Managing Director
Mr. Richard M. Conroy | Managing Director
Ms. Krista F. Holt | Managing Director
Mr. Michael J. Lasinski | Managing Director
Mr. James Malackowski | President & CEO
Company Overview
Ocean Tomo is an Intellectual Capital Merchant Banc firm.
Established in 2003, Ocean Tomo, LLC is the leading Intellectual Capital Merchant Banc® firm
that specializes in understanding and leveraging Intellectual Property assets.
The company provides advice in IP-related mergers and acquisitions, investments, valuations,
expert services, analytics and IP auctions. Headquartered in Chicago, Ocean Tomo has offices in
San Francisco, Palm Beach, Orange County and Washington, DC.
Subsidiaries of Ocean Tomo include: Ocean Tomo Auctions, LLC; Ocean Tomo Asset
Management, LLC; and Ocean Tomo Capital, LLC -- publisher of the Ocean Tomo 300® Patent
Index (Amex: OTPAT), the Ocean Tomo 300® Patent Growth Index (Amex: OTPATG) and the
Ocean Tomo 300® Patent Value Index (Amex: OTPATV).
Services Include:
Expert Services
Financial Testimony
Surveys
Valuation
Appraisals

Analytics/IP Acquisitions
PatentRatings
Investments
Ocean Tomo Indexes
Public Equities
Private Equity & Debt
IP Enterprise Zone/
IP Exchange Chicago
Risk Management
License Management
Insurance
Alternate Dispute Resolution
IP Transactions
IP Asset Sales/Auctions
Ocean Tomo Patent/Bid-Ask
Corporate M&A
Structured Products
The Dean's List

Partnering
Ocean Tomo
n/a Not Applicable
Patent/Bid-Ask
The Dean's List n/a Not Applicable Worldwide
Office for Technology Commercialization
1000 Westgate Drive | Suite 160 | St. Paul MN 55114-8658 | United States
Phone: 612-625-8615 | Fax: 612-624-6554
Contacts
Ms. Leza Besemann | Technology Strategy Manager

Ogilvy Renault
800 Park Place 666 Burrard Street | Vancouver BC V6C 3P3 | Canada
Phone: +1.604.806.3865 | Fax: +1.604.806.0933
Contacts
Mrs. Laetitia Caporicci | Lawyer
Ms. Leanne Souquet | Partner
Company Overview
Founded in 1879, Ogilvy Renault is one of Canada’s pre-eminent law firms. Ogilvy Renault is
also one of Canada’s largest law firms with over 450 lawyers and agents located across the
country in offices in Vancouver, Toronto, Ottawa, Montréal, Québec City as well as in London,
England. Our firm’s tradition of dedication to excellence has earned it an enviable reputation for
the highest standards in the practice of law. Ogilvy Renault draws on resources from all our
offices to ensure the optimal blend of industry and legal expertise. The collective talents and
expertise of the entire firm are put at the disposal of our clients and serve to enhance our
effectiveness.
Our goal is to meet your business priorities through the timely delivery of innovative, integrated
and customized legal advice, whether using long-term strategies or short-term problem solving.
Ogilvy Renault has helped many of Canada’s leading businesses throughout every stage of their
growth, from their initial incorporation and throughout their day-to-day operations to their
expansion projects, both domestically and abroad.
Life Sciences Expertise
The rapid evolution of the life sciences industries continues to raise important legal, ethical and
scientific issues. In such a dynamic environment, companies require the timely and
knowledgeable advice of seasoned life sciences professionals. At Ogilvy Renault, our lawyers,
patent agents and trade-mark agents provide legal and technical advice to a diverse clientele in
the life sciences industries, including universities, research centres, venture capitalists,
multinational corporations, as well as start-up and mid-size companies.
Our multidisciplinary team of professionals responds creatively to the needs of businesses that
manufacture, sell or distribute in Canada biologics and biopharmaceuticals, prescription and
over-the-counter pharmaceuticals (both human and veterinary), natural health products,
nutraceuticals, medical devices, foods and cosmetics.
Ogilvy Renault’s life sciences practitioners have an in-depth knowledge of the industry sectors
we serve and a clear understanding of the business goals of companies at every stage of their
growth. We can meet all of a company’s legal needs through every step of a product’s life cycle.
We are also able to anticipate and analyze the potential effect of emerging issues to assist life
sciences companies in successfully meeting the challenges of critical changes.

Oklahoma Medical Research Foundation
755 Research Parkway | Suite 410 | Oklahoma City OK 73104 | United States
Phone: (405) 271-1846 | Fax: (405) 271-1708 | Website: www.omrf.org
Contacts
Mr. Manu S. Nair | Licensing Associate
Organization Type
Industry Sector
Health Care
Company Overview
Oklahoma Medical Research Foundation (OMRF) is one of the oldest, most respected
independent research institutes in the nation. Located in Oklahoma City - America's heartland.
OMRF fosters a worldwide reputation for excellence by following an innovative cross-
disciplinary approach to biomedical research. Breakthrough discoveries and state-of-the-art core
research facilities keep OMRF on the cutting edge of pioneering biomedical science. Through
successful industry collaborations and technology transfer, OMRF has brought several novel
therapeutic and diagnostic technologies to market. OMRF has set a clear goal to be among the
finest research institutes in the nation, and is making the investments today to keep pace with the
unprecedented growth and change occurring in the field of biomedical research. With
the recently announced $125 Million expansion project, OMRF will continue its growth, adding
more faculty members and new laboratory space in the coming years.
OMRF is committed to staying at the forefront of biomedical discovery so that "more can live
longer, healthier lives."
- Pharmaceutical, Biotech (Therapeutic & Diagnostic) Companies
- Suppliers of animal models
- Investors
- Other biomedical research labs

- Out-license novel technologies (therapeutics, diagnostics and research tools)
- Explore sponsored research/industry collaborations for OMRF researchers
- Explore investment and collaboration opportunities for OMRF spin-off/start-up companies
- Explore contract research opportunities for OMRF's core research facilities (like small-animal
MRI facility, Crystallography facility etc.)
- Continued education
Country(s)
Partnering
Extracellular histones as biomarkers
for prognosis and molecular targets Sepsis Not Applicable Worldwide
for sepsis therapy
Investment opportunities - Spin-off
companies in the field of cancer Oncology Not Applicable
(diagnostic and therapeutic)
Regulation of toll like receptors
(TLRs) on stem cells to treat
infections and to increase survival
of stem cells
Old Dominion University
4111 Monarch Way, | Office of Research, Suite 203 | Norfolk VA 23508 | United States
Phone: (757) 683-5052 | Fax: (757) 683-5902
Contacts
Mr. Zohir Handy | Technology Licensing Manager

Oncolix, Inc.
701 Grove Road | Greenville SC 29605 | United States

Phone: (281) 923-2807
Contacts
Mr. Michael T. Redman | President and CEO
Organization Type
Industry Sector
Health Care
Company Overview
Oncolix, Inc. is developing therapies for breast cancer and malignant melanoma. The breast
cancer drug is a prolactin receptor antagonist (Prolanta) that was developed by Wen Chen, PhD.
Dr. Chen also developed Somavert, which is a growth hormone receptor antagonist, which is
currently sold by Pfizer for the treatment of acromegaly. Both drugs feature a single amino acid
substitution (glycine to arginine) of prolactin and growth hormone.
Prolanta is near completion with preclinical studies. The company expects to initiate its first
human trial in the 2nd quarter of 2009 (Phase Ia in subjects) and a Phase Ib trial in patients in the
3rd quarter of the same year.
Oncolix derives its technologies from the Greenville Hospital System (GHS) in Greenville,
South Carolina. GHS, one of the largest hospital systems in the southeast US, is the majority
shareholder of Oncolix. Oncolix is funded through 2009 by GHS.

Oncolix intends to outlicense its technologies.

Networking
Product Name Therapeutic Area Phase of Development Country(s) Available for

Partnering
Breast cancer,
Prolanta Not Applicable
melanoma
Ontario Ministry of Research
56 Wellesley Street West | Toronto ON M7A 2E7 | Canada

Phone: (416) 314-3808 | Fax: (416) 314-0680
Contacts
Mr. Andrew Tomingas | Senior Policy Advisor
Onyx Pharmaceuticals, Inc.
2100 Powell Street | Emeryville CA 94608 | United States

Phone: +1.510.597.6500 | Fax: +1.510.597.6603
Contacts
Dr. Juergen Lasowski | Senior Vice President
Company Overview
Onyx is a biopharmaceutical company dedicated to developing innovative therapies that target
the molecular mechanisms that cause cancer. With our partners, we are developing small
molecule, orally available drugs with the goal of changing the way cancer is treated. Our product
candidates inhibit key enzymes responsible for uncontrolled cancerous growth in certain cells
with genetic mutations.
Our lead product is Nexavar® (sorafenib) tablets, a novel, oral multiple kinase inhibitor that
targets proteins involved in both tumor cell proliferation and angiogenesis. Nexavar® is
approved in the US and EU for the treatment of advanced renal cell carcinoma and was co-
developed with our partner Bayer Pharmaceuticals. By inhibiting RAF kinase, Nexavar® blocks
the RAF/MEK/ERK signaling pathway that is activated by the RAS gene to trigger cell
proliferation. Nexavar® also exerts an anti-proliferative effect on the endothelial cells involved
in angiogenesis by inhibiting the VEGFR-2 and PDGFR-ß receptors.
Onyx, in collaboration with Bayer, is continuing to conduct multiple clinical trials of Nexavar®,
including pivotal trials in patients with metastatic melanoma, advanced primary liver cancer, and
non-small cell lung cancer. Enrollment in the Phase III trial in metastatic melanoma was
completed in July 2006. The agent is also being studied in multiple Phase II clinical trials both as
a single agent and in combination with standard chemotherapy drugs for the treatment of various
tumors.
In collaboration with Warner-Lambert, now a subsidiary of Pfizer, Onyx identified a number of

lead compounds that modulate the activity of key enzymes that regulate the cell cycle. Mutations

in genes that regulate the cell cycle are present in a majority of human cancers. Pfizer has
initiated clinical development with a lead candidate from that collaboration, a small molecule
cell cycle inhibitor targeting cyclin-dependent kinase 4. Onyx has over 100 employees, primarily
in development, sales and marketing.
Optimata
7 Abba Hillel Street | Ramat-Gan 52522 | Israel

Phone: +972.3.751.9226 | Fax: +972.3.751.9229 | Website: www.optimata.com
Contacts
Dr. Alexander Chausovsky | VP Product Development
Industry Sector
Health Care
Company Overview
Overview
Optimata Ltd. is a modeling based biopharmaceutical company that develops computerized

tools, Virtual Patient engines, for navigating drug development towards better drugs, faster.
Using its proprietary technology, Optimata identifies derailed drug candidates and redirects their
clinical development path to market. Using bio-mathematics to develop a predictive bio-
simulation software toolkit, this technology provides a comprehensive drug development
solution, from the pre-clinical phase through treatment personalization. It thoroughly unfolds
drug<=>patient dynamic interactions, enabling drug developers to perform rapid virtual clinical
trials and to forecast optimal drug regimen<=>patient population<=>clinical indication match for
a given trial end point.
Core Business
Optimata has a two pronged approach to partnering:
 Discontinued oncology compounds - Optimata seeks to in-license those compounds and

use its Virtual Patient technology to redirect their path towards market approval.
 Supporting marketed drugs and drug candidates - Optimata offers to collaborate with
bio/pharma companies to reduce time to market and development costs and increase
success rate through the clinic.

Optimata Virtual Patient® (OVP) Technology as a Strategic Planning Tool enables to:
 Identify the best indication for a compound

 Early GO/NO-GO decision (before phase II)
 Predict benefit of new compound over gold standard
 Drug Revival
 Select the most appropriate schedules / drug combination per sub-population
Optimata has already several compounds in its pipeline, it plans to reinforce its business
development and licensing activities and continue in-licensing discontinued
oncology compounds and carry out phase II trials.
Optimata also keeps on supporting existing drugs and drug candidates by collaborating with
bio/pharma companies to reduce time to market and development costs and increase success rate
through the clinic.
Optimata is interested to meet with:

1) Pharma/biopharmaceutical companies interested in out-licensing oncology compounds.
2) Investors
Optimata's goals for attending the Annual Meeting:

1) To introduce a new and unique business model of reviving compounds in new
indications after they have failed in their initial indication (Dr. Chausovsky will be chairing the
session ”Licensing Assets to Repurpose in New Indications” on October 22 at 02:00 p.m (EDT)).
2) To initiate discussions regarding collaborations, in-licensing opportunities etc.


Partnering
Optimata Virtual Oncology,
Patient® Haematology
Oregon Health & Science University
2525 SW 1st Ave, Suite 120 | Portland Oregon 97201 | United States
Phone: 503-494-8200 | Fax: 503-494-4729 | Website: www.ohsu.edu/tech-transfer
Contacts
Dr. Michele Gunness | Senior Licensing Associate
Organization Type
Industry Sector
Company Overview
As Oregon's only health and research university, OHSU brings together education, research,
patient care and community service. While each component has its own individual goals and
mission, all of them are bound together by a common vision - to improve the well-being of
Oregonians.
The Office of Technology & Research Collaborations at OHSU has the mission to support the
university's research community by facilitating and managing research collaborations and
business partnerships, and promote a culture of innovation and entrepreneurship which enables
the transfer of research from the laboratory to the market for the benefit of the public.
OHSU has technologies available for licensing in the following areas: Diagnostics,
Therapeutics, Medical Devices, Dentistry, Engineering and Physical Sciences, Speech and
Language, Education and Training, and Vaccines. OHSU has a strong focus in the areas of
Cancer, Cardiology, Dermatology, Endocrinology, Immunology and Infectious Diseases,
Neurology and Reproductive Biology.
Further information can be found at http://www.ohsu.edu with a listing of technologies available

for licensing via the Office of Technology & Research Collaborations site
at http://www.ohsu.edu/tech-transfer/index.shtml

Organon de Brasil
Rua João Alfredo No. 353 | São Paulo SP 04747-900 | Brazil

Phone: 55 11 3882 4500 | Fax: 55 11 3882 4583 | Website: www.organon.com.br
Contacts
Mr. Wagner Messa | New Business Manager
Organization Type
Industry Sector
Health Care
Organon International, Inc.
56 Livingston Ave | Roseland 07068 | United States

Phone: +31 (412) 669369 | Website: www.organon.com
Contacts
Dr. Fernando Salles | Sr. Dir. Global Strategy and Portfolio Management
Company Overview
Organon is a mid-sized global biopharmaceutical company renowned for holding leading

positions in gynecology (contraception / menopausal therapy), fertility and selected areas of
anesthesia; and positioned for further growth. The company is poised to rebuild its neuroscience
franchise, and is expanding its biotechnology expertise with a focus on immunology and
oncology as an additional long-term growth driver.
R&D is our backbone: our goal is the development of high quality products that substantially
benefit human health and address unmet needs. Our robust pipeline in both the early and late
phases of development reflects our commitment to research in our four core therapeutic fields:
gynecology, fertility, anesthesia and neuroscience. We are actively expanding our biotechnology
expertise.
Organon is actively expanding its solid and long-standing biotechnology platform through a
Global Biotechnology Initiative in order to pursue new biological entities to diversify into new
therapeutic fields (immunology and oncology), while continuing its traditional experience in
developing and marketing new chemical entities (NCEs).

 Our Cambridge (Mass., US) research facility (opened in June 2005) and our Global
Biotechnology Initiative will fuel our future pipeline through expanded research activities
into new biological entities (NBEs); this will also be done by seeking partnerships and
through strategic acquisitions.
 Biotech research not only supports our existing therapeutic areas (such as the
development of Org 36286, a long-acting fertility treatment), but will also allow us to
pursue new opportunities in the fields of immunology and oncology.
 Organon already offers full-service biopharmaceutical contract manufacturing services

for recombinant products, to support pre-clinical, clinical as well as commercial
production, allowing us to grow as a ‘one-stop shop’ in NBEs.
Organon actively seeks and develops partnership to complement our extensive experience in-
house believing that the best way to deliver long-term success is through partnerships and
teamwork – whether that is with research partners, academia other companies, customers and
healthcare professionals or the communities in which we work.
We are actively looking for products and compounds in the psychiatry space that have
promotional needs or require development collaboration.
 As a mid-sized company, our strong emphasis on partnerships give us access to expertise

that complements that available in-house and critical mass where needed while allowing
the company to remain more flexible, dynamic and creative than many of our larger
competitors.
 We believe we make a good partner because we understand that a partnership has to be

about mutual satisfaction and success. We treat our partners with respect and as
colleagues.
 We have active partnerships with more than fifty companies and organizations all over
the world, including a large number in the USA and an increasing number in Asia
(China).
 We are committed to developing more and different types of long-term partnerships,

using our partnership expertise and culture as a strength and working with emerging
economies in particular as a source of collaborations.

We are actively looking for products and compounds in the psychiatry space that have
promotional needs and/or require development collaboration. Please contact our Business
Development Representatives at LES for further discussion.
OSI Pharmaceuticals, Inc.
58 South Service Road | Melville NY 11747 | United States

Phone: +1.631.962.2116 | Fax: +1.631.962.2021 | Website: www.osip.com
Contacts
Mr. David Ghesquiere | VP, Corporate & Business Development
Dr. Graeme Griffin | Senior Manager - Business Development
Dr. Lan Hu | Senior Director, Business Development
Company Overview
OSI Pharmaceuticals is committed to “shaping medicine and changing lives” by developing and
commercializing high-quality and novel pharmaceutical products that extend life or improve the
quality of life for patients with cancer, diabetes, and obesity.
We specialize in the discovery and development of innovative molecular targeted therapies that
address significant unmet medical needs, and strive to turn pioneering science into breakthrough
therapies for patients suffering from life-threatening diseases.
Our Oncology business is anchored by our flagship product, Tarceva® (erlotinib), a small
molecule inhibitor of the epidermal growth factor receptor, or EGFR, that was first discovered
and developed by OSI. Tarceva is the only EGFR inhibitor to have demonstrated the ability to
improve overall survival in advanced non-small cell lung cancer and advanced pancreatic cancer.
Behind Tarceva, we have an emerging oncology pipeline of molecular targeted therapies in
clinical and late-stage pre-clinical development. Our R & D strengths include high-throughput
screening, chemical libraries, medicinal and combinational chemistry and automated drug
profiling technology platforms.
Our diabetes and obesity R & D programs are conducted through Prosidion Limited, our U.K.
subsidiary dedicated to the discovery and development of novel therapies for metabolic diseases,
particularly type 2 diabetes and obesity. (OSI) Prosidion has an emerging diabetes and obesity
clinical pipeline with several innovative drug candidates that have progressed into clinical
development.
OSI has a dedicated team of approximately 500 research and development, regulatory, sales,
marketing, commercial, and business professionals. We are headquartered in Long Island, New
York with facilities in Colorado, New Jersey and the United Kingdom.

Oyen Wiggs Green & Mutala LLP
480 The Station | 601 West Cordova Street | Vancouver BC V6B 1G1 | Canada
Phone: (604) 669-3432 | Fax: (604) 681-4081
Contacts
Mr. Richard A. Johnson | Lawyer and Patent Agent
Mr. Hilton W.C. Sue | Lawyer/Patent Agent/Trademark Agent
Organization Type
Law Firm
Company Overview
IP law firm located in Vancouver, with mechanical, electrical, chenmical, biotech, licensing and
litigation expertise.
Pachira IP
3730 Richmond Road | Suite 214 | Ottawa ON K2H 5B9 | Canada

Phone: (613) 829-0067 Ext. 220 | Fax: (613) 829-6219
Contacts
Mr. Steven Adam | Vice President, Business Development
Mr. Michael Barry | Vice President, Licensing
Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
Pachira IP has deep roots in the semiconductor and microelectronics industries and is an
authority on helping patents owners extract financial value from their patents. Pachira IP
is the only one-stop-shop for semiconductor and microelectronics patent owners looking to
license or sell their patents.
Pachira IP, whose experts have participated in hundreds of licensing programs, serves
customers around the world.


We conduct offensive patent licensing campaigns. We also sell patents for clients.
Paladin Labs Inc.
6111 Royalmount Avenue | Suite 102 | Montréal Quebec H4P 2T4 | Canada
Phone: +1.514.340.5052 | Fax: +1.514.344.4675 | Website: www.paladinlabs.com
Contacts
Mr. Mark H. Nawacki | Vice President, Business & Corporate Development
Ms. Janis Peleshok | Director, Business Development
Mr. Farrukh Rehan | Director, Coporate Development
Organization Type
Industry Sector
Health Care
Company Overview
Established: 1996
Date Listed on TSX: 2000
Number of Employees: 105
Industry Sector: Life Sciences / Biotech
Paladin Labs Inc. is a rapidly growing pharmaceutical company that is focused on acquiring or
in-licensing specialty pharmaceutical products. With a seasoned national sales force calling on
specialty physicians, Paladin is one of Canada’s most profitable publicly traded pharmaceutical
companies.
Palo Alto Research Center
3333 Coyote Hill Road | Palo Alto CA 94304 | United States

Phone: (650) 812-4021 | Fax: (650) 812-4274
Contacts
Mr. Damon Matteo | Vice President & Chief Intellectual Property Officer

Panasonic Corporation of North America
c/o Amster, Rothestein & Ebenstein LLP | 90 Park Avenue | New York NY 10016 | United States
Phone: (212) 336-8000 | Fax: (212) 336-8001
Contacts
Mr. Takao Saito | Senior IP Specialist
Industry Sector
Consumer Products
PARAGON Development
1485 Dunbar Hill Road | Hamden CT 6514 | United States

Phone: (203) 288-4154 | Fax: (203) 288-4215
Contacts
Mr. Jack T. Peregrim | President
Organization Type
Consulting Firm
Company Overview
PARAGON has pioneered the Voice-of-Market(TM) process where we employ our 40,000+
experts to create new value from client's technologies. (Licensing, commercial development,
partners, etc). Our clients are not industry specific but they do represent a large percentage of the
Global 400 corporations.

Business strategy and technology development

Meet clients with technologies looking to evaluate, valuate, and capture optimal value from
them.
Parsa Wireless Communications
1081 East Putnam Avenue | Suite #7 | Greenwich CT 6878 | United States

Phone: (203) 504-2544 | Fax: (203) 504-2545 | Website: www.parsawireless.com
Contacts
Mr. Joseph E. Sabella | Director of Business Development

Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
Parsa Wireless Communications (www.parsawireless.com) is a consulting firm and subject
matter experts on wireless communications based in Greenwich, Connecticut. We provide IP
professionals with key services such as IP evaluation, patent mapping or expert witness
testimony that might be required in the wireless communications area.
A sample of the patent services provided are:
 Quick analysis service:

o Patent assessment
 Detailed analysis service:
o Patent mapping to various technologies and products:
o Preparation of infringement claim charts
o Preparation of power-point mapping for licensing purposes
 Preparation of invalidity charts
We can also help evaluate wireless IP that firms may be considering to sell, purchase
or considering an investment.
Additionally, we offer innovation services to create wireless IP for clients and provide training in
wireless communications.

Wireless Communications: Hardware, software, semiconductor chips and systems architecture
Patents
Litigation
Tech transfer
Valuation
Training
University research.

Wireless Technology companies
- Hardware
- Software
- Systems designers
- Semiconductor companies
Wireless Service providers
IP Firms
Law firms representing wireless technology companies
Promote Parsa Wireless services
Meet potential clients
Partners HealthCare System, Inc.
101 Huntington Avenue | 4th Floor | Boston MA 02199 | United States

Phone: (617) 954-9394 | Fax: (617) 954-9356 | Website: www.partners.org/rvl; www.hpcgg.org
Contacts
Ms. Mary Auge | Manager, Business Development
Patentanwaltskanzlei Blickle
Marienstrasse 28 | Stuttgart 70178 | Germany

Phone: (0049)711-6698234 | Fax: (0049)711-6698210
Contacts
Mr. Werner K. Blickle | European Patent and Trademark Attorney

PatentBridge LLC
2460 Sand Hill Road | Suite 101 | Menlo Park CA 94025 | United States
Phone: (650) 233-1150 | Fax: (650) 257-4023
Contacts
Mr. Mark Holmes | CEO
PatentCafe
United States
Phone: 9999999999
Contacts
Mr. Andrew H. Gibbs | President & CEO
Mr. David Schab | Vice President Sales
PATEV GmbH & Co. KG
Albert-Einstein-Strasse 62 | Karlsruhe 76228 | Germany

Phone: +49-721-945 40 60 | Fax: +49-721-947 34 53
Contacts
Dr. Alexander J. Wurzer | Managing Director
Paul Capital Partners
140 E 45th St, 44th Floor | New York New York 10017 | United States
Phone: 646-264-1100 | Website: www.paulcapitalhealthcare.com
Contacts
Mr. John R. Leone | Partner
Mr. Matthew L. Wotiz | Associate
Company Overview
Paul Capital Partners established Paul Capital Healthcare in 1999 to meet the financing needs of
healthcare companies, institutions and inventors. Today, the firm manages one of the largest
dedicated healthcare funds globally with a total of $1.4 billion in assets under management. Paul
Capital Healthcare has offices in New York, San Francisco, and London.

The Fund focuses on commercial stage healthcare products and investment opportunities in
North America, Europe and Asia. To date Paul Capital Healthcare has closed more than 30
investments in the pharmaceutical, biotechnology, medical device and diagnostics areas. Public
and private companies, research institutions and universities, and individual inventors have all
benefited from the flexibility of Paul Capital Healthcare’s investment approach. This capital has
enabled them to transfer product risk, finance clinical and commercial development projects,
acquire new products, fund university programs and capital needs, avoid conflicts of interest,
unlock shareholder value and monetize product royalties.
Paul Capital Healthcare plays a passive or active role in its investments depending on the
structure and size of the transaction. As active participants the Fund may take a seat on the board
of directors or have board observer rights.
Focus: Commercial stage healthcare products and investment opportunities
Investment Size: $20-$100+ million
Investment Characteristics: Royalty, revenue interest, debt, equity and hybrid structures
Term of Investment: 5-10+ years
Please visit our website http://www.paulcapitalhealthcare.com for more details on our

investment criteria and portfolio companies and institutions.
Perception Partners
768 Marietta St NW | Suite 102 | Atlanta GA 30318 | United States

Phone: 404-523-5990 | Fax: | Website: www.perceptionpartners.com
Contacts
Mr. Barry Brager | Managing Partner
Dr. Jeffrey M. Davidson | Chief Operations Officer
Organization Type
Consulting Firm
Industry Sector
Health Care
Company Overview
Perception Partners provides strategic insights that inform better business decisions about
leveraging innovation. Our team of experts assists in matters of technology investment, business
development and IP exploitation. Our clients gain greater certainty about IP value and risk in

user-friendly analytic reports that can be quickly read and understood.
We specifically offer:
Technology Investment
 Frontier Research
 R&D Collaboration
 Competitive Technical Intelligence
Business Development
 Technology Scouting
 Product Commercialization
 Mergers & Acquisitions
IP Exploitation
 Portfolio Optimization
 IP Valuation & Monetization
 Litigation Forecasting
Our firm collaborates with a world-class team of more than 200 technical, legal and business IP
specialists. Please stop by our booth at the Tech Fair to learn how we influence perception - the
intellectual component of value - to bring our clients an IP Advantage.(TM)

IP valuation, infringement analysis, licensee identification, technology scouting, competitive
technical intelligence, landscape analysis, IP due diligence

Biomedical Device, Pharmaceutical, Chemicals, Energy, Materials, Health Care, Consumer
Products

Research collaborations with new customers by providing contract patent analytics services

Partnering

IP Screening and Due

Diligence
IP Valuation n/a Not Applicable Worldwide
Patent Litigation
Analysis
Patent Mining and
Mapping
PerkinElmer, Inc.
940 Winter Street | Waltham MA 02451 | United States

Phone: (781) 663-5832 | Website: www.perkinelmer.com
Contacts
Mr. John A. Hamilton | IP Licensing Counsel
Industry Sector
Health Care
Company Overview
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences
and Photonics markets to improve the quality of life. A few examples of where we are focusing
our efforts are genetic screening, medical imaging, biodiscovery, analytical sciences and lab
services. We have many technologies available for out license.
Pfizer Animal Health
150 E 42nd St. | New York New York 10017 | United States
Phone: 212-733-4091
Contacts
Dr. Peggy Dillender | Director, Strategic Business Initiatives
Organization Type
Industry Sector
Health Care
Company Overview
Pfizer Animal Health is the world's largest animal health company (2006 sales >US$3 bn), with

leading vaccines and pharmaceutical products for companion animals, livestock and poultry.
Recent acquisitions have expanded our interest in animal genetic testing products and markers.
We seek to in-license products that we can develop for use in animal health amd productivity.
We have a long history of collaboration and development projects with universities, biotechs,
and small and large pharma companies.

Identify potential partners with technologies applicable to animal health.
Pfizer Inc.
201 Tabor Road | Morris Plains NJ 07950-2614 | United States

Phone: (973) 385-5041 | Fax: (973) 385-2151
Contacts
Ms. Stefanie Hansen | Director
Ms. Kelly Longo | Director
Ms. Christina C. Wan | Director, Worldwide Business Development
Company Overview
Pfizer is one of the world’s leading pharmaceutical companies. Our medicines help over 150
million people a year worldwide. At Pfizer, we dedicate ourselves to humanity's quest for
longer, healthier, happier lives through innovation in pharmaceutical and animal health
products. With 2006 R&D expenses of $7.5 billion, Pfizer Global Research and Development is
the world's largest privately funded biomedical research organization. We have links with more
than 250 partners in academia and industry to strengthen our position on the cutting edge of
science and biotechnology.
Phillips Lytle LLP
Omni Plaza | 30 South Pearl Street | Albany NY 12207 | United States

Phone: (518) 472-1227 | Fax: (518) 472-1227 | Website: www.phillipslytle.com
Contacts
Mr. Richard Honen | Partner
Ms. Kelly Mooney Lester | Partner
Organization Type
Law Firm
Company Overview

Phillips Lytle has the reputation as a premier law firm for companies doing business in New
York State. We provide representation to some of America's best companies and global financial
institutions with complex litigation, high-end disputes or transactions, and sophisticated
commercial and lending matters in New York State.
Our clients come to us because they need attorneys committed to solving their problems with
intelligence and creativity. Phillips Lytle has been forming, guiding, and representing a
distinquished client roster that includes companies from as far back as 1867 - Fortune 500
corporations, global financial institutions, mid-size clients, new companies and ventures on the
cutting edge, not-for-profit organizations, and local companies.
Pluritas
731 Market Street | 6th Floor | San Francisco CA 94103 | United States
Phone: (415) 354-1760 ext 104 | Fax: (415) 869-9710 | Website: www.pluritas.com
Contacts
Mr. Robert Aronoff | Managing Director
Mr. Anderson Scott | Partner
Organization Type
Financial Services
Industry Sector
High Technology
Company Overview
Experts in transacting Intellectual Properties.
Pluritas is a transaction advisory firm specializing in divestitures, acquisitions, and mergers

where Intellectual Property (IP) is a major component of the transaction.

Companies, Universities, and other entities that have Intellectual Property they would like to
transact -- buying or selling.
PLx Pharma Inc.
8285 El Rio | Suite 130 | Houston TX 77054 | United States

Phone: +1.713.842.1249 | Fax: +1.713.842.3052

Contacts
Mr. Ronald Zimmerman | CEO
Organization Type
Industry Sector
Health Care
Company Overview
PLx Pharma is a pharmaceutical company developing novel formulations of drugs to improve

their safety and therapeutic effectiveness. Products include:
PL 1100 Ibuprofen-PC 400mg is an Rx product which in an endoscopy trial in osteoarthritic

patients over 55 years of age has demonstrated enhanced GI safety for market
differentiation. This formulation uses the surfactant qualities of Phosphatidylcholine
(PC) formulated with ibuprofen to mitigate GI toxicity. As ibuprofen and PC are previously
approved FDA products an accelerated 505(b)(2) regulatory path is available for expedited
approval. Additional endoscopy trials are planned for differentiation to support a product
launch.
PL 1200 Ibuprofen-PC 200mg is an OTC product that is in late stage development and with a
launch potential within two years and could be the first GI safer ibuprofen product in the multi-
billion dollar OTC analgesic market.
PL 2200 Aspirin-PC 325mg is an OTC product that has demonstrated 70% less gastric lesions
than aspirin in a pilot endoscopy clinical trial and recently demonstrataed anti-platelet
and bioequivalence in a PK/PD trial. This formulation may represent the next generation GI
safer aspirin for chronic use for its cardiovascular benefits and at higher doses for analgesic and
anti-inflammatory efficacy as well as chemo-prevention.
PL 3100 Naproxen-PC 250mg is an Rx product in the formulation optimization and final IND
preparation stage. This GI safer naproxen formulation has blockbuster potential to be the
preferred chronic treatment for osteoarthritis given its cardiovascular and GI safety profile.
Using the 505(b)(2) path combined with endoscopy trials for product differentiation this product
could be approved and launched within two - three years.
PL 9100 5ASA-PC is an Rx product being jointly developed with Cambrex Corp. (leading
supplier of 5-ASA). This PC formulation is demonstrating in pre-clinical studies a substantially
enhanced therapeutic effectiveness of 5-ASA when complexed with PC and may reduce the
capsule count burden for this 'gold standard' Ulcerative Colitis therapy.
PL 4500 Indomethacin-PC IV is an Rx product under development for Patent Ductus Arteriosus,

a congenital heart condition in underweight premature infants. Pre-clinical studies suggest a

dramatically GI safer formulation that has the potential to mitigate severe GI side effects of the
current indomethacin IV therapy.
This platform is applicable to many NSAIDs for oral and IV dose forms (for post operative
pain with opiate sparing attributes) with pre-clinical data on several additional products in
development.
GI toxicity induced by NSAIDs is multifactorial. While selective Cox-2 inhibition may partially
protect the GI mucosa, this approach does not protect against surface injury to the GI
tract. NSAIDs are weak acids that specifically bind to PC, erode the mucosa and allow acid to
penetrate. PC is a normal component of the GI tract that prevents such acid penetration. By pre-
associating NSAIDs with PC, this topical mucosal damage is dramatically reduced.

PLx will be seeking Pharma partners to commercialize its products. There is a wide range of
products needing different counterparties. These include large market oral products that address
Rx and OTC multi-billion markets as well as specialty pharma products for niche
indications such as IV products for the hospital care setting.

PLx would like to meet with companies seeking to in-license Rx and OTC products.
Country(s)
Partnering
PL 1100 Ibuprofen- Arthritis, pain, inflammation,
Phase II Worldwide
PC 400mg Rx fever
PL 1200 Ibuprofen-
Pain, inflammation, fever Phase III Worldwide
PC 200mg OTC
PL 2200 Aspirin-PC
Pain, fever, cardiovascular Phase I Worldwide
325mg OTC
PL 3100 Naproxen-
arthritis, pain, inflammation Preclinical Testing Worldwide
PC 250mg Rx
PL 4500
pain, inflammation, patent
Indomethacin-PC IV Preclinical Testing Worldwide
ductus arteriosus, PDA
Rx
PL 9100 5ASA-PC IBD, ulcerative colitis,
Preclinical Testing Worldwide
Rx inflammation
PL NSAID-PC IV - post operative pain, fever Preclinical Testing Worldwide

various Rx
PL NSAID-PC Oral
pain, inflammation, gout Preclinical Testing Worldwide
Various Rx
Posner Associates
2232 N. Stone Ridge Lane | Villanova PA 19085 | United States

Phone: (610) 525-1153 | Fax: (610) 525-1153
Contacts
Mr. Ernest G. Posner | Principal
Prasco Laboratories
7155 E. Kemper Road | Cincinnati OH 45249 | United States

Phone: 513-618-3333 | Fax: 513-618-3344 | Website: www.prasco.com
Contacts
Mr. Jonathan Lapps | VP Business Development
Mr. Otis K. Ranson | Regional Vice President, Business Development
Company Overview
Prasco has ascended to the leadership position in Authorized Generics. As one of the fastest
growing pharmaceutical companies in the industry, Prasco has successfully launched the largest
number of Authorized Generics in the industry.
Using its unique background and experience in both the branded and generic businesses, Prasco
has developed a business model that allows pharmaceutical companies to optimally extend the
lifecycle of select branded products faced with current or near-term generic competition. This
model calls for Prasco to market those products as Prasco Authorized Generics under the Prasco
label, and share profits with the brand company.
Prasco’s advantage is the completeness of the company’s approach to its partnerships and
relationships. To best execute these relationships, Prasco has constructed a tightly-knit, team-
based infrastructure to minimize the amount of partner management time and resources to
implement the plan.
PricewaterhouseCoopers LLP
250 Howe Street, Suite 700 | Vancouver BC V6C 3S7 | Canada

Phone: +1 604 806 7000 | Fax: +1 604 806 7806
Contacts
Mr. Phillip Barnett | Managing Director

Mr. Jonathan Kurtz | Director, Client Services

Mr. Jeff Leedom | Director
Mr. David L. Marston | Partner
Company Overview
PricewaterhouseCoopers (www.pwc.com) provides industry-focused assurance, tax and advisory

services to build public trust and enhance value for its clients and their stakeholders. More than
146,000 people in 150 countries across our network share their thinking, experience and
solutions to develop fresh perspectives and practical advice. Now celebrating 100 years of
excellence in Canada, PriceaterhouseCoopers LLP (www.pwc.com/ca) and its related entities
have more than 5,200 partners and staff across the coutnry.
PricewaterhouseCoopers is proud to be a sponsor of BioPartnering North America for the sixth

consecutive year.
Contacts
Mr. Tracy Lefteroff, Global Managing Partner, Life Sciences Services.

Tracy.t.lefteroff@us.pwc.com
Mr. John DeLucchi, Canadian Leader, Technology Group john.delucchi@ca.pwc.com
Mr. Gord Jans, Canadian Leader, Life Sciences Group, gordon.r.jans@ca.pwc.com
Mr. Dennis Blumenthal, Partner, Tax services, dennis.b.blumenthal@ca.pwc.com

Mr. Don Furney, Partner, Tax services, don.furney@ca.pwc.com
Mr. Ian Gergovich, Partner, Tax services, mailto:ian.gergovich@ca.pwc.com
Mr. Ian Heine, Senior Manager, Tax services, ian.heine@ca.pwc.com
Ms. Isabelle Pepin, Director, Audit and Assurance services, isabelle.pepin@ca.pwc.com
Ms. Lisa Simeoni, Partner, Audit and Assurance services, lisa.simeoni@ca.pwc.com
Mr. Randy Garg, Senior Advisor, Corporate Finance, randy.garg@ca.pwc.com
Mr. Phillip W. Barnett, Managing Director, Knowledge Services, phil.barnett@us.pwc.com
Ms. Mary Shelton Rose, Partner, Advisory/Licensing Management,
mary.shelton.rose@us.pwc.com
Mr. Geoffrey H. Osborne, Partner, Advisory/Crisis Management,
geoffrey.h.osborne@us.pwc.com
Mr. David L. Marston, Partner, Advisory/Licensing Management, david.l.marston@us.pwc.com
Licensing Compliance and Controls

Compliance and controls includes the stewardship of licenses: The PricewaterhouseCoopers

Licensing Management Services Practice is a globally integrated network of fully dedicated
licensing professionals committed to helping companies optimize their revenues, capitalize on
and protect their intellectual property, and successfully manage risk. By identifying potential
levels of under-reported royalties and internal control improvements, we help ensure more
accurate and independent reporting with diplomacy and global reach. Visit us at
www.pwc.com/us/licensing.
Leadership in the Life Sciences Sector
PricewaterhouseCoopers (PwC) is the recognized leader in providing professional services to the

life sciences and pharmaceutical sectors. We provide audit services to 40% of the largest public
biotechnology companies, 45% of the largest public medical device and diagnostic companies
and 55% of the world’s top 50 pharmaceutical and healthcare products companies. We provide
tax and advisory services to 75% of the world’s largest pharmaceutical and life sciences
companies. PwC also provides professional services to a significant number of the most active
venture capital and private equity funds in the United States and Canada.
When you work with PwC, you join our extensive network of industry clients and contacts. We
can quickly put you in touch with the people you need to know.
Whether your company is a growing start-up, mature multi-national, or somewhere in between,

we can assist you with today’s business issues and help you prepare for those that lie ahead.
Industry Research and Resources
PwC provides timely and relevant information on business issues and trends affecting the life
sciences sector. We regularly publish research and host discussions on topics such as emerging
business trends in the life sciences sector, public equity markets, alternative funding
arrangements, partnering, mergers and acquistions, merger integration, and talent management.
On-line publications and resources include:
www.pwc.com/tech: PwC’s global technology home page

www.pwc.com/ca/lifesciences: PwC Canada’s life sciences home page
www.pwcv2r.com: A program serving companies with extraordinary potential
www.pwcmoneytree.com: quarterly survey of venture capital investment
www.pwcvc.com: venture capital best practices survey

Princeton University
Office of Technology & Licensing | 4 New South Bldg | Princeton NJ 8540 | United States
Phone: (609) 258-1570 | Fax: (609) 258-1159
Contacts
Mr. John F. Ritter | Director, OTL
Procter & Gamble Co.
11810 East Mimai River Road | Cincinnati Ohio 45253 | United States
Phone: + 1 513 627-0822
Contacts
Mr. Michael Miller | Associate Director, External Business Development
Ms. Mary L. Ralles | External Relations Manager
Company Overview
The Procter & Gamble Company (NYSE: PG) is the largest consumer goods company in the
world with global sales of more than $80 Billion and its mission is to improve the lives of the
world's consumers. The Corporate Bioscience Business Development Group is seeking
bioscience related technologies to improve P&G's products and make them even more
competitive in the marketplace. Product focus areas are: OTC respiratory, GI, pain, and oral
care; skin and hair health and beauty; female uro-genital health; dog and cat health; microbe
control and cleaning products. Technologies of interest range from entities that elicit beneficial
biological response in consumers (bioactives) to technologies that used in product formulation
(e.g., biopolymers) and testing (e.g., pre-clinical and clinical). We are primarily interested in
non-Rx products and technologies.
Procter & Gamble Pharmaceuticals, Inc.
8700 S. Mason Montgomery Road | Mason OH 45040 | United States

Phone: (513) 622-3649 | Fax: (513) 622-5328
Contacts
Dr. Kevin E Driscoll | Executive Director, Global New Business & Technology Development
Mrs. Rimma S. Driscoll | Director, Licenising and Acquisitions

PTC Therapeutics, Inc.
100 Corporate Court | South Plainfield NJ 07080 | United States

Phone: +1.908.222.7000 | Fax: +1.908.222.7231 | Website: www.ptcbio.com
Contacts
Dr. Morgan Conn | Senior Director, Business Development
Company Overview
PTC THERAPEUTICS, INC. (PTC) is a biopharmaceutical company focused on the discovery,

development and commercialization of orally administered, proprietary small-molecule drugs
that target post-transcriptional control processes. Post-transcriptional control processes regulate
the rate and timing of protein production and are of central importance to proper cellular
function. PTC has assembled proprietary technologies and extensive knowledge of post-
transcriptional control processes that it applies in its drug discovery and development activities.
PTC's current pipeline of clinical and preclinical product candidates addresses multiple
therapeutic areas including genetic disorders, oncology, and infectious diseases.
PTC's Programs and Technology
PTC's lead drug candidate, PTC124, is currently in Phase 2b registration-directed clinical trials
for the treatment of cystic fibrosis and Duchenne muscular dystrophy. PTC124 is a novel drug
for the treatment of genetic disorders due to nonsense mutations. PTC124 induces the cellular
translation machinery to read through nonsense mutations, inducing production of full-length,
functional proteins. PTC124 has demonstrated proof of concept in phase 2a clinical trials. Across
all clinical studies to date, PTC124 has been generally well tolerated. PTC believes that PTC124
represents a unique opportunity to use a single small-molecule drug to address multiple chronic
and life-threatening diseases of high unmet medical need.
PTC has developed a proprietary drug discovery technology called GEMS (Gene Expression
Modulation by Small-molecules) which exploits the regulatory mechanisms found in the
untranslated regions of messenger RNA to identify small-molecule drugs that can treat diseases
by selectively increasing or decreasing the expression of key proteins. The ability to identify
orally bioavailable molecules that modulate the expression of specific proteins in cells also
allows PTC to pursue targets currently only addressed by protein drugs. PTC has successfully
employed the GEMS technology in several drug discovery programs across multiple therapeutic
areas, including oncology, infectious diseases, and neuromuscular disorders. GEMS is being
utilized in multiple therapeutic areas as the basis for collaborations with leading pharmaceutical
and biotechnology companies such as Pfizer, Celgene, CV Therapeutics, and Schering-Plough.

PTC299 is a novel, orally administered, small molecule designed to inhibit the production of
VEGF. PTC299 was discovered through PTC’s GEMS technology by targeting the post-
transcriptional processes that regulate VEGF synthesis. PTC is currently developing PTC299 for
the treatment of cancer, and has conducted multiple in vitro and in vivo preclinical studies of
PTC299. Key findings of these studies include:
• PTC299 is a potent inhibitor of production of all VEGF splice variants in vitro. PTC299
demonstrates a broad range of activity blocking VEGF synthesis in multiple tumor types,
including breast, cervical, colorectal, fibrosarcoma, gastric, lung, melanoma,
neuroblastoma, ovarian, pancreatic, prostate, and renal cell cancer lines.
• Single agent oral dosing of PTC299 significantly inhibited human VEGF levels within
tumors and plasma, reduced tumor microvessel density, and promoted substantial delay
of tumor progression when tested in multiple tumor xenograft models. In addition,
PTC299 was shown to be complementary when given in combination with
chemotherapeutic agents. The enhanced efficacy observed with a combination of PTC299
and anti-VEGF treatments in tumor studies demonstrates the advantage of targeting the
VEGF pathway through multiple mechanisms.
75. PTC has completed single-dose and multiple-dose Phase 1 studies in healthy volunteers
with no clinically significant toxicities observed. All doses tested in the multiple-dose
study achieved or exceeded the target plasma concentrations that were established from
studies using mouse models. PTC299 is now being studied in a Phase 1b study in patients
with solid tumors and a Phase 1b/2 study in women with breast cancer. A Phase 1b/2
study in patients with human-immunodeficiency (HIV)-related Kaposi sarcoma will
initiate shortly.
Country(s)
Partnering
Oncology, Inflammation,
GEMS
Metabolic Disorders, CNS, Preclinical Testing Worldwide
Technology
Infectious Diseases

Pullan Consulting
4400 Paseo Santa Rosa | Newbury Park CA 91320 | United States

Phone: (805) 558-0361
Contacts
Dr. Linda M. Pullan |
Organization Type
Consulting Firm
Industry Sector
Health Care
Company Overview
Pullan Consulting (www.pullanconsulting.com) provides help in all aspects of partnering for

therapeutics, from designing a presentation or a teaser communication, to making contacts and
representing you in partnering discussions, to evaluations and valuations, to negotiations. Linda
Pullan has over 20 years of experience in the industry with a background in drug discovery at
what is now Pfizer and AstraZeneca and in licensing and business development at AstraZeneca,
Amgen and Kosan Biosciences. How can Pullan Consulting help you?
lpullan@msn.com cell: 805-558-0361

Linda Pullan of Pullan Consulting (http://www.pullanconsulting.com/) would like to talk to
companies potentially interested in licensing the therapeutic candidates of her clients. Linda
would also like to discuss ways I might work with your company to help your partnering efforts,
from designing messages, to making contacts, to evaluations and valuations, to negotiations.

I would like to meet with companies interested in licensing-in therapeutic drug candidates or
therapeutic companies interested in help with their partnering efforts.

Out-licensing drug candidates for a variety of clients. Research collaborations. Finding
customers for business development consulting.

Country(s)
Partnering
Affitech antibody discovery cancer, infection Not Applicable
Airmid Kv1.3 inhibitors for autoimmune, MS, RA,
Not Applicable
autoimmune disorders type 1 diabetes, psoriasis
Array's preclinical cancer
cancer Not Applicable
programs
Attenuon's small molecule
Crohn's, inflammation Not Applicable
for Crohn's
Attenuon's small molecule in
cancer Not Applicable Worldwide
clinical for cancer
Attenuon's uPAR Antibody
for cancer
Cara Therapeutic's
cannabinoid for inflammation, pain,
inflammation, pain, overactive bladder
overactive bladder
Cara Therapeutics peripheral
pain, CNS Not Applicable Worldwide
kappa agonists for pain
Chembridge kinase inhibitor cancer, inflammation,
Not Applicable
collection asset sale others
ImmunGene next gen cancer, rheumatoid
Not Applicable
antibodies arthritis, inflammation
Neumedicine's radiation cancer, radiation
Not Applicable
chemo protection poisoning
Suven's small molecule for Alzheimer's,
Not Applicable
Alzheimer's schizophrenia, cognition
Viriome's small molecules HCV, hepatitis, anti-
Not Applicable
for HCV viral, infection
Zenobia's fragment based
CNS, others Not Applicable
lead discovery
Purdue Pharma, L.P.
One Stamford Forum | 201 Tresser Blvd | Stamford Connecticut 06901 | United States
Phone: +1.203.588.8000

Contacts
Mr. James Dolan | Senior Vice President
Mr. Allen Downs | Sr. Exec. Director, Licensing & Bus. Dev.
Ms. Ann Kraft | Executive Director, Licensing & Business Development
Ms. Leif-Ann Reilly | Senior Manager, Licensing & Business Development
Mr. Jerry Risco | Executive Director, Marketing Business Development
Ms. Brianne Weingarten | Executive Director
Company Overview
Company Profile:
Purdue Pharma L.P. is a privately held U.S. specialty pharmaceutical company with US sales of
over $1 billion in 2007. Purdue’s corporate headquarters are located in Stamford, CT.
Internationally, Purdue is associated with Mundipharma in the EU and Asia, Napp Laboratories
in the UK, and Purdue Pharma in Canada. Additionally, joint ventures are established in China,
India, and Latin America.
In the US, Purdue’s expertise lies in marketing pain products and laxatives. Purdue is a leader in
the strong analgesic market – principally with MS Contin® C-II (morphine sulfate controlled-
release) Tablets and OxyContin® C-II (oxycodone HCl controlled-release) Tablets. Purdue’s
OTC brands include Senokot®, Colace®, and Peri-Colace® branded laxatives and stool
softeners for constipation. The business is fully integrated from discovery, development,
registration, manufacturing, and sales & marketing to support operations in the U.S. and those of
Purdue’s associated companies around the world.
Additionally in Canada, Purdue has recently launched the following controlled-release products:
Uromax® (oxybutynin chloride), Biphentin® (methylphenidate HCl), and Zytram® XL
(tramadol HCl).
Alliances and Partnerships:

Purdue seeks late development stage or approved analgesic products in the fields of neuropathic
pain, topical NSAIDs and non-narcotic analgesics for mild-to-moderate pain management.
Purdue also seeks OTC products that have the potential to complement our branded lines of
supportive care products.
Additionally in Canada only, Purdue is interested in product opportunities in the fields of

urology, and pediatrics.

Qinetiq, Ltd.
DX103 | St Andrews Road | Malvern Worcs WR14 3PS | United Kingdom

Phone: +44 1684 894942 | Fax: +44 1684 894073 | Website: www.qinetiq.com
Contacts
Dr. Anthony W Higgs | Licensing Director
Organization Type
Industry Sector
High Technology
Company Overview
Today's big problems demand inspired solutions. At QinetiQ, we provide research, technical
advice, technology solutions and services to customers in core markets of defence and security,
building upon our vast depth and breadth of knowledge and expertise. As such Intellectual
Property is a principal asset and part of our lifeblood, with licensing out of technology being an
important part of our business. We are increasingly working to transfer our expertise and
capabilities into adjacent markets such as energy and environment. We operate principally in the
UK and North America and have recently entered the Australian defence consulting market.
QinetiQ is traded on the UK London Stock Exchange and is a FTSE 250 company (ticket QQ.L).
In the fiscal year ending March 2008, we employed 14,000 staff and our turnover was £1.37M
(~US $2.7Bn). QinetiQ is organised in to two principal businesses, QinetiQ EMEA and QinetiQ
North America, which split roughly 60% / 40% in both turnover and numbers of employees.
The QinetiQ EMEA business is built on a heritage of deep technical expertise at the forefront of
research in a wide field of technologies. Our position as a trusted advisor to the UK MOD
provides us with access to every major UK military programme and enables expansion into other
maturing defence and security markets. The EMEA business focuses on Applied Technologies,
technology-led Consulting, Integrated Systems and Managed Services.
QinetiQ North America has established itself as a significant provider of technology-based

solutions and services to US defence, security and intelligence customers. It consists of three
divisions: Technology Solutions Group, Systems Engineering Group, and Missions Solutions
Group.
The technology solutions generated by QinetiQ have spawned a number of products.

Examples include:

Cerberus - Provides early detection for harbour, ship or vulnerable assets from the threat of
attack.
Footsee - The foot gauge measures feet quickly and accurately providing highly detailed length,
girth and shape data, helping to ensure the best shoe fit possible.
Ocellus S100 - Designed for Surveillance and Tracking applications.
Ocellus T100 - A high performance GPS tracking device for Fleet Management applications.
Optasens - Effectively supporting security activities over land and sea perimeters as well as
along oil, gas and water pipelines.
Sat-ID - Satellite Signal Location enables satellite operators to identify and resolve interference
issues faster.
SPO-20 - Standoff security screening to detect concealed items on people.
Talon - Talon® Robots are powerful, durable, man portable tracked vehicles widely used for
explosive ordnance disposal (EOD) and reconnaissance.
Tarsier - Supports safe, high capacity, efficient airport operations with continuous runway
inspections.
X-net - The X-Net® system can fully arrest a range of vehicles using a unique spiked net design.
Zephyr - Ultra-lightweight solar-powered aircraft holding the record for the longest duration
unmanned flight.
Further details about QinetiQ maybe obtained from its website at www.QinetiQ.com.

QinetiQ is interested in technology transfer, licensing out its patents and trademarks, and also
sale of patents.

QinetiQ would like to meet with companies seeking solutions to their technological problems, be
it via contract R&D, consulting or licensing in of technology. Anthony Higgs is attending the
LES Annual Meeting and would be pleased to discuss any potential opportunities.

QLT Inc.
887 Great Northern Way | Vancouver BC V5T 4T5 | Canada

Phone: +1.604.707.7000 | Fax: +1.604.873.0816 | Website: www.qltinc.com
Contacts
Mr. Jonathan Jafari | Director, Marketing & Business Development
Organization Type
Industry Sector
Health Care
Company Overview
QLT is a global biopharmaceutical company dedicated to the discovery, development and
commercialization of innovative therapies. Our research and development efforts are focused on
pharmaceutical products in the fields of ophthalmology and dermatology. Utilizing two unique
technology platforms, photodynamic therapy (PDT) and Atrigel®, QLT has created Visudyne®,
the first approved treatment for age-related macular degeneration (AMD), and Eligard®, a
proprietary sustained release formulation of leuprolide acetate for prostate cancer.
Based in Vancouver, British Columbia, QLT was founded in 1981 and became a public company
in 1986. In 2004, we acquired Atrix Laboratories, Inc. (now known as "QLT USA"), a Fort
Collins, Colorado based biopharmaceutical company focused on advanced drug delivery. With
QLT USA, we expanded and diversified our portfolio of approved products, products in
development or under regulatory review, and proprietary technologies.
PRODUCT PORTFOLIO
V ISUDYNE QLT's first commercial product is in the field of PDT, which uses photosensitizers
(light activated drugs) in the treatment of disease. Our lead commercial product, Visudyne,
utilizes PDT to treat the eye disease known as wet AMD, the leading cause of blindness in
people over the age of 55 in North America and Europe. Visudyne is commercially available in
more than 75 countries, including USA, Canada, Japan and the European Union countries, for
the treatment of a form of wet AMD known as predominantly classic subfoveal choroidal
neovascularization (CNV), and in more than 50 countries for the form of wet AMD known as
occult subfoveal CNV. Visudyne is reimbursed in USA by the Centers for Medicare & Medicaid
Services for certain patients with the occult and minimally classic forms of wet AMD. It is also
approved in more than 60 countries, including USA, Canada and the European Union countries,
for the treatment of subfoveal CNV due to pathologic myopia (severe near-sightedness). In
some countries, including the USA and Canada, Visudyne is also approved for presumed ocular
histoplasmosis or other macular diseases. Visudyne was co-developed by QLT and Novartis
Pharma AG of Switzerland ("Novartis Ophthalmics") and is manufactured by QLT and sold by

Novartis Ophthalmics under the terms of a co-development, manufacturing and

commercialization agreement.
E LIGARD In addition, we market (through commercial licensees) the Eligard line of products for
the treatment of prostate cancer. The Eligard product line includes four different commercial
formulations of our Atrigel® technology combined with leuprolide acetate for the treatment of
prostate cancer. The U.S. Food and Drug Administration (FDA) has approved all four products:
Eligard 7.5-mg (one-month), Eligard 22.5-mg (three-month), Eligard 30.0-mg (four-month), and
Eligard 45.0-mg (six-month). The Eligard 7.5-mg and Eligard 22.5-mg products are also
approved in a number of other countries, including 25 European countries, Canada, Australia,
New Zealand, India and a number of Latin American countries. In addition to the U.S., Eligard
30-mg (four-month) is approved in Canada, Australia, New Zealand and India while Eligard
45.0-mg (six-month) is approved in Germany, Canada, Australia and India.
A CZONE ™ Our most advanced proprietary dermatology product, Aczone, utilizes a proprietary
drug delivery Solvent Microparticle System (SMP™) system. It was approved by the U.S. FDA
in July 2005 and by Health Canada in June 2006. Based on a post-approval commitment
requested by the FDA, we conducted a Phase IV clinical trial of Aczone in more than 50 patients
with glucose-6-phosphate dehydrogenase (G6PD) deficiency and communicated to the FDA the
positive outcome of this study in November 2006. We have submitted a label revision
supplement to the FDA during the second quarter of 2007. A decision with respect to the
commercialization of Aczone is pending the outcome of the decision by the FDA to remove the
restriction currently on the approved label for the product.
RESEARCH & DEVELOPMENT
QLT is actively pursuing our goal of growing our pipeline and our objective of becoming a fully-
integrated company. We perform research in the core therapeutic areas of ophthalmology and
dermatology and are seeking in-licensing, co-development or acquisition opportunities in the
core therapeutic areas. In addition, QLT sold the generic dermatology business, dental business
and the manufacturing facility of QLT USA to Tolmar, Inc. in 2006 in order to focus our
business on the research and development of proprietary products in the core therapeutic areas.
We are also looking to out-license rights to the Atrigel delivery platform technology, including
development-stage programs which use the Atrigel delivery system.

Looking for collaborative or licensing opportunities with institutions and companies that have:
 Innovative products in eye diseases and dermatology

 Breakthrough products/technologies in early research, preclinical, and clinical stages in
same therapeutic areas


Biotechnology and Pharmaceutical companies with products and technologies in ophthalmology
and dermatology.

Looking for collaborative or licensing opportunities with institutions and companies that have:
 Innovative products in eye diseases and dermatology

 Breakthrough products/technologies in early research, preclinical, and clinical stages in
same therapeutic areas
Quarles & Brady LLP
1 Renaissance Square | 2 N. Central Avenue | Phoenix AZ 85004-2391 | United States

Phone: (602) 229-5200 | Fax: (602) 229-5690
Contacts
Mr. Bradley DeSandro | Patent Attorney
for Partnering
Intellectual Legal Services; Patent Law;
Not Applicable
Property Licensing
Rambus Inc.
4440 El Camino Real | Los Altos CA 94025 | United States

Phone: (650) 947-5519
Contacts
Mr. Stefan Tamme | Director of Licensing and Marketing

RAND Corporation
1776 Main Street | P.O. Box 2138 | Santa Monica CA 90407-2138 | United States
Phone: (310) 393-0411 ext 7190 | Fax: (310) 260-8155
Contacts
Ms. Robin Meili | Director, Product Development & Licensing
Raytheon Company
870 Winter Street | Waltham MA 2451 | United States

Phone: (781) 522-3055 | Website: www.raytheon.com
Contacts
Mr. William McInnis | Licensing Manager
Mr. Elliot G. Swan | Director, Technology Licensing
Organization Type
Industry Sector
High Technology
Recap (Recombinant Capital, LLC)
2033 N. Main St. | Suite 1050 | Walnut Creek CA 94596 | United States
Phone: 925.952.3870 | Fax: 925.952.3871 | Website: www.recap.com
Contacts
Mr. Mark G. Edwards | Principal
Company Overview
Recombinant Capital (Recap) is a San Francisco Bay Area-based consulting firm specializing in
biotechnology alliances, earned alliance revenues, product sales, employment agreements,
company information and capitalization. Recap was founded in 1988 by Mark Edwards.
Recap Consulting maintains independent and confidential client relations with major
pharmaceutical and biotech companies, start-up biotechs, venture capital funds, investment
banks, law firms, consultancies and universities. Our history, experience, and access to premium
data make us an essential resource to our clients as we are uniquely able to provide expert
opinions, supported by documented analyses, on biotechnology alliances and industry trends. For
over 18 years, we have been providing our clients with expert advice and in-depth analysis in the

areas of alliance structuring and deal valuation in the pharmaceutical and biotech industries. Our
consulting expertise has been retained to assist in hundreds of biotech transactions with a total
value to date of over $10 billion.
Recap’s data services, accessible at www.recap.com and www.rdna.com, have proven to be an

invaluable asset to over 1,500 companies operating and involved in the biotech arena. Our
Alliances Database is the most extensive source for information on worldwide partnering and
business development, offering information on biotech alliances, with contracts and deal
analyses prepared by our analyst staff.
Reckitt Benckiser, Inc.
1 Phillips Parkway | Montvale NJ 07645 | United States

Phone: (201) 573-6394 | Fax: (201) 573-6046
Contacts
Dr. John A. Creek | IP Research Scientist
Organization Type
Industry Sector
Consumer Products
Red Chalk Group, LLC
850 West Elmhurst Road | Elk Grove Village IL 60007 | United States
Phone: (847) 390-0704 | Fax: (847) 390-0707 | Website: www.redchalkgroup.com
Contacts
Mr. John Koepke | Partner
Mr. Raymond Zenkich | Partner
Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
Red Chalk Group, LLC is an intellectual property professional services firm focused on
serving senior executives seeking to address their most challenging and urgent patent related
issues. Within many industries, intellectual property has become a key strategic lever creating

significant competitive advantage and barriers to entry, including price, margin, and share
advantages.
Our expertise can augment traditional analyses by providing additional depth and understanding
in regard to patents and patent portfolios. At Red Chalk, we integrate business, technical, and
legal expertise, while leveraging our proprietary patent database, to deliver decision grade
information and results in a timely and economic fashion.
Who We Are
76. We are consulting/research professionals with business, technical, and legal experience who
understand intellectual property issues as well as their impact on company performance and
subsequent executive decision-making.
77. Our backgrounds include careers at McKinsey & Co., Accenture, Gartner, Arthur D. Little,
and Howrey (a premier IP litigation firm)
78. We provide objective, quantitative-based insight into patent portfolios and synthesize results
into actionable, decision-grade information.
79. We are not lawyers - but we understand how to integrate their efforts in developing business
recommendations.
Our Experience
We have applied our skills and capabilities across a variety of industries/sectors including:
communications equipment, wireless telecom, semiconductor equipment & materials, medical
technology & devices, pharma, consumer electronics, biotechnology, software, hardware,
networking equipment, alternative fuels (biodesel/bioethanol), chemicals, and nanotechnology –
to name a few.
Our Clients
Our clients are comprised of corporate executives (including R&D managers, CTO's, IP
licensing & commercialization managers, M&A and business development professionals, and
IP/legal counsel) as well as individuals in the investment community (including asset/fund
managers, hedge fund managers, investment bankers, private equity principals, venture capital
professionals, and equity research teams)
Technical and Legal Expertise

When appropriate, we call upon our global network of technical experts, many of whom hold
patents, to provide detailed technical knowledge. Finally, and only as needed, we utilize industry
specific IP attorneys to augment our own perspectives. Our network is a critical and unique
element of our firm.

Practice Areas
At Red Chalk Group, we continually build and develop our practice areas by “institutionalizing”
our knowledge and experience. Our five practices areas include:
Technology Evaluation: Because technology is evolving at an accelerating rate, it is difficult to

objectively assess at any moment in time. However, there remains one truth – most all critical
inventions are patented. Red Chalk Group can assist you in evaluating a specific technology by
identifying all related patents and applications, aggregating the patents by owner, assessing for
seminality and technical strength, and ultimately identifying the short list of technology leaders.
M&A Support: In today’s competitive environment, internal R&D efforts simply can’t keep
pace with the need for innovation. Thus, many companies are accelerating their acquisition
efforts as a means of acquiring innovative technology. Red Chalk Group can augment these
efforts by providing intellectual property related research, due diligence, and acquisition idea
generation. We also assist legal teams acquire specific portfolios for both offensive and
defensive purposes as well as assist in post-merger integration of portfolios.
Industry/Competitive Analysis: Competitor’s aren’t standing still. In fact, the rate of

patenting, patent related litigation, and technology commercialization & licensing is increasing -
driving the need to fully understand your industry and related competitive dynamics. Red Chalk
Group has the unique capabilities to identify and evaluate the intellectual property portfolios
within an industry or specific competitor - providing you with the decision-grade information
and results required to not only keep pace, but pass your competitors.
Portfolio/Patent/Application Valuation: As the mechanisms for monetizing intellectual

property grow, so does the need for valuation. However, the value of a patent or portfolio
depends upon one’s perspective. The same patent is likely to have different value for different
owners. Red Chalk Group augments standard methodologies and techniques with market driven
factors to ensure you have fully considered the potential value of your property – yielding the
greatest possible results for your monetization efforts.
Licensing & Commercialization Support: Organizations are no longer content to build a

portfolio for “defensive” purposes – the investment demands a return. Red Chalk Group assists
our clients by identifying licensing and commercialization opportunities (as well as liabilities),
ensuring that efforts are aligned with overall business strategy. By segmenting, assessing, and
prioritizing a portfolio, we can help you build the strategy to deliver both long-term and short-
term results.

Work Style
We work very collaboratively, providing the information needed in a timely and economic
fashion. We maintain a profound respect for client privilege and confidentiality.
Rembrandt IP Management LLC
401 City Avenue | Suite 900 | Bala Cynwyd PA 19004 | United States
Phone: (610) 822 0111 | Fax: (610) 822 0123
Contacts
Mr. Thomas A. Goodwin | Senior Technologist
Ms. Katie Lartigue | New Business Manager
Organization Type
Consulting Firm
Research Foundation of New York
Stony Brook University | Stony Brook NY 11794 | United States

Phone: 631-632-6952
Contacts
Dr. Sean Boykevisch | Licensing Associate
Organization Type
Industry Sector
Health Care
Rexahn Pharmaceuticals
9620 Medical Center Drive | Rockville MD 20850 | United States

Phone: (240) 268-5300 X310
Contacts
Mr. Rick Soni | Chief Business Officer
Organization Type

Industry Sector
Health Care
Company Overview
Rexahn is a clinical stage biopharmaceutical company focussed on discovery, development and

commercialization of innovative treatments in Oncology and CNS. The company is committed to
developing innovative and first-in-class products that improve quality of life for patients.
The company currently has three drugs in Phase II trials in Oncology, CNS and Sexual
Dysfunction. Rexahn also has a oncology portfolio of 7 pre-clinical drug candidates as well as a
genomic based Drug Discovery Platform.
Rexahn is actively seeking collaborations and partnerships for development and

commercialization of its innovative product portfolio.
- Out-licensing
- In-licensing
-Development and Commercialization collaboration/ partnerships
- Research partnerships

Partnering
Archexin Oncology Not Applicable Worldwide
MUTAL Drug Discovery
Oncology Not Applicable Worldwide
Platform
Serdaxin CNS Not Applicable Worldwide
Zoraxel CNS Not Applicable Worldwide

RHEI Pharmaceuticals
Steenweg op Mol 129 | Oud-Turnhout 2360 | Belgium

Phone: 32-475-35-1891 | Fax: 32-14-72-0299 | Website: www.rheipharma.com
Contacts
Mr. Scott B Kozak | Senior Vice President
Industry Sector
Health Care
Company Overview
RHEI Pharmaceuticals is a specialty pharmaceutical company whose mission it is to bring the
best medicine to the people of China. We in license marketed and late stage products in areas of
unmet need including Cardiovascular/Metabolic, Oncology and Antiviral. We have the ability to
develop, commercialize and manufacture.
Rheonix, Inc.
22 Thornwood Drive | Ithaca NY 14850 | United States

Phone: (607) 257-1242 | Fax: (607) 257-0979
Contacts
Mr. John A. Brenner | Vice-President
Organization Type
Industry Sector
Health Care
Company Overview

Rheonix is a former division of Kionix, Inc. a world class high

technology manufacturing company located in Ithaca, New York. Due to Kionix’s origins as a
MEMS product company the Rheonix team experienced the burden of silicon and glassed based
MEMS fluidic systems and embarked upon the creation of a new system free of such
limitations. The result is the Rheonix Chemistry and Reagent Device (CARDTM) which is an
entirely different microfluidic system. It is the first ever to perform all of the fundamental
functions of a molecular biology lab (sample preparation, purification, amplification and
analysis) in one hand’s-off integrated system. Rheonix’s competitors can only offer complex

robotic mechanical systems that accomplish parts of the same set of tasks only under the
supervision of highly trained personnel in specially controlled environments. Rheonix’s portable
pneumatic controllers take the lab to the sample and dispose of the high fixed costs of operating
a central lab. Rheonix’s initial systems are targeted to individual near patient services where
molecular diagnostics are not currently possible, and later, fixed position higher capacity
installations will be developed.
Unique plastic chips which are the disposable component of each
analysis performed by the CARDTM are produced in an inexpensive lamination process.
Prototypes are produced on standard machine shop equipment, using readily available materials
and existing lamination systems. Higher volumes will use injection molded components that will
later be laminated.
Rheonix’s chips are manufactured from three layers of polystyrene.

The first layer is a 1mm thick plate with shallow voids and through holes that mate with the
pneumatic control system. The second layer is a continuous membrane sandwiched between the
first and the third layer. The third layer, also 1mm thick, is the channel layer. Where there is a
void the membrane that is suspended can now act as a valve and with the correct sequence of
opening and closing of adjacent valves the combination operates as a pump. The channels are
then arbitrarily useful by any combination of pumping or valving. The simplicity of the chip’s
manufacture thus leads to useful fluidic manipulation and reaction systems.
The reaction volumes of most competitors’ chips are in the range of picoliters to nanoliters. The
Rheonix CARDTM operates with milliliter to microliter volumes. Therefore the sample collected
for most diagnostic purposes is well suited for direct analysis on the Rheonix CARDTM.
Analysis is performed using classical systems such as the reverse-dot-blot or other compatible
amplicon hybridizations schemes.
Rheonix has established a joint venture in China where we are entering our first clinical trial for
a Point-of-Care diagnostic system. We are entertaining other commercial relationships in other
geographic regions and for other indications including non-clinical industrial, environmental and
research markets.

Rheonix is entertaining commercial relationships to deploy the CARDTM system for interesting
clinical diagnostic indications and certain non-clinical industrial, environmental and research
opportunities.

Rheonix is interested in meeting with companies that want to expand their clinical diagnostic
reach or certain non-clinical industrial, environmental and research reach to the point of care or

point of sample acquisition with a simple, flexible system that does not require extensive
laboratory experience to operate.

Rheonix’s goal is to establish a marketing partnership, joint venture, out-licensing arrangement
or acquisition as a result of LES 2008.

Partnering
Rheonix point of care
CARD diagnostics
Rice University
6100 Main Street | Houston TX 77005 | United States

Phone: (713) 348-6289
Contacts
Ms. Nila Bhakuni | Director, Office of Technology Transfer
Richards Layton & Finger
One Rodney Square | 920 North King Street | Wilmington DE 19899 | United States
Phone: (302) 651-7634 | Fax: (302) 498-7634
Contacts
Mr. Robert W. Whetzel |
Riches, McKenzie & Herbert, LLP
2 Bloor Street East, Suite 1800 | Toronto ON M4W 3J5 | Canada

Phone: (416) 961-5000 | Fax: (416) 961-5081
Contacts
Mr. Gary M. Travis | Lawyer

Ridout & Maybee LLP
One Queen Street East | Suite 2400 | Toronto ON M5C 3B1 | Canada
Phone: (416) 865-3518 | Fax: (416) 362-0823
Contacts
Mr. Charles Boulakia | Lawyer
Mr. Mitchell Charness | Lawyer
Robins, Kaplan, Miller & Ciresi LLP
2800 LaSalle Plaza | 800 LaSalle Avenue | Minneapolis MN 55402-2015 | United States
Phone: (612) 349-8435 | Fax: (612) 339-4181
Contacts
Mr. Ronald J. Schutz | Partner/Attorney
Company Overview
Intellectual Property Litigation
Representing both plaintiffs and defendants, we have gained decades of experience litigating
both large and small cases involving virtually every kind of technology. We have litigated
patents from a wide range of technology disciplines, including software, semiconductors,
computer peripherals, biotechnology, pharmaceuticals, medical products, telecommunications,
and industrial machinery. We are proud to have been selected to litigate patent matters on behalf
of established companies such as Honeywell, Pitney Bowes, Medtronic, General Electric,
General Mills, as well as many younger, growing corporations. We also represent a number of
leading academic institutions, including the University of California.
Our patent infringement trial lawyers include lawyers experienced in a variety of technical
disciplines ranging from biophysics to electrical engineering. Many of these trial lawyers are
registered to practice before the U.S. Patent and Trademark Office. But, first and foremost, we
are trial lawyers who try patent infringement cases, argue Federal Circuit appeals, structure and
negotiate business resolutions of patent infringement disputes, and counsel clients on patent
matters.
Robinwood Consulting
566 W. Adams Street | Suite 300 | Chicago IL 60661 | United States

Phone: (312) 544-6541 | Fax: (312) 559-0113

Contacts
Mr. Mark Peterson | Chief Executive Officer
Organization Type
Consulting Firm

Roche Diagnostics GmbH
Sandhofer Strasse 116 | Mannheim Not Applicable 68305 | Germany

Phone: 49-621-759-4131 | Fax: 49-621-759-8512 | Website: www.roche.com
Contacts
Dr. Norbert Grzibek | Divisional Licensing/External Cooperations
Company Overview
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused
healthcare groups in the fields of pharmaceuticals and diagnostics.
As the world’s biggest biotech company and an innovator of products and services for the early
detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad
range of fronts to improving people’s health and quality of life.
Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is
a market leader in virology. It is also active in other major therapeutic areas such as autoimmune
diseases, inflammatory and metabolic disorders and diseases of the central nervous system.
In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the
Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic
alliances with numerous partners, including majority ownership interests in Genentech and
Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group
employs about 79,000 people.
When Fritz Hoffmann founded F. Hoffmann-La Roche & Co. in 1896, he realised what was then
a revolutionary idea - producing medicines on an industrial scale outside the pharmacy and
selling them on the international market. Innovation has been one of Roche's hallmarks ever
since, and many of our pharmaceutical products have become milestones in drug therapy. Upon
these products we built our present world leadership in the hospital pharmacy market.
At Roche’s Pharmaceuticals Division, we view continuous innovation as the most promising

way to bring new medicines to the patient. Looking to the future, our long-standing expertise in
medicinal chemistry and biotechnology have put us in an excellent position to exploit the huge
potential of molecular medicine.
Roche's Diagnostics Division, the world leader in in-vitro diagnostics, offers a wide range of
products and services in all fields of medical testing. We have a unique capacity in people and
technology to provide innovative, cost-effective, timely and reliable solutions in biomedical
research, laboratory diagnostics and patient self-monitoring.
All over the world, we are dedicated to working with our customers - researchers, clinicians and

patients - to help them meet their individual needs. It has been said there is not a laboratory in the
world that does not contain one of our diagnostic products
Roche Molecular Systems, Inc.
1145 Atlantic Avenue | Alameda CA 94501 | United States

Phone: (510) 814-2968 | Fax: (510) 814-2763
Contacts
Mr. Joe Tasto | Senior Licensing Manager
Rochester Institute of Technology
145 Lomb Memorial Drive | Rochester NY 14623-5608 | United States

Phone: (585) 475-2986 | Fax: (585) 475-7950 | Website: www.saic.com
Contacts
Mr. William E. Bond | Director, IP Management Office
Rockwell Collins, Inc.
400 Collins Road, NE | M/S 124-303 | Cedar Rapids IA 52498 | United States
Phone: (319) 295-2290 | Fax: (319) 295-8937 | Website: www.rockwellcollins.com
Contacts
Mr. William C. Elkington | Sr. Director, Strategic Technology
Organization Type
Industry Sector
High Technology
Company Overview
Overview

For
over
70
year
s,
Roc
kwe
ll
Coll
ins
(NY
SE:
CO
L)
has
bee
n
reco
gniz
ed
as a
lead
er in
the
desi
gn,
prod
ucti
on,
and
sup
port
of
com
mun
icati
on
and
avia
tion
elec
tron
ics
for
cust
ome
rs
worl
dwi
de.
C
m
m
rc
al
Sy
te
m
Su
pp
yi
g
av
on
cs
an
d
ca
in
el
ct
on
cs
to
bu
si
es
av
at
on
an
d
co
m
m
rc
al
ai
tr
ns
po
t
op
ra
io
s
w
rl
w
de
Gr
ow
th
op
por Company LES Interests
tun
itie 1. Intellectual Asset Valuation
s
2. Intellectual Asset Management
Ro
ck 3. Licensing of Intellectual Assets into Fields Outside Our Own
wel
l
Col
lin Types of Companies your Company Would Like to Meet with
s is
wel 1. Venture Capital & Private Equity Companies
l-
pos 2. Entrepreneurs Interested in Taking Rockwell Collins Technologies into Markets we do
itio not Serve
ne
d 3. Sources of Technology to Differentiate Rockwell Collins's Product Lines
in
six
key
are Rohm and Haas Company
as
of Spring House Technical Centre | 727 Norristown Road | SPRING HOUSE PA 19477-
hig 0904 | United States
h Phone: 61.2 6213.6429 | Fax: 61.04.1860.9418
gro
wt Contacts
h Mr. Reginald K. Taylor | Director of Licensing
pot
ent
ial: Royalty Pharma
110 East 59th Street | 33rd Floor | New York NY 10022 | United States
Phone: (212) 883-2265 | Fax: (212) 883-2260
Contacts
Mr. Michael S. Herman | Vice President
RoyaltySource

155 Gaither Drive | Suite A | Mt. Laurel NJ 08054 | United States

Phone: (856) 234-1199 | Fax: (856) 234-8371 | Website: www.royaltysource.com
Contacts
Mr. David G. Weiler | Managing Director
Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
The RoyaltySource® suite of databases and services is designed to supply licensing and financial
professionals with a reliable and inexpensive source of …
Market comparable royalty rates and intellectual property sales,

Negotiated license agreements,
Revenue forecasting tools,
Valuation models,
Online IP valuation education and
IP news reporting in the Licensing Economics Review
These tools are designed to assist professionals in licensing negotiations, IP valuations and
infringement damage measurement.
RoyaltyZone, Inc.
1001 Beaver Trail #A | Austin TX 78746 | United States

Phone: (512) 349-7189 | Fax: (641) 453-9718 | Website: www.royaltyzone.com
Contacts
Mr. Lou Ellman | CEO
Organization Type
Financial Services
Company Overview
RoyaltyZone is a software-as-a-service (SaaS) company enabling online royalty reporting and
electronic payments to help maximize your licensing revenue.

RoyaltyZone lets you:
* Configure your agreement terms in an online repository

* Share information within your organization and with licensees
* Get everyone on the same page around license interpretation
* Send invoices, monitor and collect payments
* Receive online royalty reports in your specified format
* Review and analyze reporting periods
* Get paid accurately and on time!
RoyaltyZone is affordable, configurable, scalable, secure, and on demand. Completely web

based, RoyaltyZone is easy for everyone involved to use.
Visit us at the Tech Expo or www.royaltyzone.com to sign up for a free test drive!

Looking forward to meeting with companies that would like to maximize their licensing revenue
and streamline royalty management processes.

Potential customers: companies that would like to maximize their licensing revenue and
streamline royalty management processes.
Potential partners: software or service companies selling to technology licensors. Possible

integration and co-marketing opportunities.

Partnering
RoyaltyZone n/a Not Applicable Worldwide
RSM McGladrey
1 South Wacker Drive | Suite 800 | Chicago IL 60606 | United States

Phone: (312) 634-4752 | Fax: (312) 634-3410
Contacts
Mr. Lawrence Levine | Director

Organization Type
Consulting Firm
Company Overview
McGladrey is the nation's 5th largest accounting and consulting firm. Our Financial Advisory
Services Practice provides valuation and related financial advisory services to technology firms.
Valuation, Intellectual Asset Management, Patents, Trademarks
Rutgers University
ASB III | 3 Rutgers Plaza | New Brunswick NJ 8901 | United States

Phone: (732) 932-0115 ext 3002 | Fax: (732) 932-0146
Contacts
Mr. William T. Adams | Director, OCLTT
Dr. Gene Slowinski | Director, Strategic Alliance Studies
Ryder Resources
6500 Chapmans Road | Suite 300 | Allentown PA 18106 | United States

Phone: (610) 336-9575 | Fax: (610) 336-9576
Contacts
Mr. Thomas G. Ryder | President
S.C. Johnson & Son, Inc.
1525 Howe Street | Racine WI 53403 | United States

Phone: (262) 260-3791 | Fax: (262) 260-2901
Contacts
Mr. Michael J. Colucci | Technology Aquisition Manager
Organization Type
Industry Sector
Consumer Products

Sage Group
3322 Route 22 West | Building 2, Suite 201 | Branchburg New Jersey 08876 | United States
Phone: (908) 231-9644 | Fax: (908) 231-9692 | Website: www.sagehealthcare.com
Contacts
Mr. R. Douglas Hulse | Executive Director
Organization Type
Consulting Firm
Industry Sector
Health Care
Company Overview
The Sage Group offers outstanding expertise in healthcare business strategy and transactional
support to the management, boards and investors of biopharmaceutical and healthcare
companies. Through in-depth industry knowledge and our extensive experience and network
worldwide, we create value-enhancing opportunities for our clients.
We assist our clients to transform their enterprise into commercial success and shareholder value.
We are based in the USA, Europe and Japan.
We have extensive experience in M&A transactions, licensing, strategic partnering, strategy

development and implementation, valuations and due diligence, new venture development and
financing.
Sage have for more than fifteen years provided authoritative, knowledge-driven and value-
creating services to the healthcare industry in more than 300 client engagements.
Total transaction volume of the principals has exceeded $3Bn.
We have led numerous transactions ranging from strategic planning to partnering, licensing and
mergers, to acquisitions and divestments of value from $5-500m.
Our ability to provide your company rapid and efficient access to top level healthcare decision-
makers worldwide is unparalleled. Our experience and success in planning and efficient
execution of transactions to suit your needs within and across geographic boundaries is unique.

Sage assists clients in technology transfer, mergers and acquisitions, strategy and valuations. We

also serve as expert witnesses.

We are interested in meeting potential clients for our strategic and transactional services.

Our principal goal for the Annual Meeting is finding potential clients.

Country(s)
Partnering
Ampligen Chronic Fatigue Syndrome Not Applicable Worldwide
depression, anxiety, cravings,
BTL-ng Not Applicable Worldwide
constipation
idiopathic pulmonary fibrosis,
BTL-slo Not Applicable Worldwide
scleroderma, scarring
anemia, neutropenia, Europe, North
PEG-EPO Not Applicable
chemotherapy America
oncology, infectious disease, North America,
PEG-GCSF Not Applicable
immunotherapy Europe
PEGylated bovine blood substitutes, trauma,
hemoglobin blood transfusion
Auto-immune disease, Type I
Stable Galectin-9 Not Applicable Worldwide
diabetes, asthma, allergy
Salvat USA Inc.
2655 Le Jeune Road | Suite 810 | Coral Gables FL 33134 | United States
Phone: (305) 774-9727 | Fax: (305) 774-9767 | Website: www.salvatbiotech.com/eng_index.html
Contacts
Ms. Cristina Viayna | BD & Licensing Manager
Organization Type
Industry Sector
Health Care
Company Overview
Company: SALVAT is a private, independent, wholly Spanish owned biopharmaceutical

group. SALVAT is a research driven group that identifies, develops, manufactures and markets
innovative pharmaceuticals, wound care products and diagnostic methods.
Research: Innovation is the heart of our business strategy. SALVAT devotes 20% of its total
revenues and 18% of its staff to the R+D of new products. SALVAT´s pipeline balances projects
at different development stages using medicinal chemistry, biotechnology and drug delivery.

Areas of research are urology, antimicrobials, dermatology, regenerative medicine, organ

transplants and predictive medicine. Our projects include NCE, New formulations of existing
drugs and diagnostic kits for oncology. Our expertise in preclinical and clinical development and
our flexibility allows us to speed up the development, being the objective reach POC/Phase II
clinical trials.
Commercialization: SALVAT has commercial structure in Spain. The main business areas are
gastroenterology, urology, anti-infectives , dermatology, OTC and wound healing.
International: SALVAT has set its aim on the expansion of the company by entering into new
territories establishing fruitful, long-term relationships with the international pharmaceutical
community. SALVAT has sales in more than 30 countries by means of licensing agreements and
exports.
Partnering: Our alliances are mainly licensing-out agreements, global and regional, with both Big
pharma and mid-size companies. Our partners include Merck, Bayer, Abbott, Sanofi-Aventis,
Organon, Dr. Reddy's, Chiesi, Zambon, Prostakan, Synthon, Vianex, Taro, Uriach, IF Cantabria
and Techsphere, among others.
SALVAT's interests in the LES Meeting are technology transfer including Licensing-Out and In.
Potential commercial partners in US: Pharmaceutical companies with a focus in Pediatrics, ENT,
PCP and Dermatology.
Potential commercial and development partners in US: Pharmaceutical companies with a focus
in Urology, Women's Health and Dermatology.
Licensing-out: SALVAT looks for commercial and development partners in USA (see products
and projects)

Licensing-in: SALVAT looks for in-licensing opportunities for Spain and the export countries


Partnering
CETRAXAL Pediatric, ENT and PCP Not Applicable United States, Canada
North America, South America,
Eberconazole Dermatology Not Applicable
Europe
Impetigo,
Dermatology Not Applicable Worldwide
Acne
Psoriasis Dermatology Not Applicable Worldwide
Urology, Women's
Tarafenacin Not Applicable Worldwide
Health
Sandia National Laboratories
P.O. Box 5800 | MS 0114 | Albuquerque NM 87185-0114 | United States

Phone: (505) 845-9737 | Fax: (505) 844-8011 | Website: www.sandia.gov
Contacts
Mr. Nathan L. Golden | Licensing Executive
Ms. Laura E. Santos | Business Development Manager
Mr. Craig A. Smith | Technology Licensing Manager
Dr. Paul M. Smith | Principle Member of Technical Staff
Organization Type
Industry Sector
Company Overview
Sandia National Laboratories is a premier science and engineering lab for national security and
technology innovation. Sandia has two main facilities, the original laboratory and corporate
headquarters in Albuquerque, N.M., and a second R&D laboratory in Livermore, California.
Sandia’s enduring mission has been to apply science and technology to create a more secure
world. The initial focus on providing engineering design for nonnuclear components in the
nation’s nuclear weapons has expanded over the years to encompass the everchanging issues of
concern to national security. Sandia’s world-class team now performs a wide variety of R&D
work to meet national needs.

We promote technology transition by licensing and partnering with industry. We also

collaborate with universities, and state and local governments.
We invite you to browse through our technology portfolios to learn about our capabilities and
ongoing projects in different technology areas. Then contact one of Sandia's Business
Development and Licensing staff members to help you to find out more about partnering.
 Biosciences & Biotechnology

 Combustion Sciences
 Energy: Hydrogen & Biofuels
 Engineering Sciences
 Homeland Security
 Laser & Optical Sensing Technologies
 Materials Science
 Microfluidics Research
 Nanotechnology
 Scientific Computing
 Systems Analysis
Sandia works closely with industry, small business, universities, and government agencies to
bring new technologies to the marketplace. Sandia has been transferring technology to external
partners for more than three decades, especially where such agreements benefit Sandia’s primary
mission for the Department of Energy.
Sandia is seeking commercial partners to license Sandia intellectual property or contribute to the
continued development of it's technology. Sandia has a strong track record of partnerships that
result in successful commercial products, and is open to discuss opportunities with interested
organizations.
Country(s)
Partnering
Microscale Immune Drug discovery and therapeutics,
and Cell Analysis Diagnostics, Personalized Not Applicable
(MICA) medicine, Immune and infectious

disease, Biomarker discovery

TRUE TEMP composite, tooling material, foam Not Applicable

Sanofi-Aventis
13, quai Jules Guesde | Vitry-sur-Seine 94403 | France

Phone: +33 1 5893 3355
Contacts
Mrs. Manon Decelles | Manager, Business Development
Mr. Martin DuFour | Manager, Business Development
Mr. Thomas Wiatrowski | Director
Company Overview
Sanofi-aventis is the world’s third largest pharmaceutical company, ranking number one in
Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading
positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic
disease, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY). For more details please visit our website
http://en.sanofi-aventis.com/
Sanofi-Aventis Pharmaceuticals
55 Corporate Drive | Mailstop: 55B-320A | Bridgewater NJ 7030 | United States

Phone: (908) 981-7435 | Fax: (908) 243-9259
Contacts
Dr. John E. Cullity | Sr. Director, Business Development
Dr. Carole Wilmot | Senior Director, U.S. Business Development
Company Overview
Sanofi-aventis is the world’s third largest pharmaceutical company, ranking number one in
Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading
positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic
disease, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY). For more details please visit our website
http://en.sanofi-aventis.com/
Santarus, Inc.
10590 West Ocean Air Drive | Suite 200 | San Diego CA 92130 | United States
Phone: +1.858.314.5763 | Fax: +1.858.314.5705 | Website: www.santarus.com
Contacts
Mr. John W. Hicks | Senior Manager, Business Development

Industry Sector
Health Care
Company Overview
We are a specialty pharmaceutical company focused on acquiring, developing and

commercializing proprietary products that treat gastrointestinal diseases and disorders and
enhance the quality of life for patients. Our current marketed products are:
ZEGERID® (omeprazole/sodium bicarbonate) the first and only immediate-release oral PPIs
approved by the U.S. Food and Drug Administration. ZEGERID® is available in both capsule
and powder for suspension forms.
GLUMETZ® (metformin HCl extended release tablets) an adjunct to diet and exercise to
improve glycemic control in patients 18 years of age and older with type 2 diabetes through a
promotion agreement with Depomed, Inc.
We currently promote Zegerid® to gastroenterologists and primary care physicians and

Glumetza® to endocrinologists and primary care physicians through our 300 person sales force.
Santarus, Inc. is focused on licensing or acquiring late-stage or marketed specialty products.

In-licensing, out-licensing, promotion agreements, late-stage pipeline and marketed
product acquisitions.

Partnering
gastrointestinal
Zegerid Currently Marketed Worldwide
drug
Sargent & Krahn
Avda. Andres Bello 2711 | Piso 19 | Las Condes Santiago Chile

Phone: 56(2)3683500

Contacts
Mr. Juan Pablo Ega¤a Bertogua | Partner
SAS Institute Inc.
SAS Campus Drive | Cary NC 27513 | United States

Phone: (919) 531-0621 | Fax: (919) 677-4444
Contacts
Mr. Dennis McCarron | Head of Corp Development & Planning
Saul Ewing LLP
500 E. Pratt St. | Baltimore MD 21111 | United States

Phone: (410) 332-8719 | Fax: (410) 332-8114 | Website: www.saul.com
Contacts
Ms. Tanya Berlage | Partner
Organization Type
Law Firm
Company Overview
Experienced counselors, litigators, and deal-makers, our Life Sciences attorneys assist our clients
in the pharmaceutical, medical device, biotechnology, and healthcare industries in thinking – and
moving – ahead.
Saul Ewing's Life Sciences Practices offers a wide range of legal services to our clients in these
industries, and represents a wide array of clients – from multinational pharmaceutical and device
manufacturers, to aspiring new entrants in the biotechnology field, to major teaching hospitals
and healthcare systems, to community hospitals, health agencies, and practitioners, to healthcare
service entities of any variety.
The attorneys comprising our Life Sciences Practices can be found in nearly every Saul Ewing
department and discipline, meeting our clients' needs in litigation, risk management and risk
counseling, civil and criminal investigation and enforcement, financing, corporate and
transactional law, tax, general regulatory advice, reimbursement and payor relations, medical
device approval, and privacy and data management counseling. We have served our clients' life
sciences needs in the Mid-Atlantic region, across the United States, and internationally.
In addition to maintaining their active law practices, our Life Sciences attorneys are also frequent
speakers, panelists, and participants in pharmaceutical, medical device, biotechnology, and

health law seminars and presentations, and have published widely on matters affecting the life
sciences industries. Our attorneys include active members in the Food, Drug & Law Institute, the
Defense Research Institute, and the International Association of Defense Counsel's Drug,
Device, and Biotech Committee. Our attorneys have often been quoted authorities by the media
on matters affecting the life sciences industries. In just the recent past, for example, our attorneys
have been quoted in USAToday, Pharmaceutical Processing, MedAd News, PharmaVoice, FDA
News-Pharmaceutical Corporate Compliance Report, Managed Healthcare Executive, CN-8
Television, The Philadelphia Inquirer, The Legal Intelligencer, and various other publications on
core issues such as pharmaceutical e-commerce, reimportation, federal regulatory structure and
reliability, direct-to-consumer advertising, drug withdrawals, anticipated industry developments
and growth areas, and other critical issues confronting these industries.
For many years, Saul Ewing's Life Sciences Practices has counseled, negotiated, advised and
defended clients in the life sciences industries, accumulating a knowledge and experience
reservoir that makes Saul Ewing a true destination law firm for life sciences representation. The
attorneys in Life Sciences Practices focus their talents in three core areas of our clients' legal
needs – managing litigation risks, pioneering transactions and strategic alliances, and conferring
regulatory, privacy, and healthcare contracting advice.
Country(s)
Partnering
Intellectual property; patent
prosecution and counseling
Life Sciences Transactions n/a Not Applicable Worldwide
Strategic alliances, in-licensing,
out-licensing, product sales and n/a Not Applicable Worldwide
acquisitions
Savient Pharmaceuticals, Inc.
One Tower Center Blvd. | 14th Floor | East Brunswick New Jersey 08816 | United States
Phone: 732-565-4745
Contacts
Mr. Robert Coburn | Senior Director Business Development
Mr. Stephen Glockenmeier | V.P. Global Portfolio Marketing
Schering-Plough Consumer Healthcare

56 Livingston Avenue | Roseland NJ 7068 | United States

Phone: (862) 245-5148 | Fax: (862) 245-4054
Contacts
Ms. Susan B. Levy-Cantor | Director, Global New Ventures & Strategic Commercial
Development
Ms. Nancy Miller-Rich | Group VP, New Ventrue & Strategic Commerical Development
Schering-Plough Corp.
2000 Galloping Hill Road | Kenilworth NJ 07033 | United States

Phone: 908-298-4157
Contacts
Mr. Gerard Reinhardt | Sr. Counsel, Patents
Dr. Gregory J. Sumner | Director, Business Developement
Organization Type
Industry Sector
Health Care
Company Overview
Schering-Plough Corporation (NYSE: SGP) is a global science-based health care company with
leading prescription, consumer and animal health products. Through internal research and
collaborations with partners, Schering-Plough discovers, develops, manufactures and markets
advanced drug therapies to meet important medical needs.
Schering-Plough’s vision is to earn the trust of physicians, patients and other customers.
Following the acquisition in November 2007 of Organon BioSciences (OBS), a Dutch human
health (Organon) and animal health (Intervet) company, Schering-Plough now has approximately
50,000 colleagues around the world. Our products reach patients and caregivers in more than
140 countries. For 2007, Schering-Plough reported adjusted net sales1 of $15.2 billion2.
Schering-Plough is continuing a fundamental transformation under a six- to eight-year Action

Agenda that began in 2003 upon the arrival of Chairman and CEO Fred Hassan. Schering-
Plough colleagues are building a new kind of health care company  a company that seeks to
operate with excellence and to be in tune with the needs and the expectations of doctors, patients
and other stakeholders. By doing this well, the company intends to build the foundation for

long-term, sustainable growth and to provide a steady flow of innovative, science-based

medicines and services. Integral to Schering-Plough’s efforts is a commitment to business
integrity, quality and compliance.
Throughout its history, Schering-Plough has focused on discovering and developing innovative
new therapies in the human prescription, animal health and consumer health customer segments.
The combination with Organon and Intervet strengthens our portfolio in several areas. In human
prescription pharmaceuticals, we expand beyond our existing portfolios in cardiovascular care,
respiratory care, immunology and infectious disease, and oncology into the important new areas
of women’s health and central nervous system therapies. In animal health, our combination
brings together complementary lines of pharmaceuticals and biologics.
The company is science-centered and continues to make significant investments in research and
development. In 2007, Schering-Plough invested $2.9 billion3 in research and development.
1
Includes assumed 50% contribution from Joint Venture sales of VYTORIN and ZETIA. Please
refer to reconciliation tables under “Financial Highlights” on the Investor Relations section of
the Schering-Plough Web site: http://phx.corporate-ir.net/phoenix.zhtml?c=89839&p=irol-
fundamentals2
2
Includes $626 million of Organon BioSciences net sales from the period as of the closing date
of the acquisition on Nov. 19, 2007, through Dec. 31, 2007
3
Includes $111 million of OBS R&D investment from the period as of the closing date of the
acquisition on Nov. 19, 2007, through Dec. 31, 2007.
Compounds in the research and development pipeline include:

Acadesine to prevent ischemia reperfusion injury after coronary artery bypass surgery
A thrombin receptor antagonist for acute coronary syndrome and secondary prevention
Vicriviroc, a CCR5 receptor antagonist for HIV infection
Boceprevir, a protease inhibitor for hepatitis C
Golimumab, a monoclonal antibody for inflammatory diseases
A sublingual tablet-based immunotherapy for grass pollen allergies
A combination of ASMANEX and Novartis’ Foradil for the treatment of asthma and
chronic obstructive pulmonary disease
 Corifollitropin alfa for fertility
 NOMAC/E2 natural estrogen oral contraceptive
 ORG 50081 for insomnia and hot flashes
Compounds under regulatory review include:
 Asenapine for schizophrenia and bipolar mania disorders (U.S.)

 Sugammadex, a neuromuscular blocker reversal agent (EU, U.S. and Japan)

 CLARITIN/Singular combination for allergy and nasal congestion (U.S.)
 ASMANEX for asthma (Japan)
 NASONEX for perennial allergic rhinitis (Japan)
 REMERON antidepressant (Japan)
Major Human Prescription Products:
(Products in alphabetical order; not all products listed)
1. ASMANEX TWISTHALER Orally inhaled corticosteroid for asthma
2. AVELOX1 and CIPRO1 antibiotics
3. CAELYX2 for ovarian cancer, Kaposi’s sarcoma and metastatic breast cancer
4. CERAZETTE Oral contraceptive
5. CLARINEX Family of nonsedating antihistamines (some in combination with a
decongestant) for allergies
6. DESOGEN /MARVELON / MERCILON Low-dose combined oral contraceptive
7. FOLLISTIM / PUREGON Fertility treatment
8. IMPLANON Subdermal contraceptive implant
9. INTEGRILIN For patients with acute coronary syndrome and those undergoing
percutaneous coronary intervention\
10. INTRON A / INTRONA Alpha interferon for chronic hepatitis B and C and certain
cancers
11. LIVIAL2 Menopausal therapy
1. NASONEX Nasally-inhaled corticosteroid for prevention and treatment of nasal allergy
symptoms
12. NUVARING Vaginal contraceptive ring
13. ORGARAN Non-heparin antithrombotic
14. PEGINTRON Pegylated interferon for chronic hepatitis C
15. REMERON Antidepressant
16. REMICADE3 Monoclonal antibody for rheumatoid arthritis, psoriatic arthritis, Crohn’s
disease, ankylosing spondylitis, ulcerative colitis and psoriasis
17. TEMODAR Oral, cytotoxic alkylating agent for certain types of brain tumors
18. VYTORIN4 Cholesterol-lowering medicine containing ZETIA and Merck & Co., Inc.’s
statin Zocor
19. ZEMURON / ESMERON Muscle relaxant
20. ZETIA4,5 Novel cholesterol-absorption inhibitor
1
Sold by Schering-Plough in the U.S. only
2
Sold by Schering-Plough outside the U.S. only
3
Sold by Schering-Plough in all countries outside the U.S. except Japan and parts of the
Far East
4
Managed through a joint venture with Merck & Co., Inc.

5
Also sold in Japan through a separate co-marketing agreement with Bayer

Schlumberger Technology Corporation
One Hampshire Street | Cambridge MA 2139 | United States

Phone: (203) 323-3391
Contacts
Ms. Jody Destefanis | Managing IP Counsel, Research
Mr. David G. Matthews | Counsel - IP Licensing & Litigation
Schwegman Lundberg Woessner
121 S 8th Street | Suite 1600 | Minneapolis MN 55402-2841 | United States

Phone: (612) 373-6903 | Fax: (612) 339-3061
Contacts
Mr. Warren Woessner | Founding Shareholder
SciDose LLC
123 Blackberry Lane | Amherst MA 1002 | United States

Phone: (413) 549-5770 | Fax: (413) 549-9696
Contacts
Mr. Joseph Bohan | CEO & President
Organization Type
Industry Sector
Health Care
Company Overview
SciDose is a Drug Delivery company focusing on hard to develop injectible products as 505b2
opportunities. Our first FDA approval with one of partners was on June 27 of this year. We
currently have 25 products under development. We develop novel formulations, conduct clinical
studies then license the products to pharma partners.

We would like to arrange meetings with specialty pharma companies who focus in oncology and
the hospital markets

We are looking for development and marketing partners for products in all geographic areas
Sciele Pharma, Inc.
Five Concourse Parkway | Suite 1800 | Atlanta GA 30328 | United States

Phone: (678) 341-1487 | Website: www.sciele.com
Contacts
Dr. Brian Adams | Director, Business Development
Dr. John W. Sharkey | VP, Business Development
Organization Type
Industry Sector
Health Care
Company Overview
Sciele Pharma, Inc. (NASDAQ: SCRX) is a pharmaceutical company specializing in sales,

marketing and development of branded prescription products focused on Cardiovascular,
Diabetes, Women's Health and Pediatrics. The Company's Cardiovascular and Diabetes products
treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and Type 2
diabetes; its Women's Health products are designed to improve the health and well-being of
women and mothers and their babies; and its Pediatrics products treat allergies, asthma, coughs
and colds, and attention deficit/hyperactivity disorder (ADHD).
Founded in 1992 and headquartered in Atlanta, Georgia, Sciele Pharma employs more than 900
people. The Company's success is based on placing the needs of patients first, improving health
and quality of life, and implementing its business platform - an Entrepreneurial Spirit,
Innovation, Execution Excellence, Simplicity, and Teamwork.
Sciele Pharma, Inc. is committed to continue its growth through business development initiatives
– primarily licensing and acquiring products and/or companies. Licensing and acquiring late
stage and commercialized products for sale in the United States are key to our near and long term
success. To date, the Company has in-licensed or acquired products from companies including
AstraZeneca, Bayer AG, Warner-Lambert, Sanofi-Aventis, Wyeth, Elan, SkyePharma, Andrx,
Pohl-Boskamp, Biovail, Galephar, Addrenex, Summers Labs, Plethora Solutions, LifeCycle
Pharma, and Novo Nordisk.

We are interested in opportunities in the following areas: cardiovascular, diabetes, women's

health, pediatrics and products prescribed by primary care physicians. Additionally, we are
interested in leveraging our current business model by licensing and acquiring products and/or
companies in other specialty therapeutic areas, such as urology, allergy, gastroenterology, and
pain.
Science & Technology Law Center
22F., No.216, Sec. 2, Dunhua S. Rd. | Taipei None 106 | United States
Phone: 886-2-2739-8171 ext. 170 | Fax: 886-2-2378-2709
Contacts
Mr. Shih-Chang Sun | Legal Researcher
Organization Type
Industry Sector
Company Overview
Our Mission: Commitment to Excellence
The mission of the STLC is to provide guidance for Taiwan's hi-tech sector to cope with rapid
changes in technology, and assist technology companies to achieve new heights of growth and
development with its successful experience and a focus on innovation. The STLC has been
consistently striving to achieve profound expertise in providing effective and practical solutions
in face of challenges from the development of information, technology and globalization. These
include consultation on legal affairs for the Institute for Information Industry, advice on
technology transfer plan management and assisting government agency in building a high-
quality environment for the development of high technology, and guidance for Taiwan's hi-tech
industries to identify keys to success in global competition.
Based on its strengths in legalization and regulatory strategies, the STLC will be expanding its
expertise and facilitating more international exchange and collaborations in the future for more
impact at the global level. It will develop into a hub of legal and technical advancement that
connects Taiwan to business and academia worldwide.
Historical Background
In 1989, the Institute for Information Industry (III) established an Information Law Research
Unit within its Market Intelligence Center (MIC). The Center was aimed to assist Taiwan's

information industry keeping pace with global trends and building first-rate international
competitiveness by creating a sound legal and regulatory environment for the island's high
technology to grow and flourish.
In 1996, the Information Law Research Unit was restructured as an independent unit – the
Science & Technology Law Center (STLC) - with funding support from Ministry of Economic
Affairs. Ever since its establishment, the STLC has been serving as a think-tank, advising on
policy issues regarding science and technology.
Staffing Credibility in R&D
The STLC's professional team consists of high-caliber individuals of extensive qualifications.

Such a combination makes us highly capable and competitive in coping with various challenges.
All the staff in the STLC have obtained a Master's degree Ph.D. or attorney, and are experienced
and familiar with the latest developments in technology law in the advanced nations.
Our staffing policy transcends the boundaries between technology and law, which helps in
developing a broader vision for the internationalization of Taiwan's hi-tech sector.
 Legal research
 Policy think-tank
 Drafting and revision of legislation
 Promotion of legal and regulatory knowledge
 Education and training
 Consulting services
Specialized Fields and Services
The STLC assists and advises on the formulation of laws and regulations covering the following
areas:
R&D
 Technology and Industrial Development

 Technology Research and Development Plans
 Technology Transfer
 Government Procurement
 International Trade
 Intellectual Property Rights
Emerging Technologies
 Information and Communications Technology

 Information Security
 e-Commerce
 Biotechnology

 Open Source Software / Free Software

 Digital Content
 Nanotechnology
 Green Technology
Science Applications International Corporation
5 Fellview Drive | Pittsford NY 14534 | United States

Phone: (585) 586-9605 | Fax: (585) 586-1375
Contacts
Mr. David Snyder | Vice President - Technology Commercialization
SCOLR Pharma, Inc.
3625 132nd Avenue SE | Suite 400 | Bellevue WA 98006 | United States

Phone: (425) 373-0171 | Fax: (425) 373-0181 | Website: www.scolr.com
Contacts
Mr. Alan M. Mitchel | Chief Legal Officer, Senior VP of Business Affairs
Company Overview
SCOLR Pharma is a specialty pharmaceutical company engaged in the development and

licensing of our Controlled Delivery Technology (CDT®). Our CDT platform is based on
multiple issued and pending patents and other intellectual property for the programmed release
or enhanced performance of active pharmaceutical ingredients and nutritional products. Our
technology is applicable across a broad range of drug types and classes and offers significant
advantages over alternative drug delivery platforms.
SCOLR is advancing commercialization of a 12 hour ibuprofen OTC product candidate and has
completed PK studies comparing ourCDT based 600mg 12 hour extended-release tablets to three
200 mg. immediate release reference tablets. We have initiated the third of three pivotal trals to
evaluate the safety and efficacy of our formulation and expect to complete the trial in late 2008.
If approved, SCOLR believes its ibuprofen product would be the first and only OTC 12-hour
extended-release ibuprofen product on the market in the US.
In August 2008, SCOLR submitted an ANDA for a 120 mg. 12-hour pseudoephedrine tablet
based on its CDT platform. This is the first application submitted by SCOLR based on its CDT
platform. SCOLR has been able to demonstrate bio-equivalence for the product while
significantly reducing overall tablet size, gaining important manufacturing margin advantages
over currently available tablets.

SCOLR has developed multiple private label extended release nutritional products incorporating
itsCDT platform that are sold in national retailers. SCOLR has a strategic alliance with Perrigo
for the manufacture, marketing, and sale of certain dietary supplement products in the U.S.
Perrigo currently markets five products incorporating our CDT technology, including all day
formulations of glucosamine/chondroitin and calcium.
SCOLR is also developing CDT-based extended release formulations of ondansetron,

rivastigmine, and risperidone, as well as an immediate release formulation of raloxifene.
SCOLR has a collaborationand license agreement with Dr. Reddy's Laboratories to pursue
development and commercialization of an undisclosed oral prescription drug with significant
potential for the cardiopulmonary market using our CDT technology. SCOLR also has a research
collaboration with BioCryst Pharmaceuticals to develop an oral formulation of peramivir, a
promising antiviral compound using our CDT platform.
We seek collaborative arrangements and alliances with corporate partners, licensors, and
licensees to provide funding for the research, development, clinical testing, manufacturing,
marketing, and commercialization of our product candidates.

Partnering
Ibuprofen 12 hr. (in
n/a Not Applicable
development)
Semiconductor Insights, Inc.
3000 Solandt Road | Ottawa ON K2K 2X2 | Canada

Phone: (613) 599-6500 | Fax: (613) 599-6501 | Website: www.semiconductor.com
Contacts
Mr. Peter DiPaolo | Senior Consultant
Mr. Michael McLean | VP, Professional Services
Mr. Abdullah Rahal | Sr Consultant, Professional Services

Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
Identify, Protect, & Optimize Your Technology Assets
Semiconductor Insights helps leading edge technology companies and licensing professionals
attain their product and intellectual property goals by providing in-depth technical and patent
analyses of integrated circuits and structures.
We provide:
 Technical evaluation of intellectual assets for patents and

licensing
 Technical investigation of circuit design and process

innovations for competitive intelligence
 Strategic sourcing and procurement of parts
Technology - Technical Evaluations and Investigations
Intellectual Property, Intellectual Assets
Competitive Analysis, Circuit and Process Design
Patent
Shire Pharmaceuticals, Inc.
725 Chesterbrook Blvd. | Wayne PA 19087-5637 | United States

Phone: +1 484 595 8800 | Fax: +1 484 595 8200
Contacts
Ms. Gwen Melincoff | Senor Vice President, Business Development

Organization Type
Industry Sector
Health Care
Company Overview
Corporate Description
Shire is a leading specialty pharmaceutical company that focuses on meeting the needs of the
specialist physician. Shire's therapeutic focus is on Attention Deficit Hyperactivity Disorder
(ADHD) and other diseases of the central nervous system (CNS), human genetic therapies
(HGT), gastrointestinal (GI) and renal diseases and regenerative medicine. The structure is
sufficiently flexible to allow Shire to target new therapeutic areas to the extent that opportunities
arise through acquisitions. Shire believes that a carefully selected portfolio of later stage
products with a strategically aligned and relatively small scale sales force will deliver strong
results.
Shire's strategy is to develop and market products for specialty physicians. Shire's in-licensing
and merger and acquisition (M&A) efforts are focused on products in niche markets with strong
intellectual property protection either in the US, Europe or other international markets.
Products
Shire has a global sales and marketing infrastructure with a broad portfolio of products and its
own direct marketing capability in the United States, Canada, United Kingdom, Republic of
Ireland, France, Germany, Italy and Spain. Shire also covers other significant pharmaceutical
markets indirectly through distributors.
Shire's global search and development expertise has to date successfully provided over 20
marketed products. Shire has a total of 14 projects in full development, four of which are in
Phase II or beyond. M&A activity during the past ten years has resulted in eight completed
mergers and acquisitions.
Financial Highlights
Shire reported full year revenues for 2007 of USD$2,436M up 36% on the previous year.
 Product sales up 41% to $2,170 million

 New product sales $489 million, 23% of product sales[1]
 Non GAAP Earnings per ADS up 38% to $2.95
 US GAAP Earnings per ADS down 592% to -$8.06
 Dividend up 20% (in US$ terms)

Collaborations
Successful alliances are the cornerstone of Shire's business strategy and Shire has a history of
effective partnerships built upon a fast and flexible approach. Partners who work with Shire
enjoy the benefits of an organisation with short communication lines to key decision makers and
an efficient and fair evaluation process.
Business Highlights
Shire completed its acquisition of New River Pharmaceuticals Inc. in April 2007.
Recent Partner Announcements
 JUVISTA® - On June 19, 2007 Shire signed an agreement with Renovo Limited to
develop and commercialize JUVISTA (Human TGFb3), for the prevention and reduction
of scarring. Under the terms of the agreement Shire has the exclusive right to
commercialize JUVISTA worldwide, with the exception of EU member states.
 SPD754 - North America (U.S. and Canada) rights for the investigational HIV compound
out-licensed to Avexa Limited in January 2007.
 In November 2007 Shire in-licensed from Amicus Therapeutics, Inc. the rights to three
compounds (AMIGALTM,PLICERATM, and AT2220) in markets outside the US.
 LIALDATM – a co-promotion agreement was signed with TAP Pharmaceutical Products
Inc. in March 2008 for a three year agreement for the U.S. only.
 SPD550 (Larazotide Aceotate for GI disorders) – In December 2007 Shire licensed rights
to SPD550 (also known as AT-1001), in markets outside of the US and Japan, from Alba
Therapeutics Corporation.
Product Highlights
 VYVANSETM (ADHD) – Launched in the US in July 2007. The FDA approved three
additional dosage strenths in December 2007.
 LIALDATM (Ulcerative colitis) - Launched in the US, UK and Canada, with further
launches planned in the EU in 2008.
 DYNEPO® (Anemia associated with CKD) – Launched in several EU countries.
 FOSRENOL (Hyperphosphatemia) – International launches continued and it is now
available in 24 countries.
 ELAPRASETM – (Hunter Syndrome) – Approved in 37 countries worldwide. Launched
in Japan in October 2007, with sales and distribution managed by Genzyme Corporation.
 REPLAGAL® - Approved in 41 countries. Launched in Japan in February 2007 through
Shire’s partner Dainippon Sumitomo Pharma Co., Ltd.
Pipeline Highlights
 VYVANSE (Adult ADHD) – PDUFA action date is April 28, 2008

 INTUNIVTM (ADHD) – Approvable letter received in June 2007. Launch is anticipated
in H2 2009.

 SPD487 (Amphetamine Transdermal System (ADHD)) – Shire acquired exclusive

development rights from Noven Pharmaceuticals
 SPD465 (ADHD) – Approvable letter received
The following are trademarks of third parties:

AMIGAL (migalastat hydrochloride) – trademark of Amicus Therapeutics, Inc.
DYNEPO (epoetin delta) – trademark of Sanofi Aventis
JUVISTA – trademark of Renovo
PENTASA (mesalamine) – trademark of Ferring
PLICERA (isofagomine tartrate) - trademark of Amicus Therapeutics, Inc.
_________________________________________________________
[1]
New product sales include VYVANSE, LIALDA/MEZAVANT, DYNEPO, ELAPRASE,
FOSRENOL and DAYTRANA
Siemens Healthcare Diagnostics
511 Benedict Avenue | Tarrytown NY 10591-5097 | United States

Phone: (914) 524-3213 | Fax: (914) 524-3693
Contacts
Mr. Edward Imbrie | Senior Director, New Business Development
Organization Type
Industry Sector
Health Care
Company Overview
Siemens Healthcare Diagnostics is the largest clinical diagnostics company in the world, serving
a critical role in the health care continuum. We offer products and services designed for efficient
delivery of patient test results used for diagnosing medical conditions, monitoring patient therapy
and providing quality health care.
Built on a rich history of innovation from Diagnostic Products Corporation, Bayer HealthCare
Diagnostics and Dade Behring, we offer comprehensive solutions designed to improve clinical
outcomes, streamline workflow and enhance the operational efficiency of clinical laboratories.
Our broad portfolio of innovative products include a variety of diagnostic systems—integrated

chemistry, immunoassay, routine chemistry, automation, hematology, hemostasis, microbiology,
diabetes, urinalysis, blood gas monitoring and molecular testing. Our dedicated professionals are
committed to meet the needs of our customers by providing high-quality products and highly-

responsive service and support.

We are looking for opportunities to in license markers and devices that meet significant unmet
needs in the healthcare system.

Sigma-Aldrich Pty Ltd
2909 Laclede Ave | St. Louis MO 63130 | United States

Phone: 800-544-2760 | Website: www.sigmaaldrich.com
Contacts
Mr. Aaron Sin | Manager
Organization Type
Industry Sector
High Technology
Company Overview
Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical,
inorganic and organic chemical products and kits are used in scientific and genomic research,
biotechnology, pharmaceutical development, the diagnosis of disease and as key components and
pharmaceutical and other high technology manufacturing.
The Business Development, Licensing and Strategic Investments Group at Sigma-Aldrich is

committed to delivering novel products and services to our customers. We have developed a
results-driven strategy for evaluating potential opportunities quickly in order to match the fast-
paced life sciences and high technology sectors. Our role within Sigma-Aldrich includes the
following:
 Technology and Product Licensing

 Joint Partnerships and Collaborative Relationships with companies, universities and
researchers
 Acquisitions and Equity investments
 Intellectual Property Management including out-licensing
 Legal and Contracts
For a detailed list of technologies of interest see

http://www.sigmaaldrich.com/CustomerSupport/Customer_Service/Business_Development/Tech
nologies_of_Interest.html

Tech transfer. Licensing strategy. Collaborative Research and Development. Valuation

in-licensing, research collaborations, mergers & acquisitions

Sim & McBurney
330 University Avenue, 6th Floor | Toronto ON M5G 1R7 | Canada

Phone: (416) 595-1155 ext 234 | Fax: (416) 595-1163 | Website: www.sim-mcburney.com
Contacts
Mr. Kenneth D. McKay | Partner
Mr. Matthew D. Powell | Patent Agent (Canada; U.S.)
Company Overview
Overview
The firms of SIM & McBURNEY and SIM, LOWMAN, ASHTON & McKAY LLP were
founded in 1970 to provide a full range of services in intellectual property and commercial
litigation in Canada. Our professionals have a broad range of experience in Technology,
Licensing, Trade-mark Agency, and Patent Agency including the Advanced Sciences and
Electronics/Computers fields. Our Litigation Group provides experienced counsel for litigation
in all of the above areas of practice.
We are located in the heart of downtown Toronto, Canada’s largest city, convenient to the
Courts, local patent & trade-mark filing offices, and the offices of many of Canada’s largest
business enterprises.
SIM & McBURNEY is a partnership of patent and trade-mark agents entitled to file and
prosecute patent, trade-mark, industrial design, integrated circuit and copyright applications in
Canada and the United States, with connections to expert practitioners throughout the world to
enable clients to effectively and efficiently deal with their licensing, patent and trade-mark
requirements on a global basis.
SIM, LOWMAN, ASHTON & McKAY LLP is a partnership of lawyers specializing in

intellectual property law and commercial litigation in the Ontario Superior Court of Justice, the
Federal Court of Canada, and the Supreme Court of Canada. Our firm and its predecessors have
represented parties in much of the significant intellectual property litigation in this country.
Legal services related to licensing, enforcement and defense of intellectual property rights, and
related disputes including professional errors and omissions, product liability, employment law
and general commercial litigation are provided to a broad clientèle, both Canadian and foreign.
The two firms cooperate to provide a full range of services in the technology licensing,
intellectual property and commercial litigation field. If you require specific information, please
do not hesitate to contact us.

Sim, Lowman, Ashton & McKay LLP
330 University Avenue | 6th Floor | Toronto ON M5G 1R7 | Canada

Phone: (416) 849-8430 | Fax: (416) 595-1163 | Website: www.sim-lowman.com
Contacts
Mr. Andrew R.O. Jones | Partner
Singapore Institute of Manufacturing Technology
71 Nanyang Drive | Singapore 638075 | Singapore

Phone: (659) 048-0110 | Fax: (659) 791-6377
Contacts
Mr. Lee Chee Ming | Senior Manager, Industry Development
SIU School of Medicine
801 N. Rutledge Street | P.O. Box 19616 | Springfield IL 62794 | United States
Phone: (217) 545-8168 | Fax: (217) 545-7873 | Website: www.siumen.edu/adrfaltechtransfer
Contacts
Mr. Robert Patino | Director of Technology Transfer
Siuta Consulting, Inc.
14 Georgetown Oval | New City NY 10956 | United States

Phone: (845) 634-4491 | Fax: (845) 634-4491 | Website: www.siutaconsulting.com
Contacts
Dr. Gerald J. Siuta | President
Organization Type
Consulting Firm
Industry Sector
Health Care
Company Overview

Siuta Consulting, founded in 1995, is a pharmaceutical licensing consulting firm that provides
in- and out-licensing services to pharmaceutical companies, biotechnology companies,
universities and research institutes in order to enhance the worldwide development of new drugs.
Since 2001, we have been consulting for the Global Alliance for TB Drug Development (TB
Alliance), a not-for-profit, product development partnership whose mission is to accelerate the
discovery and development of new TB drugs that will shorten treatment, be effective against
susceptible and resistant strains, be compatible with antiretroviral therapies for those HIV-TB
patients currently on such therapies, and improve treatment of latent infection. The TB Alliance
is committed to ensuring that approved new drug regimens are affordable, widely adopted and
available to those who need them most. The TB Alliance is seeking new compounds with anti-
TB activity or new targets that can be used to discover new drugs to treat TB.
With regard to out-licensing, we have been retained by the Arizona Biomedical Research
Commission (for technologies arising out of state sponsored research at The University of
Arizona and Arizona State University) and Rutgers University to identify partners within the
pharmaceutical and biotechnology industries for the technologies listed below.
Pharmaceutical and biotechnology companies that:
(1) have novel compounds that have been shown to be active against tuberculosis;
(2) have novel targets that can be used to discover new anti-TB drugs;
(3) are interested in any of the early stage academic technologies listed below that are available
for license; or
(4) might have a need for the pharmaceutical licensing consulting services that we provide.
Country(s)
Partnering
Alginate Poly-L-Lysine
Encapsulation as a Technology for Stem Cells Not Applicable Worldwide
Controlled Differentiation of

Embryonic Stem Cells

Caffeine Sodium Benzoate – A Novel
Agent for Inhibiting Sunlight-Induced Cancer Oncology Not Applicable Worldwide
Skin Cancer
Methods and Compositions for the
CNS
Diagnosis and Treatment of Not Applicable Worldwide
Schizophrenia
Schizophrenia
Novel Compounds to Treat Infectiouse
Tuberculosis Disease
Novel Inducers of Apoptosis Cancer Not Applicable Worldwide
Novel Targets to Discover New Drugs
Infectious Disease Not Applicable Worldwide
to Treat Tuberculosis
Radial Glial Cells Promote Nerve
Regeneration and Functional
Stem Cells, CNS Not Applicable Worldwide
Recovery Following Spinal Cord
Injury
Screening Tools for Discovery of
Novel Therapeutic Agents to Treat CNS Not Applicable Worldwide
Cognitive Disorders
S-Nitrosoacetylpenicillamine (SNAP)
Induced Maturation of Embryonic Stem Cells Not Applicable
Stem Cell Derived Liver Lineage
Spray-On Wound Dressing Wound Healing Not Applicable Worldwide
Therapeutic Peptides for the
Treatment of Metastatic Breast Cancer Not Applicable Worldwide
Cancer
Skyworks Solutions Inc
20 Sylvan Rd | Woburn MA 1801 | United States

Phone: (781) 376-3197 | Fax: (781) 376-5189
Contacts
Dr. Dogan Gunes |
Mr. Daniel I. Jamison | Senior Director of IP Business Development
Smart & Biggar
55 Metcalfe Street Suite 900 | PO Box 2999 Station D | Ottawa ON K1P 5Y6 | Canada
Phone: (613) 232-2486 | Fax: (613) 232-8440 | Website: smart-biggar.ca
Contacts

Mr. Alistair Simpson | Partner

Mr. Theodore W. Sum | Partner
Organization Type
Law Firm
Company Overview
Smart & Biggar is Canada’s largest firm practising exclusively in intellectual property and
technology law with offices in Ottawa, Toronto, Montreal and Vancouver. Related to the patent
and trade-mark agency firm Fetherstonhaugh through common partners, offices, and personnel,
we have been leaders in our field for over a century. We provide advice on intellectual property
and technology law issues to a broad range of clients, from start-up companies in emerging
growth sectors to multinational corporations as well as universities and other research
institutions. We are regularly lauded as leaders in the field of IP by various independent surveys,
and partners of our firm play leading roles in national and international IP organizations. For
more information, please visit our website at www.smart-biggar.ca.
Solvay Pharmaceuticals, Inc.
901 Sawyer Road | Marietta GA 30062 | United States

Phone: (770) 578-5614 | Fax: (770) 578-5570
Contacts
Mr. Frank Jaeger | Associate Director, Business Development
Mr. Greg D. Tackoor | Director, Business Development
Company Overview
SOLVAY is an international chemical and pharmaceutical Group with headquarters in Brussels.

It employs some 30,000 people in 50 countries. In 2006 its consolidated sales amounted to EUR
9.4 billion, generated by its three activity sectors: Chemicals, Plastics and Pharmaceuticals.
SOLVAY (Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR) is listed on the
Euronext stock exchange in Brussels. Details are available at
http://pharmalicensing.com/company/dc/www.solvay.com
Solvay Pharmaceuticals is a research driven group of companies that constitute the global
pharmaceutical business of the Solvay Group. The company seeks to fulfill carefully selected,
unmet medical needs in the therapeutic areas of neuroscience, cardio-metabolic, influenza
vaccines, gastroenterology, and men’s and women’s health. Its 2006 sales were EUR 2.6 billion
and it employs approximately 10,000 people worldwide. For more information, visit
http://pharmalicensing.com/company/dc/www.solvaypharmaceuticals.com.

Solvay Pharmaceuticals recognizes that our industry faces unprecedented challenges due to the
turbulent dynamics of today's health care system. The growing need for quality products and
services in every dimension of health care provides an extraordinary opportunity for Solvay
Pharmaceuticals to meet future health care necessities.
While our human health care strategy has always included discovery and development of our
own innovative products, we also focus significantly on licensing and acquisition of
pharmaceuticals and technologies that complement our therapeutic categories.
We believe that collaboration with others is a major factor in our strength and innovation. By
working together with government, patient groups and professional associations, we are better
able to understand and meet the needs of our customers and physicians. By working together
with other pharmaceutical companies, we are able to accelerate the rate at which we can make
products available to the market.
Formed: 1863
Annual Turnover: 2.0 billion
Number of employees: 10000
Stock Exchange symbol: SOLB.BE
Southern Research Institute
2000 Ninth Avenue South | Birmingham AL 35205 | United States

Phone: (205) 581-2922 | Fax: (205) 581-2568 | Website: www.southernresearch.org
Contacts
Dr. Nancy Gray | Vice President
Company Overview
Southern Research Institute (http://www.southernresearch.org/) conducts basic and applied

research for clients and partners in the pharmaceutical, biotechnology, defense, aerospace,
environmental, and energy industries.
Southern Research specializes in:
 Drug Discovery and Preclinical Drug Development with a focus on therapeutics for
cancer and infectious diseases/emerging pathogens including Highly Pathogenic Avian
Influenza. Southern Research has discovered 20 drugs that have entered clinical trials, 6
of the FDA-approved cancer drugs currently on the market, and another 6 which are in
various stages of preclinical and clinical development. From our discovery programs,

Southern Research generates IP that is available for licensing and collaborative

development. Preclinical contract services offered by Southern Research include non-
GLP & GLP-compliant Toxicology; ADME/PK, Bioanalytical Services, and a variety of
Efficacy Models.
 Advanced Engineering primarily in the areas of mechanical and materials development

and testing; optics and systems development; air quality/emissions control testing; and,
alternative fuels and transportation technologies evaluation and development. The
Carbon-to-Liquids Development Center, recently established by Southern Research in
Durham, NC, develops new technologies and works with developers to optimize
technologies which are capable of converting Biomass to clean fuels and electric power.
SparkIP
75 5th Street, NW | Suite 220 | Atlanta GA 30308 | United States

Phone: 404-477-2525 | Fax: 404-477-2511 | Website: www.sparkip.com
Contacts
Mr. Paul A. Schwartz | Director, Business Development
Industry Sector
High Technology
Company Overview
SparkIP is the world's leading intellectual property research and marketplace platform with over
50 million patent documents and 10,000 licensable technologies, all organized in an interactive
visual landscape of more than 70,000 SparkClusters.
Squire, Sanders & Dempsey LLP
6611 North 64th Place | Paradise Valley AZ 85253-4346 | United States

Phone: (480) 607-1940 | Fax: (480) 607-1923 | Website: www.mlechter.com
Contacts
Mr. Michael A. Lechter | CEO
St. Louis University

3700 West Pine Mall | Fusz Memorial Hall, Room 253 | St. Louis MO 63108 | United States
Phone: (314) 977-7731 | Fax: (314) 977-1008
Contacts
Mr. Thomas A. Meyer | Head Innovationist

Stanford University
School of Medicine | 300 Pasteur Drive | Palo Alto California 94305 | United States
Phone: 650.725.7687 | Website: otl.stanford.edu
Contacts
Ms. Linda Chao | Senior Associate
Ms. Imelda Oropeza | Copyright Licensing Specialist
Stemcall Technologies Inc.
400 - 570 West 7th Avenue | Vancouver BC V5Z 1B3 | Canada

Phone: (800) 667-0322 | Fax: (800) 567-2899
Contacts
Ms. Krystie Hall | Business Development Administrative Assistant
StemCell Technologies, Inc
400 - 570 West 7th Avenue | Vancouver BC V5Z 1B3 | Canada

Phone: +1.604.668.0854 | Fax: +1.604.877.0704
Contacts
Mr. Luba Metlitskaia | Senior Business Development Officer
Company Overview
StemCell Technologies is a private company that was created in 1993 to take over the media
preparation service of the BC Cancer Agency's Terry Fox Laboratory. Since then, StemCell’s
lead product, MethoCult™, has gone on to become the world’s best selling methylcellulose-
based medium for hematopoietic colony assays and is now the industry standard. Additionally,
the company has developed specialized growth media products for hematopoietic (StemSpan™,
MyeloCult™), mesenchymal (MesenCult™), neural (NeuroCult™) and endothelial
(EndoCult™) stem cells and/or progenitors. The breadth of these successful products has
positioned StemCell Technologies as the primary source of specialized media products for stem
cell research. StemCell’s scientific and technical expertise in these areas is also routinely
accessed by both large and small pharmaceutical and biotechnology companies via the
company’s contract assay service.
StemCell Technologies is also a major player in the cell separation market with StemSep™,
RosetteSep™, and EasySep™, three unique cell enrichment systems that utilize StemCell’s
patented tetrameric antibody complex (TAC) technology, and SpinSep™ for murine cell
separations, that utilizes an alternate technology. RoboSep™, a fully automated cell separator
based upon column-free EasySep technology, will be available in early 2005.

Another active area of interest for StemCell Technologies is stem cell expansion technologies
and applications.
StemCell has an effective global sales and marketing infrastructure, with offices and/or
distribution centers in Canada, the USA, France and England, and a strong network of
international distributors. This infrastructure and StemCell’s bioreagents sales and marketing
know-how is being increasingly tapped into by other companies to sell their products to the
global life sciences community.
Sterne, Kessler, Goldstein & Fox
1100 New York Avenue, N.W. | Washington DC 20005-3934 | United States

Phone: (202) 772-8674 | Fax: (202) 371-2540
Contacts
Mr. Marvin C. Guthrie | Of Counsel
Mr. Michael Lee | Director
Stiefel Laboratories, Inc
255, Alhambra Circle | Suite 1000 - Coral Gables | Miami FL 33134 | United States
Phone: (305) 443-3800 | Fax: (305) 461-7910
Contacts
Mr. Patricia Fox-Butler | Assistant General Counsel
Mr. James Loerop | Sr. VP, Global Corporate Development
Stites & Harbison
400 W. Market Street | Suite 1800 | Louisville KY 40202-3352 | United States

Phone: (502) 587-3400 | Fax: (502) 587-6391 | Website: www.stites.com
Contacts
Mr. David W. Nagle | Patent Attorney
Company Overview
Stites & Harbison, PLLC is a preeminent law firm based in strategic Southeastern locations and
sought by business and institutional clients nationwide for sophisticated transactions, difficult
litigation and complex regulatory matters.
The Intellectual Property and Technology (IPT) Service Group of Stites & Harbison, PLLC uses
a team approach to provide clients with comprehensive intellectual property services. Our team

identifies, protects, acquires, transfers and defends our clients' intellectual property rights. Our
attorneys practice throughout the nation and the world in the areas of patents, trademarks,
copyrights, trade secrets, licensing, intellectual property rights for construction drawings,
computer software property rights, privacy, e-commerce and Internet transactions and IP
litigation (including infringement and unfair competition actions).
Sixteen members of the IPT Group are Registered U.S. Patent Attorneys. More than 30 attorneys
with the firm, including members of the IPT Group, have technical backgrounds in fields such as
engineering, including bioengineering, chemical, civil, electrical, industrial, mechanical and
nuclear engineering; life sciences/biotechnology, including biochemistry, cell biology, genetics,
immunology, microbiology, molecular biology and pharmacology; and other scientific and
technical disciplines such as chemistry, computer science, manufacturing, mining, physics and
telecommunications.
STONE Group
333 Hudson Street | Loft 304 | New York NY 10013 | United States
Phone: (012) 126-4535 x01
Contacts
Ms. Emily Stone |
Organization Type
Consulting Firm
Industry Sector
Consumer Products
Company Overview
Stone Group provides business visioning and licensing services to property owners of consumer
and luxury brands. Located in New York City, the firm works with clients in fashion, design,
the arts, and consumer products to develop and execute strategies that make a positive difference
to the brand and its owner.
President and founder, Emily Stone, is a strategic activist with extensive experience in global
brand building for image-driven companies. Working with leading marketing companies such as
Calvin Klein, Revlon, Bausch & Lomb, Kimberly-Clark, and Karl Lagerfeld for Tommy Hilfiger
Corporation, she designed programs to expand brand awareness, develop or reinvigorate
profitable revenue streams and enhance brand value.

Emily Stone and Stone Group have a successful history in licensing and strategic partnerships,
providing expertise for companies to successfully leverage intangible assets – their brands.
Stone Group was founded in 2001.

Trademarks, valuation
Trademark and brand licensors

Finding customers for in-licensing and out-licensing
Stony Brook University
N5002 Melville Library | SUNY at Stony Brook | Stony Brook NY 11794-3369 | United States
Phone: (631) 632-1361 | Fax: (631) 632-1505
Contacts
Ms. Jennifer Hsieh | Licensing Officer
Stout Risius Ross, Inc.
32255 Northwestern Highway | Farmington Hills MI 48334 | United States

Phone: (248) 208-8800
Contacts
Mr. David Cavallaro | Manager
Strategic Pharma Consulting Group LLC
P O Box 41 | Madison NJ 07940 | United States

Phone: +1-973-796-2653 | Fax: +1-973-796-2710 | Website: www.strategicpharma.com
Contacts
Dr. Mark Ravera | Principal

Organization Type
Consulting Firm
Industry Sector
Health Care
Company Overview
The Strategic Pharma Consulting Group was formed to help pharmaceutical and biotechnology
companies bridge the divide between developed and emerging markets. We provide strategic
advice to emerging market companies that are looking to grow their business operations into
more developed markets, and to pharmaceutical and biotechnology companies in more
developed markets that are looking to establish or expand their presence in emerging markets.
These market entry and expansion strategies can be based on organic growth, partnering and/or
acquisition. We believe that good strategy development and implementation take time and
commitment. For this reason, our firm looks to develop long-term relationships with clients in
order to work with them on an on-going basis as their businesses grow and evolve.

We are interested in meeting biotechnology and pharmaceutical companies that would like to
explore opportunities offered by emerging markets such as India and China. These opportunities
include:
 Outsourcing: Discovery, Development and/or Manufacturing

 Partnering: Co-Development; Co-Marketing
 In- and Out-Licensing
Smaller companies can especially benefit from the cost and time savings that can result from an
emerging markets initiative. We would be happy to discuss ways in which such an initiative can
be incorporated into a company's overall strategic plan.
Ström & Gulliksson AB
P O Box 4188 | | Malmö SE-203 13 | Sweden

Phone: +046 40 757 45 | Fax: +46 40 23 78 97
Contacts
Mr. Björn E. Andersson | European Patent Attorney
Mr. Lars Schonbeck | Managing Director
Organization Type
Law Firm
Company Overview
Leading the way to successful business

Ström & Gulliksson is a Swedish IP firm that offers a comprehensive range of services to
develop, protect, commercialize and defend our clients’ ideas in order to ensure their long-term
profitability. We stand apart from most other IP firms in the Nordic market in that we combine
expertise within technology and law with commercial and strategic counseling. Thus we handle
the whole chain of assignments from a first search to possible disputes and litigations. Thanks to
our unique cooperation with the law firm Gulliksson Advocates we also handle matters
concerning everything from trademarks, design rights and copyrights to market law, IT law,
domain names and licensing.
Clients
In our relations with our clients we always strive for top quality. It is thus our aim to offer all the
professional support they need and to accomplish our commissions in such a way that they will
be able to maximize the long-term value of their ideas. Our clients range from small and
medium-sized companies right up to global groups of companies within a wide spectrum of
business areas. Some of them seek advice from us in specific matters while others use our
services in their day-to-day operations instead of or as a backup to an in-house patent
department.
Our team
Among our professionals you will find patent attorneys, including European patent attorneys and
PhD's, as well as assistants with extensive experience. Through the combined knowledge and
experience of our professionals we can handle matters concerning inventions within all areas of
technology. Our services cover everything from patent prosecution and IP strategies to business
intelligence, risk analyses and litigation.
Network
Ström & Gulliksson is a subsidiary of the Arator Group – one of the major intellectual property
consultancy groups in the Nordic region with representatives in Denmark, Germany, Norway,
Sweden and USA. We continuously cooperate with the law firm Gulliksson Advocates with
which we share offices on the same premises at several locations in Sweden. We have also an
extensive cooperation with other law firms and patent attorneys around the world. Furthermore,
we are members of various Swedish and international organizations that give us access to an

extensive base of knowledge and open the doors to lines of businesses and companies both
within and outside the borders of Sweden.
Contact
Please feel free to contact any of our patent attorneys or assistants. You will find further
information and contact details on our website, www.sg.se.
Uniting Innovative Minds

We always emphasize the importance of cooperation – both between our professionals and
in our client relations. Through cooperation we can accomplish a dynamic fusion,
contributing not only to the development of existing ideas but also to the creation of brand
new ideas and good business opportunities. In this context we will consistently encourage
our clients to choose the right paths to ensure the commercial success of their ideas.

Being a European patent and law firm, we would like to explore possible co-operation
opportunities with industrial corporations and universities in the US and abroad. Also, we are
very interested in establishing new relations (and, of course, strengthening existing ones) with
patent and law firms particularly in the US, Canada and Asia. Quality and reciprocity are
parameters that we cherish.
Sunesis Pharmaceuticals, Inc.
341 Oyster Point Blvd. | South San Francisco California 94080 | United States
Phone: 650-266-3500 | Fax: 650-266-3506 | Website: www.sunesis.com
Contacts
Dr. Lesley Stolz | Vice President, Corporate & Business Development
Company Overview
Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development

and commercialization of novel small molecule therapeutics for oncology and other unmet
medical needs. We have built our product candidate portfolio through internal discovery and the
in-licensing of novel cancer therapeutics. We are advancing our product candidates through in-
house research and development efforts and strategic collaborations with leading pharmaceutical
and biopharmaceutical companies. We believe the quality and breadth of our product candidate
pipeline, platform technology, strategic collaborations and scientific team will enable us to
become a fully integrated biopharmaceutical company with a diversified portfolio of novel
therapeutics for major diseases.

We are advancing three proprietary oncology product candidates, SNS-595, SNS-032 and SNS-
314, through in-house research and development efforts. All three are inhibitors of the cell
division process, known as cell-cycle inhibitors, intended for the treatment of cancer. Sunesis has
developed a proprietary method of discovering drugs in pieces, or fragments. We call this
fragment-based discovery approach "Tethering®." Tethering® is a process whereby a target
protein known to be involved in a disease process is engineered to facilitate the binding of small
drug fragments. Once a small fragment is identified, the fragment is built out using the target
protein’s surface as a template to make a new full-size therapeutic compound.
We combine Tethering® with other drug discovery tools, such as structure-based design and
medicinal chemistry, to discover and develop novel therapeutics for major diseases. In addition
to its use in our internal drug discovery efforts, Tethering® is the basis of our five strategic
collaborations with Biogen Idec, Johnson & Johnson PRD and Merck. Since June 2004, each of
our current collaboration partners has either extended its existing collaboration or entered into a
new collaboration with our company.
We believe that our strategic collaborations will enable us to leverage and expand our internal
development capabilities, manage our cash expenditures and diversify risk across our pipeline
for Partnering
Fragment based drug
Oncology and others Lead Series
discovery capabilities
SNS-032 Oncology Phase II
SNS-314 Oncology Phase I
Cancer: Ovarian,
SNS-595 Phase II
Leukemias
SUNY at Stony Brook

Melville Library N5002 | Stony Brook NY 11794 | United States
Phone: (631) 632-9009 | Fax: (631) 632-1505
Contacts
Mr. Adam DeRosa | Licensing Associate
Ms. Donna Tumminello | Assistant Director
Syngenta Biotechnology, Inc.
3054 E. Cornwallis Road | Research Triangle Park NC 27709 | United States

Phone: 919.597.3066 | Fax: | Website: www.syngentabiotech.com

Contacts
Dr. Martha Dunn | Licensing Manager
Organization Type
Company Overview
Syngenta Biotechnology Inc. delivers innovative biotechnology products to Syngenta's

businesses through research, development and regulatory activities. We deliver outstanding crop
solutions in the agronomic, biofuels and crop processing business sectors, emphasizing
transgenic and native traits approaches across a broad range of crops and production systems.
Syracuse University
College of Law | Syracuse NY 13244 | United States

Phone: (315) 443-2534 | Fax: (315) 443-4141
Contacts
Mr. Ted Hagelin | Dir. NYS Science & Technology Law Center
Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
CAVTEC is the exclusive licensee of a patented IP valuation method called Competitive

Advantage Valuation® or CAV. The CAV method:
 Links principal determinants of technology value in a logical way

 Is easy to use and understand
 Can be used in multiple valuation contexts
 Can be scaled for simple and complex valuations
 Is neutral as between licensors and licensees
The CAV method has been embodied in a unique software program. The CAV software
program:
 Calculates a dollar value for discrete IP assets

 Is especially useful in valuing early-stage technologies

 Focuses attention on input values, rather than input variables
 Can be used to value licenses, plan R&D projects, measure return on R&D expenditures,
negotiate venture investments, calculate infringement damages and perform due diligence
investigations
CAVTEC seeks licensees for this unique valuation tool for IP managers and entrepreneurs.

CAVTEC's singular focus is on the valuation of IP assets, especially in the context of early-stage
technologies.

CAVTEC is interested in meeting with any organization involved in the valuation of intellectual
property assets including companies, consulting firms, law firms, accounting firms, universities,
research laboratories, early-stage companies and others.

CAVTEC's goals for the 2008 LES Annual Meeting are: (1) to debut the CAV software program
in the Annual Meeting Poster Session; and (2) to discuss licensing the CAV software program
with potential licensees.
for Partnering
Competitive Advantage
NA Not Applicable
Valuation Software Program
TAEUS International Corporation
1155 Kelly Johnson Blvd | Suite 400 | Colorado Springs CO 80920 | United States
Phone: (719) 325-5000 | Fax: (719) 632-5175 | Website: www.taeus.com
Contacts
Mr. Arthur Nutter | President and CEO
Mr. Matthew Troyer | Marketing Director
Mr. Glenn Wheeler | Vice President, Engineering
Organization Type
Consulting Firm

Industry Sector
High Technology
Company Overview
TAEUS International Corporation is the leader in applying engineering principles to patents.
TAEUS provides its clients with an elite network of technical experts using unique engineering
perspectives and innovative business methods to solve licensing and litigation problems
involving complex IP. Through an array of services, including portfolio analysis, reverse
engineering, prior art searches, patent valuation, and licensing support, TAEUS has helped some
of the world’s largest companies “protect and capitalize” on their intellectual assets.
Since 1992, TAEUS has reviewed more than 50,000 patents and performed over 1,600 technical
investigations for leading corporations, law firms, and other advisors. TAEUS is headquartered
in Colorado Springs, Colorado and has offices in Silicon Valley, Chicago, Austin, London,
Zurich, Tokyo, Seoul, Taipei, Shanghai, St. Petersburg, Moscow, and Romania. More
information about TAEUS can be found at www.taeus.com.

Our recent R&D focus has been developing new and innovative ways to simplify the tech
transfer process. We are interested in all ideas both new and old to help decrease the complexity
of tech transfer and speed up the tech transfer process.

TAEUS is in the high-technology space, and as such, we look forward to networking with both
vendors and new / existing customers. Our new products we will be better able to support the
life sciences field, as well as the small inventor. We feel we have something to offer and receive
from almost all the participants involved in LES.

TAEUS is a long-time sponsor of LES, and is proud to have major participation in this Fall's
Annual Meeting. We will have a large presence this year, sending seven TAEUS employees and
their spouses to the event.
Our goals are to continue to develop new relationships, nurture existing ones and participate
fully in all the educational opportunities this conference offers the TAEUS staff.
TAEUS is introducing some exciting new products this Fall. We are excited to properly vet our
approach to our new offerings with our fellow IP professionals.


Partnering
Patent Store n/a Not Applicable
Reverse Engineering
n/a Not Applicable
Services
Talecris Biotherapeutics
4101 Research Commons | T.W. Alexander Drive | RTP NC 27709 | United States
Phone: (919) 316-2081 | Fax: (919) 316-6031
Contacts
Mr. Dan Menichella | SVP, Corporate Business Development
Targacept, Inc.
200 East First Street, Suite 300 | Winston-Salem NC 27101-4165 | United States
Phone: +1.336.480.2100 | Fax: +1.336.480.2103
Contacts
Mr. Jeffrey Brennan | VP Business & Commercial Development
Mr. Scott Cullison | Director, Business & Commercial Development
Ms. Beth W. Fordham-Meier | Senior Director, Business & Commercial Development
Company Overview
Targacept, Inc. is a leading central nervous system (CNS)-focused biopharmaceutical company
with an extensive portfolio of candidates for first-in class therapeutics. Privately held, Targacept
is focused on the design, discovery, development and commercialization of a new class of drugs
to treat a variety of neurodegenerative, neuropsychiatric and gastrointestinal diseases.
Targacept’s researchers are world leaders in the design, discovery and development of a new
class of drugs that selectively modulate a unique class of molecular targets called neuronal
nicotinic receptors (NNRs), which are involved in regulating the nervous system’s activity.
Targacept’s neuropharmacology knowledge base and expertise in selectivity modulating NNRs
are distinct advantages in the CNS field, enabling the identification of drug candidates that target
specific receptors and provide therapeutic benefit with limited side effects. PentadTM, the
company’s powerful and proprietary in-silico drug discovery engine, further enhances our ability
to produce novel drug candidates for development even in the absence of the protein target’s
structure and to address multiple endpoints. Pentad provides the company with a strong
competitive advantage, and Targacept will continue to broaden its pipeline by developing
additional CNS drug candidates.

Targacept currently has one product on the market, Inversine® for the management of
hypertension, and has multiple product candidates in clinical development for treating various
disorders, including mild cognitive impairment and dementia (phase II), attention deficit
hyperactivity disorder (phase II), ulcerative colitis (phase II), and pain (Phase I). Targacept also
has preclinical candidates in development for Alzheimer’s disease, depression/anxiety,
schizophrenia, and smoking cessation, as well as discovery programs in obesity, Parkinson’s, and
inflammation.
Targacept secured $30.4 million in its first round of venture capital financing to advance its
research and development pipeline, and in 2003 completed a $60 million round of venture capital
financing from top-tier life science investors, further supporting the advancement and expansion
of the company’s clinical and discovery-stage product portfolio. With an broad portfolio of
candidates for first-in class therapeutics, decades of management experience, and an extensive
patent estate, Targacept is pioneering the next generation of CNS therapeutics.

Partnering
TBD Schizophrenia Preclinical Testing Worldwide
TBD Parkinson's Target Validation Worldwide
Memory & Cognitive
TC-1734 Phase II Worldwide
Disorders
TC-2286 & TC-
Depression/Anxiety Preclinical Testing Worldwide
2216
TC-2403 Ulcerative Colitis Phase II North America, Asia
TC-2696 Pain Phase I Worldwide
TC-5231 ADHD Phase II Worldwide
TBK-Patent
Bavariaring 4-6 | Munich 80336 | Germany

Phone: +49 89 544 690 | Fax: +49 89 544 692
Contacts
Dr. Georgi Chivarov |
Technology & Patent Research Int'l, Inc.

17055 Via Del Campo | Suite 200 | San Diego CA 92127 | United States
Phone: (858) 592-9084 | Fax: (858) 592-0045
Contacts
Mr. Mark Hower | Manager
Mr. Ford Khorsandian | President
Company Overview
Technology & Patent Research (TPR) International, Inc. (www.TPRInternational.com) is a full
service search firm specializing in researching U.S. and worldwide patent and non-patent
information sources for all areas of technology.
TPR services include analysis of prior art for patentability and state-of-the-art searches
through to infringement and validity studies.
TPR Researchers are professional searchers with long-standing experience and specialized skills
for searching the relevant resources and databases to their fullest potential. Our research experts
can provide all levels of help from the simplest author or patentee search, through to a
complicated biosequence, polymer composition, pharmaceutical Markush structure query or
electronics device search.
Technology Catalysts International Corp.
605 Park Avenue | Falls Church VA 22046 | United States

Phone: +1 703 531 0257 | Fax: +1 703 237 0042
Contacts
Mr. Richard DiCicco | President
Mr. Ajay Rastogi | Vice President
Organization Type
Consulting Firm
Industry Sector
Health Care
Company Overview
Technology Catalysts International is a technology and business consulting company offering
services in pharmaceutical, drug delivery, consumer care, and specialty chemical industries. Our
consulting services include drug delivery information services, licensing, technology transfer,
market research, business intelligence, deal structuring, valuation, IP management, and M&A.
We have offices in the US, Latin America, UK, Germany, Czech Republic, India, China, Korea,
and Japan.


We are very interested in tech transfer, valuation, IP management, university research.

We would like to meet pharmaceutical, drug delivery, consumer care, specialty chemical
companies.

We are interested in meeting with pharmaceutical, consumer care, and specialty chemical
companies to discuss in- and out-licensing needs, explain and discuss our services in drug
delivery consulting, offer our multiclient reports on:
Novel Drug Delivery Systems

Orally Disintegrating Tablets and Film Technologies
Strategies for Bioavailability Enhancement of Poorly Soluble Drugs
Active Skin Care Technologies
Technology Vision Group LLC
5200 Soquel Ave | Suite 202 | Santa Cruz California 95062 | United States
Phone: +1.831.464.4230 | Fax: +1.831.464.4240 | Website: techvision.com
Contacts
Ms. Jaroslava Dockalova | Project Specialist
Ms. Kim A Parisi | Administrative Assistant
Mr. Rick Perper | Meeting Assistant
Company Overview
Technology Vision Group LLC (TVG) is one of the leading business development organizations
in the life science industries. Since 1992, TVG has been developing innovative methods to help
life science and associated technology companies attract partners and investors, acquire new
products and technologies, and achieve a variety of other strategic business development goals.
As the annual producer of three of the leading life science industry conferences (C21
BioVentures, BioPartnering Europe, and BioPartnering North America), TVG has helped
members of the life science community successfully meet their business development objectives,
and has been instrumental in bringing innovative and emerging companies together with key
members of the pharmaceutical, venture capital, and finance industries for the express purpose of

partnering and collaboration. In 1995 we pioneered the development of what is now known as
“web enabled” conferences - a database accessible to conference delegates via the internet, with
searchable company profiles, meeting scheduling, and access to other important password-
protected information. We have continued to develop this unique and robust web platform,
biopartnering.com, which enables users to “contact, connect, collaborate” with a virtual
international community. biopartnering.com features a robust set of time management and
business development tools which help conference attendees proactively research and plan their
conference experience, giving them optimal opportunities for successfully achieving their
business development objectives. Since 2004, all of our conferences have been hosted on the
biopartnering.com site, which offers unprecedented opportunities for communication,
community and e-commerce. See www.biopartnering.com for details.
Because of its effectiveness and popularity, TVG began licensing biopartnering.com for use by
non-TVG hosted conferences in 2005. Since that time, some of the life science industry's leading
conferences and meetings have chosen biopartnering.com to support their event by empowering
their attendees with proactive business development, research, and organizational planning tools.
biopartnering.com has been the partnering platform of choice for BioFusion, AusBiotech, and
BioSquare, among others. This year, we will also be partnering new events with BioLatina and
the annual meeting of the Licencing Executives Society.
In 2007, the TVG team released another innovative multi-media product to help get the word out
for their clients, called “biopartnering.TV” - bp.TV (http://www.biopartnering.tv/). bp.TV is a
streaming video website featuring the current leaders in the lifesciences field, speaking on
relevant topics and displaying cutting-edge product development.
TVG also founded the Global Bioscience Partnership in 2003 - a virtual business development
group represented by international biotech associations. The new Global Bioscience Partnership
2.0 is a consortium of business development organizations and stakeholders whose goal is to
further promote the regional business development of the life science industries, through
networking and co-promotional opportunities. With a focus on bioclusters and their role in the
life science world, The Global Bioscience Partnership 2.0 is moving forward to create a virtual
hub for regional life science business development information, and utilize its resources to
further promote the goals of members.
This year TVG continues its collaborations with The Scientist magazine to produce a new global
lifescience business publication called Biotech360. The magazine was launched in May 2007 at
the BIO International Convention, and is the lifescience version of People and Wired magazines,
featuring interesting stories on biotech and the personalities that drive the biotech world.
TechTransfer Associates, Inc.

107 Primrose | Blacksburg VA 24060 | United States

Phone: (540) 953-1712 | Fax: (540) 953-1712
Contacts
Mr. Michael Martin | President
Organization Type
Consulting Firm
Industry Sector
Company Overview
80. Based on over 30 years of management experience in starting and growing intellectual
property management systems, TechTransfer Associates can: measure the potential of the
faculty, students, and staff to generate invention disclosures; the effectiveness of the office in
providing review of research contracts; soliciting disclosures; valuation; marketing;
patenting; licensing; the effectiveness of the relationship with the faculty and the University
administration; and recommend improvements
81.
82. TTA is representing a firm that has developed an expert system to evaluate medical device
inventions and a web protal that provides partnership opportunities and commercialization
resources. TTA is interested in discussing the demand for this new service.
83.

University Tech Transfer Offices and Medical Device Companies.
Terahertz Technologies LLC
536 N Civic Drive Suite A | Walnut Creek CA 94597 | United States

Phone: (510) 305-5320 | Fax: (925) 930-0966 | Website: terahertztech.net
Contacts
Dr. Boris G. Tankhilevich | President & CEO
Organization Type
Industry Sector
High Technology

Company Overview
Terahertz Technologies LLC has developed a revolutionary new terahertz laser technology for
wide range of life sciences, biomedical research, cancer research, bio discovery, drug discovery,
gene research, and other applications. Terahertz Technologies LLC has secured US and
worldwide protection of its revolutionary new technology. Terahertz Technologies LLC has
received the US National Science Foundation award in 2007. Terahertz Technologies LLC is
interested in out-licensing, collaboration, product development, etc.

Terahertz Technologies LLC is seeking early stage strategic partners and licensing investors to
accelerate technical development and technology insertion.
Medical equipment companies
Medical research companies.
Pharmaceutical companies.
Bioscience
Genetics research
Cancer research

Out-licensing. Research collaborations. Marketing agreements. Finding customers or services.
Country(s)
Partnering
Generation of Terahertz life sciences, biomedical
waves ; Tunable research, cancer research, bio
generation of terahertz discovery, drug discovery,
radiation gene research
Tessera Inc.

3099 Orchard Drive | San Jose CA 95134 | United States

Phone: (408) 383-3630 | Fax: (408) 894-0190 | Website: www.tessera.com
Contacts
Mr. Sandeep Agarwal | Director, Patent Analysis
Organization Type
Industry Sector
High Technology
Company Overview
Since 1990, Tessera has been developing technologies that have anticipated and successfully
addressed market demands for smaller, higher-performing electronic products at lower cost. By
meeting these requirements, the company’s technology has enabled the development of a broad
range of electronics used by millions of people every day. Cellular phones, PDAs, PCs, laptops,
gaming consoles, MP3 players, hearing implants and defense electronics are just a few of the
products that incorporate Tessera’s patented technology.
Tessera’s product offering includes a wide range of semiconductor packaging, interconnect and
consumer optics technologies. In the packaging & interconnect space, Tessera’s µZ® multi-chip
product line builds on the company’s foundational µBGA® chip-scale technology and enables
adopters to stack multiple chips within the footprint of a single package. Tessera’s wafer-level
SHELLCASE technology offering makes it possible to package images sensors and other optical
devices in form factors essentially identical in size to the chip itself. The company’s consumer
optics technologies are used to shape and influence light and are integrated into a number of
applications, including semiconductor equipment optics and communications devices.
Tessera opened its research and development facilities in Yokohama, Japan in February of 2007.
This facility is focused on addressing the challenges of electronic products miniaturization from
a system perspective, specifically through the dense interconnection of components, extensive
use of three-dimensional packaging technologies, and the use of micro-optics technologies. Our
advanced packaging substrate efforts focus on developing packaging prototypes that utilize and
leverage the benefits of our substrate technology and working with customers to incorporate our
technology into their products.
Companies involved in Semiconductor supply chain and Optics (especially as related to

miniaturization of cameras)

The key goals are education and networking.

Teva Neuroscience, Inc.
901 W. 104th Street | Kansas City MO 64131 | United States

Phone: (816) 508-5164 | Fax: (816) 508-5525 | Website: www.tevaneuroscience.com
Contacts
Mr. Michael McHugh | Vice President, Strategic Planning & Business Development
Mr. Michael E. Ragsdale | Corporate Counsel
Mr. James A. Rodenberg | Assistant General Counsel
Mr. Karl Strohmeier | Director Business Development
Mr. Kenneth Wentzel | Sr. Project Manager
Organization Type
Company Overview
Teva Neuroscience is the branded neurological products franchise of Teva Pharmaceutical

Industries Ltd. and is responsible for the development, registration and marketing for Teva's
branded neurological products in North America. Teva Neuroscience has administrative,
commercial marketing, and other leadership functions based in Kansas City, MO at its North
American headquarters, as well as a facility in Horsham, PA, home to the company's clinical
research activities and regulatory functions, and an office in Montreal, Quebec, headquarters for
the company's Canadian presence.
Teva Neuroscience markets COPAXONE® (glatiramer acetate injection) and AZILECT®

(rasagiline tablets).

Pharmaceutical product opportunities in the following areas: multiple sclerosis, neurology,
autoimmune disorders and oncology.

Teva Neuroscience is interested in meeting with entities that have an interest in finding a
development and commercialization partner for drugs targeting multiple sclerosis,
neurology autoimmune disorders and oncology.

To find licensing opportunities in the following areas: multiple sclerosis, neurology, oncology
and autoimmune disorders.
Texelerate

2119 Delancey Place | Philadelphia PA 19103 | United States

Phone: (215) 275-8492
Contacts
Mr. Louis Berneman |
Textron Innovations Inc.
40 Westminster Street | Providence RI 02903 | United States

Phone: (401) 457-3577 | Fax: (401) 457-3666
Contacts
Mr. Robert J. Pascal | Intellectual Property Director
Mr. James P. Runstadler | Vice President, Licensing
Thallion Pharmaceuticals Inc.
7150 Alexander Fleming | Montreal Quebec H4S 2C8 | Canada

Phone: +1 (514) 940-3611 | Fax: +1 (514) 228-3621 | Website: www.thallion.com
Contacts
Dr. Allan Mandelzys | Executive Vice President, Licensing and Corporate Development
Organization Type
Industry Sector
Health Care
Company Overview
Thallion Pharmaceuticals Inc. is a biotechnology company focussed on developing new
treatments for under-served markets in oncology and infectious diseases. Thallion currently has
three products in clinical development that target infectious disease and multiple oncology
indications. These products offer multiple opportunities in a range of markets including orphan
drug indications such as shiga toxin infection, primary glioma and metastatic melanoma and
larger markets like renal cell carcinoma and pancreatic cancer where limited treatment options
exist.
Thallion's first product candidate is Shigamabs®, a dual antibody product for the treatment of
Shigatoxin-producing E. coli bacterial infections. Thallions is also developing two oncology
products based on targeted therapy; ECO-4601, a novel small molecule derived from a

nonpathogenic microorganism targeting the ras/raf pathway and CAP-232, a novel peptide with
potential efficacy in multiple oncology indications as well as neuropathic pain.
DECIPHER®, Thallion's proprietary technology platform, is a powerful drug discovery engine

that uses a combination of genomics and bioinformatics to predict the structures of secondary
metabolites based on gene sequences obtained by scanning bacterial genomes. To date, the
company has identified over 70,000 gene sequences, 1,600 biosynthetic enzyme loci and has
isolated and profiled more than 60 NCEs. Thallion's ECO-4601 compound was discovered using
the Decipher platform.

Global development and commercialization companies with proven track-record in drug
development
Thallion is seeking global development and commercialization partners for its 3 clinical-stage
programs.
1- ECO-4601, a small molecule that binds to the peripheral benzodiazepine receptor (PBR)
and inhibits the RAS-mitogen-activated phosphokinase (MAPK) pathway. ECO-4601 has
the potential to treat multiple solid tumors. Currently in Phase I/II trials.
2- Shigamabs, an immunotherapy to prevent and treat complications resulting from Shiga

Toxin E. coli infections. Currently gearing up for pivotal Phase II/III trials.
3- CAP-232, a novel peptide against solid tumors with clinical proof of concept in metastatic
melanoma and pre-clinical proof of concept in neuropathic pain. Currently in phase II in
Renal Cell Carcinoma; gearing up for Phase II trial in metastatic melanoma.
In addition, Thallion is seeking to enter into strategic alliances for the Decipher platform to
enable the identification of novel natural compounds with broad therapeutic potential.
for Partnering
CAP-232 Oncology, Pain Phase II Worldwide
Oncology, Inflammation,
Decipher Lead Series Worldwide
Infectious Diseases
ECO-4601 Oncology Phase II Worldwide
Shigamabs Infectious Disease Phase II Worldwide


The Boeing Company
Intellectual Property Management | PO Box 3707, MC 14-29 | Seattle WA 98124 | United States
Phone: (206) 655-5235
Contacts
Mr. Michael L. Griffin | Director, Intellectual Property & Technology Licensing, Logistics
Support System
Mr. Jonathan B. Jones | Contracts Manager
Ms. Gail M. Roth | Director, Consumer Products Licensing
Mr. David A. Vaughan |
Organization Type
Industry Sector
High Technology

Partnering
Aerospace
none Not Applicable
Technology
The Boeing Management Company
15460 Laguna Canyon Road | MC 1650-7002 | Irvine CA 92618 | United States

Phone: (949) 790-1331 | Fax: (949) 790-1331
Contacts
Mr. Terrance Mason | IDS Technology Licensing Mngr
The Brattle Group
44 Brattle Street | Cambridge MA 2138 | United States

Phone: (617) 864-7900 | Fax: (617) 864-1576 | Website: www.brattle.com
Contacts
Mr. Michael Dansky | Principal

Company Overview
The Brattle Group provides consulting and expert testimony in economics, finance, and
regulation to corporations, law firms, and governments around the world. We combine in-depth
industry experience, rigorous analyses, and principled techniques to help clients answer complex
economic and financial questions in litigation and regulation, develop strategies for changing
markets, and make critical business decisions.
Our consultants and advisors are internationally recognized experts from both the public and
private sectors and have participated in many high profile litigation efforts over the past two
decades. Project teams are led by principals and senior advisors who share a strong commitment
to their profession, clients, and colleagues.
The Brattle Group first opened its doors in 1990 in Cambridge, MA with a staff of five. The
founders were dedicated to establishing a firm recognized for integrity and excellence in
economic and financial consulting across a range of practices and industries. In 1995 the firm
combined with Incentives Research, Incorporated to strengthen its expertise in energy matters.
Since the firm’s founding our staff has grown to more than 200. Our goal, however, remains the
same: to provide our clients the highest quality consulting services in our industry.

The Brattle Group provides expert services and strategic guidance to law firms, corporations,
and institutions around the world in a wide range of intellectual property matters. We value IP
assets for transactional, tax, and other strategic purposes. Our clients often engage us to assist in
due diligence, strategy development and execution, and risk analysis. We also assess damages
and liability issues resulting from allegations of IP infringement involving patents, copyrights,
trademarks, and trade secrets. We have provided expert testimony in many high profile IP
litigation efforts over the last twenty years.
Our team includes Ph.D.s, economists, and M.B.A.s, a number of whom have held senior
management positions at public and private companies where they managed, evaluated, and
leveraged IP assets. The Brattle Group is distinguished by our multidisciplinary, team oriented
approach that allows us to match our industry and technical skills to the challenges facing our
clients.

The Brattle Group assists corporations and law firms with strategy, planning, litigation, and
regulatory matters. Please contact Michael Dansky at 617.864.7900 for more information.
The Church of Jesus Christ of Latter-day Saints
50 E. North Temple Street | Rm. 1880 | Salt Lake City UT 84150-3012 | United States
Phone: (801) 240-8099 | Fax: (801) 240-1187

Contacts
Mr. Barry Taggart | Manager, IPO
The Coca-Cola Company
11870 Devon Downs Trail | Alpharetta GA 30005 | United States

Phone: (678) 417-4999 | Fax: (678) 417-4999
Contacts
Mr. H. Brock Kolls | External Technology Acquistion Director
The College of William and Mary
158 Nina Lane | Williamsburg VA 23188 | United States

Phone: 919 451 2345 | Fax:
Contacts
Mr. Jason McDevitt |
Company Overview
I have extensive experience at comprehending novel technological concepts, identifying
customers, gathering data on potential market sizes, and formulating a business plan. I am also
familiar with the matrixed corporate structure of international pharmaceutical companies and the
priorities of such an organization. I believe that the combination of my MS in genetics and my
MBA degrees will offer great value in determining the strategic fit of drug candidates in the
development pipeline.
The Dow Chemical Company
4510 Executive Drive | Suite 206 | San Diego CA 92121 | United States
Phone: +1 (858) 550-0959 Ext.107
Contacts
Mr. Bruce Story | Intellectual Asset Director
Ms. Catherine A. Wedelstaedt | Sr. Intellectual Capital Leader
Organization Type
Industry Sector
Chemicals

Company Overview
Dow is a diversified chemical company that harnesses the power of innovation, science and
technology to constantly improve what is essential to human progress. The Company offers a
broad range of products and services to customers in more than 175 countries, helping them to
provide everything from fresh water, food and pharmaceuticals to paints, packaging and personal
care products. Built on a commitment to its principles of sustainability, Dow has annual sales of
$49 billion and employs 43,000 people worldwide.
Dow Biosciences was established to renew and accelerate Dow’s pursuit of business
opportunities in the growing bioscience arena. With goals of driving value growth and improving
the success and sustainability of our customers and our company, the Biosciences team has
developed a multi-phased vision and identified key areas of focus to support Dow’s Biosciences
platform. At Dow, sustainability not only refers to the environment, but also involves creating
sustainable business practices, two objectives Biosciences hopes to meet.
The Dow Biosciences team has extensive expertise in raw materials and biofeedstock trends,
exploring new biobased feedstock and product opportunities and taking on early stage research
and development risk. To accelerate the success in creating new biobased customer solutions and
access innovative and emerging conversion technologies, the Biosciences team seeks
partnerships and collaborations with world-leading research, university-based and commercial
organizations.
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
1401 Rockville Pike | Suite 600 | Rockville MD 20852 | United States

Phone: (301) 294-1223 | Fax: (301) 294-8130 | Website: www.hjf.org
Contacts
Ms. Carol C Lavrich | Director
Country(s)
Partnering
ABeta Channel Blocking
Pharmaceutical to Treat
Peptides to treat Alzheimer's Not Applicable Worldwide
Alzheimer's Disease
disease

Abeta channel blocking

Small Molecules to treat Alzheimer's disease Not Applicable Worldwide
Alzheimer's Disease

The Mattson Jack Group

300 W State Street | Suite 304 | Media PA 19063 | United States
Phone: 484.442.1416 | Fax: 484.442.1466 | Website: www.mattsonjack.com
Contacts
Mr. Joseph S. Dillon | Senior Vice President
Mr. William Mattson | Chairman
Organization Type
Consulting Firm
Industry Sector
Health Care
Company Overview
Formed in 1986, MattsonJack focuses its client support in three areas of
Competency: Business Analytics, Brand Optimization, and Corporate
Development services in the pharmaceutical and biotech markets.
MattsonJack consultants have expertise in pricing and reimbursement,
custom epidemiology, technology assessment, business and strategic plan
development, due diligence and licensing support, market modeling and
forecasting, and primary market research. MattsonJack's client list ranges
from emerging companies to some of the most recognized pharmaceutical and
biotech companies in the world, such as Abbott, Amgen, AstraZeneca,
Genentech, GlaxoSmithKline, Johnson & Johnson Companies, Merck, Novartis,
Pfizer, Roche, Wyeth, and many others.
MattsonJack's knowledgeware and client productivity tools include Epi

Database(R) and Forecast Architect(R). Additionally, MattsonJack, as one
of the largest global oncology consulting firms, supports its clients'
cancer interests through its MattsonJack DaVinci multiclient offerings,
including CancerMPact(R), CancerNSight(TM), and Oncology Marketing
Strategies(TM).
MattsonJack is part of Kantar Group, the information, insight, and

consultancy division of WPP, a world leader in marketing communications
services.

MattsonJack and it's executives have been long time members and supporters of LES. Mr. Dillon
is a member of LES's Health Care Sector Executive Committee and Chairperson of it's Education
Committee. We have many colleagues and business associates who also attend the LES
functions. So, we are able to pursue our partnering and business development engagements on
behalf of our clients while we attend the LES functions.


Pharmaceutical and biotechnology focused companies worldwide.

In-licensing, out-licensing and general business development. We currently represent clients on
both the buy and sell sides.
The Moore Law Group
228 Hamilton Avenue | 3rd Floor | Palo Alto CA 94301 | United States
Phone: (650) 798-5354 | Fax: (650) 798-5001
Contacts
Mr. Thomas Moore | Partner
The Nath Law Group
112 South West Street | Alexandria VA 22314 | United States

Phone: (703) 548-6284 | Fax: (703) 683-8396
Contacts
Mr. Ross Epstein | Partner
Mr. Jerald Meyer | Partner
Mr. Gary Nath | Managing Partner
Organization Type
Law Firm
Company Overview
By way of introduction, The Nath Law Group is a medium sized intellectual property and
business law firm specializing in patent and trademark prosecution, licensing and enforcement,
as well as general transactional matters. Our scientific expertise spans all technical disciplines
with particular emphasis on chemical, pharmaceutical, biotechnology and biomedical, electrical,
and mechanical inventions. We also have strong expertise in filing and prosecuting foreign origin
applications before the U.S. Patent and Trademark Office as well as advising on foreign and
domestic transactions.
Our services include domestic and foreign patent and trademark preparation and prosecution,
licensing consultation and portfolio evaluation, interference and litigation, corporate structuring
and finance, mergers and acquisitions as well as general counsel services.

The Nath Law Group successfully conducts business in over 130 countries with colleagues and
clients. Our firm is highly accomplished at developing worldwide patent strategies; providing
patent validity and infringement opinions; conducting comprehensive searches for patentability,
infringement and enforcement matters. Our patent attorneys, registered patent agents and
technical advisors have extensive technical training and hands-on expertise in every area of
technology and intellectual property law.
The Nath Law Group originated in 1993 and is now celebrating its 15th year anniversary. We
have offices in the Washington, DC area and San Diego, CA. Our firm now consists of
approximately twenty professionals and twenty support staff. Our size and staff permit an
approach which results in our clients receiving the technical expertise needed at a reasonable cost
with the personal attention larger firms rarely deliver.
We take great pride in being able to provide our clients with high quality work from highly
qualified personnel on a cost effective basis.

The Nath Law Group's LES interests include providing legal services for patents, trademarks,
tech transfer, valuation, and intellectual asset management.
The types of companies that representatives from The Nath Law Group are interested in meeting
with are potential clients from major U.S., European or Asian multinational corporations;
universities and other research institutions; small businesses and start-up companies; sole
inventors; authors and publishers.
We are also interested in meeting with colleagues from intellectual property law firms that are
based outside of the U.S.
Contact Gary Nath or Ross Epstein to setup meetings.
The Nielsen Company
10 Waterview Blvd. | Parsippany NJ 7054 | United States

Phone: (973) 299-2207
Contacts
Mr. Dennis Melton | VP - Intellectual Property

The Rockefeller University
1230 York Avenue | 502 Founders Hall | New York NY 10021 | United States
Phone: (212) 327-7095 | Fax: (212) 327-8267
Contacts
Dr. Kathleen Denis |
Mr. Adam Forman | Intellectual Property Advisor
Organization Type
University
Industry Sector
Health Care
Company Overview
Rockefeller University is an biomedical research academic institution located on the Upper East
Side of Manhattan. The areas of research covered by the 71 laboratories on campus cover
biochemistry, structural biology, molecular, cell, and developmental biology, immunology,
virology, microbiology, human genetics, neuroscience, physics, and mathematical biology.
Rockefeller has been associated with 29 Nobel laureates and 19 Lasker Award recipients, and
our discoveries have included: DNA is the basic material of heredity, cancer can be caused by a
virus, confirming the connection between cholesterol and heart disease, developing methadone
maintenance for heroin addicts, and developing the AIDS cocktail drug therapy.
The Office of Technology Transfer at Rockefeller University promotes and supports the research
enterprise at the University by creating relationships with the private sector to develop, protect,
transfer, and commercialize research results for the public benefit.
The UAB Research Foundation
1120G Administration Building | 701 20th Street South | Birmingham AL 35294 | United States
Phone: 205-975-6851 | Fax: 205-934-5427 | Website: www.uab.edu/vabof
Contacts
Dr. Deborah Bidanset | Program Director/ Licensing Associate
Mr. David Winwood | Chief Executive Officer
The University of Mississippi

1009 Thad Cochran Research Center | University MS 38677 | United States

Phone: (662) 915-7188 | Fax: (662) 915-
1006 | Website: www.olemiss.edu/depts/research/technology
Contacts
Ms. Allyson M. Best | Assistant Director, Division of Technology Management
Dr. Walter G. Chambliss | Director, Technology Management
Organization Type
University
Industry Sector
Country(s)
Partnering
A Mobile Process for Solubilization
and Disposal of Radioactive Scale
Oil and Gas Industry Not Applicable
and Sludge from Oil and Gas
Production
Electropulsation Mediated Drug
Drug Delivery Not Applicable
Therapy for Nail Disorders
HIF Anticancer Agents Cancer Not Applicable
High-Speed Data Compression
Based on Set-Associative Cache n/a Not Applicable
Mapping Techniques
Detection and
Human Detection Sensor Not Applicable
Security
Method of Screening Anticancer Research Tool for
Not Applicable
Compounds Cancer
Methods and Compositions for
Cancer Not Applicable
Isolating Taxanes
New Indolizidine Antiinfective
Antiinfective Not Applicable
Compounds
Novel Analogs of Artemisinin as
Broad Spectrum Anti-infective Antiinfective Not Applicable
Agents
Novel Class of Anticancer Agents Cancer Not Applicable

Novel Controlled Release Pellet Formulation/Drug

Not Applicable
Technology Delivery
Predictive Preclinical Screening Research Tool for
Not Applicable
Model for Anxiety and Depression CNS
Prevention/Prophylactic Treatment
Dermatology Not Applicable
of Poison Ivy Dermatitis
Reduction of Nitrogen Oxide by a
Mixed Fuel by Reburning During Combustion Not Applicable
Coal Combustion
Selective Algaecide for Control of
Agrochemical Not Applicable
Cyanochloronta
Topical Psoriasis Agent Dermatology Not Applicable
Transmucosal Delivery of
Drug Delivery Not Applicable
Cannabinoids
Treatment for Cryptosporidiosis and
Antiinfective Not Applicable
Giardiasis
Treatment for Drugs of Abuse
Drugs of Abuse,
Toxicity: Selective Sigma Receptor Not Applicable
Research Tool
Ligands
Underwater Biomass Assessment Aquaculture and
Not Applicable
Device and Method Seafood Industry
The UT M.D. Anderson Cancer Center
7515 S. Main St. | Suite 490 | Houston TX 77030 | United States

Phone: (713) 745-9639 | Fax: (713) 563-9568
Contacts
Dr. Andrew Dennis | Manager, Licensing
The Walt Disney Company
500 South Buena Vista Street | Burbank CA 91521 | United States

Phone: (818) 560-3927 | Fax: (818) 848-5099
Contacts
Ms. Elaine Paul | Senior Vice President of Corporate Strategy
Theratechnologies Inc.

2310, Alfred-Nobel Blvd. | Montreal H4S 2A4 | Canada

Phone: 514-336-7800
Contacts
Mr. Claude Larose | Director, Business Development
ThinkFire Services USA Ltd
25 Independence Boulevard | Suite 402 | Warren NJ 07059 | United States

Phone: (908) 991-9006 | Fax: (908) 991-9038
Contacts
Mr. Bernard Kang | Director
Mr. Robert Lopes | CTO
Mr. Richard Misiag | Vice President, Licensing
Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
ThinkFire is an intellectual property licensing and advisory firm that works with leading
technology companies and investors worldwide. We partner with clients to maximize financial
return on inventions, expertise and costly R&D and to enhance shareholder value.
Thomson Reuters
Headquarters | 3 Times Square | New York NY 10036 | United States

Phone: +1 646.223.4000 | Website: www.thomsonreuters.com
Contacts
Mr. David Brown | EVP Corporate Markets
Dr. Isabelle M. Gorrillot | Product Manager, Business Solutions
Mr. Patrick Hayford | Manager, Strategic Accounts
Mr. Stuart Recher | Director, Strategic Accounts Group
Industry Sector
Health Care
Company Overview

The Scientific business of Thomson Reuters (Thomson Scientific) assists companies uncover
new technology and get it to market faster, for researchers to find relevant papers and know
what's newly published in their subject and for businesses to optimize their intellectual property,
find competitive intelligence, and opportunities for commercialisation.
Thomson Scientific commercializes a broad array of knowledge management solutions,

including products specifically targeted to the biopharmaceutical industry business development
and licensing, strategic alliances, and corporate venture needs. Are you looking for in-/out-
license opportunities? Do you want to monitor a particular franchise? or company? Thomson
Scientific commercializes three complementary database products, Thomson Pharma, IDdb3,
and SDdb to address most of your partnering due diligence needs.
Thomson Scientific is a business unit of Thomson-Reuters (NYSE/TSX/LSX/NASDAQ: TRI),

the world's leading source of Intelligent Information for businesses and professionals. Thomson
Reuters was named 44th in the BusinessWeek 2008 ranking of the Top 100 Global Brands.
Thomson-Reuters counts approximately 50,000 employees in 93 countries, and generates about
86% of its revenues from products and services that are recurring or subscription based in nature.

Thomson Scientific, a business unit of Thomson Reuters is interested in connecting with BDL,
Strategic Alliances and Investment professionals regarding your experience with knowledge
management products, their relevance to your daily needs, and how you would like to see such
solutions to be improved to more effectively address your needs. We are also interested in
meeting software companies potentially interested in partnering with us for the development of
new market and business intelligence products serving the biopharmaceutical industry.

In-licensing opportunities, professional feedback (customer as well as non-customers),
customers.
Country(s)
Partnering
BIOMARKERcentre all major therapy areas Not Applicable Worldwide
all major therapy areas
IDRAC Not Applicable Worldwide
including medical devices
Investigational Drugs
All Not Applicable Worldwide
Database IDdb3
Strategic Drugs Database
All Not Applicable Worldwide
(SDdb)
THOMSON Innovation All major therapy areas Not Applicable Worldwide

THOMSON Pharma All major therapy areas Not Applicable Worldwide
Toray Industries (America), Inc.
461 Fifth Avenue | 9th Floor | New York NY 10017 | United States
Phone: (212) 922-7211 | Fax: (212) 972-4279
Contacts
Dr. Hiroshi Ohno | Director Pharmaceuticals & Medical
Organization Type
Industry Sector
Health Care
Company Overview
Toray Industries, Inc. is a Japanese chemical based company. We have pharmaceutical and
medical device division as well as biotechnology labs. Our total sales is more than $13B, and the
sales of pharmaceuticals and medical device divisions is about $600M.
www.toray.com
We are interested in out-licensing and/or collaborations regarding following technologies,
DNA chips
Hepatitis C Virus (HCV) Vaccine
Animal Cancer Diagnostics
PEG-Interferon
Integrin Antagonist
And also we are interested in marketing agreement of medical devices in Japan.
Tore Stenholm Advokatbyrå AB

P.O. Box 55931 | Stockholm 102 16 | Sweden

Phone: +46 8 6676615
Contacts
Mr. Tore K. Stenholm | Attorney

Toscana Ventures, Inc.
5340 Toscana Way F202 | San Diego CA 92122 | United States

Phone: 858.652.1392
Contacts
Mr. Jasper Schaible | President
Organization Type
Consulting Firm
Industry Sector
Health Care
Company Overview
Toscana Ventures, Inc. is a boutique biopharmaceutical consultancy, working with companies of
all types to meet their business development needs. We are specifically engaged in general
corporate development activities such as in-license evaluations, out license assignments,
opportunity marketing and messaging, spin outs and M&A. And we are also actively evaluating
pre-IND to PhII clinical stage biopharmaceutical development opportunities, with the goal of
incubating spinout / startup ventures.
As the 2007-2008 Chair of the LES (USA & Canada) Health Care Sector, I also welcome
discussions on suggestions to improve our meetings and organization in general.
Also, interested to meet with companies with opportunities descibed below.
1. Biotech and pharmaceutical companies, as well as university and government offices of

tech transfer, seeking business development, corporate development, negotiating and
arbitration support.
2. Companies, as well as university and government offices of tech transfer, seeking to out
license early stage drug development opportunities.

Transpacific IP Pte Ltd
7 Temasek Boulevard #08-02B | Suntec Tower One | Singapore 38987 | Singapore

Phone: 65-8233-3874
Contacts
Ms. Diana Chen | Vice President, Business Development
Mr. Sean Lu | Portfolio Manager
Mr. Kevin Mulroy | Manager Business Development
Mr. Guy Proulx |
Tribute Pharmaceuticals Inc
57 Martin Street | Milton ON L9T2R1 | Canada

Phone: (905) 815-3577 | Fax: (905) 876-4675
Contacts
Mr. Rob P. Harris | President
Organization Type
Industry Sector
Health Care
Company Overview
Tribute Pharma is engaged in the acquisition and management of mature pharmaceutical
products in the United States, Canada, Europe and Latin America. Tribute Pharma is also
interested in licensing new chemical entities or new formulations for Canada.

Pharmaceutical (including Specialty Pharmaceutical) Companies
We are interested in meeting with pharmaceutical companies that are considering divesting
mature pharmaceutical products in the USA, Canada, Europe or Latin America. We are also
interested in any licensing opportunites of new products or formulations for Canada.
Tubay Consultancy & Law Firm

Saglik Sokak 46 D.14 | Yenisehir | Ankara 6420 | Turkey

Phone: 90.532-451-9055 | Fax: 90.312-435-5509
Contacts
Ms. Tuna Yurtseven | European Patent Attorney
Tufts University
136 Harrison Avenue | Suite 75K-950 | Boston MA 02111 | United States

Phone: (617) 636-0366 | Fax: (617) 636-2917 | Website: techtransfer.tufts.edu
Contacts
Mr. John Cosmopoulos | Senior Manager, Business Development
Organization Type
University
Industry Sector
\
Company Overview
Tufts University is a private university encompassing eight undergraduate, graduate and

professional schools: Arts and Sciences, Engineering, Medicine, Dental Medicine, Veterinary
Medicine, Nutrition Science and Policy, the Fletcher School of Law and Diplomacy and the
Sackler School of Graduate Biomedical Sciences. Extramural research support totaled $160
million for the University including its affiliates. Tufts University is located at three campuses in
Massachusetts: the Boston campus housing the medical, dental and nutrition schools as well as
the Jean Mayer USDA Human Nutrition Research Center on Aging, the Grafton campus in
Western Massachusetts housing the veterinary school, and the Medford/Somerville campus
housing the arts and sciences and engineering schools.
School of Medicine: The School of Medicine draws on the talents of more than 3,500 faculty
members counting both basic science faculty and clinicians associated with its affiliated
hospitals, the New England Medical Center, St. Elizabeth's Hospital, the Lahey Clinic and
Baystate Hospital. Also affiliated with Tufts is the Tufts Center for the Study of Drug
Development. Established in 1976, the Center provides strategic information to help drug
developers, regulators and policy makers improve the quality and efficiency of pharmaceutical
development, review and utilization.
School of Dental Medicine: Closely associated with the medical school is the School of Dental
Medicine, sharing the basic science faculty. In addition, the dental school has its own clinical

faculty of 378 professionals and operates clinics which record more than 36,000 patient visits per
year, making the School of Dental Medicine an excellent clinical trials site.
Tufts Friedman School of Nutrition Science and Policy, Jean Mayer USDA Human
Nutrition Research Center on Aging (HNRC): The HNRC, an integral part of the Tufts
School of Nutrition Science and Policy, is one of six research centers funded by the USDA's
Agricultural Research Service. Since its opening in 1982, the HNRC has been a leader in
nutrition research focused on the prevention and delay of chronic diseases common among the
aging population. Clinical studies, along with those conducted in cell culture and animal models
have uncovered critical links between nutrition, aging and health and have helped to define new
dietary requirements for older adults.
Tufts Cummings School of Veterinary Medicine: With a total of approximately 70 basic and
clinical faculty, the School of Veterinary Medicine offers state-of-the-art clinical and research
facilities in over 20 clinical specialties, expertise in diverse animal populations and disease
models, large and small animal surgical services and behavioral pharmacology. The veterinary
school is uniquely positioned to perform high quality research, development and testing of
biomedical products and devices for both human and veterinary medical applications.
School of Arts and Sciences, School of Engineering: The Tufts Medford/Somerville campus is
home to the traditional scientific and liberal arts disciplines of the School of Arts and Sciences,
as well as the School of Engineering. With roughly 100 faculty members in total, the School of
Engineering houses programs in Chemical, Civil and Environmental, Electrical and Computer
Sciences, Electro-Optics and Mechanical Engineering. An integral part of the engineering
school is the Center in Bioengineering and Biomedical Engineering, which draws on expertise in
the areas of biomedical instrumentation, biomaterials and tissue engineering, and drug discovery
and assessment.
\
technology transfer, sponsored research, out-licensing, royalty audits
\
pharmaceutical and biotechnology companies, investors with an interest in early-stage
technologies
\
out-licensing of Tufts technologies, research collaborations
\
Tulane University

1430 Tulane Avenue | TB-32 | New Orleans LA 70112 | United States

Phone: (504) 988-3344 | Fax: (504) 988-
2473 | Website: www.tmc.tulane.edu/departments/techdev/OTD.html
Contacts
Mr. John M. Christie | Associate Director
Tulving-Blais International & Tech Law
181 University Avenue | Suite 2200 | Toronto ON M5H 3M7 | Canada

Phone: (416) 642-3585 | Fax: (866) 288-2916
Contacts
Ms. Elo Tulving-Blais |
Organization Type
Law Firm
Company Overview
This law firm provides legal services in all aspects of international and cross-border licensing:
negotiations, contracts, distribution, strategic alliances, R & D collaboration, Co-marketing. It
also offers corporate law services required by technology companies that operate across borders.
The firm’s technology based clients are active in biotechnology, nanotechnology, medical
technologies, environmental technologies and information technologies (software and
telecommunications.) Small and medium companies, start-ups and entrepreneurs are particularly
highly regarded at this firm.

We would like to extend our network internationally. We would like to meet law firms,
accounting firms, consultants and government representatives who are active in the technology
sectors. Meeting prospective clients would always be nice, too.

Partnering
Legal services n/a Not Applicable
Two River Group Holdings, LLC

689 Fifth Avenue | 12th Floor | New York New York 10022 | United States
Phone: 212-871-7930 | Fax: 212-871-7934
Contacts
Mr. Benjamin Bernstein | Director If Business Development
Dr. Paul Bolno | Director of Research
Mr. Christopher Francis | Associate
Company Overview
Two River Group Holdings, LLC is an independent New York based venture capital firm that
specializes in building biotechnology and pharmaceutical companies. The Two River team has
significant experience building companies to develop novel human therapeutic technologies to
address a broad range of diseases, including oncology, infectious disease, CNS, cardiovascular,
ophthalmology and dermatology.
Two River’s goal is to create a limited number of high quality companies, each having a pipeline
of clinical and preclinical compounds that address a common therapeutic area. To achieve this
goal, the Two River team conducts rigorous clinical, legal and financial due diligence on
hundreds of technologies each year, choosing only a select few to acquire for commercial
development.
Once a technology is acquired, the Two River team has the comprehensive skills required to run
a developmental stage biotechnology company, including an in-depth knowledge of clinical trial
design, regulatory pathways, chemistry manufacturing control, intellectual property management
and effective clinical trial execution.
Two River then recruits a highly skilled management team with a combination of drug
development experience and leadership excellence for each portfolio company. These leading
minds are drawn from both academia and industry, often with prior experience as senior
management in large pharmaceutical or leading biotechnology companies.
In addition, Two River is able to provide its portfolio companies with access to financial
markets. Two River’s affiliate, Riverbank Capital Securities, Inc., through its global network of
investors, is able to assist portfolio companies in obtaining financing without receiving cash or
equity commissions, so that 100% of the proceeds are used by the company to develop its
compounds.
Uhthoff, Gomez Vega & Uhthoff, SC
Hamburgo 260, | Col. Juarez | Mexico City 06600 | Mexico

Phone: +52 55 5533 5060 | Fax: +52 55 5208 8387 | Website: www.uhthoff.com.mx

Contacts
Mr. Carlos Trujillo | Partner

UHY Advisors
12 Greenway Plaza | 8th Floor | Houston TX 77046-1291 | United States

Phone: (713) 407-3939 | Fax: (713) 968-7140
Contacts
Mr. Wayne Hoeberlein | Managing Director
Mr. Ronald Vollmar | Managing Director
Universit‚ Laval
Vice-rectorat … la recherche | Pav. Sciences de l'‚ducation, local 1466 | Quebec QC G1K

7P4 | Canada
Phone: (418) 655-2131 ext 12344 | Fax: (416) 656-2506 | Website: www.vrr.ulaval.ca
Contacts
Dr. Antoine Bellemare | Research Management Advisor
University of Alabama-Tech Transfer
P.O. Box 870207 | Tuscaloosa AL 35487 | United States

Phone: (205) 348-8583 | Fax: (205) 348-3510 | Website: ott.ua.edu
Contacts
Dr. Richard P. Swatloski | Licensing Associate
Organization Type
University
Industry Sector
Company Overview
To develop and implement an integrated, market-driven technology deployment plan that will
facilitate commercialization of intellectual property generated by UA faculty, staff and students,
as well as contribute to economic development in Western Alabama via UA start start-up and
spin spin-off ventures.

Out licensing and sponsored research collaborations



Companies interested in In-Licensing University Intellectual Property. For more information
please contact Richard P. Swatloski via email at RPSwatloski@ua.edu.

We would like to meet with potential business partners to discuss technologies available for out-
licensing from the University of Alabama. Information about our office may be found at
http://ott.ua.edu.
University of California - San Diego
9500 Gilman Drive | Mailstop:0910 | La Jolla CA 92093 | United States

Phone: (858) 534-7305 | Fax: (858) 534-7345
Contacts
Dr. Donna M. Shaw | Assistant Director, Life Science Licensing
University of California - Santa Barbara
342 Lagoon Road | Mail Code 2055 | Santa Barbara CA 93106-2055 | United States
Phone: (805) 893-5138 | Fax: (805) 893-5236 | Website: research.ucsb.edu/tia
Contacts
Mr. Adam R. Jones | Associate Director, Licensing & Business Development
Organization Type
University
Industry Sector

Patents, Copyrights, Intellectual Property Asset Management, etc.
UCSB is a premiere research institution. Our office performs out-licensing of UCSB technology
as well as negotiation agreements supporting research (research agreements, material transfer
agreements, etc.) with the for-profit sector.

We are seeking new licensing and research collaboration opportunities.
Country(s)
Available
for
Partnering
A VIDEO FINGERPRINTING
METHOD FOR DUPLICATE Video duplication Not Applicable
DETECTION
COST-EFFICIENT,
BIODEGRADABLE
MICROSPHERES WITH
Drug delivery Not Applicable
CONTROL OF DIAMETER,
DENSITY, COLOR AND SURFACE
CHEMISTRY
Diabetes,
DIABETES PORTFOLIO Continuous Glucose Not Applicable
Monitoring
Diabetes,
DYNAMIC BASAL-BOLUS
Continuous Glucose Not Applicable
ADVISOR
Monitoring
HIGH PERFORMANCE
COMPOSITE OXIDE CATALYSTS Auto gases
Not Applicable
FOR PURIFYING AUTO purification
EXHAUST GASES
MAGNETIC MESOPOROUS-
CONFINED MICELLE ARRAYS
FOR DECONTAMINATION OF Water Purification Not Applicable
SOILS, AQUEOUS SOLUTIONS
AND OTHER MEDIA
PEPTIDE SEQUENCES FOR THE
DIAGNOSIS OF CELIAC DISEASE
Celiac Disease Not Applicable
AND THERAPEUTIC USE
THEREOF
PORTABLE DEVICE FOR
DYNAMIC NUCLEAR Imaging Not Applicable
POLARIZATION (DNP)
SOLID BASE Transesterification
Not Applicable
TRANSESTERIFICATION process of vegetable

CATALYSTS oils
SUPRAMOLECULAR BLOCK
Microelectronics,
COPOLYMER COMPOSITIONS
Sub-micron Not Applicable
FOR SUB-MICRON
lithography
LITHOGRAPHY
TARGETED, RAPID RELEASE
DRUG DELIVERY THROUGH Targeted Drug
Not Applicable
GOLD NANOSHELL DISRUPTED Delivery, Cancer
LISOSOMES AND VESOSOMES
THERMAL GROUND PLANE FOR
COOLING CHIPS AND Cooling device Not Applicable
SEMICONDUCTOR DEVICES
TUNED OSCILLATORS AS
energy harvesting Not Applicable
ENERGY HARVESTERS
USE OF MAGNETIC
NANOPARTICLES TO REMOVE
Water purification Not Applicable
DISPERSED NANOPARTICLES
FROM AQUEOUS SOLUTIONS
University of Central Florida
12201 Research Parkway | Suite 501 | Orlando FL 32826 | United States

Phone: (407) 882-1117 | Fax: (407) 823-3299
Contacts
Mr. Joe Giampapa | Associate Director, Tech Transfer
University of Central Florida Incubation Program
12565 Research Parkway | Suite 300 | Orlando FL 32826 | United States

Phone: (407) 234-5900
Contacts
Mr. Gordon Hogan |
University of Chicago
Office of Technology & Intellectual Property | 5555 S Woodlawn

Ave | Chicago IL 60637 | United States
Phone: (773) 834-0746 | Fax: (773) 702-0741 | Website: tech.uchicago.edu/
Contacts
Mr. Eric J. Ginsburg | Senior Project Manager

Organization Type
University

Technology transfer
Out-licensing
Research collaborations
University of Cincinnati
9864 Belleford CT | Cincinnati OH 45242 | United States

Phone: (513) 295-0309 | Fax: (800) 876-9785
Contacts
Mr. Daniel J. O'Neill | Associate Director
Industry Sector
Consumer Products
University of Connecticut
263 Farmington Avenue | Dowling N-2 | Farmington CT 06030-6207 | United States

Phone: (860) 679-8185 | Fax: (860) 679-7512 | Website: www.cstc.uchc.edu
Contacts
Dr. Mansoor A. Khan | Director, Technology Licensing
University of Dundee
Research & Innovation Services | 11 Perth Rd | Dundee Dundee DD1 4HN | United Kingdom
Phone: 44 (0 ) 1382 345896 | Website: www.dundee.ac.uk/research
Contacts
Mr. James Houston | Director RIS
Ms. Diane Taylor | Head of Business Development

Organization Type
University
Industry Sector
Company Overview
The University of Dundee has established a reputation as an international academic centre in the
fields of biomedical and life sciences research. This has translated successfully into working with
the pharmaceutical sector through research collaborations, licensing deals and in the creation of
spinout companies. The University has invested heavily in infrastructure to enable it to ensure
that it is poised to add value to the needs of the pharmaceutical sector.
Key research strengths include cancer, diabetes, kinase research, cardiovascular disease,
neurological disease, inflammatory disease and health informatics. The University's annual
research awards total to date for 2007/2008 was £86m (US $172M) with 80% of this funding
directed at the biomedical/life sciences sector. Over the last 5 years, the University has earned
almost £10m ($20m) from its IP Portfolio.
The University's Technology Transfer Office manages a portfolio of licensing and spinout
opportunities and is seeking partners for its licensing and research collaborations relevant to drug
discovery: these include targets and hits for the development of novel compounds that have
emerged from its research activities in cancer, diabetes, inflammatory, infectious and metabolic
diseases.
Key Funders
The University has a strong relationship with both the Wellcome Trust and The MRC which
have been strongly instrumental in funding infrastructure and projects in the University: these
include: major investment in the College of Life Science’s Wellcome Trust Biocentre( £10m ) ,
the MRC Protein Phosphorylation Unit ( £14M for current 5 year period )( to facilitate the
development of drugs to treat diseases caused by abnormalities in the phosphorylation process)
and further Wellcome Trust funding for its Drug Discovery for Tropical Disease Initiative (
£8.1m ).
The University has several large ongoing collaborations with the pharmaceutical industry and is
pleased to discuss opportunities in this area with the pharmaceutical industry: current
collaborations are

84. The Division of Signal Transduction Therapy (DSTT) is a very successful protein
kinase/phosphotase consortium involving 6 major pharmaceutical companies which is
now entering its third phase, taking the collaboration into its second decade.
 The Translational Medicine Research Collaboration with Wyeth – to develop biomarkers

fro serious diseases. This is as a 5 year £33M (US $57 M) Scottish wide collaboration
with Wyeth, 3 other universities with medical faculties in Scotland plus the National
Health Service in the Translational Medicine Research Collaboration (TMRC).
Corporate highlights
Drug Discovery Unit
The University has integrated BioPharma style drug discovery with academic excellence by
setting up a Drug Discovery unit .The unit combines industry approaches and standards in this
groundbreaking approach , key to this has been the recruitment of senior staff from industry. The
Unit brings together almost 80 cell biologists, biochemists and medicinal chemists in an
interdisciplinary team. Significantly, in the 2 years since its opening, the unit has developed
several validated targets to the hits-to- lead stage. The DDU’s aim is to develop licensable
projects for the pharmaceutical industry.
The DDU carries out
 HTS
 Computational drug design
 Medicinal Chemistry
 Drug Metabolism and Pharmacokinetics
Current Therapeutic areas include
2. Oncology
3. Neglected Tropical Diseases
4. Fungal Diseases
5. Stem Cell Technology
6. AD
Licence deal drug in Phase I trials

A recent licence deal (07/07) between the University and Modern Biosciences plc for a cancer
compound, rimcazole, as a cancer treatment has now progressed to Phase I trials. The Phase Ia
trial will include 12 healthy volunteers and will examine safety and pharmacokinetics. Results
are expected in the second half of 2008. A Phase Ib trial designed to yield proof-of-principle data
is expected to start in early 2009.
Opening of new Clinical Trials Facility

The University has increased its capacity for clinical trials and patient studies with the opening
of a dedicated ($30M) trial facility at its teaching hospital, this will offer state of the art imaging
and specialist trial staff. A current trial highlight is the SCOT trial, a major safety study
comparing the cardiovascular safety of celecoxib vs. traditional NSAID therapy for the treatment
of arthritis.
The Scottish Institute for Cell Signalling to be set up at Dundee University

The Scottish Government announced in April an investment of £10m ($20m US) to help set up
the Scottish Institute for cell Signalling (SCILLS) in Dundee. The £10 million will be used to set
up the first division of SCILLS, a Protein Ubiquitination Unit. The founding Director of the
Institute will be Sir Philip Cohen, who is currently the Director of the Medical Research Council
Protein Phosphorylation Unit (MRC-PPU) at the University.
The aim of the Protein Ubiquitination Unit is to develop exceptional strengths in another field of
cell signalling, which is predicted to become of major importance for drug discovery in the
future. Dundee has been developing strength in protein ubiquitination in recent years and
SCILLS will enable a critical mass to develop in this field.
Key academics
Professor Sir David Lane is best known for his discovery of the p53 tumour suppressing-
protein and is founder of the drug discovery company Cyclacel. He has recently returned from a
2 year sabbatical from the University of Dundee as the Executive Director of Singapore's
A*STAR Institute of Molecular and Cell Biology (IMCB) to lead the new Division of Molecular
Medicine in the College of Life Sciences . In April 2007, Cancer Research UK appointed
Professor Sir David Lane as its first Chief Scientist.
Professor Sir Philip Cohen is renowned in the area of signal transduction and has been
instrumental in the continued growth and expansion of the University’s College of Life sciences
which now employs over 700 scientific staff. The College is renowned for the quality and impact
of its work. Sir Philip is the recipient of numerous awards from the scientific community the
most recent of which is his election as a Foreign Associate of the US National Academy of
Sciences (NAS) in recognition of his significant contributions to science. Membership of the
NAS is one of the highest honours given to a scientist or engineer in the United States.
Professor Irwin McLean leads an international team in the discovery of the filaggrin gene that
causes dry skin and leads to eczema and asthma. Professor Mc Lean is a member of a significant

node in skin disorders based at the University. Additional members include Professor Irene
Leigh and Professor Birgitte Lane.


The University of Dundee is seeking partners for licensing and research colloborations.
Country(s)
Partnering
Anti Siglec-9 mAb for the
haematology,
development of a novel therapy Not Applicable Worldwide
oncology
for subsets of AML
Atopic Dermatitis: Genetic Test
Dermatology Not Applicable Worldwide
& Therapeutic Target
Division of Signal Transduction
Various Not Applicable Worldwide
Therapy
Novel Chronic / Neuropathic
CNS, Neurology Not Applicable Worldwide
Pain Agent
P53 Activators Drug Discovery
Various Lead Series Worldwide
Programme
Single step gene silencing and
Various Not Applicable Worldwide
replacement tool
Sirtuin inhibitors for the
treatment of cancer and other Oncology Lead Series Worldwide
proliferative disorders
University of Florida
PO Box 115500 | Gainesville FL 32611 | United States

Phone: 352-392-8929 | Fax: 352-392-6600
Contacts
Mr. David Day | Director
Dr. Winfred M. Phillips | Vice President, Research
Ms. Anita Rao | Assistant Director
Company Overview
The University of Florida received over $470 million in research awards and almost 300
invention disclosures last year alone. Our commercial successes include Gatorade, the glaucoma
drug Trusopt, and Sentricon for termite control. UF is a leader in technology commercialization
and new venture creation.

For those looking for new technologies to license or to use as the platform for a new company,
you will want to sign up for our newest service -- UF TechAlert. This free service is designed to
help companies, investors, or anyone wanting to stay abreast of the latest technologies being
generated at the University of Florida. http://www.otl.ufl.edu
The University of Florida's highly acclaimed Sid Martin Biotechnology Development Incubator
is another resource available to house promising companies from university-based discoveries.
http://www.biotech.ufl.org/
To learn more about the University of Florida’s commercialization efforts, please contact us 352-
392-8929 or visit our website at www.otl.ufl.edu or http://www.biotech.ufl.org/.
University of Illinois at Chicago
1853 West Polk Street | Suite 446, MC 682 | Chicago IL 60612 | United States
Phone: (312) 996-0447 | Fax: (312) 996-1995
Contacts
Dr. Connie M. Cleary | Associate Director, OTM
Dr. David L. Gulley | Associate Vice President
Mr. Colin James | Technology Manager
Mr. Shayan Sartipi | Technology Manager
Dr. Shrijay Vijayan | Technology Manager
Organization Type
University
Industry Sector
Company Overview
Company Profile - LES Annual Meeting
University of Illinois at Chicago
Division: Office of Technology Management
Cancer, Antibodies, Drug Delivery, Cardiovascular, Immunology, Musculoskeletal,

Proteomics, Stem Cells, Med Devices, Stem Cells, Research Tools- Antibodies, Miscellaneous
(reformulations, new uses) , Engineering- (VR, NRG)
Office of Technology Management

University of Illinois at Chicago (MC 682)

1853 West Polk Street, Suite 446

Chicago, IL 60612-7335
USA
Phone: (312) 996-7018

Fax: (312) 996-1995
http://www.otm.uic.edu/
Dr. David L. Gulley, Interim Director

Dr. Connie Cleary, Associate Director
Adam Falconer, Technology Manager
Colin James, Technology Manager
Dr. Shrijay Vijayan, Technology Manager
Shayan Sartipi, Technology Manager
Highlights
The University of Illinois spends over $800 million annually in research
expenditures and recognizes that a robust system for technology
commercialization is essential to realizing the full public benefit of the
resulting innovations.
The University of Illinois has in place a series of resources designed to

facilitate the journey from lab bench to end product and to address many
of the hurdles that commonly impede technology transfer. The Office of
Technology Management (OTM) is responsible for commercializing
University research discoveries.
The OTM’s staff is able to draw on a large pool of outside business and
legal consultants who help develop the best possible protection and
licensing strategies and provide a thorough understanding of the market
conditions affecting various technologies.
Corporate Mission
The mission of the Offices of Technology Management (OTMs) is to encourage
innovation, enhance research, and facilitate economic development through the
transfer of intellectual property. The OTMs provide services that include the

identification, evaluation, protection, marketing, and licensing of intellectual

property. In fiscal year 2006, more than 319 technology disclosures were
received and more than 290 patent applications were filed. In addition, 80
licenses and options were signed, with 16 going to start-up companies. Currently
the OTMs manage a portfolio of more than 1,300 technologies.
Proprietary Technology:
* Pharmaceutical Sciences
* Biotechnology
* Medical Devices
* Life Sciences
* Physical Sciences
* Engineering Sciences
Current Alliances
IllinoisVENTURES, LLC was created by the University of Illinois Board of
Trustees in order to catalyze the creation and accelerate the early development
of potentially rapid growth companies based upon University technologies.
IllinoisVENTURES works closely with departments within the University
infrastructure to offer a comprehensive system of resources for the
entrepreneur. A substantial gap exists between company formation and the point
at which companies have accomplished the critical value milestones to merit
venture capital funding. IllinoisVENTURES assists these companies in bridging
common points of failure by providing business development expertise as well as
early proof of concept capital. In addition, IllinoisVENTURES is responsible for
making developmental investments to assist these companies in meeting these
milestones. IllinoisVENTURES also manages the $20 million Illinois Emerging
Technologies Fund that makes early-stage equity and equity-related investments
in promising new companies. A five-member external board of managers comprised
of members with high-level business and investing experience advises the
IllinoisVENTURES staff and underscores the best-of-class resources available to
client companies.
Intellectual Property Status

Currently the OTM’s manage a portfolio of more than 1,300 technologies.

The University of Ilinois at Chicago is interested in technology transfer

We would like to meet with potential business partners in the following areas:

Cancer, Antibodies, Drug Delivery, Cardiovascular, Immunology, Musculoskeletal,

Proteomics, Stem Cells, Med Devices, Stem Cells, Research Tools- Antibodies, Miscellaneous
(reformulations, new uses) , Engineering- (VR, NRG)

We would like to meet with potential business partners to discuss technologies available for out-
licensing from the University of Illinois at Chicago. Information about our office may be found
at http://www.otm.uic.edu
Country(s)
Available
for
Partnering
CP09: Sterically-Stabilized Liposome
Formulations of Vasoactive Intestinal
Peptide to Enhance Its Biological
Activities (US 6,348,214 B1)
CP28: A Device and Method for
Screening Molecular Diversity for
Agents which Bind Macromolecules
and Their Complexes (US 5,872,015)
CQ50: Screening of Xenobiotics for
Metabolism and Bioavailability (US n/a Not Applicable Worldwide
6,995,022 B1)
CS55: Microtextured Polymeric
Platforms for Cellular Attachment (US n/a Not Applicable Worldwide
6,942,873)
CU08: Human CD34+ Stem Cells
Express The HIWI Gene, A
Homologue Of The Drosophila Gene
PIWI (US 2005/0233386)
CV103: Organ Preservation, Protection
And Resuscitation With Local n/a Not Applicable Worldwide
Anesthetic
CV11: Peptide Functionalized
Polymeric Platforms for Cellular

Attachment
CV13: Primary Battery Having a Built-
In Controller to Extend Battery Run n/a Not Applicable Worldwide
Time (US 6,198,250 B1)
CV29: Use of a commercially available
compound for increasing stem cell n/a Not Applicable Worldwide
numbers in vivo (US 2003/0139410)
CV40: A Novel Model for Discovery of
Gene Function by Protein Surface n/a Not Applicable Worldwide
Matching
CV49: A Class of Novel HIV Protease
Inhibitors (US 7,157,489)
CV59: A Simple Method To Prepare
Highly Loaded, Highly- Dispersed Pt
On Carbon Substances
(PCT/US03/28586)
CV63: Novel Methods For Culturing
Human Stem Cells (US 2003/0148513)
CV66: Novel Method Of Creating
Human Brain Cells From Human
Mesenchymal Stem Cells (US
2003/0219898)
CW013: An Efficient Enantioselective
Synthesis Of (3R,3aS,6aR)-3-
Hydroxydroxyhexa- hydrofuro/ 2,3-
b/furan (Compound 6) Which Is A n/a Not Applicable Worldwide
Ligand For Many Potent HIV Protease
Inhibitors Including TMC-114 (US
6,919,465 B1)
CW032: Reprogramming And
Expansion Of Primitive Hematopoetic
Progenitor Cells In Vitro
(US2005/0276793)
CW035: Pain management, and
prevention and treatment of tolerance to
opioid drugs by inhibiting calcium n/a Not Applicable Worldwide
calmodulin kinase (CaMKII) activity
(US7,256,200)
CW045: Cardiac Sound Separator n/a Not Applicable Worldwide
CW046: Conducting Polymer Films
Produced via Surface Polymerizaton by
Ion Assisted Deposition (US7179508
B1)

CX057: A Method for Timing

Optimization of Digital Circuits by n/a Not Applicable Worldwide
Placement-Coupled Logic Replication
CX058: Esophageal Stethoscope for
Extraction of Discrete Heart Sounds
from the Heart Sound (WO 05076148
A1)
CX072: Separation of Fetal
Phonocardiograms of a Multi-Fetal n/a Not Applicable Worldwide
Pregnancy (US 2005/0113708)
CY014: A Light-Driven Microactuator
(WO2006/034377A3)
CY018: Compliant Valves, Fluidic
Circuit Boards, Reservoirs, Sensors,
Electronic Components, and other n/a Not Applicable Worldwide
Microfluidic Structures
(WO2006/119274)
CY029: Dermorphinin Analogues for
the Target-Delivery of Novel Therapies
for Pain and Opioid Addiction
(PCT/US2006/007323)
CY035: Use of specific inhibitors of
stress-activated protein kinases to
preserve fast axonal transport function
in the treatment of polyglutamine
expansion neurodegenerative diseases
(PCT/US2007/069847)
Protein Kinase C (PKC) isoforms to
normalize fast axonal transport function n/a Not Applicable Worldwide
in the treatment of familial and sporadic
forms of Parkinson's disease
stress-activated protein kinases to
preserve fast axonal transport function n/a Not Applicable Worldwide
for the treatment of neurodegeneration
in amylotrophic lateral sclerosis (ALS)
CY055: Prostanoid for treatments of
medical disorders (WO 2007/047372 n/a Not Applicable Worldwide
A2)
CY056: Vanilloid receptor ligands for
treatment of medical disorders (WO n/a Not Applicable Worldwide
2007/047575)

CY059: Calcitonin gene-related peptide

agents for treatment of medical n/a Not Applicable Worldwide
disorders (WO 07047577 A2)
CY060: Antitussive agent for treatment
of medical disorders (WO 07047576 n/a Not Applicable Worldwide
A1)
CY077: Splice Site Prediction Using
Inhomogeneous Markov Chain and n/a Not Applicable Worldwide
Neural Network
CY080: Individual Snore Sound
Extraction and Analysis Device in a
Noisy and Multiple Snore Sound
Environment
CY083: Fully Optically Controlled
Heterojunction Power Semiconductor n/a Not Applicable Worldwide
Device For Fast Repetitive Switching
CY083: Fully Optically Controlled
Heterojunction Power Semiconductor
Device For Fast Repetitive Switching
(WO 2007/002603)
CZ001: ImmsersaDesk4:A Passive
Stereo Virtual Reality System Using
Circularly Polarized High Resolution
LCD Panels
CZ006: Human Umbilical Cord Blood-
Derived f-macrophages Retain
Pluripotentiality After Thrombopoietin
Expansion
CZ016: Isoform Selective Inhibitors of
Histone deacetylase (HDAC)
CZ024 & DA013: Characterization of
Human Embryonic Stem Cell-Like Cell
from Umbilical Cord Blood
(US2006/038524)
CZ027: A Simple Method to Synthesize
Highly Loaded, Highly Dispersed Pt on n/a Not Applicable Worldwide
Carbon (US2007/0105007A1)
CZ029: A Novel Power-Management
Control for Fuel Cell Power
Conditioning System (WO
2007/050577)
CZ035: New Design For The
Endotracheal Tube

CZ036: Rapid Formation of Metal,

Semiconductor, and Dielectric n/a Not Applicable Worldwide
Structures
CZ052: An Organic-Inorganic
Nanocomposite Film for Photovoltaic n/a Not Applicable Worldwide
and Optical Limiting Applications
CZ057: Microstructures in Three
Dimensional Gel Suspensions for the n/a Not Applicable Worldwide
Growth of Cells
CZ058: Tolerogenic Biodegradable
Artificial Antigen Presenting System
for the Treatment of Autoimmune n/a Not Applicable Worldwide
Diseases and Transplant Rejection (WO
2007/087341 A2)
CZ073: A Screen for Molecules that
Inhibit Formations of A-Beta n/a Not Applicable Worldwide
Oligomers
CZ092: Estrogen Improving Osteogenic
Differentiation Of Progenitor Cells Of
Cells From Bone Marrow And Fat
Tissues
CZ108: Selected Antipsychotic Drugs
for the Treatment of Chronic Pain
CZ115: Estrogen Improving
Proliferation of Adult Bone Marrow n/a Not Applicable Worldwide
Mesenchymal Stem Cells
CZ121: Multivariate Color
Enhancement of Composite RGB n/a Not Applicable Worldwide
Magnetic Resonance Images
DA002: Circumcision Dispenser n/a Not Applicable Worldwide
DA014: An Adult Human Blood-
Derived Cell Population Displays
Embryonic Markers and High Potential
Giving Rise to Insulin-Producing Cells
DA022: VirtuaTouch n/a Not Applicable Worldwide
DA024: Method for Non-invasive
Diagnosis of Endometriosis
DA026: A New Device Providing
Increased Safety, Improved Cosmetic
Outcomes and Decreased Operative
Times for Circumcisions
DA045: Intestinal Stream Alimentation n/a Not Applicable Worldwide

Assit Conduit (ISAAC)

DA048: Use of Noradrenaline Uptake
Inhibitors for Neuroprotection
DA058: Temporal Release of Growth
Factors from 3D Micro Rod Scaffolds n/a Not Applicable Worldwide
for Tissue Regeneration
DA059: Nanoparticles for the Elution
of Growth Factors for Recovery and n/a Not Applicable Worldwide
Regeneration of Organs
DA062: Adenovirus Vectored Vaccine
for Alzheimer’s Disease
DA063: BDA-410, An orally active
synthetic calpain inhibitor against blood n/a Not Applicable Worldwide
stage malaria
DA066: A Simplicity-Based Fuzzy
Clustering Approach for Detection and
Extraction of Murmurs from the
Phonocardiogram
DA076: Removal of Benzene from
Hydrocarbons using Selective n/a Not Applicable Worldwide
Adsorption
DA077: Engineering the Gas
Concentrations Within a Multiwell n/a Not Applicable Worldwide
Plate
DA079: Modified Human Interleukin-2
and the Method for Its Use
DA080: New Beta-secretase Inhibitors
and Their Use Thereof
DA089: Method for Inducing
Therapeutic T Cells for Immune n/a Not Applicable Worldwide
Diseases
DA096: Preventive Cancer Vaccines n/a Not Applicable Worldwide
DA100: Use of eNOS Inhibitor and/or
Agonist of Protein Kinase G for n/a Not Applicable Worldwide
Treatment of Pulmonary Hypertension
DA107: Method for the Determination
of Viable and Functional Human n/a Not Applicable Worldwide
Insulin-producing Beta Cells
DA112: NA Reuptake Inhibitors for
Treatment of Neurological Diseases
DA32: Use of Pioglitazone to Improve
Neuronal Function in

Neurodegenerative Diseases
DA60: Dynallax: Solid State Dynamic
Parallax Barrier Autostereoscopic n/a Not Applicable Worldwide
Virtual Reality Display
DB008: Novel Peptides Inhibitors of
Protein Synthesis, Methods of n/a Not Applicable Worldwide
Identifying and Their Use
University of Illinois at Urbana-Champaign
105 South Goodwin Avenue | 311A Ceramics Building | Urbana IL 61801 | United States
Phone: (217) 265-0548 | Fax: (217) 265-0548
Contacts
Ms. Lesley Millar | Director, Office of Technology Management
Company Overview
The University of Illinois at Urbana-Champaign is a world-class research institution boasting a
respected faculty, high national rankings, and state-of-the-art facilities. The University’s
accomplishments include 21 Nobel Laureates among its faculty and alumni, and a history of
ground-breaking research. Annually, the University spends close to $500 million in research
expenditures, placing it among the nation’s top engines of innovation.
University of Kentucky
A248 ASTeCC Bldg | Lexington KY 40506-0286 | United States

Phone: (859) 218-6512 | Fax: (859) 323-1023
Contacts
Ms. Taunya Phillips | Assistant VP, Commercialization & Economic Development
University of Manitoba
631 Drake Centre | 181 Freedman Crescent | Winnipeg Manitoba | Canada

Phone: 204-474-6200 | Fax: 204-474-261-3475 | Website: www.umanitoba.ca/research
Contacts
Mr. Garold Breit | Executive Director
Dr. Odd Bres | Technology Transfer Manager
Dr. Neeraj Visen | Technology Transfer Manager

Company Overview
The University of Manitoba, Technology Transfer Office is made up of a group of industry
professionals that provide a wide range of intellectual property services to the University
community and the people of Manitoba.
One of Canada’s most successful programs, the TTO has licensed many important technologies
in the agricultural, engineering, and physical and life sciences fields. The TTO has launched
start-ups in Winnipeg and have made University of Manitoba developed technologies available
around the world.
University of Maryland, Baltimore County
620 West Lexington Street | 4th Floor | Baltimore MD 21093 | United States
Phone: (410) 706-6723 | Fax: (410) 706-1066
Contacts
Mr. Stephen Kinsey | Technology Licensing Officer
Organization Type
University
Industry Sector

tech transfer, university/ industry collaborations

out-licensing, research collaborations with industry, developmental partnerships
University of Miami
1475 NW 12th Avenue | Suite 2012 | Miami FL 33136 | United States

Phone: (305) 243-4589 | Fax: (305) 243-3510
Contacts
Dr. Christine Neipert | Licensing Manager
Organization Type
University

Industry Sector
Company Overview
The University of Miami is a select, private research university in one of the fastest growing
areas of the Nation. Despite its relatively small size, it is one of the Nation’s leading research
universities, with research and sponsored program expenditures of nearly $270 million last year.
The Office of Technology Transfer aids in the protection of intellectual property and in
generating research and licensing agreements between the University and interested business
partners.
The Office is one component of the newly established UM Innovation initiative, which also
includes the Wallace H. Coulter Center for Translational Research and a future Life Science
Park. UM Innovation facilitates the rapid advancement of early stage technologies, especially in
the areas of ophthalmology, cancer, neuroscience, orthopedics and cardiology. The Wallace H.
Coulter Center serves as a biotechnology incubator and provides internal "venture capital".

We would like to meet companies primarily in the life sciences sector interested in establishing
research collaborations with dynamic, world-class scientists and/or explore licensing
opportunities with a private, select research university.
Your point of contact at this meeting is Junko Kazumi. Her primary responsibilities are in the
life sciences disciplines, but having spent some of her career working in the College of
Engineering, also welcomes inquiries from companies in the physical sciences/engineering
sectors.

Our goal is to develop collaborative partnerships with companies for research and licensing
agreements that would be of benefit to both parties, and ultimately, to serve the public. We
welcome any inquiries regarding our technologies, and look forward to working with companies
to move innovations from the lab to the commercial sector.
University of Minnesota
Office for Technology Commercialization | 1000 Westgate Drive, Suite 160 | St.
Paul MN 55114-8658 | United States
Phone: (612) 625-8356 | Fax: (612) 624-6554 | Website: www.ptm.umn.edu
Contacts

Dr. Michael F. Moore | Compliance Manager

Ms. Barbara Nelsen | Associate Director
University of Missouri - Columbia
W1025 Lafferre Hall | MU-Columbia | Columbia MO 65211-1400 | United States

Phone: (573) 884-3302 | Fax: (573) 882-1160
Contacts
Mr. Wayne C. McDaniel | Senior Licensing & Business Development Associate
University of North Texas Health Science Center at Fort Worth
3500 Camp Bowie Blvd | CBH-304 | Fort Worth TX 76107-2699 | United States
Phone: (817) 735-2618 | Fax: (817) 735-5485 | Website: www.hsc.unt.edu/research/ttc
Contacts
Dr. Robert D. McClain | Associate VP Tech Transfer & Commercialization
Organization Type
University
Industry Sector
Health Care
University of Oklahoma
Office of Technology Development | 350 David L. Boren Blvd, Suite 1510 | Norman OK 73072-
7162 | United States
Phone: (405) 325-3800 | Fax: (405) 325-7162
Contacts
Mr. Cameron McCoy | Director of Technology Marketing
Organization Type
University
Industry Sector
Company Overview

The Mission of the University of Oklahoma is to provide the best possible educatinoal
experience for our students through excellence in teaching, research, and creative activity, and
service to the state and society.
During the past decade, research expenditures have more than doubled at OU and sponsored
research has grown at twice the national growth rate. In fiscal year 2006, OU set a new record
high of $239 million in external funding for research and sponsored programs, more than $17
million above the previous year. Particularly successful university research programs including
weather, genomics, chemistry, health sciences, nanosciences, education, and applied social
research as well as technology development and transfer will continue to grow with the
development of the University Research Campus. The buildings and spaces on the research
campus support a true community of ideas that reflects the core mission and values of the
university, but with a decidedly modern approach that includes academia, government and the
private sector.
"OU was ranked in the top 10 universities in the nation in the Freshmen Year Experience,
according to a national study by the Policy Center on the First Year of College."
Since 1995, almost $1.5 billion in construction projects have been completed, are under way or
are forthcoming on OU’s three campuses. As each new facility opens, we bring to the campus
national and international figures in relevant fields of study. Among the largest facilities that
have opened recently include the $18.7 million renovation and expansion of historic Holmberg
Hall, home of music and dance programs; the $67 million National Weather Center, largest
research center of its kind in the nation; the $19 million Price Hall, serving the Michael F. Price
College of Business; the $17 million Gaylord Hall for journalism and mass communication; the
$27 million Stephenson Research and Technology Center; and the $83.5 million stadium project.
Projects currently under construction include the 38,000-square-foot Lissa and Cy Wagner
Student Academic Services Center, which will greatly enhance a wide variety of services –
including academic advising and tutoring – designed to help our students succeed in their
academic goals. Construction is also underway on Devon Energy Hall which will provide 80,000
square feet of instructional and research space for our College of Engineering. Just next to it, the
ExxonMobil Lawrence G. Rawl Engineering Practice Facility is also under construction and will
be a center of interdisciplinary research and experiments.

Tech Transfer

Companies interested in In-Licensing University Intellectual Property may contact Cameron
McCoy via email at cmccoy@ou.edu

out-licensing, research collaboration, marketing agreements, entreprenuerial relationships

Country(s)
Partnering
A Novel Class of Inhibitors
Drug Discovery,
of Gamma-Glutamyl Not Applicable Worldwide
Therapeutics, Cancer
Transpeptidase (GGT)
A Vaccine and Diagnostic
Tool for West Nile Virus
Vaccine Development Not Applicable Worldwide
Using a Methodology that
can be applied to Other R
Cost-Effective, High-
Volume Generation of Diagnostics, Drug
Substrate for Protein Discovery
Tyrosine Kinase Assays
Cytotoxic Agent Targeted to Cancer Treatment, targeted
Cancer Cells cell therapy
Enhancing Tumor Imaging
Using Semi-Automated Diagnostics, imaging,
Active Deformational cancer,
Segmentation
High-Throughput Assay for Cell Biology, cancer,
Screening Inhibitors of diagnostics, tissue Not Applicable Worldwide
GGT engineering
Keratinocyte Growth Factor
Receptor Tyrosine Kinase
Cancer Treatment, Not Applicable Worldwide
Specific Inhibitors for
Cancer Metastasis Prev
Mouse Model of
Drug Discover, Molecular
Myeloproliferative Not Applicable Worldwide
Biology
Disorders
Non-Radioactive Rab5 Endocytosis, Cell Signaling,
Assay Reduces Time Signal Transduction,
Required and Increases Cytoskeletal organization
Safety and Intracellular trafficking
Novel Biomarkers for the
Pancreatic Cancer,
Identification of Early Stage Not Applicable Worldwide
Biomarkers, Diagnostics
Pancreatic Cancer
Novel Enzyme Target for
Thrombotic disease,
Treatment of Thrombotic Not Applicable Worldwide
Pharmacology,
Disease
Novel Method for Screening Drug Discovery, Molecular Not Applicable Worldwide

Assembly-Directed Antiviral Biology

Compounds
Novel Sindbis Viral Vector
Enables Expression of
Cancer Therapy, Cancer
Functional Genes Not Applicable Worldwide
Research, Diagnostic Assay
Nonstructural Region of
Cell
Tissue Engineering for Tissue Regeneration,
Bladder Reconstruction Bladder, Urology
Treatment and Inhibition of Therapeutics, Disease
Disease Conditions Using Prevention, Veterinary Not Applicable Worldwide
Flexible Heteroarotinoids Medicine, Cancer treatment
Treatments of Colorectal
Cancer Treatment Not Applicable Worldwide
Cancer
University of Pittsburgh
200 Gardner Steel Conference Center | Thackeray and O'Hara

Streets | Pittsburgh PA 15260 | United States
Phone: (412) 624-8787 | Fax: (412) 648-2259 | Website: www.otm.pitt.edu
Contacts
Dr. Marc Malandro | Associate Vice Chancellor, Technology Management & Commercialization
Ms. Amy B. Phillips | Business Development Associate
Organization Type
University
Company Overview
Interested in learning more about the University of Pittsburgh? Come see us at Booth 34
during the LES Tech Fair!
University of Pittsburgh facts:
 $620 Million in total annual research expenditures in 2007

 Ranked 6th in NIH funding in 2007
 Among top 20 elite US public national universities according to US News & World
Report 2008 rankings
 Closely affiliated with the University of Pittsburgh Medical Center (UPMC)

Multi-disciplinary research strengths include:
 Medical device development

 Cancer detection/treatment
 Tissue Engineering
 Neuroscience
 Drug discovery
 Nanoscience/engineering
 Regenerative medicine
 Gene therapy
 Advanced materials
 Aging
 Rehabilitation science
 Translational medicine
 Organ transplantation
The University of Pittsburgh's Office of Technology Management assists in the fulfillment of the
University's mission of education, research, and public service. The Office exists to serve the
faculty, staff, students, and administration of the University and the public by carrying out its
mission to:
To facilitate the development of products and processes from University technology for the
benefit of the University, its faculty,staff, students and the community.

We would like to meet with companies that are interested in building a relationship with the
University of Pittsburgh. Our main focus is the out licensing of University technology and
development of research collaborations.

Our goal is to build relationships that will result in the licensing of University of Pittsburgh
technologies and the development of sponsored research agreements for University faculty.
Country(s)
Available
for
Partnering
cancer, oncology, malignant
A Novel Approach for
melanoma, atherosclerosis, Not Applicable
targeting and treating
diabetic nephropathy,

melanoma macular degeneration, and

retinitis pigmentosa
Adenosine Cyclic Ketals:
hypertension, vasodilation,
Analogues for Cardiovascular Not Applicable
and ischemia
Pharmacotherapy
Administration of Estradiol
Metabolites for Inhibition of nephrotoxicity Not Applicable
Drug-Induced Nephrotoxicity
ANK-1 monoclonal antibody central nervous system,
Not Applicable
and hybridoma cells immunology
Assay to Monitor Organ Transplant, liver
Rejection Anytime after transplantation, small bowel Not Applicable
Transplantation transplantation
ATM/ATR as Markers of
Carcinoma Prognosis and cancer, oncology Not Applicable
Therapy
Atomic emission spectroscopy
chemical analysis Not Applicable
on a chip
Automated Montioring and
Validation of Clinical nursing, health care Not Applicable
Management Protocols
Automatically Retracting
Needle-Tip Electrocautery surgery, electrocautery Not Applicable
Device
Coronary heart disease,
CHD, Peripheral artery
disease, PAD, arterial vein
Biodegradable Electrospun
graft, AVG, coronary artery Not Applicable
Polymer Wrap
bypass grafting, CABG,
Peripheral artery bypass
grafting, PABG
atrial septal defect, ASD,
patent foramen ovale PFO,
Biologic Matrix for Cardiac
cardiovascular patch Not Applicable
Repair
resorbable bioscaffold
device
motor neuron disease,
diagnostic, ALS,
Biomarkers for Motor Neuron
Amyotrophic lateral Not Applicable
Disease
sclerosis, Lou Gehrig's
Disease
Cancer Immunotherapy using cancer, oncology, infectious
Not Applicable
Vesicular stomatitis virus disease

(VSV)
Cloned tumor specific MHC-
unrestricted T Cell Receptor
for gene cancer, oncology Not Applicable
therapy/immunotherapy of
over 85% of human tumors
Combinatorial approaches to Sleep Disordered Breathing,
physiologic pattern Chronic Kidney Disease, Not Applicable
recognition (CAPPER) heart failure, hypertension
Diagnostic to Detect Cancer
Cancer, oncology Not Applicable
Stem Cells and Metastasis
Dictyostatin Analogs as Potent
Microtubule Stabilizers in cancer, onclogy Not Applicable
Cancer Therapy
Dynamic Bi-Plane X-Ray
osteoarthritis, surgery Not Applicable
Imaging System
Early detection biomarker of BPH, Benign prostatic
Not Applicable
Benign Prostatic Hyperplasia hyperplasia
EKG reconstruction from ischemia, myocardial
implanted device electrograms infarction, electrolyte Not Applicable
EGM imbalance
Energy Delivery Method and
Apparatus Using Volume
energy delivery Not Applicable
Conduction for Medical
Applications
infectious disease, cancer,
oncology, AIDS, HIV,
tuberculosis, leprosy,
leishmaniasis, hepatitis B
Enhancing Preventative and
and C, cytomegalia, EBV,
Therapeutic Vaccines (in vivo Not Applicable
Herpes simplex, HPV,
dendritic cell activation)
influenza, SARS,
leishmaniasis, tuberculosis,
leprosy, malaria,
bioterrorism
Estradiol Metabolites for the Pulmonary hypertension,
Treatment of Pulmonary heart failure, cardiac Not Applicable
Hypertension dysfunction
Ethyl Pyruvate: A Method for
Treating Alcoholic Hepatitis & hepatitis, pancreatitis Not Applicable
Pancreatitis
Ethyl Pyruvate: A Novel Eye
Wound healing, eye surgery Not Applicable
and Skin Wound Healing

Agent
Ethyl Pyruvate: A Novel
inflammatory disease Not Applicable
Treatment for Inflammation
Ethyl Pyruvate: A Radio- oncology, radiation
Not Applicable
protective Agent protection
Food Intake and Physical
obesity, weight control Not Applicable
Activity Assessment
arthritis, sepsis, asthma,
FSTL-1: A Novel Target for
septic shock, diabetes, Not Applicable
Inflammation
autoimmune disease
Genomic Biomarkers to
trauma, brain injury, post
Diagnose Post Traumatic Not Applicable
traumatic seizure
Seizure
hemorrhagic shock, septic
shock, stroke, inflammatory
Gramicidin S based bowel disease (chronic
Mitochondrial Targeting ulcerative colitis and/or Not Applicable
Agents Crohn's disease),
inflammation, mitochondrial
disease
Head and Neck Cancer Cell
cancer, oncology Not Applicable
Lines
Identification of a Novel
Chemical Probe for nausea, glaucoma, cancer,
Cannabinoid Receptor stroke, pain, neuronal
Not Applicable
Subtype 2(CB2): diazenyl- disorders, multiple sclerosis,
propanamide compound and and autoimmune disorders
its analogs
acute lung failure, ARDS,
Impeller Designs for an
Acute-on-chronic lung
Internal Impeller Respiratory Not Applicable
failure (ae-COPD), acute
Assist Catheter (iPRAC)
respiratory failure
Cancer, neoplasms, prostate
Integrin alpha 7 Mutations in cancer, liver cancer,
Not Applicable
Cancer glioblastoma multiforme,
and leiomyosarcoma
Kaufmann-Goitz Distal
Interphalangeal Joint (DIP) osteoarthritis, arthritis Not Applicable
Hemi-Arthroplasty
Korrect Bracket:
Repositionable Orthodontic orthodontics, dental Not Applicable
Bracket
Manganese Superoxide cancer supportive therapy Not Applicable

Dismutase (MnSOD) as a
Chemo and Radio Protective
Agent
Method for treatment of drug-
HIV, AIDS Not Applicable
resistant HIV-1
Method in Detecting AZT
HIV, AIDS Not Applicable
Resistance in HIV
Method of treating BK virus BKV-associated
Not Applicable
nephropathy nephropathy
Method to Selectively
Minimize Immune Response transplant Not Applicable
Toward a Donor Organ
tissue engineering, venous
Microintegrated biodegradable
valve, vocal chords, a
elastomeric scaffolds and Not Applicable
cardiac patch, genitourinary
methods of use
structures and wraps
wound healing, diabetes,
inflammatory diseases
Modeling Wound Healing gastrointestinal tract, Not Applicable
vascular injury, arterial
restenosis
Monkeys with Brain Sensors
paralysis, prosthesis Not Applicable
Control Robotic Arms
Monoclonal antibodies for av research use Not Applicable
Monoclonal antibodies for
research use Not Applicable
avb3
Monoclonal antibodies for B2
microglobulin
Monoclonal Antibodies for
HLA- B27
HLA-A2, A28
Monoclonal Antibodies for
HLA-A2, B17
ICAM-1
Monoclonal antibody for beta
chain of HLA II—anti-HLA- research use Not Applicable
DR, -DQ and -DP beta chains
Monoclonal Antibody for
High Molecular Weight- research use Not Applicable
Melanoma Associated

Antigen
Monoclonal antibody for
HLA-A2 class I
Monoclonal antibody for
HLA-Class II
Mood and therapeutic genes in
an animal model of depression depression Not Applicable
and of antidepressant reversal
MRI-Based Breast Cancer cancer, oncology, breast
Not Applicable
Imaging Device cancer
New Biomarkers to Predict
Cancer Metastasis to Bone
Novel Aldehyde cancer, oncology, squamous
Dehydrogenase Tumor cell carcinoma of the head Not Applicable
Associated Antigen and neck, SCCHN
Novel Biosensors for Live Type I diabetes, Type II
Not Applicable
Cell Imaging of Insulin diabetes
Novel EGFR Tumor-
Associated Antigens and cancer, oncology Not Applicable
Enhanced Agonist Epitopes
Novel High Molecular Weight
Melanoma Associated Antigen
Monoclonal Antibodies Cancer, melanoma Not Applicable
(HMW-MAA) for Cancer
Diagnostics and Therapeutics
Nystagmus Buffers to treat
nystagmus, eye, strabismus Not Applicable
unwanted eye movements
Optical device to detect and diagnosis, cancer,
Not Applicable
quantify pathogenic DNA inflammation, infection
Pain evaluation and
pain, pancreatic disease,
modification via P2Y2 Not Applicable
pancreatic cancer
receptor
PC4d Identifies Patients at
cerebrovascular thrombosis,
Risk for Cerebrovascular Not Applicable
stroke
Thrombosis
Peritoneal Lavage with High intestinal transplantation,
Concentrations of Adenosine hemorrhagic shock,
or Adenosine Analogues to intestinal ischemia,
Produce Beneficial Local necrotizing entercolitis, Not Applicable
Effects of Adenosine on the adhesion prevention
Intestines without Systemic following surgery,
Adverse Effects gastrointestinal disease,

ulcerative colitis, crohn's

disease
Peroxisome-Proliferator
transplant, organ
Activated Receptor-Alpha
preservation, acute organ Not Applicable
Agonists for Organ
failure, renal failure,
Preservation
Pharmacologic Inhibition of
cancer oncology Not Applicable
Myc Function
Preparation-Free Electrode
Sleep, epilepsy, neurology,
with Conducting Not Applicable
psychiatry
Polymer/Hydrogel
Preparation-Free Skin-Screw
Sleep, epilepsy, neurology,
Electrode for Rapid Not Applicable
psychiatry
Installation
Prevention of Cancer Stem
cancer oncology Not Applicable
Cell Differentiation
Prognostic utility of human
15-lipoxygenase-1 promoter Cancer, oncology Not Applicable
methylation in human cancers
Purified, Endotoxin Free
Recombinant Soluble receptor
for advanced glycation end-
products (sRAGE)
Real-Time Messaging
communication Not Applicable
Architecture
Recorded Speaking Activity
language learning Not Applicable
(RSA)
overactive bladder, detrusor
Restoration of genitourinary sphincter dyssynergia,
Not Applicable
function urinary incontinence,
detrusor hyperreflexia
Security and Item Level RFID
pharmaceutical tracking Not Applicable
on Blister Packs
Surface-Active Antifungal
antifungal, antimicrobial Not Applicable
Polyquaternary Amine
cystic fibrosis, inhalation
therapy, asthma, chronic
Surfactant Based Tobramycin obstructive pulmonary
Not Applicable
Solution for Inhalation disease (COPD), lung
transplant rejection,
nosocomial infections
Synthetic templates for nanotechnology Not Applicable

controlling nanoparticles
assembly
Targeted delivery of glycine
pain, neuropathic pain,
receptors to peripheral neurons Not Applicable
neurological disorders
as treatment for pain
allergy, asthma,
Targeting c-Kit to Combat
inflammatory bowel disease, Not Applicable
Allergens and Asthma
autoimmune disease, cancer
arthritis, inflammatory
bowel disease, cachexia,
Targeting IKK/NF-kB for anti- muscular dystrophy,
Not Applicable
ageing diabetes, cardiovascular
disease, dementia, bone
fractures, and cancer
The Hsp110 Molecular
Chaperone Controls ApoB heart disease, cardiology Not Applicable
Biogenesis
The Use of Estradiol
Metabolites for Treatment of Obesity, Syndrome X.,
Obesity, Syndrome X., Heart Heart Failure, Renal
Not Applicable
Failure, Renal Dysfunction Dysfunction and Vascular
and Vascular Endothelial Endothelial Dysfunction
Dysfunction
tissue engineering, cardiac,
Thermoresponsive,
cosmetic surgery,
Biodegradable, Elastomeric Not Applicable
pulmonary, transplantation,
Material
drug delivery
eye infection, pink eye,
Topical treatment against
conjunctivitis, Not Applicable
adenoviral infection of the eye
keratoconjunctivitis
Total Synthesis of N14-
Desacetoxytubulysin H
Use of immunomodulatory necrotizing enterocolitis,
Not Applicable
DNA to treat systemic sepsis NEC
Vacuum Seeding Rotational Tissue engineering, bypass
Not Applicable
Device surgery

University of Rochester
345 Culver Road | Rochester NY 14607 | United States

Phone: (585) 273-3250 | Fax: (585) 473-6717
Contacts
Dr. Lawrence Fraser | Manager, Technology Licensing
Organization Type
University
Industry Sector
High Technology

The University of Rochester is seeking to license patents in CMOS circuit design, lasers, optical
metrology and digital image processing.
Firms which license semiconductor intellectual property, which would benefit from acquiring
novel, patented CMOS circuit designs for mixed signal devices from the University of
Rochester.
Firms interested in femtosecond laser, optical swithching and optical metrology patents.

I would like to meet potential partners in the semiconductor IP space for a portfolio of CMOS
circuit design patents for mixed signal devices, high dynamic range ADCs, image sensors with
effiicent jpeg compression, infra-red image sensors, UWB radio pulse generators, and a new
concept for 3D chip power circuitry.
University of Rochester Medical Center
601 Elmwood Drive | Box OTT | Rochester NY 14642 | United States

Phone: (585) 784-8850 | Fax: (585) 785-8829
Contacts
Mr. Michael G. Rusnak | Associate Director, Biological Sciences

Organization Type
University
Industry Sector
Health Care
Company Overview
The University of Rochester Medical Center Office of Technology Transfer facilitates the
protection of Intellectual Property and the commercialization—or transfer—of technologies
resulting from the cutting-edge research being conducted by our world-class scientists, faculty,
and staff .The Office's mission is the translation of scientific innovation into tangible products or
methods that advance knowledge and serve the public good while returning income to the
inventor and to the University to support further research.

The University of Rochester has over 100 technologies that it is currently marketing to the life
science industry. Please check the University's Office of technology transfer Office web site for a
comprehensive listing: http://www.urmc.rochester.edu/technology-transfer/

Biotech and Pharma

The objectives of the University of Rochester in sponsoring my participation involves both an
educational and partnering/networking component. I represent an Office whose goal is both
finding excellent partnerships and ensuring the deals are structured in today's terms.
Country(s)
Partnering
Caspase Inhibitors as Anti-Cancer
Agents
Cooperation Response Genes as
Targets for Cancer Intervention
Novel Approach to Prostate
Hormone Therapy—New and
prostate cancer Not Applicable
Radical Understandings of
Androgen
Novel Glial Restricted Precursor
Cells in the Embryonic
Telencephalon (tGRPs) for
Transplantation

Polyclonal Antibody Therapy for the

Treatment of Multiple Myeloma, cancer Not Applicable
Other B Cell Lymphomas,
Reduction in the Synthesis and
Creation of the Atherogenic Risk cardio Not Applicable
Factor, Apolipoprotein B100
Thioredoxin Interacting Protein
(TXNIP or VDUP1) as a Regulator cardiovascualr Not Applicable
of Vascular Function
Tissue Factor Pathway Inhibition as
a Treatment Strategy for Severe cardio Not Applicable
Pulmonary
Use of Gene Signatures to Design
Novel Cancer Treatment Regimens
Uses of Zebularine and Its Analogs
as Context-Dependent-Inhibitors of
metabolic disease Not Applicable
APOBEC-1 Related Proteins that
Act on DNA or RNA
University of Texas at Arlington
Office of Technology Management | Box 19161; 202 E. Border Street, Ste.

214 | Arlington TX 76019-0161 | United States
Phone: (817) 272-1119 | Fax: (817) 272-1110 | Website: www.uta.edu/ra/real/
Contacts
Dr. Sumita C. Ghosh | Director
Organization Type
University
Industry Sector
Company Overview
With over 100 years of history, The University of Texas at Arlington is one of the top research
institutions in North Texas. UT Arlington enrolls approximately 25,000 students and offers 78
bachelor’s, 74 master’s and 33 doctoral degrees within 10 colleges and schools. It is also a home
for almost 800 professors and research scholars working on projects ranging from
nanotechnology and advanced materials to unmanned aerial vehicles and industrial processes.
For more expertise on drug delivery systems, advanced optics, software, medical devices, green

technologies, sensor networks, wireless applications, and many other areas, please visit our
reSearch profile™ web-site at https://www.uta.edu/ra/real/. A robust search engine will allow
you to find not only technologies available for licensing, but also opportunities for collaboration
with UT Arlington research groups and state-of-the-art facilities and equipment available for use.

Technology transfer, sponsored research, research collaborations and partnering

Companies interested in in-licensing University Intellectual Property, sponsored research and
research collaborations.
Key areas of expertise: nanotechnology, advanced materials, medical devices, hyperspectral

imaging, microscale manufacturing, sensors, pain management, magnetic materials, drug
delivery systems, biodegradable polymers, nanocomposites, propulsion systems, stem cells,
RFID, piezoelectric materials, software.
Please contact Sumita Ghosh (sumita@uta.edu) or Natalia Toth (ntoth@uta.edu) for more
information.

We would like to meet with potential business partners to discuss out-licensing and collaboration
opportunities from The University of Texas at Arlington.
Country(s)
Partnering
Biodegradable Nanoparticles Drug Delivery,
for Targeted Drug Delivery to Cardiovascular Not Applicable
Treat Cardiovascular Diseases Diseases
Integrative Wireless Sensor and
Stimulator for Pain Pain Management Not Applicable
Management
Optical Imaging System to
Visualize Bile Ducts During Imaging Not Applicable
Surgery

Optical Method for In Situ

Detection of Positive Prostate Imaging Not Applicable
and Kidney Cancer Margins
Versatile Biodegradable Elastic
Tissue Engineering,
Polymers for Biomedical Not Applicable
Drug Delivery
Applications
Wireless CO2 Monitor to
Prevent Sudden Infant Death CO2 Monitoring Not Applicable
yndrome (SIDS)
University of Texas at Austin
Office of Technology Commercialization | 3925 W. Braker Ln., Suite 1.9A, MC

R3500 | Austin TX 78759 | United States
Phone: (512) 475-7659 | Fax: (512) 475-6894 | Website: www.otc.utexas.edu
Contacts
Dr. Raymond Atilano | Technology Licensing Specialist
Mr. Richard Friedman | Associate Director
Mr. Max Green | Licensing Specialist
Organization Type
University
Industry Sector
Company Overview
As one of the Nation’s premier public research institutions, the University of Texas at Austin
(UT) is the originator of many novel and useful discoveries each year. The Office of Technology
Commercialization (OTC) assists University employees protect and commercialize new and
useful inventions that are potentially patentable or copyrightable. In support of the University’s
mission, the OTC:
 Educates the UT community about the patent and commercialization process;

 Protects, Markets and Licenses UT inventions and software to industry, entrepreneurs
and the equity community;
 Assists in the formation of start-up ventures;
 Promotes UT-industry collaborations and relationships.
The University of Texas at Austin---What Starts Here Changes the World

 Out-license univeristy intellectual property;

 Develop research relationships with companies; and
 Promote the competencies of The University of Texas:
o Drug delivery;
o Medical devices and instrumentation;
o Wireless communication;
o Clean energy; and
o Smart materials.
University of Utah
615 Arapeen Way | Suite 310 | Salt Lake City UT 84108 | United States
Phone: (801) 581-7792 | Fax: (801) 581-7538 | Website: www.tco.utah.edu
Contacts
Dr. Eric C. Gosink | Licensing Associate
Dr. Rajiv K. Kulkarni | Sr. Licensing Manager
Organization Type
University
Industry Sector
Health Care

out-licensing, research collaborations, marketing agreements, finding customers
University of Washington
4311 11th Avenue #500 | Campus Box 354990 | Seattle WA 98105-4608 | United States
Phone: +1.206.543.3970 | Fax: +1.206.685.4767 | Website: depts.washington.edu/techtran/
Contacts
Dr. Valerie Carricaburu | Technology Manager
Dr. Angela Loihl | Licensing Officer, UW Tech Transfer

Organization Type
University
Industry Sector
University of Western Ontario
Stevenson-Lawson Building #328 | London ON N6A 5B8 | Canada

Phone: (519) 661-4005 | Fax: (519) 661-3709 | Website: www.uwo.ca
Contacts
Mr. Peter M. Ross | Legal Manager
Organization Type
University
Industry Sector
Company Overview
Western is one of the top 10 research universities in Canada, and has recently brought the world
recognized Robarts Research Institute within its auspices. A portfolio of technologies and non-
confidential summaries is available on Western's website (www.uwo.ca/its/research), and there is
an active technology transfer and licensing support group. Primary technologies lie in life
sciences, drug delivery, engineering and bio-fuels.

Interest in out-licensing tech transfer and funding opportunities to support the platform of
technologies.

exposure of Western's technologies and possible collaborative research initiatives
Upsher-Smith Laboratories, Inc.
6701 Evenstad Drive | Maple Grove MN 55369 | United States

Phone: (763) 315-2000 | Fax: (763) 315-2244 | Website: www.upsher-smith.com
Contacts
Mr. Joel Green | Vice President and General Counsel
Mr. Mike McBride | Director, Industry Relations
Mr. Troy Windt | Senior Director, Corporate Development

Organization Type
Company Overview
Upsher-Smith Laboratories, Inc. is a rapidly growing pharmaceutical company that manufactures
and markets both prescription and consumer products. Privately held since 1919, the company
strives to recognize the unmet healthcare needs of our customers. Upsher-Smith prides itself in
providing safe and effective therapies to meet unmet needs in the healthcare environment.
Upsher-Smith is a fully integrated pharmaceutical company with a growing product portfolio

promoted to health care professionals. The company currently has a portfolio of Women's
Health products and is building a portfolio of Central Nervous System (CNS) therapies, with a
focus on epilepsy and Parkinson’s disease.
Product development activities include internal product development, licensing & acquisition,
co-development & co-promotion.

Our primary goals for the LES Annual Meeting is to identify companies with pharmaceutical
products available to in-license within the women's health and CNS. In addition to in-licensing
product opportunities, finding synergistic co-promotion opportunities within women's health for
2008 is of interest.
US Army Medical Research & Material Command
504 Scott Street | Fort Detrick MD United States

Phone: (301) 619-6664 | Fax: (301) 619-5034
Contacts
Mr. Paul C. Mele |
USDA-ARS-SRRC
1100 Robert E. Lee Blvd. | New Orleans LA 70124 | United States

Phone: (504) 286-4541 | Fax: (504) 286-4390
Contacts
Dr. Brian Condon | Research Leader

UT Southwestern Medical Center
5323 Harry Hines Blvd | Dallas TX 75390-9094 | United States

Phone: (214) 648-1881 | Fax: (214) 648-1889 | Website: www3.utsouthwestern.edu
Contacts
Mr. Ray Wheatley | Director, Technology Development
Organization Type
University
Industry Sector
Health Care
Company Overview
Mission
 To improve health care in our community, Texas, our nation, and the world through innovation
and education.
 To educate the next generation of leaders in patient care, biomedical science and disease
prevention.
 To conduct high-impact, internationally recognized research.
 To deliver patient care that brings UT Southwestern's scientific advances to the bedside —
focusing on quality, safety and service.
Utah State University
570 Research Park Way | Suite 101 | North Logan UT 84341-2032 | United States
Phone: (435) 797-4569 | Fax: (435) 797-9612
Contacts
Dr. Raymond DeVito | Director
Dr. Berry Treat | Senior Commercialization Assoc.
Organization Type
University
Industry Sector

Company Overview
Utah State University(x)
The Technology Commercialization Office (TCO) at Utah State University facilitates the
transition of university-based research into commercial products and services. Staffed with
experienced tech-savvy businesspeople, the TCO is well-equipped to work together with
commercial partners to make this a reality. As part of the state’s land- and space-grant university,
the TCO has a diverse array of technologies available for licensing. We invite interested
companies and entrepreneurs to view these technologies at the TCO website at tco.usu.edu and to
contact the TCO with any questions. Technology Commercialization Office (www.tco.usu.edu)
Experienced Associates in licensing of life science technologies; pharma/biotech industry or life

science research
1. Evaluate and execute technology

commercialization strategies for the
University
2. Manage University intellectual
property protections including
patents, copyrights and trademarks
3. Proactively manage university
invention disclosure
4. Negotiate and maintain license
agreements
5. Market University technologies
6. Advise start-up ventures
Products: See
http://www.ibridgenetwork.org/US
U
Contact :
Berry J. Treat
Sr.Technology Commercialization Associate| Life Sciences |
Utah State University | Technology Commercialization Office |
570 Research Park Way, Suit 101, North Logan, UT 84341 |
( PH 435-797-4569 or Cell 435-757-0714 | * Berry.Treat@usu.edu|

"You must be the change you wish to see in the world" - M Gandhi
Utah State University(x)
The Technology Commercialization Office (TCO) at Utah State University facilitates the
transition of university-based research into commercial products and services. Staffed with
experienced tech-savvy businesspeople, the TCO is well-equipped to work together with
commercial partners to make this a reality. As part of the state’s land- and space-grant university,
the TCO has a diverse array of technologies available for licensing. We invite interested
companies and entrepreneurs to view these technologies at the TCO website at tco.usu.edu and to
contact the TCO with any questions. Technology Commercialization Office
Utah State University
Country(s)
Partnering
Coanda-Assisted Spray
NA Not Applicable
Manipulation
Cool Jet- Cooling Device Without

NA Not Applicable
Moving Parts
Listeria Control in Meat Products NA Not Applicable
POWERPAY™ Debt Reduction

NA Not Applicable
Software Tool
Self-Assembled Quantum
na Not Applicable
Nanostructures
Twisteron- Airborne Vehicle

Technology for Reducing Drag NA Not Applicable
and Fuel Needs
UTEK Corporation

2109 E. Palm Avenue | Tampa FL 33605 | United States

Phone: (813) 754-4330 | Fax: (813) 754-2383 | Website: www.utekcorp.com
Contacts
Mr. William B. Porter | Chief Technology Transfer Officer
Organization Type
Consulting Firm
Industry Sector
High Technology
Company Overview
UTEK® is a leading innovation services company. Our services enable clients to become
stronger innovators, rapidly source externally developed technologies and create value from their
intellectual property
We offer a comprehensive suite of services for businesses seeking to accelerate growth and
reduce costs through the development of enhanced innovation capabilities. We provide foresight
as to the direction of customer and industry trends and help our clients effectuate innovation
within and outside of their core markets.
UTEK has built what we believe to be the world’s largest database of intellectual properties
available for immediate license, which when combined with its global network of universities,
research laboratories and companies, provides clients with unparalleled access to external
innovation.
For more information about UTEK, please visit its website at www.utekcorp.com.


Partnering
U2B n/a Not Applicable Worldwide
UTMB Center for Technology Development

1700 The Strand, Suite 1200 | 301 University Blvd | Galveston TX 77555-0926 | United States
Phone: (409) 772-7962 | Website: research.utmb.edu/ctd/index.asp

Contacts
Dr. Michael Perham | Licensing Associate
Organization Type
University
Industry Sector
Health Care
Company Overview
The UTMB Center for Technology Development (CTD) was created in 2004 to take advantage
of changes made to the Texas Education Code concerning the commercialization of proprietary
technology. The new rules allowed for the creation of centers that could have broader control
over the discovery, development, protection, and commercialization of proprietary intellectual
property.
UVA Patent Foundation
250 W. Main Street | Suite 300 | Charlottesville VA 22902 | United States

Phone: (434) 924-2175 | Fax: (434) 982-1583
Contacts
Dr. Robert S. MacWright | CEO and Executive Director
Valeant Canada Limited
4787 Levy Street | Montreal Quebec H4R 2P9 | Canada

Phone: +1-514-744-6792 | Fax: +1-514-744-6272 | Website: www.valeant.com
Contacts
Mr. Serge Verreault | Business Development Director
Company Overview
Company Profile

Valeant Canada Ltd. is a wholly owned subsidiary of Valeant Pharmaceuticals International, a

global, publicly traded, research-based, specialty pharmaceutical company that discovers,
develops, manufactures and markets a broad range of pharmaceutical products. We are currently
seeking to extend our product offerings and are interested in acquiring new products in the
therapeutic areas of pain management, sleep disorders, neurology, dermatology and infectious
diseases (virology).
Partnering Strategy
Valeant Canada is currently seeking to expand our product offerings, and is interested in
acquiring or licensing new products within our areas of Therapeutic Focus. Our strategy is to
leverage and capitalize upon our strengths within these areas.
Neurology Virology Dermatology Specialty
o Pain Management o Hepatitis o Psoriasis o Sleep

o Parkinson’s Disease o HIV o Eczema Disorders
o Epilepsy o SARS o Acne o Depression
o Multiple Sclerosis o RSV o Rosacea o Anxiety
o Huntington’s o Actinic Keratoses o Others
Disease o Squamous Cell Carcinoma
o ALS o Anti-fungals (topical)
Commercial Products
Cesamet® : Antiemetic Agent
Xyrem® : Cataplexy associated with Narcolepsy
Efudex® : Actinic Keratoses / SBCC
Mestinon® : Myasthenia Gravis
Valeo Management L.P.

550 Sherbrooke West | Suite 100 | Montreal QC H3A 1B9 | Canada

Phone: +1.514.840.1226 | Fax: +1.514.840.1299
Contacts
Ms. Natacha Mongeau | Intellectual Property Manager
Company Overview
Valeo Management is a limited partnership that commercializes technologies from a group of
four Quebec Universities. Only technologies with a solid business case and meeting important
industry needs are promoted.
Country(s)
Partnering
Cancer, macular
A new anti-angiogenesis degeneration,
Target Validation Worldwide
agent inflammation, psoriasis,
arthritis
Hepatocyte Cell Culture on

In vitro drug testing
a Tridimensional Matrix Target Validation Worldwide
(ADMET studies)
for ADMET Studies
Increased Effect of tPA on Thrombosis, Cardiology,

Target Validation Worldwide
fibrin-clot lysis Stroke
Oral delivery system for Enzyme, pancreas,

large molecules and probiotic, vaccine, oral Target Validation Worldwide
bioactive agents delivery
Gastrointestinal,
Oral protein delivery to the
Antibodies, Interferon, Pre-Target Validation Worldwide
colon
Enzyme
Van Dyke, Gardner, Linn & Burkhart, LLP

2851 Charlevoix Drive | Suite 207 | Grand Rapids MI 49546 | United States
Phone: (616) 975-5501 | Fax: (616) 975-5505 | Website: www.vglb.com
Contacts
Mr. Daniel Van Dyke | Partner
Vanderbilt University
1207 17th Avenue South | Suite 105 | Nashville Tennessee 37212 | United States
Phone: 615 343-2430 | Fax: 615 343-4419
Contacts
Dr. Christopher McKinney | Director, Office of Technology Transfer and Enterprise
Development
Organization Type
University
Industry Sector
Company Overview
Vanderbilt University is an internationally recognized research university in Nashville,

Tennessee, with strong partnerships among its 10 schools, neighboring institutions and the
community. Vanderbilt offers undergraduate programs in the liberal arts and sciences,
engineering, music, education and human development, as well as a full range of graduate and
professional degrees. The combination of cutting edge research, liberal arts and a distinguished
medical center creates an invigorating atmosphere where students tailor their education to meet
their goals and researchers collaborate to solve complex problems affecting our health, culture
and society.
Vanderbilt provides a gateway to greatness, drawing the best and brightest students from across
the nation and around the world. Vanderbilt alumni can be found in Congress, on the judicial
bench, heading corporations, conducting innovative medical research, writing for and appearing
on the stage and screen, and playing in the NFL and NBA.
An independent, privately supported university, Vanderbilt is the largest private employer in
Middle Tennessee and the second largest private employer based in the state.
The Office of Technology Transfer and Enterprise Development (OTTED) is the university
department that plays the major role in protecting and preserving the intellectual property assets
of Vanderbilt University, licensing technology developed by Vanderbilt inventors and
innovators, and assisting in the start-up of companies which commercialize Vanderbilt
technology. Through these activities, OTTED substantially benefits inventors, Vanderbilt
University, its community, and the public at-large.

The licensing professionals working in the OTTED are members of and active participants
in LES, AUTM and other professional organizations.
Interested in patent law changes arising from recent judicial, legislative and regulatory actions.
Interested in hearing about the ways in which university researchers and administrators, can
attract industry funding of early stage research.
How can we in the university technology transfer office best promote our intellectual property
assets.
Any company interested in licensing and investing in the advancement of early stage
technologies.
Companies interested in participating at future university roundtable discussions related to how

university researchers and technology transfer professionals can promote interactions with
industry.
Four members of Vanderbilt University's Office of Technology Transfer and Enterprise

Development will be in attendance at the LES Annual Meeting. They are Janis Elsner, Associate
Director; Karen Rufus, Sr. Licensing Associate (life sciences); Ashok Choudhury, Sr. Licensing
Associate (physical sciences); and Mary Koskinski, Licensing Associate (life sciences).
Our goals in attending the LES conference are to network with colleagues in the licensing
field, identify and meet with potential commercial partners to advance Vanderbilt technologies
into the marketplace, exchange ideas and perspectives about current challenges facing industry
and university licensing professionals and, hopefully, learn some novel approaches to resolve
some of these difficult issues.
for Partnering

Aqueous-based Modular,
n/a Not Applicable
Drug Delivery System
Multimodal Lanthanide
n/a Not Applicable United States, Europe
Chelate Imaging
Vanderbilt University Office of Technology Transfer and Enterprise Dev.
1207 17th Avenue South | Suite 105 | Nashville TN 37212 | United States
Phone: (615) 343-2430 | Fax: (615) 343-4419 | Website: www.ornl.gov
Contacts
Mr. Ashok Choudhury | Sr. Technology Commercialization Associate
Vanguard Technologies, LLC
525 Mendon Road | North Attleboro MA 2760 | United States

Phone: (508) 801-5127 | Fax: (508) 399-5126
Cotacts
Ms. Tracey Dodenhoff | CEO
Vatera Capital
499 Park Ave. | 6th Floor | New York NY 10022 | United States
Phone: (646) 328-1333 | Fax: 646 328 1348 | Website: www.vateracapital.com
Contacts
Ms. Lyn Baranowski | Sr. Associate
Organization Type
Financial Services
Industry Sector
Health Care
Company Overview

Vatera Capital is a private equity firm established by Mr. Michael Jaharis, founder of Key and
Kos Pharmaceuticals. We focus on investing in healthcare biopharmaceutical products and
companies with the goal of building specialty pharmaceutical companies using our track record
of success, strong network of established relationships, and credibility.
We are interested in both:
- Acquiring / licensing approved or late-stage biopharmaceutical products, with a strong

preference for products marketed in the US in specialty disease areas.
- Investing in / acquiring specialty biopharmaceutical companies with the goal of growing those
companies using our team's experience, particularly in commercialization.
We are interested to meet with:
- Representatives from pharma and biotech companies that are responsible / involved with out-
licensing and divesting
- Representatives from companies with late-stage development assets in specialty disease areas
that are seeking equity investment capital
Interested parties should contact Lyn Baranowski via email at lbaranowski@vateracapital.com to

set up a meeting.

We are interested to in-license or acquire cash-generating specialty biopharmaceutical products
and/or companies.
Venable LLP
575 7th Street, N.W. | Washington DC 20004-1601 | United States

Phone: 202.344.4614 | Fax: 202.344.8300 | Website: www.Venable.com
Contacts

Miss JoAnna Esty |

Ms. Aida M. Lebbos | Attorney at Law
Organization Type
Law Firm
Vertex Intellectual Property Strategies Inc.
115 Brentwood Road North | Toronto ON M8X 2C7 | Canada

Phone: (416) 239-7779 | Fax: (416) 239-5707
Contacts
Mr. David Tyrrell | President
Organization Type
Consulting Firm
Company Overview
Vertex Intellectual Property Strategies Inc. applies proven technology management approaches
to help businesses and technology development organizations fully identify, appropriately
safeguard, and effectively exploit their intellectual assets. Vertex brings together a team of
seasoned professionals with diversified experience to meet your specific Intellectual Property
management and technology commercialization needs. Since 1998 Vertex has effectively
bridged the gap between the legal profession and businesses to help them fully capitalize on their
technology and know-how.
Our Customized Services include:
85. Intellectual Asset Management

1. Analyzing and benchmarking practices
2. Developing and implementing policies and protocols
86. Licensing strategy – formulation and execution
1. Identifying who to approach,
2. Setting the royalty rate
3. Developing terms for agreements
4. Negotiating agreements
87. Market research
1. Competitive assessment
2. Market intelligence

88. Software for Intellectual Asset Management

89. Software Based Patent Analysis for:
1. Patent landscapes and competitive assessments
2. Development of R&D and patent licensing strategies
90. Technology acquisition assistance
91. Valuation
1. Benefit-Investment Valuations (VTV™ Analysis)
2. Technology valuation for licensing and business valuation
92. Workshops designed to meet specific IP training needs

To meet businesses that require assistance with intellectual asset management and licensing
initiatives.

Vertical*i
132 Nassau Street | Suite 711 | New York NY 10038 | United States
Phone: 212.608.0771 | Fax: 212.608.0772
Contacts
Mr. Frank Cole | Account Executive
Mr. Guy Henninger | VP, Sales & Marketing
Mr. Hansruedi Kottmann | CEO
Mr. Scott Lyon | Executive Director, Sales
Organization Type
Industry Sector
High Technology
Company Overview
Vertical*i enables lifescience and health companies to effectively manage their business
ecosystems.
In order to bring new drugs to market faster and more cost-effectively, companies rely more than
ever on business partners, strategic alliances and license arrangements to enhance and
compliment their internal research and development capabilities.
Vertical*i provides a business application platform for Business Development & Licensing
(BD&L) to evaluate, compare and select opportunities and projects; manage partnerships and
alliances; Vertical*i furthermore provides valuation tools for product, project, portfolio and
company valuations.
Over 1'000 users in over 35 biopharma organization rely on our solutions to support their daily
BD&L activities.

Seeking companies who have an interest in optimizing their Business Development processes,
better manage their licensing deals, and get the most out of their partnerships and alliances.

Pharma, biotech, medical device, consumer health and lifescience companies involved in in-
licensing, out-licensing, alliance management and portfolio optimization.


Partnering
Vertical*i Application
Suite
Victory Pharma, Inc.
3700 Regency Parkway #130 | Cary NC 27518 | United States

Phone: (919) 459-3914
Contacts
Mr. Thomas Heck | Vice President
Mr. David Tomasso | Exec. Director, Business Development
Organization Type
Industry Sector
Health Care
Company Overview
Victory Pharma
Victory is a specialty pharmaceutical company whose primary focus is pain management. We
have a portfolio of products that we market to Health Care Providers through our growing
commercial organization. In addition, we are developing novel products that effectively treat
chronic pain, while also minimizing side effects commonly associated with other, widely-used
pain therapeutics. In so doing, we provide pain management solutions that enable a better
quality of life for patients.

Victory Pharma is interested in finding IP based Pain and related CNS products to market in
concert with Naprelan 375, 500, & 750 mg tablets which are patented through 2014 and growing
rapidly.

Victory would like to speak with companies that have IP or Exclusivity based prescription
strength products to license or divest for marketing and distribution in the USA.

Victory seeks to identify or partner with companies during the meeting. We seek US approvals
or near term approvals in Pain and related categories ( CNS to include sleep, anxiety,
musculoskeletal, pain, etc.)
Vifor‐Aspreva Pharmaceuticals Inc.
#1203 - 4464 Markham Street | Vancouver Island Technology Park | Victoria BC V8Z
7X8 | Canada
Phone: +1.250.744.2488 | Fax: +1.250.744.2498
Contacts
Mr. Michael R Martin | Director, BD & Licensing
Organization Type
Industry Sector
Health Care
Company Overview
Vifor-Aspreva Pharmaceuticals
Vifor-Aspreva is a wholly owned subsidiary of the Galenica group. Galenica is a diversified

company active throughout the healthcare market which among other things develops,
manufactures and markets pharmaceutical products, runs pharmacies, provides logistical services
and access to data bases. The Galenica group enjoys a leading position in all its areas of activity,
pharmaceuticals, manufacturing, pre-wholesaling, distribution, healthcare information and
retailing.
Vifor-Aspreva is the recently merged entity of Aspreva Pharmaceuticals Inc. and Vifor
International. Prior to the acquisition and merger, Aspreva was a global pharmaceutical
company that pioneered a novel indication partnering approach to pharmaceutical business
development, this is best exemplified within the Aspreva-Roche agreement for CellCept for the
treatment of autoimmune diseases. Asprevas therapeutic focus was Nephrology & Autoimmune
Disease, A significant number of global milestones where met by Aspreva prior to being

acquired by the Galenica group. Prior to the merger Vifor International via it’s iron franchise
was the world leader in the market for pharmaceutical iron products. Based in Zurich,
Switzerland, the company supplies customers in over 80 countries with finished products and
active compounds including oral and parenteral iron products for the treatment and prophylaxis
of iron deficiency anemia.
The combined entity of Aspreva and Vifor now called Vifor Pharma has a specialization in
Nephrology, Anemia and Autoimmune diseases. Our corporate goal is to in-license products in
various stages of development in order to fill out our development pipeline within the areas of
our therapeutic interest. We possess a fully integrated set of capabilities incorporating all aspects
of the pharmaceutical value chain.

It is Vifors objective to in-license technologies or products within our areas of therapeutic
interest, Anemai, Nephrology, and Autoimmune Diseases

We are interested in meeting with companies with products in phase I or later development
within our areas of therapeutic interest, Nephrology, Anemia, and Autoimmune Diseases.
Our objectives for the LES are to generate viable leads for products within our areas of
therapeutic interest that we can further evaluate and make go no-go decisions for in-licensing.

Partnering
CellCept Autoimmune Diseases Not Applicable
Iron Defficiencey
Ferrinject Not Applicable
Anemia
Iron Defficiencey
Ferrinject Not Applicable
Anemia

Virginia Commonwealth University
800 East Leigh Street | Suite 113 | Richmond VA 23219 | United States
Phone: (804) 828-5188 | Fax: (804) 827-0087 | Website: www.research.vcu.edu/ott/index.htm
Contacts
Dr. Maureen C Kelly | Licensing Associate
Organization Type
University
Industry Sector
Company Overview
Virginia Commonwealth University (VCU) is ranked nationally by the Carnegie Foundation as

a top research institution. The research enterprise at VCU has made substantial forward steps in
recent years, doubling the sponsored award base to more than $200 Million and investing in
state-of-the-art research facilities.
VCU Technology Transfer’s mission is to commercialize inventions and other valuable

intellectual property developed from scholarly activity by university members, for the benefit of
the university, its members, and the public. VCU Technology Transfer’s vision is to bring
world-class recognition and value to VCU and its members through commercialization of
intellectual property developed at the university.
VCU Technology Transfer seeks commercial partners to develop and bring promising VCU
technologies to the marketplace. VCU Technology Transfer encourages industrial research
partnerships between VCU researchers and for-profit companies through the Industrial
Partnerships Office. We encourage you to learn about VCU and the business opportunities that
we have to offer by contacting VCU Tech Transfer.
VCU Core Competencies and Technologies:

· Surgical care and devices
· Trauma care devices and techniques
· Cancer diagnostics and therapies
· Non-invasive diagnostics
· Small molecules
· Pharmaceutical and biologics development
· Nanotechnology

· Bio- and chemical sensors

· Biotech discovery tools
· Medical and dental education software
· Clinical trials

We are interested in out-licensing, developmental collaborations, and technology transfer.
Please contact Maureen Kelly to set up a meeting during the conference.

VCU Tech Transfer seeks to out-license VCU technologies for commercialization by industry.
We also wish to collaborate with industry and academic institutions in research & development.
Country(s)
Partnering
A Novel Compound to Treat

Malaria Not Applicable Worldwide
Malaria
Delivering an Accurate Dose of

Medical Device Not Applicable Worldwide
Medication to the Lungs
Genetic Marker to Predict

Diagnostic Not Applicable Worldwide
Premature Delivery
Innovative Methods to Improve

Computer
the Design of Pharmaceutical Not Applicable Worldwide
Modeling
Spray Inhalers
Novel Anti-coagulants Coagulation Not Applicable Worldwide
Small Molecule for the Treatment

Cancer Not Applicable Worldwide
of Cancer
Treatment for Brain Cancer Cancer Not Applicable United States
Vaccines and Diagnostics for Vaccine,

Cryptosporidium Diagnostic

Watson Pharmaceuticals, Inc.
360 Mt. Kemble Avenue | Morristown NJ 07962 | United States

Phone: (973) 355-8185 | Fax: (973) 355-8581
Contacts
Ms. Stacey S. Cirillo | Associate Director Business Development
Mr. Kevin Ostrander | Director, Business Development
Mr. Edward F. Tykot | Executive Director,Business Development
Organization Type
Industry Sector
Health Care
Company Overview
Watson Pharmaceuticals, Inc. engages in the development, manufacture, marketing, and
distribution of branded and generic pharmaceutical products in the United States. The company's
products are used in various therapeutic areas, which include central nervous system,
nephrology, hormones and synthetic substitutes, cardiovascular, women's health and other areas.
It operates in three segments: Generic, Brand, and Distribution. The Generic segment
manufactures and sells generic products for various therapeutic classes, including anti-
depressant, anti-hypertensive, anti-diabetic, anti-hypertensive, analgesic, oral contraceptives,
analgesic, and hormone replacement products. The Brand segment principally offers products for
male hormone replacement, hematinic, overactive bladder, women's health and prostate cancer
therapeutics, as well as specialty products that focus on urology and nephrology.
WBTshowcase
14358 N. Frank Lloyd Wright Blvd. | Suite 14 | Scottsdale AZ 85260 | United States
Phone: (480) 477-6408 | Fax: (877) 671-5998 | Website: www.wbtshowcase.com
Contacts
Ms. Amanda Radovic | Director
Industry Sector
High Technology
Company Overview
The WBTshowcase is the world’s premier event exposing undiscovered, revolutionary energy,

life science, physical science and information technologies emerging from top universities, labs
and research institutions. Each WBT represents an almost year long collaborative effort resulting
in deals vetted and mentored by investors and licensee for investors and licensees. The WBT
offers an unparalleled forum that is deal-focused with a proven track record of success.
Process:
The WBTshowcase is a hands-on, competitive event where each selected presenter becomes our
client. We leverage industry pros from the moment an application is submitted, work with each
selected presenter to reach out to specific investors and partners, and provide a wealth of
resources including two dedicated "mentors" to help prepare for the event.
Success:
The success and quality of WBT presenters is proven. Six full years of past performance indicate
over 1/3 of all WBT presenters have or will succeed in raising private equity, securing a strategic
partnership or licensing agreement, or selling their IP outright. Over $400 Million has been
raised to date
Ready to Expose your company or technology to investors and licensees?
We are currently accepting application to present at the WBT09 set for March 24-25 in
Arlington-DFW. For more details and to complete a brief on-line application visit
www.wbtshowcase.com and select, Submit your Technology.
I am interested in meeting with:
 Organizations seeking to license and commercialize IP

 Seed and Early Stage companies seeking private equity
 Technology entrepreneurs
 Researchers
 Research institutions
 Tech Transfer Directors representing university innovations
 Seed and early stage venture investors
 Commercial and corporate licensing investors
 Corporate venture investors
 Technology officers
 CRADA Partners
 SBIR Award recipients
 Federal R&D Program Managers

 Scientists
 Business, legal, and finance experts
My colleagues (Paul Huleatt, Wiley Larsen) and I will be available during the LES conference to
meet with you. I look forward to speaking with you.
We are interested in networking to discuss Phase I and Phase II SBIR services, our mentoring
program and the WBTshowcase.
We are currently accepting applications to present at the event in March 2009. Stop by our booth
or schedule an appointment to talk about your funding and or licensing opportunities.
WBTshowcase
14358 N. Frank Lloyd Wright Blvd | Suite 14 | Scottsdale AZ 85260 | United States
Phone: (480) 477-6410 | Website: www.wbtshowcase.com
Contacts
Mr. Wiley Larsen | Relationship Manager
Organization Type
Consulting Firm
Industry Sector
Company Overview
Leveraging industry professionals in the selection and mentoring of each year's presenting
technologies, the WBTshowcase continues to define the market for seed stage investment and
licensing opportunities. The WBTshowcase is only event of its kind focused exclusively on
sourcing, screening, preparing, and presenting the most promising breakthrough technologies to
the most active investment and licensing professionals worldwide.
The process begins with the review of every application by the WBT screening panel, comprised
of over 80 venture investors and licensing pros. Direct feedback from the screening panel is
provided to all applicants.
The WBTshowcase will feature 100 technologies from universities, federal labs, and the private
sector. Applications for technology presenters are due Nov. 17. Deals are selected in early

January, and presenters are taken through our one-of-a-kind mentoring process leading up to the
show. The forum takes place in Arlington, Texas March 24-25, 2009.
For more information, visit www.wbtshowcase.com.
WBT is actively recruiting deals for the show, as well as qualified investors and licensing
professionals for our network of screeners, mentors, and attendees.

Corporate technology scouts, law firms, and service providers who know or work with early
stage technologies that are seeking to gain traction and national exposure.
WBT is looking for additions to our screening panel, mentor pool, and attendees, as well as great
presenters in our 4 tracks: Life Science, Energy, IT, and Manufacturing.
Weisse & Wolgast
Bleibtreustrasse 38 | Berlin DE 10623 | Germany

Phone: +49 (0)30 21 47 84 89 | Fax: +49 (0)30 21 47 84 93 | Website: www.weisse-
patent.de/EN/us.htm
Contacts
Dr. Renate Weisse | Dipl.-Phys. Dr. Ing. LL.M
Organization Type
Law Firm
Industry Sector
High Technology
Company Overview
Patentanwälte Weisse & Wolgast is a German law firm established in 1951 in Velbert and
Berlin. We represent overseas clients before the German and European Patent Offices and Courts
to obtain, validate and litigate their protective rights including patents, trademarks, designs
and utility models. We advise our clients in all matters relating to German employees invention
law, draft and negotiate licensing agreements and monitor markets and patent activities of
competitors.
Senior Partner Dr. Renate Weisse is a German and European Patent Attorney with great
experience in engineering, computer technology, optics and spectrometers. She has a
university degree in Physics (Diplom) and Chemistry (Vordiplom) and is working in the Berlin
Office. She has working experience in a law firm in Dublin/Ireland, with Perkin Elmer and
represents many cases for US-clients.

Weisse & Wolgast is interested in all matters of intellectual property, such as patents,
trademarks, designs and licensing agreements.
Representatives of small patent law firms having clients with overseas activities
Representatives of companies with overseas activities

Finding cooperation partners for reciprocating cooperation
Westford Technology Associates
911 Roundelay Lane | West Chester PA 19382 | United States

Phone: (610) 793-2654 | Fax: (610) 793-2945
Contacts
Mr. Nicholas J. Di Marino | President
Westport Innovations Inc.
Suite 101, 1750 W 75th Avenue | Vancouver BC V6P 6G2 | Canada

Phone: (604) 718-8370 | Fax: (604) 718-2001
Contacts
Mr. Lance Follett | Senior Director, Licensing and Intellectual Property Commercialization
Organization Type
Industry Sector
High Technology

Company Overview
Westport Innovations Inc. is a leading global supplier of proprietary solutions that allow engines
to operate on clean-burning fuels such as compressed natural gas (CNG), liquefied natural gas
(LNG), hydrogen, and biofuels such as landfill gas. Cummins Westport Inc., Westport’s joint
venture with Cummins Inc., manufactures and sells the world's broadest range of low-emissions
alternative fuel engines for commercial transportation applications such as trucks and buses.
Weichai Westport Inc., a joint venture between Westport and Weichai Power based in Weifang,
China, develops gaseous fuelled engines based on Weichai engine platforms for a variety of
different medium and heavy duty applications. BTIC Westport Inc., Westport’s joint venture
with Beijing Tianhai Industry Co. Ltd., manufactures and sells LNG fuel tanks for vehicles.
Westport's unique technologies reduce nitrogen oxides (NOx), particulate matter (PM) and
greenhouse gas emissions (GHG) while preserving the power, torque, and fuel efficiency of
diesel engines.
Westport’s commercially available LNG fuel system product for heavy-duty trucks includes a
Cummins ISX 15-litre diesel engine operating on natural gas using the Westport technologies,
and a complete natural gas fuel system including proprietary LNG fuel storage tanks and fuel
pumps.
Our corporate offices and engine laboratories are located in Vancouver, Canada. Our facilities
total over 11,150 m2 (120,000 ft2) and feature eight engine test cells suitable for engines up to
1,200 hp, and a medium-duty chassis dynamometer. Westport is publicly traded on NASDAQ
(WPRT) and the Toronto Stock Exchange (WPT).

Organizations that develop, commercialize, use and license-out and license-in fuel system
technology for internal combustion engines.

Country(s)
Partnering
Accelerometer-based combustion
n/a Not Applicable
control system
Hot surface ignition high

pressure direct injection gaseous n/a Not Applicable
fuel system
Westport LNG fuel system for

n/a Not Applicable
heavy-duty trucks
Wi-Lan Inc.
11 Holland Avenue | Suite 608 | Ottawa ON K1Y 4S1 | Canada

Phone: (613) 688-3893 | Fax: (613) 688-4894
Contacts
Mr. Michael McCartney | Director of Intellectual Property
Mr. Derek Nuhn | Vice President, DSL Technology
Mr. Andrew Parolin | VP, Business Development
Mr. Prashant Watchmaker | Corporate Secretrary and Assistant General Counsel
Organization Type
Industry Sector
High Technology
Company Overview
Wi-LAN, founded in 1992, licenses intellectual property applicable to a full range of products
providing access in the communications and consumer electronics markets. Some of the
fundamental technologies covered by Wi-LAN's patents include: CDMA, DOCSIS, DSL, V-
chip, Wi-Fi and WiMAX. Wi-LAN has already licensed its intellectual property - which includes
227 issued or pending patents - to a number of the world's largest companies, including Nokia,
Cisco, Fujitsu, and Redline Communications.
Windhover Information, Inc.

10 Hoyt Street | Norwalk CT 6851 | United States

Phone: (203) 838-4401 x232 | Fax: (203) 838-3214
Contacts
Mr. Roger Longman | Managing Partner
Wong, Cabello, Lutsch, Rutherford & Brucculeri, L.
20333 SH 249 | Suite 600 | Houston TX 77070 | United States

Phone: (832) 446-2405 | Fax: (832) 446-2424 | Website: www.counselip.com
Contacts
Mr. Keith Lutsch | Shareholder
Woodcock Washburn LLP
Cira Centre, 12th Floor | 2929 Arch Street | Philadelphia PA 19104-2891 | United States
Phone: 215.568.3100 | Fax: 215.568.3439
Contacts
Mr. Michael Dunnam | Partner
Company Overview
Woodcock Washburn LLP, with offices in Atlanta, Philadelphia, and Seattle, has built a wealth
of experience in patent, trademark and copyright law, litigation and trade secret protection for
more than 60 years. The firm's attorneys and scientific advisors service regional, national and
international clients, offering their expertise in biotechnology, chemistry, chemical, electrical and
mechanical engineering, and software. Most Woodcock Washburn attorneys have technical
degrees to complement their legal education, and many have advanced degrees and industry
experience. Woodcock Washburn attorneys specialize in patent prosecution, IP litigation, IP
strategy development, IP transactions, and interference practice, particularly in pharmaceuticals,
biotechnology and biochemistry. Areas of expertise include molecular biology, genomics,
immunology, virology, vaccine development, drug delivery, nucleic acid chemistry,
nanotechnology, and bioinformatics. Woodcock attorneys also assist clients with validity and
infringement opinions, freedom to operate opinions, and licensing negotiations.
Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail | Suite 300 | Raleigh NC 27607 | United States
Phone: (919) 781-4000 | Fax: (919) 781-4865 | Website: www.wyrick.com
Contacts
Mr. Jason S. Wood |
Yale University
433 Temple Street | New Haven CT 6511 | United States

Phone: (203) 436-3946 | Website: www.yale.edu/ocr
Contacts
Mr. David Fung | Associate Director
Yet2.com, Inc.
175 Highland Ave | Needham MA 02494 | United States

Phone: 781-972-0600 | Fax: 781-972-0601 | Website: www.yet2.com
Contacts
Mr. Benjamin F. du Pont | President
Organization Type
Consulting Firm
Company Overview
yet2.com helps companies scout for and acquire new technology to drive growth and yet2.com
helps companies out license patents and/or underutilized technology. We have +200 clients and
we close deals - on average - every 2 weeks. We have offices in; Tokyo, London, Boston and
Wilmington Delaware.
Country(s)
Partnering

active marketing for both out-

licensing and technology n/a Not Applicable Worldwide
acquisition

You Me Patent & Law Firm
1233 20th St., N.W., Ste 701 | Washington DC 20036 | United States
Phone: (202) 776-9390 | Fax: (202) 776-9361
Contacts
Mr. Hunjoon Kim | Attorney
Zacco
Sveavagen 151 | Stockholm SE 104 35 | Sweden

Phone: (514) 452-1661
Contacts
Mr. Pierre Kary | European Patent Attorney / Regional Manager North America
ZenithBIO, LLC
784 Morris Turnpike | Suite 201 | Short Hills NJ 7078 | United States
Phone: (973) 467-8732 | Fax: (973) 467-8734 | Website: www.zenithbio.com
Contacts
Ms. Ruth A Plager | President
Organization Type
Consulting Firm
Industry Sector
Health Care
Company Overview
Ruth Plager, President, ZenithBIO LLC, a Strategic Business Development Consultancy, is a
results-oriented biopharmaceutical executive with more than 25 years of commercial experience
across all therapy areas.
ZenithBIO offers a wide range of business development consulting services, with the primarily
focus on emerging biopharmaceutical companies on both coasts. Our decade of consulting
includes identifying, evaluating, and valuing a wide range of in- and out-licensing opportunities

to drive go/no-go decisions, negotiations and due diligence—and ultimately win-win deals!
Identified opportunities require comprehensive analysis--including secondary data, primary

research and forecast scenarios—the integrated summary is translated into the development of
non-confidential and confidential partnering presentations.
Our biopharmaceutical Clients have included

♦ CoTherix (M&A Actelion) ♦ Enzo Therapeutics ♦ Nektar ♦ NeoStrata ♦ SciDose ♦ ♦
TopoTarget U.S. ♦ ♦ Valera Pharma (M&A Indevus) ♦ Bayer Biotech & Pharma ♦ Corvas
(Dendreon) ♦ Genencor ♦ IntraBiotics ♦ Questcor ♦ Roche Bioscience ♦ Scios ♦ Syntex ♦ Trius
Therapeutics ♦ UCB Pharma
Analyses of business development opportunities are grounded in a commercial perspective

gained from early successes at Pfizer in New Product Planning and Line Product Marketing for
novel and mature products, at Syntex International and later at Enzon in Business Development
and Strategic Market Planning.
Our early experience in cancer research coupled with Health Economics courses in addition to
our extensive commercial experience insures that our clients receive excellent results which help
accelerate their business development services.
Our network benefits from Ruth Plager's active involvement in the LES HealthCare committee.
Ruth has been involved in developing panels and presentations for LES HealthCare Programs,
which included
 Repositioning In-Licensed Assets to Increase Commercial Potential

 Negotiating Mechanism Based Alliances
 Impact of Funding Options on Licensing Deals
 Anatomy of a Deal: Four Deals That Highlight Novel Solutions to Complex Issues

We are interested in meeting with business development executives in emerging
biopharmaceutical companies in the US and Canada, to explore how we can help you accelerate
the achievement of your goals re partnering, for in-licensing and out-licensing.

We are interested in meeting with small emerging biopharmaceutical companies whom could
benefit from our strategic business development consulting service. Our track record over a
decade assures our clients Value and Results.

2008 LES Membership Directory

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

2008 LES Membership Directory

Uploaded by

Copyright:

Available Formats

Make the

Contact LES today at (703) 836-3106 or visit our website at www.lespowernetworking.org

“We are serious abo

One Broadway, New York, NY 10004 I Ph: 212.425.7200 I Fax: 212.425.5288

2009 POWER NETWORKING SPONSORSHIP LEVELS

1790 Analytics & 1790 Capital

130 Haddon Avenue | Haddonfield NJ 8033 | United States

Uses our suite of quantitative, objective patent metrics

Uses our patent metrics and extensive experience in investment analysis

Uses our Patent Risk-Opportunity (PRO) analysis

Company Profiles Page 1

Uses our Technology Valuation Tool (TVT)

Uses our N-Degree analysis to navigate through citation networks

Company LES Interests

Types of Companies your Company Would Like to Meet with

Company Goals for the LES Annual Meeting

Country(s) Available for

Company Profiles Page 2

350 Campus Drive | Marlborough MA 01752 | United States

Company Profiles Page 3

Company Goals for the LES Annual Meeting

Data exchange system for use

Company Profiles Page 4

Company LES Interests

Early stage and tech transfer

The changing legal environment and application to licensing

Global licensing challenges

New trends in licensing partnerships

Intellectual property management

Types of Companies your Company Would Like to Meet with

Company Profiles Page 5

Company Goals for the LES Annual Meeting

Abe, Ikuoka, & Katayama

Fukuoka Bldg. 9F | 2-8-7 Yaesu, Chuo-ku | Tokyo 104-0028 | Japan

Acacia Technologies Group

Company Profiles Page 6

 V-Chip: $25.6 million from TV manufacturers worldwide

Company LES Interests

Company Profiles Page 7

Country(s) Available for

Neoplasms, Cancer, Europe, United States,

Neoplasms, Cancer, Europe, United States,

700 Pennsylvania Drive | Exton Pennsylvania 19341 | United States

Company Profiles Page 8

Adolor Corporation is a biopharmaceutical company dedicated to the discovery, development

Entereg® (alvimopan), Adolor's lead product, is a peripherally-acting mu opioid receptor (PAM-

Adolor is collaborating with GlaxoSmithKline (GSK) for the development and

Company Profiles Page 9

5278 Clover Drive | Sheffield Village OH 44035 | United States

Akin Gump Strauss Hauer & Feld LLP

Company Profiles Page 10

500 Beacon Parkway West | Birmingham AL 35209 | United States

Company LES Interests

Company Profiles Page 11

commercialization and licensing opportunities in Alabama.

Alexion Pharmaceuticals, Inc.

352 Knotter Drive | Cheshire CT 06410 | United States

For more information, visit www.alexionpharm.com or www.soliris.net.

Company Profiles Page 12

Country(s) Available for

Alfred Mann Foundation for Biomedical Engineering

Company Profiles Page 13

signage, medical and military applications, etc.